

# PROGRAM







DAY 1 - August 18	DAY 2 - August 19	9	DAY	3 - Au	gust 20	$\neg$
(27.1. 7.10 <b>3</b> 00. 10)	(2711 2 710 <b>3</b> 001 1	ر:		istration (		
Registration (all day) Registration (all day)				orning Sy 7:00–08:1		
Post-Graduate Congress Meeting 08:30–13:00 TID 2016 Conference 08:30–18:00	Post-Graduate Courses 08:30–13:00 14:00–17:30		Basic a	ary Session of Transles Sciences 8:30–10:0 offee Brea 0:00–10:3 and Mini-Sessions 0:30–12:3	ational 00 00 00 00 Orals	
Exhibition Set-up		Exhibition Set-up	Lunch Break / Sym Exhibition Sym 12:30–13:30		ndustry mposium 30–13:30	posium 0–13:30 rt spinition
			Sta			
			Coffee Break 15:00—15:30			
			1.	0		
			Wkshop	Campfire and		
	Opening Ceremony 17:30–18:30		& Net. Event 17:00– 19:00	Poster Sessions 17:00– 18:30	Industry Symp. 17:30– 19:00	
	Welcome Reception 18:30–20:00	Exhibition	chibition			
		۵	Young Investigators' Networking Event 19:30–21:30 (ticketed)			

DAY 4 - August 21		DAY 5 - August 22			DAY 6 - August 23		
Registration (all day)		Registration (all day)			Registration (all day)		
Early Morning Symposia 07:00–08:15		Early Morning Symposia 07:00–08:15			Early Morning Symposia 07:00–08:15		
Plenary Session 2: Antibody Mediated Injury 08:30–10:00		Plenary Session 3: Hepatitis C Virus in Solid Organ Transplantation Have the Rules Changed? 08:30–10:00	1:		Plenary Session 4: Transformational Sciences in Transplantation? 08:30–10:00		
Coffee Break 10:00–10:30		Coffee Break 10:00–10:30			Coffee Break 10:00–10:30		
Orals and Mini-Orals Sessions 10:30–12:30		President's Plenary and Awards 10:30–12:30			Orals Sessions 10:30–12:00		
Lunch Break / Exhibition 12:30–13:30 12:30–13:30		Lunch Break / Exhibition 12:30–13:30			Plenary Session 5: What Changes Will We See in Tx over the Next Five Years 12:00–13:00 Closing Ceremony 13:00–13:30		
State-of-the-Art Sessions 13:30–15:00	Exhibition	State-of-the-Art Sessions 13:30–15:00		Exhibition			
Coffee Break 15:00–15:30		Coffee Break 15:00–15:30					
Orals Sessions 15:30–17:00		Orals Sessions 15:30–17:00					
Campfire and Poster Sessions 17:00–18:30  TTS Mentee-Mentor Awards / Networking Event 18:30–19:30 (by invitation)		TTS Business Meeting 17:00–18:00	-				
		Campfire and Poster Sessions 18:00–19:00  Congress Networking Event 19:00–22:00 (ticketed)		nwc			
				Exhibition Tear-Down			

The 26th International Congress of The Transplantation Society extends its appreciation to the following sponsors for their support:

#### PREMIER SPONSOR



ADVANCING TRANSPLANTATION—TOGETHER

#### PRINCIPAL SPONSOR



#### **SPONSORS**

# neovii





A Thermo Fisher Scientific Brand

#### CONTRIBUTORS







# TABLE OF CONTENTS

using the Program	•••••	
Web App and WiFi Information		3
Welcome Messages		4–6
Society Information		7–9
50 <sup>th</sup> Anniversary of TTS		10
Congress Committees List		11–16
Invited Speakers		17-23
Session Chairs		24-28
Abstract Reviewers		29-35
Award Winners		
Young Investigator Scientific Awards		36-38
Transplantation Science		
Mentee-Mentor Awards		39-43
Congress Information		
Venue and Floor Plans		45-51
Operating Hours		52-54
Program Schedule		55-56
Events Schedule		57
Use of Name Badge		58
Abstract Publication		59
Web Recordings and Live Broadcasting		59-61
Presenter Guidelines and Poster Sessions		62
CME Information		63-64
Onsite Services		65-69
Affiliate Events		69
Social Activities		70-73
Detailed Program		
Day 1: Thursday, August 18		77-85
Day 2: Friday, August 19		89-103
Day 3: Saturday, August 20		
Day 4: Sunday, August 21		163-214
Day 5: Monday, August 22		217-250
Day 6: Tuesday, August 23		253-272
Poster List		273-341
Sponsored Symposia		342-344
Exhibit Information		
Exhibit Hours and Floor Plan		346-349
Sponsor Descriptions		350-353
Exhibitor Descriptions		354-366
Local Partners		
Traveler Information		
Presenter Index		378-395

# USING THE PROGRAM

As the scientific program for the Congress touches on a wide base of sub-programs, we have included the following icons for ease of knowledge on what topic(s) is covered during each Symposium, Oral, State-of-the-Art, and Poster Session.

In addition, in the detailed program section, each day of the Congress has been tabbed and printed with a Program-at-a-Glance for that specific day -- morning sessions on one side and afternoon sessions on the reverse -- and the subsequent pages color-coded.

# PROGRAM TRACK ICON KFY



Basic & Translational Sciences



Ethics, Community, and Economics



Kidnev Immunosuppression



Surgical Techniques



Cell Transplantation



Heart



Liver



Transplantation in Developing Countries



Complications



Histocompatibility



Luna



Transplantation Nursing



Composite Tissue



Intestine and Multivisceral



**Paediatrics** 



Women in Transplantation



Declaration of Istanbul



Diseases

ID



Pancreas and Islet



Xenotransplantation



Donation and Procurement



Kidney



Registries



# SSID: **TTS2016**

#### How to connect in three simple steps:

Step 1: Connect to the TTS 2016 SSID

Step 2: Open your favorite browser

Step 3: When the Congress welcome page loads you are ready to surf the web

#### Troubleshooting:

- · Ensure cookies are enabled on your device.
- Visit the Technology Area behind the TTS booth in Hall 5FG for help in connecting.

# Congress WebApp



TTS will be using a new WebApp completely integrated into our management software.

To login, use the same password used to register for the Congress.

#### WebApp Highlights:

- · view the program
- build your agenda
- take notes
- view sponsor/exhibitor information
- look up colleagues

No download is required, simply visit:

http://tts.guide

# **WELCOME** Messages

n behalf of the TTS Council, I would like to welcome you all to the 26th Congress of The Transplantation Society. This Congress marks the 50th Anniversary of the Society, and it is only the second time that our Congress is being held in Asia. The program committee has been working hard to deliver you an exciting and innovative program. We have outstanding international experts at the highest level giving overviews of our understanding of modern biology and how it will impact transplantation. These include presentations on the microbiome, polyreactive alloantibodies, new outcomes for hepatitis C, our understanding of the molecular biology of aging, and mapping of the human immune system. In addition to excellent plenary talks, there are a wide range of state-of-the-art lectures on every facet of transplantation, as well as an excellent and extensive education program.

Finally, I would like to remind you of the 50<sup>th</sup> Anniversary celebrations for the Society. The highlight is a series of videos capturing key events and developments that defined the term of all available past presidents of the Society. This is an extraordinary retrospective of what we have achieved in the last 50 years. I urge you all to visit the Society's booth in the Exhibit Area and view these presentations.

A warm welcome,

PJ Olamell



Philip J. O'Connell
TTS 2016 Congress Chair
President, The Transplantation Society

# **WELCOME** Messages

Dear Friends and Colleagues,

t is our tremendous pleasure and certainly an honor to extend to you a very warm welcome to the 26<sup>th</sup> International Congress and concurrent celebration of the 50<sup>th</sup> Anniversary of The Transplantation Society.

As the local host and one of the co-organizers together with the Thai Transplantation Society, we welcome you to Hong Kong, a special administrative region of China. Hong Kong, literally translated "Fragrant Harbor", is one of the most significant global financial centers as well as one of the healthiest places in the world. However, with a deceased donor organ donation rate of only a fraction of that of most Western countries, organ transplantation here relies heavily on voluntary living organ donation. We hope this international event of the transplantation community not only provides transplant professionals with an instrumental and cozy arena for intellectual exchanges, but also serves as a cultural hub for generation of new ideas in the promotion of organ donation for the region and the world.

We believe you will enjoy the world-class educational activities carefully organized by the scientific committee. The Congress will offer plenty of networking opportunities for you to meet and interact with fellow researchers, clinicians, and friends. Time out from the Congress in the evenings will be particularly refreshing. We sincerely wish you a pleasant stay in this Eastmeets-West melting pot.

Thank you for coming to Hong Kong.





**Dr. Wai Leung Chak**President, Hong Kong Society of Transplantation





**Professor See Ching Chan** TTS 2016 Congress Vice-Chair

# **WELCOME** Messages

Dear colleagues, ladies, and gentlemen,

Welcome to the TTS 2016 Congress!

s co-host of the 26<sup>th</sup> International Congress of The Transplantation Society, we, the Thai Transplantation Society, would like to extend to you our warmest welcome to the TTS 2016 Congress in Hong Kong! This is also a special occasion for us to celebrate The Transplantation Society's 50<sup>th</sup> Anniversary.

The Thai Transplantation Society has been working very hard in order to bring this important Congress to Asia. The Transplantation Society has supported this endeavor, and we are now brought together in Hong Kong.

We believe this Congress will provide an inspiring platform for transplant specialists to meet and communicate in the many forums to ensure that the TTS Congress remains at the cutting edge of our field. We shall all be very proud of the development of transplantation over the past 50 years, and excited about what is coming in the future.

We are certain that you will enjoy the Congress. Your interactions with your colleagues from many regions and countries will stimulate creative ideas and bring fresh perspectives. These will be your personal gain for attending the Congress.

The biennial TTS Congress has a long reputation of fostering friendships and new professional collaborations, and it provides an unprecedented occasion to network among transplant physicians, surgeons, and scientists in our related fields. We would like to encourage you to take part in a maximum of activities and maximize your benefits in joining the TTS 2016 Congress.

With warm wishes,

K Varanangth op.



Kriengsak Vareesangthip MD, PhD, FACP Associate Professor of Medicine President, Thai Transplantation Society

Vasant Sundther



**Vasant Sumethkul MD, FRCP**Professor of Medicine
TTS 2016 Congress Vice-Chair

# **SOCIETY** Information



The mission of The Transplantation Society is to provide global leadership in the practice of human transplantation. The responsibility of The Transplantation Society is to establish guidelines of clinical practice, advance programs of education, and to promote ethical standards for clinical care and scientific investigation.

The Transplantation Society will provide the focus for global leadership in transplantation:

- Development of the science and clinical practice
- **■** Scientific communication
- **■** Continuing education
- Guidance on the ethical practice

FOR MORE INFORMATION, VISIT www.tts.org



# **SOCIETY** Information



The Hong Kong Society of Transplantation was incorporated in March 1995 and has been very active in the region. Its major objectives include:

- To promote for the public benefit the interests in and a better understanding of the advancement of science and knowledge in the transplantation and harvesting of organs and tissues
- **■** To promote organ donation
- To promote research, education, training, and appreciation in the science and technology of transplantation, and to make available to the community up-to-date information on new developments in transplantation and organ/tissue harvesting for public benefit
- To promote academic and social exchange among local and overseas transplant community, and to organize activities/conferences in this respect

MORE INFORMATION AVAILABLE AT www.hkst.org



# **SOCIETY** Information



The Thai Transplantation Society has long been an ardent supporter of The Transplantation Society and is one of its affiliated societies. It has also worked with various international organizations, such as the World Health Organization, to improve transplantation practices in Thailand, which has a significant unfulfilled demand for transplantation treatments. To date, 330 patients in Thailand have received liver transplants from deceased donors, while a further 30 pediatric and adult patients have had liver transplants from living related donors. The total number of Thai patients who have received bone marrow and stem cell transplants now exceeds 1,000 transplantations.

Kidney transplants constitute the largest number of solid organ transplantations being performed in Thailand, with 4,202 patients to date having received kidney transplants from 23 Centres throughout the country. Fifty-five percent were kidney transplants from deceased donors and forty-five percent from living related donors. Currently, 400 kidney transplants are performed in Thailand each year. However, many more patients remain in need of transplantations.

MORE INFORMATION AVAILABLE AT www.transplantthai.org



# 50th Anniversary of TTS



CELEBRATING
FIVE DECADES
OF INTERNATIONAL
COOPERATION,
INNOVATION,
GROWTH,
AND PROGRESS

The founding members of this Society developed many of the advances that have made transplantation the success it is today. TTS has at heart to carry on this legacy and to build on this foundation in science and clinical practice, where many challenges remain.



Under the direction of our our historian, Randall Morris, we will be marking our 50<sup>th</sup> Anniversary Congress by introducing two new historical projects:

**TTS Historical Mini-Theatre**: We have filmed our Past Presidents over the past two years and the interviews will be available for the first time in a special Mini-Theatre in the TTS booth.

TTS Historical Timeline: We have built an interactive multimedia timeline which will be on display next to TTS Historical Mini-Theatre.

Following the Congress, the videos and timeline will be available on **www.tts.org**.

### **COMMITTEES**

#### Executive Committee

Philip J. O'Connell, Westmead, Australia (Chair)
See Ching Chan, Hong Kong SAR, P.R. of China (Vice-Chair)
Vasant Sumethkul, Bangkok, Thailand (Vice-Chair)
Nancy Ascher, San Francisco, CA, United States
Jeremy R. Chapman, Westmead, Australia
John J. Fung, Cleveland, OH, United States

#### **■** Finance Committee

John J. Fung, Cleveland, OH, United States (Chair) (late) Josette M. Eris, Westmead, Australia William Lee, Hong Kong SAR, P.R. of China José María Morales, Madrid, Spain Elmi M. Muller, Cape Town, South Africa Philip J. O'Connell, Westmead, Australia Denise Rainville, Montreal, QC, Canada Kriengsak Vareesangthip, Bangkok, Thailand

#### ■ Host Country Liaison Committee (Hong Kong)

Wai-Leung Chak (Chair)
See Ching Chan
Ka Foon Chau
Kai Ming Chow
Bo Ying Cindy Choy
See Ming Simon Hou
Jenny Koo

William Lee
Chung-Mau Lo
Stanley HK Lo
Nancy Kwan Man
Maggie Kam Man Ma
Matthew Kwok Lung Tong

#### ■ Scientific Program Committee

Jeremy R. Chapman, Westmead, Australia (Chair)
Nancy Ascher, San Francisco, CA, United States
Yingyos Avihingsanon, Bangkok, Thailand
Marcelo Cantarovich, Montreal, QC, Canada
Wai-Leung Chak, Hong Kong SAR, P.R. of China
Josep Grinyo, Barcelona, Spain
Philip J. O'Connell, Westmead, Australia
Vasant Sumethkul, Bangkok, Thailand
Megan Sykes, New York, NY, United States
Shiro Takahara, Osaka, Japan
Stefan G. Tullius, Boston, MA, United States

#### ■ Postgraduate Course

Marcelo Cantarovich, Canada (Co-Chair) Vivekanand Jha, India (Co-Chair) Nancy Kwan Man, Hong Kong SAR, P.R. of China (Co-Chair) David Rothstein, United States (Co-Chair)

#### ■ Basic Sciences and Translational Sciences

Carla Baan, The Netherlands (Co-Chair)
Anita Chong, United States (Co-Chair)
Curie Ahn, Korea
Shane T. Grey, Australia
Fadi G. Lakkis, United States
Xian C. Li, United States
Giovanna Lombardi, United Kingdom
Minnie M. Sarwal, United States
Birgit S. Sawitzki, Germany
Qizhi Tang, United States

#### ■ Cell Transplantation/ Bone Marrow/ HSC

Anil Dhawan, United Kingdom (Co-Chair) Maria Koulmanda, United States (Co-Chair) Jeffrey Szer, Australia

#### ■ Complications

Steve J. Chadban, Australia (Co-Chair) Angela Webster, Australia (Co-Chair) Alan G. Jardine, United Kingdom Michael A. Nalesnik, United States Shigeru Satoh, Japan Claire M. Vajdic, Australia

#### ■ Composite Tissue

Linda C. Cendales, United States (Co-Chair) Emmanuel Morelon, France (Co-Chair) Palmina Petruzzo, France (Co-Chair)

#### ■ Declaration of Istanbul

Gabriel Danovitch, United States (Co-Chair)
Francis L. Delmonico, United States (Co-Chair)
Beatriz Dominguez-Gil, Spain (Co-Chair)

#### Donation and Procurement

Marti Manyalich, Spain (Co-Chair) Kimberly Young, Canada (Co-Chair) Stephen D. Beed, Canada John S. Gill, Canada Jongwon Ha, Korea Thomas A. Nakagawa, United States Dorry Segev, United States Gregory I. Snell, Australia

#### ■ Ethics, Community and Economics

Beatriz Dominguez-Gil, Spain (Co-Chair) Dominique E. Martin, Australia (Co-Chair)

#### ■ Heart

Peter S. MacDonald, Australia (Co-Chair) Joseph Rogers, United States (Co-Chair)

#### ■ Histocompatibilty

Frans H.J. Claas, Netherlands (Co-Chair)
Peter William Nickerson, Canada (Co-Chair)
Susan V. Fuggle, United Kingdom
Howie M. Gebel, United States
Maria Gerbase-DeLima, Brazil
Rhonda Holdsworth, Australia
Anat R. Tambur, United States

#### ■ Infections Diseases

Deborah Marriott, Australia (Co-Chair) Michele I. Morris, United States (Co-Chair)

#### ■ Intestine & Multivisceral

Douglas G. Farmer, United States (Co-Chair) Debra L. Sudan, United States (Co-Chair)

#### ■ Kidney

Dirk Kuypers, Belgium (Co-Chair) Peter Stock, United States (Co-Chair) Daniel C. Brennan, United States Klemens Budde, Germany Robert B. Colvin, United States Anthony Dorling, United Kingdom (late) Josette M. Eris, Australia Paolo Ferrari, Australia Mark Haas, United States Philip F. Halloran, Canada Stuart Knechtle, United States Alan B. Leichtman, United States Henri G.D. Leuvenink, The Netherlands Valeria Mas, United States Robert M. Merion, United States Robert A. Montgomery, United States Brian J. Nankivell, Australia Milagros Samaniego, United States Kazunari Tanabe, Japan Chris J. E. Watson, United Kingdom Germaine Wong, Australia Andrea A. Zachary, United States

#### ■ Kidney Immunosuppression

Lionel Rostaing, France (Co-Chair)
Flavio Vincenti, United States (Co-Chair)
Stephan Busque, United States
Josep M. Campistol, Spain
Sandy Feng, United States
Stuart M. Flechner, United States
Edward K. Geissler, Germany
Joseph Leventhal, United States
Helio Tedesco-Silva Jr., Brazil
Teun Van Gelder, The Netherlands

#### Liver

Elizabeth A. Pomfret, United States (Co-Chair) Chung-Mau Lo, Hong Kong SAR, P.R. of China (Co-Chair) Marina Berenguer, Spain Patrizia Burra, Italy Pierre Alain Clavien, Switzerland Sandy Feng, United States Peter Friend, United Kingdom Julie K. Heimbach, United States John R. Klinck, United Kingdom Jan P. Lerut, Belgium Claus Niemann, United States Gabriel C. Oniscu, United Kingdom Andreas Pascher, Germany Johann Pratschke, Germany Saigal Sanjiv, India Abraham Shaked, United States

#### Lung

Allan R. Glanville, Australia (Chair)

#### Paediatrics

Anne I. Dipchand, Canada (Co-Chair) Ron Shapiro, United States (Co-Chair) David Briscoe, United States Helen M. Evans, New Zealand

#### ■ Pancreas and Islet

Thierry P.S. Berney, Switzerland (Co-Chair) Mitsukazu Gotoh, Japan (Co-Chair) Raja Kandaswamy, United States (Co-Chair) Jon Odorico, United States (Co-Chair)

#### Registries

Bertram L. Kasiske, United States (Co-Chair) Adisorn Lumpaopong, Thailand (Co-Chair)

#### Surgical Techniques

George W. Burke, United States (Co-Chair) Henry Pleass, Australia (Co-Chair)

#### ■ Transplantation in Developing Countries

Curie Ahn, Korea (Co-Chair) Elmi M. Muller, South Africa (Co-Chair)

#### ■ Transplantation Nursing

Kathy Kable, Australia (Co-Chair)
Patrice Pfeiffenberger, United States (Co-Chair)
Cynthia Russell, United States (Co-Chair)

#### Xenotransplantation

Agnes Azimzadeh, United States (Co-Chair) Peter Cowan, Australia (Co-Chair)

#### ■ Women in Transplantation

(late) Josette M. Eris, Australia (Co-Chair) Lori J. West, Canada (Co-Chair)

#### Post-Graduate Courses

Roberta J. Al Housani-Blakely, Abu Dhabi, United Arab Emirates Carla Baan, Rotterdam, The Netherlands Markus Barten, Hamburg, Germany Christian Benden, Zurich, Switzerland Jonathan S. Bromberg, Baltimore, MD, United States Steve J. Chadban, Camperdown, Australia Wai Ming Chan, Hong Kong SAR, P.R. of China Ka Foon Chau, Hong Kong SAR, P.R. of China Jingyu Chen, Jiangsu, People's Republic of China Menna R. Clatworthy, Cambridge, United Kingdom Jonathan Craig, Sydney, Australia Zhenhua Dai, Guangzhou, People's Republic of China Emanuele de Rinaldis, London, United Kingdom Anne I. Dipchand, Toronto, ON, Canada Kefeng Dou, Xi'an, People's Republic of China Thu Thi Ngoc Du, Ho Chi Minh, Viet Nam Magnus Fontes, Paris, France John S. Gill, Vancouver, BC, Canada Shane T. Grey, Darlinghurst, Australia Paul C. Grimm MD, Stanford, CA, United States Susan Gunderson, Minneapolis, MN, United States Yanhong Guo, Beijing, People's Republic of China Jongwon Ha, Seoul, Korea Philip F. Halloran, Edmonton, AB, Canada Paul Harden, Oxford, United Kingdom Xiaoshun He, Guangzhou, People's Republic of China Hallvard Holdaas, Oslo, Norway Jiefu Huang, Beijing, People's Republic of China Kathy Kable, Westmead, Australia John W. Kao, Hong Kong SAR, P.R. of China Daniel Kreisel, St. Louis, MO, United States Dirk Kuypers, Leuven, Belgium Janette Kwok, Hong Kong SAR, P.R. of China Christophe Michel Legendre, Paris, France Bronwyn J. Levvey, Melbourne, Australia Xian C. Li, Houston, TX, United States Qizhou Lian, Hong Kong SAR, P.R. of China Andreas Linkermann, Kiel, Germany

Chun-Jen Liu, Taipei City, Taiwan

#### ■ Post-Graduate Courses (cont.)

Chung-Mau Lo, Hong Kong SAR, P.R. of China Alexandre Loupy, Paris, France Marti Manyalich, Barcelona, Spain Valeria Mas, Charlottesville, VA, United States George V. Mazariegos, Pittsburgh, PA, United States Michael Mengel, Edmonton, AB, Canada Robert A. Montgomery, New York, NY, United States Adrian E. Morelli, Pittsburgh, PA, United States Randall E. Morris, Carmel, CA, United States Elmi M. Muller, Cape Town, South Africa Brian J. Nankivell, Westmead, Australia Anwar Nagyi, Karachi, Pakistan Howard M. Nathan, Philadelphia, PA, United States Aurora Navarro, Barcelona, Spain Kenneth A. Newell, Atlanta, GA, United States Peter William Nickerson, Winnipeg, MB, Canada José Ramón Núñez Peña, Geneva, Switzerland Philip J. O'Connell, Westmead, Australia Martin Oberbarnscheidt, Pittsburgh, PA, United States Giuseppe Orlando, Winston Salem, NC, United States Benita Padilla, San Juan City, Philippines Lars Pape, Hannover, Germany Mir M. Rahman, Chittagong, Bangladesh Elaine F. Reed, Los Angeles, CA, United States Paul Robertson, Westmead, Australia Eduardo Rocha, Rio de Janeiro, Brazil David Rothstein, Pittsburgh, PA, United States Alberto Sanchez-Fueyo, London, United Kingdom Liz Schick, Anzère, Switzerland Dorry Segev, Baltimore, MD, United States Faissal Shaheen, Riyadh, Saudi Arabia Abraham Shaked, Philadelphia, PA, United States Diana Shellmer, Pittsburgh, PA, United States Bingyi Shi, Beijing, People's Republic of China Dibya Singh, Kathmandu, Nepal Xuyong Sun, Beijing, People's Republic of China Htar Kyi Swe, Mandalay, Myanmar Ban Hock Tan, Singapore, Singapore Kazunari Tanabe, Tokyo, Japan Qizhi Tang, San Francisco, CA, United States Olivier Thaunat, Lyon, France

#### ■ Post-Graduate Courses (cont.)

Chris Thomas, Chatswood, Australia Kathryn Tinckam, Toronto, ON, Canada Burkhard Tönshoff, Heidelberg, Germany Hung Fat Tse, Hong Kong SAR, P.R. of China Marcel R.M. van den Brink, New York, NY, United States Teun Van Gelder, Rotterdam, The Netherlands Haibo Wang, Hong Kong SAR, P.R. of China Angela Webster, Sydney, Australia Piotr Witkowski, Chicago, IL, United States Germaine Wong, Westmead, Australia Aimin Xu, Hong Kong SAR, P.R. of China Qifa Ye, Wuhan, People's Republic of China Kimberly Young, Edmonton, AB, Canada Mirza Nagi Zafar, Karachi, Pakistan Nicolas Zavazava, Iowa City, IA, United States Yuan Zhai, Los Angeles, CA, United States Shusen Zheng, Hangzhou, People's Republic of China Zhe Zheng, Beijing, People's Republic of China

#### ■ TTS 2016 Congress

Roberta J. Al Housani-Blakely, Abu Dhabi, United Arab Emirates Matthew L. Albert, San Francisco, CA, United States Mona Alrukhaimi, Dubai, United Arab Emirates Dany Anglicheau, Paris, France Nancy Ascher, San Francisco, CA, United States Medhat Z. Askar, Dallas, TX, United States Agnes Azimzadeh, Baltimore, MD, United States Carla Baan, Rotterdam, The Netherlands Byambadorji Batsuuri, Ulaanbaatar, Mongolia Pierre Y. Benhamou, Grenoble, France Marina Berenguer, Valencia, Spain Thierry P.S. Berney, Geneva, Switzerland Sandra Burchett, Boston, MA, United States George W. Burke, Miami, FL, United States Alexander M. Capron, Los Angeles, CA, United States Linda C. Cendales, Durham, NC, United States Daniel T.M. Chan, Hong Kong SAR, P.R. of China See Ching Chan, Hong Kong SAR, P.R. of China Wai Ming Chan, Hong Kong SAR, P.R. of China Sindhu Chandran, San Francisco, CA, United States Jeremy R. Chapman, Westmead, Australia Chao-Long Chen, Taiwan Sharon Chen, Westmead, Australia Jacqueline J. Chin, Singapore Frans H.J. Claas, Leiden, Netherlands Menna R. Clatworthy, Cambridge, United Kingdom Peter Cowan, Melbourne, Australia Antonia Cronin, London, United Kingdom Dolly Daniel, Vellore, India Francis L. Delmonico, Waltham, MA, United States Anil Dhawan, London, United Kingdom Kumud K. Dhital, Darlinghurst, Australia Fritz Diekman, Barcelona, Spain Anne I. Dipchand, Toronto, ON, Canada Beatriz Dominguez-Gil, Madrid, Spain Duska Dragun, Berlin, Germany Joel T. Dudley, New York, NY, United States Gregory T. Everson, Aurora, CO, United States Donna L. Farber, New York, NY, United States Douglas G. Farmer, Los Angeles, CA, United States

Alton "Brad" Farris III, Atlanta, GA, United States

#### ■ TTS 2016 Congress (cont.)

Sandy Feng, San Francisco, CA, United States Paolo Ferrari, Sydney, Australia Constantino Fondevila, Barcelona, Spain James Fung, Hong Kong SAR, P.R. of China Rudolf A. Garcia-Gallont, Guatemala City, Guatemala Edward K. Geissler, Regensburg, Germany Sommer E. Gentry, Baltimore, MD, United States John S. Gill, Vancouver, BC, Canada Allan R. Glanville, Sydney, Australia Gabriel E. Gondolesi, Buenos Aires, Argentina Shane T. Grey, Darlinghurst, Australia Faikah Gueler, Hannover, Germany Duck-Jong Han, Seoul, Korea Wayne W. Hancock, Philadelphia, PA, United States Wayne J. Hawthorne, Westmead, Australia Margaret Hay, Clayton, Australia Wayne C. Hodgson, Clayton, Australia Hallvard Holdaas, Oslo, Norway Martin J. Hoogduijn, Rotterdam, The Netherlands Kirsten Howard, Sydney, Australia Jiefu Huang, Beijing, People's Republic of China Suzanne T. Ildstad, Louisville, KY, United States Trond Jenssen, Oslo, Norway Paul R. V. Johnson, Oxford, United Kingdom Raja Kandaswamy, Minneapolis, MN, United States Bertram L. Kasiske, Minneapolis, MN, United States Dixon B. Kaufman, Madison, WI, United States Brian K. Kennedy, Novato, CA, United States Gregory Alan Knoll, Ottawa, ON, Canada Wing-Man Ko, Hong Kong SAR, P.R. of China Jenny Koo, Hong Kong SAR, P.R. of China Maria Koulmanda, Boston, MA, United States Christophe Michel Legendre, Paris, France Megan Levings, Vancouver, BC, Canada Bronwyn J. Levvey, Melbourne, Australia Chung-Mau Lo, Hong Kong SAR, P.R. of China Marta López Fraga, Strasbourg, France Peter S. MacDonald, Sydney, Australia Clarisse Machado, São Paulo, Brazil Beatriz B. Mahillo, Madrid, Spain Marti Manyalich, Barcelona, Spain

#### ■ TTS 2016 Congress (cont.)

Dominique E. Martin, Geelong, Australia Olivia M. Martinez, Stanford, CA, United States Tereza Martinu, Toronto, ON, Canada Philip Masson, Edinburgh, United Kingdom George V. Mazariegos, Pittsburgh, PA, United States Sue McDiarmid, Los Angeles, CA, United States Stephen McDonald, Adelaide, Australia Raphael Meier, Geneva, Switzerland Felix Meissner, Munich, Germany Simon J. Messer, Cambridge, United Kingdom Muhammad M. Mohiuddin, Bethesda, MD, United States Robert A. Montgomery, New York, NY, United States José María Morales, Madrid, Spain Emmanuel Morelon, Lyon, France Michele I. Morris, Miami, FL, United States David W. Mudge, Brisbane, Australia Elmi M. Muller, Cape Town, South Africa Brian J. Nankivell, Westmead, Australia Kenneth A. Newell, Atlanta, GA, United States Michael L. Nicholson, Cambridge, United Kingdom Peter William Nickerson, Winnipeg, MB, Canada Claus Niemann, San Francisco, CA, United States José Ramón Núñez Peña, Geneva, Switzerland Philip J. O'Connell, Westmead, Australia Rudolf Oehler, Vienna, Austria Giuseppe Orlando, Winston Salem, NC, United States Lars Pape, Hannover, Germany Chung-Gyu Park, Seoul, Korea Myoung Hee Park, Seoul, Korea François Pattou, Lille, France Julie Pavlovic, Heidelberg, Australia Martin F. Pera, Parkville, Australia Palmina Petruzzo, Lyon, France Helen Pilmore, Auckland, New Zealand Klara M. Posfay-Barbe, Geneva, Switzerland Andrew Posselt, San Francisco, CA, United States Elaine F. Reed, Los Angeles, CA, United States Petra Reinke, Berlin, Germany Mohamed Rela, Chennai, India Adibul Hasan Rizvi, Karachi, Pakistan Franklin L. Rosenfeldt, Melbourne, Australia

#### ■ TTS 2016 Congress (cont.)

Alexander Rudensky, New York, NY, United States Alberto Sanchez-Fueyo, London, United Kingdom Minnie M. Sarwal, San Francisco, CA, United States Stefan Schaub, Basel, Switzerland Carrie A. Schinstock, Rochester, MN, United States Hanne Scholz, Oslo, Norway Christian Schuetz, Boston, MA, United States Dorry Segev, Baltimore, MD, United States Marina Sirota, San Francisco, CA, United States Yuji Soejima, Fukuoka, Japan Peter Stock, San Francisco, CA, United States Simone I. Strasser, Camperdown, Australia Kyung-Suk Suh, Seoul, Korea Vasant Sumethkul, Bangkok, Thailand Caner Süsal, Heidelberg, Germany Megan Sykes, New York, NY, United States Anat R. Tambur, Chicago, IL, United States Ban Hock Tan, Singapore, Singapore Kazunari Tanabe, Tokyo, Japan Qizhi Tang, San Francisco, CA, United States Cara Tannenbaum, Montreal, QC, Canada Alfred Joseph Tector, Birmingham, AL, United States Olivier Thaunat, Lyon, France Mirjam Tielen, Rotterdam, The Netherlands Kathryn Tinckam, Toronto, ON, Canada Yaman Tokat, Istanbul, Turkey Allison Tong, Sydney, Australia Hung Fat Tse, Hong Kong SAR, P.R. of China Stefan G. Tullius, Boston, MA, United States Flavio Vincenti, San Francisco, CA, United States Angela Webster, Sydney, Australia Chris J. Wiebe, Winnipeg, MB, Canada Colin Wilson, Newcastle-upon-Tyne, United Kingdom Michael Wolf, Chicago, IL, United States Germaine Wong, Westmead, Australia Kathryn J. Wood, Oxford, United Kingdom Di Yu, Clayton, Australia Mirza Nagi Zafar, Karachi, Pakistan Emmanuel Zorn, New York, NY, United States

Curie Ahn, Seoul, Korea Roberta J. Al Housani-Blakely, Abu Dhabi, United Arab Emirates Richard D.M. Allen, Sydney, Australia Mona Alrukhaimi, Dubai, United Arab Emirates Dany Anglicheau, Paris, France Rebeca Arroyo Hornero, Oxford, United Kingdom Nancy Ascher, San Francisco, CA, United States Medhat Z. Askar, Dallas, TX, United States Yingyos Avihingsanon, Bangkok, Thailand Agnes Azimzadeh, Baltimore, MD, United States Carla Baan, Rotterdam, Netherlands Marina Berenguer, Valencia, Spain Thierry P.S. Berney, Geneva, Switzerland Jonathan S. Bromberg, Baltimore, MD, United States Klemens Budde, Berlin, Germany Leo Buhler, Geneva, Switzerland George W. Burke, Miami, FL, United States Roy Calne, Cambridge, United Kingdom Marcelo Cantarovich, Montreal, QC, Canada Alexander M. Capron, Los Angeles, CA, United States Linda C. Cendales, Durham, NC, United States Steve J. Chadban, Camperdown, Australia Wai-Leung Chak, Hong Kong SAR, P.R. of China Albert Chan, Hong Kong SAR, P.R. of China See Ching Chan, Hong Kong SAR, P.R. of China Sindhu Chandran, San Francisco, CA, United States Li Chao, Hangzhou, People's Republic of China Jeremy R. Chapman, Westmead, Australia Ka Foon Chau, Hong Kong SAR, P.R. of China Sharon Chen, Westmead, Australia Ignatius Kum-Po Cheng, Hong Kong SAR, P.R. of China Chi Yuen Simon Cheung, Hong Kong SAR, P.R. of China Kenneth Siu Ho Chok, Hong Kong SAR, P.R. of China Bo Ying Cindy Choy, Hong Kong SAR, P.R. of China Frans H.J. Claas, Leiden, Netherlands Menna R. Clatworthy, Cambridge, United Kingdom Peter Cowan, Melbourne, Australia Jonathan Craig, Sydney, Australia Francis L. Delmonico, Waltham, MA, United States Anil Dhawan, London, United Kingdom Visist Dhitavat, Bangkok, Thailand Fritz Diekman, Barcelona, Spain Anne I. Dipchand, Toronto, ON, Canada Beatriz Dominguez-Gil, Madrid, Spain Duska Dragun, Berlin, Germany Karen Dwyer, Victoria, Australia

Hiroto Egawa, Tokyo, Japan Howard Eisen, Philadelphia, PA, United States Katherine Fan, Hong Kong SAR, P.R. of China Douglas G. Farmer, Los Angeles, CA, United States Sandy Feng, San Francisco, CA, United States Paolo Ferrari, Sydney, Australia Peter Friend, Oxford, United Kingdom James Fung, Hong Kong SAR, P.R. of China John J. Fung, Cleveland, OH, United States Rudolf A. Garcia-Gallont, Guatemala City, Guatemala Edward K. Geissler, Regensburg, Germany John S. Gill, Vancouver, BC, Canada Allan R. Glanville, Sydney, Australia Gabriel E. Gondolesi, Buenos Aires, Argentina Mitsukazu Gotoh, Osaka, Japan Shane T. Grey, Darlinghurst, Australia Josep Grinyo, Barcelona, Spain Carole Guillonneau, Nantes, France Susan Gunderson, Minneapolis, MN, United States Jongwon Ha, Seoul, Korea Mehmet Haberal, Ankara, Turkey Philip F. Halloran, Edmonton, AB, Canada Duck-Jong Han, Seoul, Korea Wayne W. Hancock, Philadelphia, PA, United States Paul Harden, Oxford, United Kingdom Wayne J. Hawthorne, Westmead, Australia Maria Hernandez-Fuentes, London, United Kingdom Kelvin Kai-Leung Ho, Hong Kong SAR, P.R. of China Hallvard Holdaas, Oslo, Norway Rhonda Holdsworth, Melbourne, Australia Martin J. Hoogduijn, Rotterdam, Netherlands See Ming Simon Hou, Hong Kong SAR, P.R. of China Feng Huo, Guangzhou, People's Republic of China Fadi Issa, Oxford, United Kingdom Vivekanand Jha, Chandigarh, India Paul R. V. Johnson, Oxford, United Kingdom Kathy Kable, Westmead, Australia Raia Kandaswamy, Minneapolis, MN, United States Bertram L. Kasiske, Minneapolis, MN, United States Dixon B. Kaufman, Madison, WI, United States Thomas Kay, Victoria, Australia Gregory Alan Knoll, Ottawa, ON, Canada Takaaki Kobayashi, Nagoya, Japan Jenny Koo, Hong Kong SAR, P.R. of China Maria Koulmanda, Boston, MA, United States Daniel Kreisel, St. Louis, MO, United States

Dirk Kuypers, Leuven, Belgium Janette Kwok, Hong Kong SAR, P.R. of China Man Fai Lam, Hong Kong SAR, P.R. of China William Lee, Hong Kong SAR, P.R. of China Christophe Michel Legendre, Paris, France Jan Lerut, Louvain-la-Neuve, Belgium Henri G.D. Leuvenink, Groningen, The Netherlands Megan Levings, Vancouver, BC, Canada Bronwyn J. Levvey, Melbourne, Australia Chun Sang Li, Hong Kong SAR, P.R. of China Xian C. Li, Houston, TX, United States Kieron Lim, Singapore, Singapore Andreas Linkermann, Kiel, Germany Chung-Mau Lo, Hong Kong SAR, P.R. of China Stanley HK Lo, Hong Kong SAR, P.R. of China Jayme E. Locke, Birmingham, AL, United States Marta López Fraga, Strasbourg, France Alexandre Loupy, Paris, France Siu Fai Lui, Hong Kong, SAR, P.R. of China Adisorn Lumpaopong, Bangkok, Thailand Xunrong Luo, Chicago, IL, United States Maggie Kam Man Ma, Hong Kong SAR, P.R. of China Peter S. MacDonald, Sydney, Australia Nancy Kwan Man, Hong Kong SAR, P.R. of China Marti Manyalich, Barcelona, Spain Deborah Marriott, Sydney, Australia Dominique E. Martin, Geelong, Australia Olivia M. Martinez, Stanford, CA, United States Tereza Martinu, Toronto, ON, Canada Valeria Mas, Charlottesville, VA, United State Philip Masson, Edinburgh, United Kingdom George V. Mazariegos, Pittsburgh, PA, United States Sue McDiarmid, Los Angeles, CA, United States Stephen McDonald, Adelaide, Australia Michael Mengel, Edmonton, AB, Canada J. Michael Millis, Chicago, IL, United States Anthony Peter Monaco, Boston, MA, United States (not confirmed) Robert A. Montgomery, New York, NY, United States José María Morales, Madrid, Spain Luis E. Morales-Buenrostro, Mexico City, Mexico Emmanuel Morelon, Lyon, France Michele I. Morris, Miami, FL, United States Peter J. Morris, London, United Kingdom Randall E. Morris, Carmel, CA, United States Elmi M. Muller, Cape Town, South Africa Thomas A. Nakagawa, St. Petersburg, FL, United States

Brian J. Nankivell, Westmead, Australia Anwar Nagyi, Karachi, Pakistan Howard M. Nathan, Philadelphia, PA, United States Kenneth A. Newell, Atlanta, GA, United States Peter William Nickerson, Winnipeg, MB, Canada Claus Niemann, San Francisco, CA, United States Alejandro Nino-Murcia, Bogota, Colombia José Ramón Núñez Peña, Geneva, Switzerland Philip J. O'Connell, Westmead, Australia Martin Oberbarnscheidt, Pittsburgh, PA, United States Jon Odorico, Madison, WI, United States Rudolf Oehler, Vienna, Austria Gerhard Opelz, Heidelberg, Germany Benita Padilla, San Juan City, Philippines Chung-Gyu Park, Seoul, Korea Myoung Hee Park, Seoul, Korea Julie Pavlovic, Heidelberg, Australia Palmina Petruzzo, Lvon, France Patrice Pfeiffenberger, Chicago, IL, United States Helen Pilmore, Auckland, New Zealand Henry Pleass, Hunters Hill, Australia Mei Lan May Pong, Hong Kong SAR, P.R. of China Andrew Posselt, San Francisco, CA, United States Elaine F. Reed, Los Angeles, CA, United States Petra Reinke, Berlin, Germany Mohamed Rela, Chennai, India Adibul Hasan Rizvi, Karachi, Pakistan Paul Robertson, Westmead, Australia Eduardo Rocha, Rio de Janeiro, Brazil Lionel Rostaing, Toulouse, France David Rothstein, Pittsburgh, PA, United States Graeme Russ, Adelaide, Australia Alberto Sanchez-Fuevo, London, United Kingdom Minnie M. Sarwal, San Francisco, CA, United States Stefan Schaub, Basel, Switzerland Carrie A. Schinstock, Rochester, MN, United States Stefan Schneeberger, Innsbruck, Austria Dorry Segey, Baltimore, MD, United States Midas Seyda, Boston, MA, United States Faissal Shaheen, Riyadh, Saudi Arabia Abraham Shaked, Philadelphia, PA, United States Ron Shapiro, New York, PA, United States William Sharr, Hong Kong SAR, P.R. of China Diana Shellmer, Pittsburgh, PA, United States Pui Yin Jocelyn Sim, Hong Kong SAR, P.R. of China Gursharam Singh, Coibatore, India

Andrew L. Singer, Phoenix, AZ, United States Sanju Sobnach, Cape Town, South Africa Yuii Soeiima, Fukuoka, Japan Jean-Paul P. Soulillou, Nantes, France Peter Stock, San Francisco, CA, United States Simone I. Strasser, Camperdown, Australia Debra L. Sudan, Durham, NC, United States Kyung-Suk Suh, Seoul, Korea Vasant Sumethkul, Bangkok, Thailand Caner Süsal, Heidelberg, Germany Megan Sykes, New York, NY, United States Shiro Takahara, Osaka, Japan Ban Hock Tan, Singapore, Singapore Kazunari Tanabe, Tokyo, Japan Qizhi Tang, San Francisco, CA, United States Olivier Thaunat, Lyon, France Chris Thomas, Chatswood, Australia Kathryn Tinckam, Toronto, ON, Canada Allison Tong, Sydney, Australia Matthew Kwok Lung Tong, Hong Kong SAR, P.R. of China Burkhard Tönshoff, Heidelberg, Germany Joyce A. Trompeta, San Francisco, CA, United States Stefan G. Tullius, Boston, MA, United States Ifeoma Ulasi, Enugu, Nigeria Marcel R.M. van den Brink, New York, NY, United States Teun Van Gelder, Rotterdam, Netherlands Anantharaman Vathsala, Singapore, Singapore Flavio Vincenti, San Francisco, CA, United States Haibo Wang, Hong Kong SAR, P.R. of China Angela Webster, Sydney, Australia Johannes Wedel, Boston, MA, United States Lori J. West, Edmonton, AB, Canada Chi Fong Wong, Hong Kong SAR, P.R. of China Germaine Wong, Westmead, Australia Kazuhiko Yamada, New York, NY, United States Hui Kim Yap, Singapore, Singapore Ming Kwong Yiu, Hong Kong SAR, P.R. of China Kimberly Young, Edmonton, AB, Canada Mirza Nagi Zafar, Karachi, Pakistan Ali Zarrinpar, Los Angeles, CA, United States Yuan Zhai, Los Angeles, CA, United States Tianshu Zhang, Baltimore, MD, United States Emmanuel Zorn, New York, NY, United States

Reza Abdi Andrew B. Adams Deborah Adey Joel Adler Dwomoa Adu Vatche Agopian Curie Ahn

Curie Ahn Enver Akalin S. Fazal Akhtar Sanjeev Akkina Khalid Al-Meshari Nada Alachkar Josefina Alberu Maria-Luisa Alegre Rodolfo Alejandro

Simi Ali

Richard D.M. Allen Hala Alshayeb

Mario Alessiani Stephen Alexander

Frederike Ambagtsheer

Leo Amodu
David Andresen
Dany Anglicheau
M. Javeed Ansari
Samantha Anthony
Süheyla Apaydin
Helmut Arbogast
Nancy Ascher
Folkert Asselbergs
Sadaf Atarod
Meredith J. Aull
Yingyos Avihingsanon
Agnes Azimzadeh
Jamil Azzi

Carla Baan John W. Baddley Stephen Badylak Jessamyn Bagley Seema J. Baid- Agrawal Zunaid Ahmed Barday Adam Barlow

Benoit Barrou Rashad S. Barsoum Markus Barten Ibrahim Batal Bryan Becker Stephen D. Beed Melena Bellin Marina Berenguer Gabriela A. Berlakovich Thierry P.S. Berney Federico Bertuzzi Chandra Bhati Kelly Birdwell G. Alex Bishop Gilles Blancho Christopher Blosser Emily A. Blumberg Georg Böhmig Ilka Boin

Ilka Boin Eleanor Bolton Geoff Bond Ann Bonner Michael Adrian Bos

Katrina Bramstedt Gerald Brandacher William E. Braun Robert Bray Kenneth I. Brayma

Kenneth L. Brayman Daniel C. Brennan Todd Brennan David Briscoe

Jonathan S. Bromberg Klemens Budde

Leo Buhler
George W. Burke
Patrizia Burra
Zeeshan Butt
Riccardo Calafiore
Chris Callaghan
Scott Campbell
Josep M. Campistol
Jeffrey Campsen
Guillaume Canaud
Diego Cantarovich
Felix Cantarovich
Marcelo Cantarovich

Tobias Cantz Domingo D. Casadei

John Casey Aimee Catalan Cunningham

Linda C. Cendales
Laurens Ceulemans
Wai-Leung Chak
Laurence Chan
See Ching Chan
Jeremy R. Chapman
Bernard Charpentier
Ka Foon Chau
Yu Fan Cheng

Aravind Cherukuri

Srinath Chinnakotla Kenneth Siu Ho Chok Anita Chong Kai Ming Chow Bo Ying Cindy Choy Dale Christiansen

Eduardo Chuluyan Frans H.J. Claas

Menna R. Clatworthy Edward Herman Cole

Edward Herman Co Robert Cole Michael Collins Robert B. Colvin Patrizia Comoli Jennifer Conway David K. C. Cooper Matthew Cooper Lisa A. Coscia Lionel Couzi

Peter Cowan Emanuele Cozzi Paolo Cravedi Marta Crespo Barrio

Gonzalo Crespo David Cronin John Crosson Joseph Cruzado Darshana Dadhania

Dag Olav Dahle Gabriel Danovitch Lara Danziger-Isakov

John Dark

Leonardo de Castro Hanneke de Kort Sacha De Serres Nicolas Degauque Marry DeKlerk Göran Dellgren Francis L. Delmonico Christian Denecke Mary Amanda Dew

Anil Dhawan
Esme Dijke
Anne I. Dipchand
Ian D. Dittmer
Fabienne Dobbels
Beatriz Dominguez-Gil
Jose-Maria Dominguez-

Roldan

Frank J.M.F. Dor Anthony Dorling Karen Elizabeth Doucette

Alden Doyle

Cinthia B. Drachenberg François Durand Magdalena Durlik

Antoine Durrbach Karen Dwyer Hiroto Egawa Bijan Eghtesad

Susumu Eguchi Burcin Ekser Christine Ellis Matt Ellis

Matt Ellis Sukru Emre Amir Emtiazjoo Karen English Carlos O. Esquivel Helen M. Evans Matthew J. Everly

Gregory T. Everson Mohamed Ezzelarab Robert L. Fairchild Katherine Fan

Douglas G. Farmer Alton Farris Richard Fatica Jonathan Fawcett Sandy Feng

Mario Fernández-Ruiz

Luis Fernandez
Paolo Ferrari
Kevin Ferreri
Charles Ferro
Nowell M. Fine
Erik Finger
Roy First
Robert A. Fisher
Stuart M. Flechner
Constantino Fondevila

Mandy Ford John L.R. Forsythe Marie-Chantal Fortin Bethany Foster

Ira J. Fox Ross S. Francis Ulrich Frei Peter Friend Susan V. Fuggle Valentin Fuhrmann

James Fung John J. Fung

Brian J. Gallay Lorenzo Gallon Rainer Ganschow Luis García Covarrubias Rudolf A. Garcia-Gallont Juan Carlos Garcia-Valdecasas

Jordan Gauthier Howie M. Gebel

Maria Gerbase-DeLima

Undine Gerlach

Nasrollah Ghahramani

Mark Ghobrial Pierre Gianello Edoardo G. Giannini

John S. Gill Richard Gilroy Matthias Girndt Allan R. Glanville Jonathan Gleadle

Denis Glotz Gabriel E. Gondolesi

Stevan Gonzalez

David J. Goodman Simin Goral Vijay Gorantla Masafumi Goto Mitsukazu Gotoh Daniel Gotthardt David Gottlieb Amit Govil

David M. Gracey Darla K. Granger Dale L. Greiner Shane T. Grey Matthew Griffin Paul C. Grimm

H. Albin Gritsch Paolo A. Grossi

Josep Grinyo

Rainer W.G. Gruessner Christina Guerra Lluis Guirado Perich Sandeep Guleria Susan Gunderson

Sanjeev Gupta Jongwon Ha Mark Haas

Bernadette Haase-Kromwijk Mehmet Haberal Wayne W. Hancock

Douglas W. Hanto

Mark A. Hardy Abdolreza Haririan William E. Harmon Tomonori Hasegawa Koji Hashimoto

Koji Hashimoto Wayne J. Hawthorne Ilkka Helantera Roberto Hernandez-

Alejandro

Maria Hernandez-Fuentes

J. Ignacio Herrero
Dennis Hesselink
Luis G. Hidalgo
Jonathan Hind
Hallvard Holdaas
Rhonda Holdsworth
Christer Holmberg
Mark Holmes
Johnny C. Hong
Simon Horslen
See Ming Simon Hou

Jean-Michel Hougardy

Dieter Hover Michael Hsin Luis Ibanez Hirohito Ichii Naotsugu Ichimaru Francesco Ierino Suzanne Ildstad Ashlev Bruce Irish Hideki Ishida Michael Ison Fadi Issa Naim Issa Neal Iwakoshi Daiki Iwami Annette Jackson Nichon N.E. Jansen Alan G. Jardine Emilia Jaskula Vivekanand Jha Haofeng Ji Ina Jochmans Sven Jonas Dong Jin Joo Stanley C. Jordan

Michelle Josephson Kusum Joshi Annemarie Kaan Joseph Kahwaji Fady Kaldas

Igal Kam Nassim Kamar Raia Kandaswamy John Kanellis Mureo Kasahara Bertram L. Kasiske Christina Kaufman Dixon B. Kaufman Lori M. Kautzman Tatsuo Kawai Liise Kayler **Brendan Keating** 

Andrew P. Keaveny Takashi Kenmochi Sean Kennedy Ronald Kerman Jesper Kers Viiav Kher Kiran Khush Bryce Alan Kiberd Richard Kirk

John R. Klinck Richard J. Knight Simon Knight Gregory Alan Knoll Takaaki Kobayashi Martina Koch Jenny Koo

Wouter Kopp

Günter Kirste

Beverly Kosmach-Park

Katia Kotsch Sradha Kotwal Maria Koulmanda Tomasz Kozlowski Bernhard Krämer Sheri Krams Edward S. Kraus Daniel Kreisel Aleksandra Kukla Deepali Kumar Vineeta Kumar Martin Kumnia Vivek Kute Dirk Kuypers

Janette Kwok

Choon Hyuck David Kwon Keren Ladin Jennifer C. Lai John Lake Fadi G. Lakkis

David Landsberg Ali Asghar A. Lanewala

Audrev Lau

Irmeli Lautenschlager Yvon Lebranchu Nicolae Leca

John Lee Seuna Duk Lee SungGyu Lee Mary S. Leffell Debra Lefkowitz Leslie Lehmann Alan B. Leichtman Maria Crespo Leiro Phillippe Lemaitre Francine Lemos

Karl Lemstrom Henri G.D. Leuvenink Joseph Leventhal Eric Levesque David Levi Megan Levings Garv Levv Marlon F. Levy Xian C. Li

Kieron Lim Wai Lim Per Liungman

Marc Llordella Martinez

Stanley H.K. Lo Jayme E. Locke Giovanna Lombardi Marcos Lopez-Hovos

Lina Lu

Adisorn Lumpaopong

Xunrong Luo **Grant Luxton** Stephen V. Lynch Maggie Kam Man Ma Peter S. MacDonald Clarisse Machado Iain MacPhee Joren C. Madsen John C. Magee

Mitra Mahdavi-Mazdeh Jacques F.I.R. Malaise Jonathan Maltzman Daniel G. Maluf Nizam Mamode Alex Manara Martin Mangino

# **ABSTRACT** Reviewers

Roslyn B. Mannon
Oriol Manuel
Marti Manyalich
Hannah Maple
Pierre Marquet
Dominique E. Martin
Olivia M. Martinez
Jaume Martorell
Valeria Mas
Marco Masetti
Allan Massie
Steven Masson
David W. Mathes
Cal Matsumoto
Shinichi Matsumoto

Lisa McElroy Dianne McKay Jose Medina Pestana Bruno Meiser Edoardo Melilli

George V. Mazariegos

Solomon Menahem Michael Mengel Robert M. Merion J. Michael Millis Shuji Miyagawa Pranjal Modi Cyril Moers Martina Mogl

Saeed Mohammad Sumit Mohan Thalachallour Mohanakumar Muhammad M. Mohiuddin

Ernesto Molmenti Eduard Montanya Edna Montero Carolina Moore Deonna Moore

Luis E. Morales-Buenrostro José María Morales

Adrian E. Morelli

Francisco Moreso Mateos

Michele I. Morris Peter J. Morris Paul Morrissey Sherif Mossad Asha Moudgil Istvan Mucsi Thomas F. Muelle

Thomas F. Mueller Elmi M. Muller William R. Mulley David C. Mulligan Gerhard Mundinger Thangamani Muthukumar

Silvio Nadalin
Satish N. Nadig
Maarten Naesens
Abhijit Naik
Nader Najafian
Thomas A. Nakagawa
Atsunori Nakao
Michael A. Nalesnik
Brian J. Nankivell
Björn Nashan
Howard M. Nathan

Kyla Naylor James Neuberger Thomas Nevins Volker Nickeleit Peter William Nickerson

Claus Niemann Heiner Niemann Gertrude Nieuwenhuijs

Johan Nilsson

Alejandro Nino-Murcia Marina Noris Douglas J. Norman Grzegorz Nowak

Patrick Gerald O'Callaghan Philip J. O'Connell Kevin J. O'Connor John O'Grady Jacqueline G. O'Leary Jordi Cano Ochando

Jon Odorico Hideki Ohdan Mihai Oltean Nicholas Onaca Gabriel C. Oniscu Helen Opdam Gerhard Opelz

Federico Oppenheimer

Babak Orandi Giuseppe Orlando Susan Orloff Klearchos K. Papas

Lars Pape Chung-Gyu Park Julio Pascual Julie Pavlovic Thamara Perera Norberto Perico

## **ABSTRACT** Reviewers

Dana Perry Todd Pesavento Henrik Petrowsky Palmina Petruzzo Patrice Pfeiffenberger

Ligia Pierrotti Richard N. Pierson Helen Pilmore Sean Pinney Loris Pironi John D. Pirsch Henry Pleass Rutger J. Ploeg

**Andrew Posselt** 

Luciano Potena Raaj K. Praseedom Jutta Krista Preiksaitis

Jeffrey D. Punch Luis F. Quintana Cristiano Quintini Marion Rabant Hamid Rabb Lorraine Racusen Axel Rahmel

Angelique Ralph

Gurch Randhawa Parmjeet Singh Randhawa

Gopi Rangan Pandu Rao

Nathanael Raschzok Kadiyala Ravindra William D. Rawlinson

Gina R. Rayat

Raymund Razonable Kunam S. Reddy Elaine F. Reed Michael A. Rees Heinz Regele Tomas Reischig

John Renz

Alejandro Restrepo

Giuseppe Remuzzi

Jorge Reyes Mike Rickels Camillo Ricordi Robert Rieben Leonardo Riella Adele Rike-Shields Paul Viktor Ritschl Thomas Ritter Adibul Hasan Rizvi Paul Robertson Simon C. Robson Eduardo Rocha Bruno Roche Emilio Rodrigo James R. Rodrigue Christin Rogers Joseph Rogers

Darling Rojas-Canales Alvaro Rojas-Peña Charles B. Rosen Ana Rossi

Lionel Rostaing Ajda Rowshani

Prajej Ruangkanchanasetr

Phillip Ruiz

David Nicholas Rush

Tapani Ruutu David Sachs Behnam Sadeghi Kourosh Saeb-Parsy Junichiro Sageshima Faouzi Saliba

Mauro S. Sandrin Saigal Sanjiv Alfonso Santos Ruth Sapir-Pichhadze Minnie M. Sarwal Shigeru Satoh rantisek Saudek Deirdre Sawinski John D. Scandling

Peter Schemmer Francesco Paolo Schena Thomas Schiano

Janet Scheel

Thomas Schiano Stefan Schneeberger Constanze Schoenemann

Jesse Schold Bernd Schroeppel Henk Jan Schuurman Antonio Secchi

Daniel Seehofer Dorry Segev Joana Sellares Roig Markus Selzner Nazia Selzner Daniel Seron Martina Sester Faissal Shaheen Michael F.E. Shapiro

# **ABSTRACT** Reviewers

Ron Shapiro Fuad Shihab Rebecca Shilling Tsuyoshi Shimamura Sunil Shroff Mary Ann Simpson Rakesh Sindhi Ashwani Singal

Mary Ann Simpsor Rakesh Sindhi Ashwani Singal Jon Snyder Arvinder Soin Mario Solari Hans W. Sollinger Marijn Speeckaert

Carlo Sposito Jean-Paul Squifflet Titte R. Srinivas Jürg Steiger

Peter Stock Simone I. Strasser Robert J. Stratta Samuel Strober Kamal Sud Debra L. Sudan

Yasuhiko Sugawara Vasant Sumethkul Suchitra Sumitran-

Holgersson
Caner Süsal
Stuart Sweet
Megan Sykes
Jeffrey Szer
David Taber
Brian Duncan Tait
Shiro Takahara
Anat R. Tambur

Carmela D. Tan Kazunari Tanabe Timucin Taner Bekir Tanriover

Ban Hock Tan

Helen Te Nicole Theodoropoulos Julie A. Thompson

Angus W. Thomson Raphael Thuillier Lee Anne Tibbles Kathryn Tinckam Allison Tong

Matthew Kwok Lung Tong

Burkhard Tönshoff
Juan Ambros Torras

Armando Torres Christian Toso Chutwichai Tovikkai Roberto Troisi

Richard Trompeter Christoph Troppmann

Pavel Trunecka Donald Tsai Ray Tsai

Bernard E. Tuch Gunnar Tufveson Stefan G. Tullius Nicole Turgeon Heth Turnquist Andreas G. Tzakis

Andreas G. Tzakis Ifeoma Ulasi Simon Urschel Parsia A. Vagefi Claire M. Vajdic Anna Valujskikh Kristof Van Assche

Marcel R.M. van den Brink J. A. Van der Vliet

H. van Goor Bernard van Hove Cees van Kooten Steven Van Laecke Dirk van Raemdonck

Robert Venick Stijn Verleden Richard Viebahn Denis Viglietti Ondrej Viklicky Flavio Vincenti Robin Vos Rowan G. Walker

Haibo Wang Wei Wang Andreas Wannhoff Angela Webster

Lori J. West Chi Fong Wong Kazuhiko Yamada Alvin Lerrmann Young Kimberly Young

Kimberiy Young Mirza Naqi Zafar

## ■ TTS Young Investigator Scientific Awards

The Transplantation Society is pleased to announce the recipients of the 2016 Young Investigator Scientific Awards. The awards will be presented in conjunction with the President's Plenary on Monday, August 22, from 10:30 to 12:30.

Look for the winners.



in the program, which identifies the award

#### Penelope Allen, Australia

550.3 THE IMPACT OF RECURRENT GLOMERULONEPHRITIS
AFTER KIDNEY TRANSPLANTATION IN THE ERA OF
CONTEMPORARY MAINTENANCE
IMMUNOSUPPRESSION

#### Vaishnavi Calisa, Australia

453.1 THE RELATIVE COSTS AND HEALTH BENEFITS OF AN AGE-MATCHED DECEASED DONOR ALLOCATION ALGORITHM COMPARED TO CURRENT PRACTICE

#### **Aravind Cherukuri, United States**

358.2 EARLY DE NOVO DSA WITH T CELL MEDIATED
REJECTION (TCMR) IS ASSOCIATED WITH ALLOGRAFT
DYSFUNCTION WITH CHRONIC INJURY

#### **Jason Davis, United States**

329.8 CHANGES IN LIVER ALLOGRAFT STEATOSIS AND ITS IMPACT ON EARLY GRAFT FUNCTION AND LONG TERM SURVIVAL

#### **Denis Efimov, Belarus**

355.2 DAMP-ASSOCIATED PRESERVATION INJURY AND COMPLICATIONS AFTER LIVER TRANSPLANTATION: PROOF OF CONCEPT

#### Shaimaa Elkholy, Egypt

425.6 PREDICTORS OF MORTALITY IN LIVING DONOR LIVER TRANSPLANTATION

#### **Jianing Fu, United States**

451.5 GENERATION OF NAÏVE DONOR-DERIVED LYMPHOCYTES FROM GRAFT-RESIDENT LYMPHOID PROGENITORS AFTER HUMAN INTESTINAL TRANSPLANTATION

#### Barbara Kern, Austria

329.13 NONALCOHOLIC STEATOHEPATITIS AS INDICATION FOR LIVER TRANSPLANTATION IN EUROPE. CLINICAL ANALYSIS OF OVER 37.000 PATIENTS.

#### **Qiang Liu, United States**

322.1 TRIGLYCERIDE EXPORTATION IN THE PRESERVATION
OF DISCARDED STEATOTIC HUMAN LIVERS USING 24
HOURS EX-VIVO NORMOTHERMIC MACHINE
PERFUSION

#### **David Nasralla, United Kingdom**

355.1 A MULTICENTRE RANDOMISED CONTROLLED TRIAL TO COMPARE THE EFFICACY OF NORMOTHERMIC MACHINE PERFUSION WITH STATIC COLD STORAGE IN HUMAN LIVER TRANSPLANTATION: EARLY OUTCOMES

#### Kevin Tak-Pan Ng, Hong Kong SAR, P.R. of China

625.2 UP-REGULATION OF GSTA2 AT EARLY-PHASE AFTER LIVER TRANSPLANTATION INCREASES THE RISK OF LATE-PHASE HEPATOCELLULAR CARCINOMA RECURRENCE

#### **Thomas Schachtner, Germany**

424.1 KINETICS OF CMV-SPECIFIC T-CELLS FROM PRE-TO-POSTTRANSPLANTATION PREDICT OUTCOMES IN CMV-SERONEGATIVE KIDNEY TRANSPLANT RECIPIENTS

#### Oscar Serrano, United States

422.1 DEFINING THE TIPPING POINT IN SURGICAL PERFORMANCE IN LAPAROSCOPIC DONOR NEPHRECTOMY DURING ABDOMINAL TRANSPLANT SURGERY FELLOWSHIP: A LEARNING CURVE ANALYSIS

#### Rashmi Shingde, Australia

550.4 TROJAN KIDNEYS: UNEXPECTED DONOR-DERIVED VIRAL TRANSMISSION IN KIDNEY TRANSPLANT RECIPIENTS – A SYSTEMATIC REVIEW

#### **Umang Thakkar, India**

456.9 STEM CELL THERAPY AS AN EMERGING MODALITY FOR POST-TRAUMATIC PARAPLEGIA AND FOR RENAL PARENCHYMAL DISEASES

#### Mirjam Tielen, The Netherlands

626.3 IMPORTANCE OF EARLY MEDICATION ADHERENCE FOR LONG-TERM GRAFT SURVIVAL: A PROSPECTIVE, SINGLE-CENTRE COHORT STUDY

#### Thomas Vanhove, Belgium

556.2 TUBULOINTERSTITIAL EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR IN RENAL ALLOGRAFT PROTOCOL BIOPSIES AT 3 MONTHS PREDICTS INTERSTITIAL FIBROSIS AT 5 YEARS

#### **Georgios Vrakas, United Kingdom**

451.6 DE NOVO DONOR-SPECIFIC HLA ANTIBODIES AFTER COMBINED INTESTINAL AND VASCULARIZED COMPOSITE ALLOTRANSPLANTATION

#### **Johannes Wedel, United States**

427.2 DEPTOR MODULATES ALLOIMMUNITY BY
INCREASING REGULATORY T CELL FUNCTION AND
STABILIZING FOXP3 EXPRESSION

#### Cheng Yang, People's Republic of China

428.3 CYCLIC HELIX B PEPTIDE INHIBITS ISCHEMIA
REPERFUSION-INDUCED RENAL FIBROSIS VIA THE
PI3K/AKT/FOXO3A PATHWAY

#### Wai Ho Oscar Yeung, Hong Kong SAR, P.R. of China

625.1 DYSREGULATION OF TRANSFORMING GROWTH
FACTOR BETA RECEPTOR III INDUCES TUMOR
PROMOTING MACROPHAGES VIA COMPLEMENT C3A
IN HEPATOCELLULAR CARCINOMA RECURRENCE
AFTER LIVER TRANSPLANTATION

# 2016 International Transplantation Science Mentee-Mentor Awards



The Transplantation Society (TTS) along with the collaboration of its Affiliated Societies celebrates the contributions of basic science to the field of transplantation with the International Transplantation Science Mentee-Mentor Awards by recognizing the efforts of basic scientists who have advanced our understanding transplant science/immunobiology and/or treatment of transplant recipients, and the young investigators who will be the future leaders in transplantation.

The Awards will be given on Sunday, August 21, during the International Transplantation Science Mentee-Mentor Networking Event to be held from 18:30 to 19:30 in the Convention Hall A - Level 1 (attendance by invitation only).

#### **TTS-CST AWARD**



This award was made possible with the contribution of the Canadian Society of Transplantation (CST).

#### Minal Borkar, Canada – Mentee Lori J. West – Mentor

550.1 PROSPECTIVE TREATMENT AND NOVEL BIOMARKERS OF BK POLYOMAVIRUS ASSOCIATED NEPHROPATHY

#### **TTS-DTG AWARDS**



These awards were made possible with the contribution of the Deutsche Transplantationsgesellschaft (DTG).

#### Midas Seyda, Germany – Mentee Stefan G. Tullius – Mentor

357.1 CELL-FREE MITOCHONDRIAL DNA ACTIVATES DCS IN AN AGE-DEPENDENT FASHION AND COMPROMISES THE SURVIVAL OF OLDER GRAFTS

#### Markus Quante, United States – Mentee Stefan G. Tullius – Mentor

427.7 METABOLITES ASSOCIATED WITH BARIATRIC SURGERY REVERSE ACCELERATED REJECTION AND AUGMENTED ALLOIMMUNITY IN OBESE ALLOGRAFT RECIPIENTS

#### **TTS-ISOT AWARDS**



These awards were made possible with the contribution of the Indian Society of Organ Transplantation (ISOT).

#### Vivek Kute, India – Mentee Pankaj R. Shah – Mentor

422.10 IMPACT OF SINGLE CENTRE KIDNEY PAIRED
DONATION TRANSPLANTATION TO INCREASE DONOR
POOL IN INDIA

#### Brijesh Yadav, India – Mentee Narayan Prasad – Mentor

427.1 IMBALANCE OF T HELPER 17 CELLS AND T
REGULATORY CELLS IS ASSOCIATED WITH CHRONIC
ACTIVE ANTIBODY MEDIATED REJECTION IN RENAL
ALLOGRAFT RECIPIENTS

#### Sailaja Kesiraju, India – Mentee Sahariah Sarbeshwar – Mentor

556.8 PERIPHERAL NK-CELL REPERTOIRE DISTRIBUTION IN CHRONIC ALLOGRAFT DYSFUNCTION AFTER RENAL TRANSPI ANTATION

#### Shailesh Raval, India – Mentee Vijay Gorantla – Mentor

624.2 ULTRA-HIGH RESOLUTION NON-CONTRAST IMAGING FOR CHRONIC REJECTION MONITORING AND PROCEDURAL PLANNING IN RECONSTRUCTIVE TRANSPLANTATION

#### Sonia Mehotra, India – Mentee RajKumar Sharma – Mentor

P.1053 DEVELOPMENT OF DE-NOVO DONOR SPECIFIC
ANTIBODY (DSA) AND VITAMIN D STATUS AFTER
RENAL TRANSPLANTATION

#### **TTS-JST AWARDS**



These awards were made possible with the contribution of the Japan Society for Transplantation (JST).

#### Kazuhiro Taguchi , Japan - Mentee Takashi Onoe – Mentor

451.2 CLINICAL AND IMMUNOLOGICAL SIGNIFICANCE OF CONTROLLING PORTAL VEIN PRESSURE IN LIVING DONOR LIVER TRANSPLANTATION

#### Songjie Cai, Japan - Mentee Shiro Takahara – Mentor

457.2 SYSTEMIC THERAPY OF REGULATORY DENDRITIC
CELLS DERIVED FORM INDUCED PLURIPOTENT STEM
CELLS ALLOWS ALLOGENEIC CARDIAC GRAFTS
ACCEPTANCE

#### Hiroshi Sakai, Japan - Mentee Yuka Tanaka – Mentor

628.3 VARIOUS PATHOGENIC MICROBES INDUCE CNI-RESISTANCE IN B-CELLS RESPONDING TO BLOOD GROUP ANTIGENS THROUGH TI R-MYD88 PATHWAY

#### **TTS-NTV AWARD**



This award was made possible with the contribution of the Nederlandse Transplantatie Vereniging (NTV).

#### Gretchen de Graav, Netherlands - Mentee Carla Baan – Mentor

427.6 BELATACEPT FAILS TO INHIBIT DONOR-REACTIVE
TFH-B CELL INTERACTION, BUT FAVORS A
REGULATORY TRANSITIONAL B CELL PROFILE OVER
TACROLIMUS

#### **TTS-SFT AWARD**



This award was made possible with the contribution of the Société Française de Transplantation (SFT).

#### Séverine Bézie, France - Mentee Carole Guillonneau – Mentor

356.3 INTERLEUKIN-34 IS A TREG-SPECIFIC CYTOKINE AND MEDIATES TRANSPI ANT TOI FRANCE

#### **TTS-SMT AWARD**



This award was made possible with the contribution of the Sociedad Mexicana de Trasplantes (SMT).

#### José Manuel Arreola Guerra, Mexico - Mentee Luis Eduardo Morales Buenrostro – Mentor

323.2 PRE-TRANSPLANT AT1RABS ARE ASSOCIATED WITH ACUTE REJECTION IN 2-HAPLOTYPES KIDNEY TRANSPLANT RECIPIENTS

#### TTS-TSANZ AWARDS



These awards were made possible with the contribution of the Transplantation Society of Australia and New Zealand (TSANZ).

#### Sebastian Olivier Stead, Australia - Mentee Patrick Coates – Mentor

428.8 DENDRITIC CELL PHENOTYPE AND FUNCTION MODIFICATION WITH TARGETED POROUS SILICON NANOPARTICLES

#### Anjan Bongoni, Australia - Mentee Peter Cowan – Mentor

429.9 SURFACE MODIFICATION OF PORCINE AORTIC ENDOTHELIAL CELLS WITH CORLINE HEPARIN CONJUGATE (CHC) PROTECTS AGAINST XENOGENEIC THROMBOSIS AND INFLAMMATION

#### Imogen Thomson, Australia - Mentee Angela C. Webster – Mentor

552.9 RISKY ORGANS: TRENDS IN COMORBIDITIES AMONG POTENTIAL AND ACTUAL AUSTRALIAN ORGAN DONORS IN NEW SOUTH WALES

#### Moumita Paul-Heng, Australia - Mentee Alexandra Sharland – Mentor

628.6 DISRUPTION OF CD8-CORECEPTOR BINDING
ABROGATES TOLERANCE INDUCTION VIA LIVERDIRECTED EXPRESSION OF DONOR MHC CLASS I

#### **TTS AWARDS**



These awards were made possible with the contribution of The Transplantation Society (TTS).

#### Jiang Liu, Hong Kong - Mentee Chung Mau Lo – Mentor

357.8 AMP-ACTIVATED PROTEIN KINASE ATTENUATED MARGINAL LIVER GRAFT INJURY VIA PROMOTING MITOCHONDRIAL BIOGENESIS AND RESPIRATORY FUNCTION

#### Rebeca Arroyo Hornero, United Kingdom - Mentee Kathryn Wood – Mentor

456.2 CD45RA IDENTIFIES TSDR DEMETHYLATED
REGULATORY T CELLS WITH A STABLE PHENOTYPE
AND SUPPRESSIVE CYTOKINE PROFILE

#### Sai Vineela Bontha, United States - Mentee Valeria Mas – Mentor

556.3 EFFECT OF EPIGENETIC MODIFICATIONS IN GRAFT KIDNEYS PROGRESSING TO CHRONIC ALLOGRAFT DYSFUNCTION

#### Xiang Qi, Hong Kong - Mentee Nancy Kwan Man – Mentor

625.4 THE CLINICAL SIGNIFICANCE AND POTENTIAL THERAPEUTIC ROLE OF GPX3 IN TUMOR RECURRENCE AFTER LIVER TRANSPLANTATION

#### Chien-Chia Chen, France - Mentee Olivier Thaunat – Mentor

628.5 VASCULAR SEQUESTRATION OF DONOR-SPECIFIC ANTIBODIES PROTECTS ALLOGENEIC ISLETS FROM HUMORAL REJECTION

#### Joshua Chan, United States - Mentee Muhammad Mohiuddin - Mentor

629.8 HUMAN ANTI THROMBOTIC GENES DO NOT OBVIATE
THE NEED FOR ANTICOAGULATION IN AIDING LONG
TERM XENOGRAFT SURVIVAL



#### THE ISN-TTS SISTER TRANSPLANT CENTER PROGRAM

is a new joint partnership between the International Society of Nephrology (ISN) and The Transplantation Society (TTS) to create new kidney transplant centers and develop existing kidney transplant programs in emerging countries. This initiative encourages transplant centers to work together to increase opportunities for kidney transplant patients in developing countries. An experienced transplant center in the developed world lends its support to an emerging transplant center to facilitate vital multidisciplinary training and encourage both centers to exchange their knowledge and expertise. www.theisn.org/programs/sister-transplant-centers-program



#### ■ Venue




香 港 會 議 展 覽 中 心 Hong Kong Convention and Exhibition Centre 1 Expo Drive, Wanchai, Hong Kong, SAR, P.R. of China

Framed by Hong Kong's stunning skyline, the Hong Kong Convention and Exhibition Centre (HKCEC) is a magnificent multi-purpose venue located right in the heart of Hong Kong on Victoria Harbour.




The brilliant glass structure, which extends into the harbour, is designed to resemble a bird soaring into flight. The HKCEC is one of the largest multi-use venues in Asia and continues to be a globally recognised landmark complimenting Hong Kong's cityscape. Not only does the harbour location provide a spectacular backdrop to the proceedings, but it also means Hong Kong's Central Business District, along with the best of this vibrant, colourful city, is at the Centre's doorstep. The HKCEC is also connected to two world-class hotels, and within walking distance to nearly 6,000 hotel rooms.




- Post-Graduate Course Rooms
- Session Rooms:


Theatre 1 & 2 Convention Hall A/B/C




# LEVEL 1 DETAIL




# GROUND FLOOR DETAIL






This level not in use during the TTS 2016 Congress





This level not in use during the TTS 2016 Congress




- Session Room S221
- Speaker Ready Room
- Meeting Rooms
- Offices

# LEVEL 2 DETAIL





- Registration
- Plenary Room: Hall 5BC
- Session Rooms:
   Hall 5D
   Hall 5E1/5E2/5E3
- Exhibit Area
   Campfires & Poster Sessions



All TTS 2016 events will take place in the Hong Kong Convention and Exhibition Centre (HKCEC) unless otherwise noted.

## Operating Hours - Services

#### **REGISTRATION (LEVEL 1 & 5)**

Registration for the Post-Graduate Course (PGC) will be located on Level 1 and registration for the Congress on Level 5 at the following opening hours.

Date	Time	Location
Wednesday, Aug 17	15:00-19:00	Conv. Foyer - L1 (PGC)
Thursday, Aug 18	07:00-17:00	Conv. Foyer - L1 (PGC)
Friday, Aug 19	07:30-17:30	Conv. Foyer - L1 (PGC)
Friday, Aug 19	07:30-19:00	Hall 5FG - L5 (Congress)
Saturday, Aug 20	06:30-18:00	Hall 5FG - L5
Sunday, Aug 21	06:30-18:00	Hall 5FG - L5
Monday, Aug 22	06:30-18:00	Hall 5FG - L5
Tuesday, Aug 23	06:30-13:30	Hall 5E S. Concourse - L5

#### **DELEGATE SERVICES AREA (LEVEL 5)**

Housing, Information Desk, Media Accreditation, and Airline Boarding Pass Self-Printing Station on August 22-23 (Hall 5E South Concourse - Level 5)

Date	Time
Friday, Aug 19	12:00-19:00
Saturday, Aug 20	10:00*-18:00
Sunday, Aug 21	10:00*-18:00
Monday, Aug 22	10:00*-19:00
Tuesday, Aug 23	06:30**-13:30

<sup>\*</sup>Media desk will open at 08:00

<sup>\*\*</sup>Housing desk will open at 08:30

#### **SPEAKER READY ROOM (ROOM S223 - LEVEL 2)**

Date	Time
Wednesday, Aug 17	15:00-19:00
Thursday, Aug 18	07:00-17:00
Friday, Aug 19	07:30-19:00
Saturday, Aug 20	06:00-18:30
Sunday, Aug 21	06:30-18:30
Monday, Aug 22	06:30-18:00
Tuesday Aug 23	06:30-13:30

#### **EXHIBIT HALL (HALL 5FG - LEVEL 5)**

Date	Time
Friday, Aug 19	18:30-20:00
Saturday, Aug 20	09:30-18:30
Sunday, Aug 21	09:30-18:30
Monday, Aug 22	09:30-19:00

#### **TECHNOLOGY CENTRE (HALL 5FG - LEVEL 5)**

Date	Time
Friday, Aug 19	18:30-20:00
Saturday, Aug 20	09:30-18:30
Sunday, Aug 21	09:30-18:30
Monday, Aug 22	09:30-19:00

#### YOUNG INVESTIGATORS' LOUNGE (HALL 5FG - LEVEL 5)

Date	Time
Friday, Aug 19	18:30-20:00
Saturday, Aug 20	09:30-18:30
Sunday, Aug 21	09:30-18:30
Monday, Aug 22	09:30-19:00

#### **MOBILE FOOD CONCESSION (HALL 5FG - LEVEL 5)**

Date	Time
Saturday, Aug 20	09:30-15:30
Sunday, Aug 21	09:30-15:30
Monday, Aug 22	09:30-15:30

### **COAT CHECK (ROOM V104 - LEVEL 1)**

Date	Time
Thursday, Aug 18	07:30-17:30
Friday, Aug 19	07:30-20:30
Saturday, Aug 20	06:30-18:30
Sunday, Aug 21	06:30-18:30
Monday, Aug 22	06:30-19:30
Tuesday, Aug 23	06:30-14:00

#### PRESS ROOM (G112 - LEVEL 1)

• • • • • • • • • • • • • • • • • • • •	•	
Date	Time	
Friday, Aug 19	15:00-19:00	
Saturday, Aug 20	08:00-18:00	
Sunday, Aug 21	08:00-18:00	
Monday, Aug 22	08:00-18:00	
Tuesday, Aug 23	08:00-13:30	

## ■ Program Schedule

#### **POST-GRADUATE COURSES**

Please refer to the Detailed Program for room locations - Level 1

	3	
Date	Time	
Thursday, Aug 18	08:30-17:30	
Friday, Aug 19	08:30-17:30	

#### **OPENING CEREMONY (HALL 5BC - LEVEL 5)**

Date	Time
Friday, Aug 19	17:30-18:30

#### **PLENARY SESSIONS**

Date	Time	Location
Saturday, Aug 20	08:30-10:00	Hall 5BC – Level 5
Sunday, Aug 21	08:30-10:00	Hall 5BC – Level 5
Monday, Aug 22	08:30-10:00 10:30-12:30	Hall 5BC – Level 5 Hall 5BC – Level 5
Tuesday, Aug 23	08:30-10:00	Hall 5E3 – Level 5

#### **EARLY MORNING SYMPOSIA**

Date	Time
Please refer to the D	Detailed Program for room locations
Saturday, Aug 20	07:00-08:15
Sunday, Aug 21	07:00-08:15
Monday, Aug 22	07:00-08:15
Tuesday, Aug 23	07:00-08:15

#### **ORAL AND MINI-ORAL SESSIONS**

Date	Time
Please refer to the D	Detailed Program for room locations
Saturday, Aug 20	10:30-12:30 15:30-17:00
Sunday, Aug 21	10:30-12:30 15:30-17:00
Monday, Aug 22	15:30-17:00
Tuesday Aug 23	10.30-12.00

#### **INDUSTRY SYMPOSIA (HALL 5E3-LEVEL 5)**

Date	Time
Saturday, Aug 20	12:30-13:30 17:30-19:00
Sunday, Aug 21	12:30-13:30
Monday, Aug 22	12:30-13:30

#### **CAMPFIRES & POSTER SESSIONS (HALL 5FG - LEVEL 5)**

Date	Time
Saturday, Aug 20	17:00-18:30
Sunday, Aug 21	17:00-18:30
Monday, Aug 22	18:00-19:00

#### **CLOSING CEREMONY (HALL 5E3 - LEVEL 5)**

Date	Time
Tuesday, Aug 23	13:00-13:30

## **■** Events Schedule

#### **WELCOME RECEPTION (HALL 5FG - LEVEL 5)**

Open to all Congress registrants

Date	Time	
Friday, Aug 19	18:30-20:00	

#### WIT NETWORKING EVENT (THEATRE 2 - LEVEL 1)

Open to all Congress registrants - by pre-registration

Date	Time
Saturday, Aug 20	17:00-19:00

#### YOUNG INVESTIGATORS' NETWORKING EVENT

Ticket required

**OFFSITE:** The Pawn, 62 Johnston Road Wan Chai, Hong Kong

Date	Time
Saturday, Aug 20	19:30-21:30

# INTERNATIONAL TRANSPLANTATION SCIENCE MENTEE-MENTOR AWARDS NETWORKING EVENT

By invitation - see page 72 for details

Date	Time	Location
Sunday, Aug 21	18:30-19:30	Convention Foyer-Level 1

#### **CONGRESS NETWORKING EVENING**

Ticket required

**OFFSITE:** Jumbo Kingdom Floating Restaurant

Date	Time
Monday, Aug 22	19:00-22:00
(Coaches depart @ 18	3:30 from HKCEC)

## ■ Use of Name Badge

For security and regulation purposes, all attendees are required to wear their name badge at all times during the Congress in order to participate in the Scientific Sessions, Social Events, and Exhibit Area.

Badge swapping is strictly prohibited.

#### **BADGE COLOUR IDENTIFICATION**

**DELEGATE MEMBER & DELEGATE** 

**ORGANIZING COMMITTEE** 

TTS: EXECUTIVE / COUNCILLOR

**INVITED SPEAKER & CHAIR** 

**STAFF & VOLUNTEER** 

**POST-GRADUATE COURSE DELEGATE, SPEAKER & CHAIR** 

**SPONSOR** 

**EXHIBITOR** 

**GUEST** 

**ACCOMPANYING PERSON** 

**MEDIA** 

#### **LOST BADGES**

In the event of a lost or forgotten badge, an administrative fee of \$25 USD will be charged for the reprinting of the badge after verification of identification (passport, driving license, or other recognised identification paper).

#### Abstracts Publication

All abstract presentations (oral, mini-oral, campfire and poster) listed in the program have been assigned consecutive program numbers. This number corresponds to the number of the abstract that can be viewed online on the Congress Web App and in the online supplement of the *Transplantation* Journal published in July 2016.

The free online version of *Transplantation* can be accessed at the the following url:

#### journals.lww.com/transplantjournal/toc/2016/07001

(click on the FREE-PDF), or via the publishers' homepage at www.transplantjournal.com.

## ■ Web Recordings and Live Broadcasting

All registered attendees will have the chance to view the Congress Session recordings online through the TTS website for up to a year after the Congress.

Only presentations for which we received pre-authorization from the presenter will be available online for viewing.





Sponsored by



# Free Access to Congress Delegates and TTS Members

We anticipate the majority of the presentations from TTS 2016 will be available to view from any device.

# **Access available at:**

http://tts.guide • Congress Delegates www.tts.org • TTS Members

# Available as of September 1!



# Our Free Plenaries Livecast



Sponsored by



# Tell your colleagues!

- Livecasts are open to all transplant professionals.
  - Chat with other online attendees and submit questions to the session chairs.
    - Missed a session? Watch recordings of the livecast with "On-Air Rewind".
    - · While online visit the "Roche Virtual Booth".

# Sign up today http://onair.tts.org



#### Presenter Guidelines

Post-Graduate Course, Plenary, Early Morning Symposium, SOTA, Oral, Mini-Oral, and Campfire presentations:

The Speaker Ready Room is located on Level 2 of the Hong Kong Convention and Exhibition Centre (Room S-223). Presenters MUST review their presentation in the Speaker Ready Room at least 3 hours prior to their scheduled presentation. The Room will be staffed with technicians who can assist with any compatibility or formatting issues. Presenters with video MUST come the day before in order to run through the media file with a technician.

#### **HOURS OF OPERATION (S-223):**

Date	Time
Wednesday, Aug 17	15:00-19:00
Thursday, Aug 18	07:00-17:00
Friday, Aug 19	07:30-19:00
Saturday, Aug 20	06:00-18:30
Sunday, Aug 21	06:30-18:30
Monday, Aug 22	06:30-18:00
Tuesday, Aug 23	06:30-13:30

All downloads and changes to your presentations will need to be done in advance at the Speaker Ready Room. The meeting rooms will not be equipped with the app to submit a presentation at the podium. Therefore, no laptop or USB device will be accepted in the meeting rooms.

#### ■ Poster Sessions

Posters will be available for attendees to view during the day from August 20 at 12:30 until August 22 at 19:00 in the Exhibit Area, Hall 5FG-Level 5.

The poster presenters are required to be available for questions only during the three Poster Sessions noted below.

Date	Time
Saturday, Aug 20	17:00-18:30
Sunday, Aug 21	17:00-18:30
Monday, Aug 22	18:00-19:00

## ■ Continuing Medical Education (ACCME)

#### **ACCREDITATION STATEMENT**

The Transplantation Society (TTS) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### **CREDIT DESIGNATION STATEMENT**

TTS designates this live activity for a maximum of 41.50 AMA PRA Category 1 Credit(s)™ (14 hours for the Post-Graduate Course and 27.50 hours for the Congress). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All social events, industry symposia, poster sessions, campfire sessions, opening ceremony, President's plenary, and closing ceremony do not qualify for CME accreditation.

#### TO CLAIM YOUR CME CERTIFICATE....

Simply go to the www.tts.cmecertificateonline.com, click on the "26th International Congress of TTS" and complete the evaluation. A certificate will be made available after the evaluation. Do not forget to print your certificate at the end of the process.

#### **IMPORTANT!**

The online certificate site will only be available until **October 28, 2016.** After that date, the site will be removed and certificates will no longer be available. If you need a CME certificate, you must complete the evaluation and certification process prior to this date, otherwise you will forfeit your credit for the Congress.

#### DISCLOSURE OF CONFLICT OF INTEREST

The disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content of CME disclosed to The Transplantation Society. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1—6.2, 6.5). See the registration desk for the complete list of disclosures.

## Continuing Medical Education in Hong Kong (CME-CNE)

#### **CME FOR DOCTORS**

Doctors from Hong Kong can be accredited by CME points from the medical colleges. Details are posted on the TTS 2016 Congress Website under the program section.

If Hong Kong delegates wish to obtain CME points, please signify your attendance DAILY at the designated area of the Registration Desk.

#### **CNE FOR NURSES**

CNE points would be accredited by The Hong Kong Society of Transplantation (HKST). HKST is accredited as a provider of CNE points by the Nursing Council of Hong Kong. Details are posted on the TTS 2016 Congress Website.

If Hong Kong nurses wish to obtain CNE points, they must complete the Evaluation Form provided at the designated Registration Desk and return it to the same Registration Desk by August 23.

A Certificate of Attendance will be emailed to the nurses by HKST after the Congress.

## ■ Congress Evaluation

A Congress evaluation form will be distributed during the Plenary Sessions on Monday, August 22. Please complete and return the form to the Registration Desk at the end of that day or at the very latest by the Closing Ceremony on August 23.

An electronic version will be available on-site. The address will be listed in the sessions' opening slides.

Please note that all attendees will also receive a follow-up questionnaire this fall and that your feedback would be greatly appreciated.

#### On-site Services

#### **DELEGATE SERVICES AREA**

Located on the Hall 5E South Concourse, the Delegate Services Area will be dedicated to ensuring TTS 2016 Congress participants fully enjoy their experience in Hong Kong. The Delegate Services Area features three dedicated counters:

- General Information: touristic information on Hong Kong, transportation, local attractions
- Media: press accreditation and communications
- Housing: ICC, TTS Official Housing Bureau, will be available on-site throughout the TTS 2016 Congress to assist participants with their hotel booking. A full map of the official hotels can be found on the back, inside cover of this program.
- A self-printing station to print your airline boarding pass will be made available on August 22 and 23.

#### The Delegate Services Area opening hours:

Date	Time
Friday, Aug 19	12:00-19:00
Saturday, Aug 20	10:00*-18:00
Sunday, Aug 21	10:00*-18:00
Monday, Aug 22	10:00*-19:00
Tuesday, Aug 23	06:30**-13:30

<sup>\*</sup>Media desk will open at 08:00

## ■ Cell Phones and Cameras

No cameras or video cameras are allowed at any event during the 26<sup>th</sup> International Congress of The Transplantation Society without proper authorizations from the meeting organizers. Continued use of any type of camera may result in your removal from the meeting venue. As a courtesy to fellow attendees, please silence cell phones during educational sessions.

Furthermore, exhibitors, their representatives, and participants will not perform or video capture any media-related interviews with any participants (delegates, staff, or exhibitors) of the Congress during the event, without written consent from the organizers. Request for permission to conduct media-related interviews may be obtained on-site at the Media Counter, located on Level 5 of the HKCEC, at the Delegate Services Area (Hall 5E South Concourse).

<sup>\*\*</sup> Housing desk will open at 08:30

#### Business Centre

Please note that there is no business centre per se at the HKCEC. Alternatively, photocopy and printing services are available at the HKCEC Information Counter at a small charge. The Information Counter is located on the Ground Floor of the HKCEC, next to the Harbour Road Café near the entrance of the facility.

## ■ Meals & Snacks, Coffee Breaks

Coffee breaks (coffee and tea only) will be served in the Exhibit Area (Hall 5FG - Level 5) at the following times:

Date	Time
Saturday, Aug 20	10:00-10:30 15:00-15:30
Sunday, Aug 21	10:00-10:30 15:00-15:30
Monday, Aug 22	10:00-10:30 15:00-15:30

Coffee will also be served for the Early Morning Symposia on August 20, 21, 22, and 23 in the Convention Foyer on Level 1.

The coffee break on Tuesday, August 23 will be served from 10:00-10:30 in the Hall 5E South Concourse.

The coffee breaks for the Post Graduate Courses will be served in the Convention Foyer, Level 1, at the following times:

Thursday, Aug 18	10:30-11:00 15:30-16:00
Friday, Aug 19	10:30-11:00 15:30-16:00

#### **MOBILE FOOD CONCESSION**

Note that no food will be served during the Congress. The TTS 2016 Congress is happy to offer its participants the option to conveniently purchase food items, such as snacks, pastries and sandwiches, within the Exhibit Area (Hall 5FG - Level 5). Enjoy a snack or your lunch while mingling with our exhibitors and sponsors, or catch up with colleagues, old and new, over a coffee.

#### **RESTAURANTS**

Hong Kong is a renowned culinary destination. Restaurants offering cuisine from all over the world and coffee shops are easily accessible outside of the HKCEC, within a 5-minute walk. The Information Desk located in the Delegate Services Area on Level 5 will have a list of restaurants and "Locals' picks" for your convenience.

## Multi Faith Prayer Rooms

The TTS 2016 Congress has dedicated spaces for delegates to use for contemplation or prayer. These quiet spaces are available for any religious or spiritual practice, and are separated by gender. Located on the Hall 5E South Concourse, these rooms are accessible throughout the duration of the Congress.

### Lost and Found

All lost and found property will be handed by the Registration Desk, located on Level 5 of the HKCEC.

## ■ Young Investigators' Lounge

Proudly supported by Roche, the Young Investigators' Lounge is located within the Exhibit Area (Hall 5FG – Level 5). It provides a quiet area for our younger attendees to mingle, take a break or even blow off some steam in a friendly foosball match. A board will be made available for institutions to post career opportunities.

## ■ Web App / On-site Technology

#### WiFi

The 26<sup>th</sup> International Congress of The Transplantation Society is pleased to offer complimentary WiFi access to all its delegates. Kindly select the network called "TTS2016" to enjoy wireless internet access throughout the venue.

#### **WEB APP**

The Transplantation Society is pleased to introduce its very own web app, developed especially for The 26<sup>th</sup> International Congress in Hong Kong. Featuring all the various sessions, complete with descriptions and speakers' biographies, the web app allows the Congress delegates to customize the Congress to their needs and schedule.

To have full functionality of the app, delegates must be logged in. Log-in details (user and password) were sent out to all registrants in a logistics email.

For further asistance visit the Technology Centre in the Exhibit Area, Hall 5FG – Level 5 of the HKCEC

Access the web app now! Go to tts.guide



### **CONGRESS** Information

### **TECHNOLOGY HELP DESK**

Our friendly and tech-savvy staff members will be happy to help Congress participants with technology-related questions and issues, including those concerning WiFi Access, the web app, or the online program. The Technology Help Desk is located in the Technology Centre in the Exhibit Area, Hall 5FG – Level 5 of the HKCEC.

### **TECHNOLOGY CENTRE**

Built around the Technology Help Desk, this lounge area will be equipped with charging stations and working desks for Congress delegates' use. The Technology Centre will also be the place to come and get information and assistance with the TTS 2016 Congress web app!

### ■ Affiliate Events

The following meetings are closed meetings, by invitation only.

■ Meeting of the Hong Kong Transplantation Societies: "Presentation of Best Abstracts from HK"

Date	Time	Location
Saturday, Aug 20	07:00-8:15	S-228, Level 2

### ■ SONG-Tx Consensus Workshop

Date	Time	Location
Saturday, Aug 20	12:00-14:00	S-228, Level 2

■ Living Donor Organ Transplantation in Asia (5th Vitallink International Workshop)

Date	Time	Location
Saturday, Aug 20	18:00-21:00	S-226, Level 2

■ Joint meeting of the Thai, Japanese, and Korean Transplantation Societies: "WHO Registry for Organ Coding & Traceability"

Date	Time	Location
Sunday, Aug 21	07:00-8:30	S-228, Level 2

### PLENARY: OPENING CEREMONY

Date	Time	Location
Friday, Aug 19	17:30-18:30	Hall 5BC-Level 5

### **OPEN TO ALL REGISTERED ATTENDEES**

### **NETWORKING EVENT: WELCOME RECEPTION**

Date	Time	Location
Friday, Aug 19	18:30-20:00	Hall 5FG-Level 5

### **OPEN TO ALL REGISTERED ATTENDEES**

Our local hosts from the Hong Kong Society of Transplantation and the Thai Transplantation Society will join our President, Dr. Philip O'Connell, and a Government official from the Hong Kong Special Administration Region, in order to officially welcome you to Hong Kong.

All participants are invited to attend the Opening Ceremony and enjoy traditional Hong Kong cultural performances; subsequently, please join the Welcome Reception in the Exhibit Hall to enjoy great food and drinks while networking with long-standing colleagues and new friends.



### WOMEN IN TRANSPLANTATION NETWORKING EVENT

### WOMEN in Transplantation on Initiative of The Transplantation Society

Date	Time	Location	
Saturday, Aug 20	17:00-19:00	Theatre 2-Level 1	_

### BY PRE-REGISTRATION ONLY

Join members of the Women in Transplantation initiative of TTS and other leaders in the field for a discussion about issues affecting women in the field of medicine as well as topics related to leadership development. This two-hour session will provide you with insight and tips from some of transplantation's top female leaders and researchers. A full program of lectures for this event will be updated in the coming weeks. The session will be followed by an opportunity to network with your peers during a light cocktail.

### YOUNG INVESTIGATORS NETWORKING EVENT

Date	Time	Location
Saturday, Aug 20	19:30-21:30	Offsite - The Pawn 62 Johnston Road Wan Chai, Hong Kong

### BY PRE-REGISTRATION ONLY - Ticketed Event (\$)

Students, Fellows and Trainees are welcome to an evening of networking, delicious food, drinks, music and good vibes. Proudly sponsored by Bridge to Life, this event will be held at The Pawn, a communal social venue for arts, design and innovative dining, located only a short walk away from the HKCEC. Don't miss your chance to mingle and learn from younger faculty who have begun successful careers, as well as a special presentation by a guest of honour which will be given over the course of the evening.



### INTERNATIONAL TRANSPLANTATION SCIENCE MENTEE-MENTOR AWARDS NETWORKING EVENT

Date	Time	Location
Sunday, Aug 21	18:30-19:30	Convention Hall A-Level 1

### BY INVITATION ONLY



The Transplantation Society, along with the collaboration of National and International Societies, celebrates the contributions of basic science to the field of transplantation with the International Transplantation Science Mentee-Mentor Travel Awards by recognizing the efforts of basic scientists, who have advanced our understanding of transplant science/immunobiology and/or treatment of transplant recipients, and the young investigators who will be the future leaders in transplantation.

### **CONGRESS NETWORKING EVENING**

Date	Time	Location
Monday, Aug 22	19:00-22:00	Offsite - Jumbo Kingdom Floating Restaurant Shum Wan Pier Dr., Aberdeen, Hong Kong

### BY PRE-REGISTRATION ONLY - Ticketed Event (\$)

\*We will sell tickets at the Registration Desk until Saturday, August 20 at 10:00.

TTS and the members of the Host Country Liaison Committee invite the participants of the 26<sup>th</sup> International Congress of The Transplantation Society to a unique evening under the theme 'Asian Market Place'. This will be held at the Jumbo Kingdom, an internationally renowned tourist attraction, ornated like an ancient Chinese palace.

Come and wander around in a Night Asian Market, the perfect place to network with colleagues from around the world, while enjoying food stalls and activities from different Asian countries! See why Hong Kong is called "the gateway to Asia" and get a taste of delicacies from our 2 host countries (Hong Kong and Thailand) as well as other Asian countries.

**Note:** Coach transportation will be provided and will depart between 18:30 and 19:00 from the Harbour Road entrance on the Ground Floor of the HKCEC.

### **CONGRESS CLOSING CEREMONY**

Date	Time	Location
Tuesday, Aug 23	13:00-13:30	Hall 5E3-Level 5

### **OPEN TO ALL REGISTERED ATTENDEES**

Closing Addresses will be given by Past-President Philip J. O'Connell from Australia, and by the new TTS President, Nancy Ascher from the United States. The Congress will close by a presentation of the TTS 2018 Congress in Madrid, Spain by the Congress Vice-Chair, José María Morales.



NOTES

### MORNING SESSIONS THURSDAY • AUGUST 18

Hall 5E2 - L5	08:30	10:30	11:00	13:00
Hall SE1 - LS				
Hall 5D-L5				
Hall 5BC - L5				
5-221 - 1.2	Satellite Meeting 08:30 to 18:00 10th Transplant Infectious Disease	Conference (TID 2016)	Not included in the TTS 2016 Congress or Post- Graduate Course	
Conv. Hall C-L1				
Conv. Hall B - L1	PGC The Beginning: Innate Immune System in Allorecognition (Basic Science)		PGC The Adaptive Immune System: T Cells (Basic Science)	
Theater 1 - L1 Theater 2 - L1 Conv. Hall A - L1 Conv. Hall B - L1 Conv. Hall C - L1		Coffee Break		Lunch Break
Theater 2 - L1				
Theater 1 - L1	<b>PGC</b> HLA and Antibodies (Clinical Science)		<b>PGC</b> (Clinical Science)	
	08:30	10:30	11:00	13:00

## **AFTERNOON SESSIONS** THURSDAY • AUGUST 18

14:00 15:30 16:00 Hall 5E2 - L5 Hall 5E1 - L5 Hall 5D-L5 Hall 5BC - L5 10th Transplant Infectious Disease Satellite Meeting 08:30 to 18:00 Congress or Post-Graduate Course Not included in the TTS 2016 Conference S-221 - L2 (TID 2016) Conv. Hall A - L1 | Conv. Hall B - L1 | Conv. Hall C - L1 Immune System: B Cells (Basic Science) Regulation of the Immune Response (Basic Science) The Adaptive 中國等官移植祭表基全會 In collaboration with Organ Tx in China ... Model in China The Brand-New... The New Era of **Coffee Break** Theater 2 - L1 Clinical Trials Design Part II Clinical Trials Design Part I Transplantation An Initiative of Pathology (Clinical Science) "Brave New World" Theater 1 - L1 (Clinical Science) 14:00 15:30 16:00



Chine Organ Transplantation Development Foundation



### POST-GRADUATE COURSE

Post-Graduate Courses (PGC) are scheduled on August 18 and 19, 2016 at the Hong Kong Convention and Exhibition Centre (HKCEC) on Level 1.

The Post-Graduate Courses program is designed specifically for medical professionals in training or for those in the early stages of their careers and is an excellent opportunity to obtain in-depth exposure to transplantation medicine. This year's PGC program offers sessions in both Clinical and Basic Science topics, in addition to specialty sessions on Clinical Trials, Organ Procurement in China, Pediatrics, Organ Donation, Transplant Nursing, Computational Immunology and a session by the World Transplant Games Federation.

Registration for the Post-Graduate Courses is required. These two-day courses are not included in the TTS 2016 Congress registration fees. On-site registration will be possible at the PGC Registration Desk located on Level 1 on August 17, 18, and 19.



### MORNING SESSIONS

08:30 - 10:30 THEATRE 1-LEVEL 1 CLINICAL SCIENCE

### **HLA** and Antibodies

Chairs: Vivekanand Jha, Chandigarh, India

Marcelo Cantarovich, Montreal, QC, Canada

100.1 TISSUE TYPING TECHNOLOGIES:
WHAT SHOULD A CLINICIAN AND
TRANSLATIONAL RESEARCHER KNOW?

Janette Kwok

Hong Kong SAR, P.R. of China

100.2 HOW CAN A SENSITIZED RECIPIENT GET AN ORGAN?

Kathryn Tinckam Toronto, ON, Canada

100.3 WHAT TO DO IN PATIENTS WITH POST-TRANSPLANT DSA?

> **Robert A. Montgomery** New York, NY, United States



100.4 HOW TO DEAL WITH NON-HLA AB IN SOLID ORGAN TX RECIPIENTS

Elaine F. Reed
Los Angeles, CA, United States

08:30 - 10:30 CONVENTION HALL B-LEVEL 1 BASIC SCIENCE

The Beginning:
Innate Immune System in Allorecognition

Chairs: David Rothstein, Pittsburgh, PA, United States Nancy Kwan Man, Hong Kong SAR, P.R. of China



101.1 INFLAMMATORY TRIGGERS OF ALLOGRAFT REJECTION THROUGH ACTIVATION OF THE INNATE IMMUNE SYSTEM BY DAMPS AND TLRS

**Daniel Kreisel** St. Louis, MO, United States



101.2 ISCHEMIA REPERFUSION INJURY AS AN INFLAMMATORY TRIGGER

**Yuan Zhai** Los Angeles, CA, United States



101.3 REGULATED CELL DEATH PATHWAYS AND ALLOGRAFT REJECTION

Andreas Linkermann Kiel, Germany



101.4 SPECIFIC ALLORECOGNITION BY THE INNATE IMMUNE SYSTEM

Martin Oberbarnscheidt
Pittsburgh, PA, United States

10:30 - 11:00 COFFEE BREAK CONVENTION FOYER-LEVEL 1

11:00 - 13:00 THEATRE 1-LEVEL 1 CLINICAL SCIENCE

Immunosuppression

Chairs: Philip F. Halloran, Edmonton, AB, Canada Brian J. Nankivell, Westmead, Australia



110.1 MECHANISM OF ACTION OF IMMUNOSUPPRESSIVE MEDICATIONS: WHAT DOES IT MEAN IN TERMS OF EFFICACY AND SIDE-EFFECTS?

Christophe Michel Legendre
Paris, France



110.2 TDM AND PHARMACOGENETICS IN TRANSPLANTATION: WHAT DOES THE EVIDENCE SAY?

Teun Van Gelder Rotterdam, Netherlands



110.3 IMMUNOSUPPRESSION IN THE HIGHLY SENSITIZED PATIENTS

> **Kazunari Tanabe** Tokyo, Japan



110.4 BIOSIMILARS AND GENERICS: DO THEY HELP OR HARM?

**Dirk Kuypers** Leuven, Belgium

11:00 - 13:00 CONVENTION HALL B-LEVEL 1 BASIC SCIENCE

The Adaptive Immune System: T Cells

Chairs: Martin Oberbarnscheidt, Pittsburgh, PA, United States Daniel Kreisel, St. Louis, MO, United States



111.1 ALLORECOGNITION BY THE ADAPTIVE IMMUNE SYSTEM: DIRECT, INDIRECT, AND SEMIDIRECT

Adrian E Morelli Pittsburgh, PA, United States



111.2 HOW THE MICROBIOTA SHAPE THE ALLORESPONSE

**Jonathan S. Bromberg**Baltimore, MD, United States



111.3 UPDATE ON CD4 EFFECTOR T CELLS:
ACTIVATION, COSTIMULATION, TH
REPERTOIRE, AND (FINALLY) EXHAUSTION!

**Xian C. Li** Houston, TX, United States



111.4 AG PRESENTATION IN THE ALLOGRAFT FOR TEFF HOMING AND FUNCTION

> Martin Oberbarnscheidt Pittsburgh, PA, United States

13:00 - 14:00 LUNCH BREAK


### AFTERNOON SESSIONS

13:30 - 15:30 CONVENTION HALL A-LEVEL 1 NOT A CME SESSION

China OPO Program - The New Era of Organ Transplantation in China

Chairs: Jeremy R. Chapman, Westmead, Australia Nancy Ascher, San Francisco, CA, United States

In collaboration with



China Organ Transplantation Development Foundation





120.1 OPENING SPEECH

Philip J. O'Connell Westmead, Australia



120.2 CHINA'S ORGAN TRANSPLANTATION
REFORM: A MAJOR FIRST STEP ON A LONG
JOURNEY

**Jiefu Huang** Beijing, People's Republic of China



120.3 THE OVERVIEW OF ORGAN DONATION AND TRANSPLANTATION IN CHINA IN THE NEW FRA

**Haibo Wang** Hong Kong SAR, P.R. of China

120.4 LIVER TRANSPLANTATION IN CHINA IN THE NEW FRA

**Shusen Zheng** Hangzhou, People's Republic of China

120.5 KIDNEY TRANSPLANTATION IN CHINA IN THE NEW ERA

**Bingyi Shi**Beijing, People's Republic of China

120.6 HEART TRANSPLANTATION IN CHINA IN THE NEW ERA

Zhe Zheng

Beijing, People's Republic of China

120.7 LUNG TRANSPLANTATION IN CHINA IN THE NEW ERA

Jingyu Chen

Wuxi, People's Republic of China

14:00 - 15:30 THEATRE 1-LEVEL 1 CLINICAL SCIENCE

### Pathology

Chairs: Kazunari Tanabe, Tokyo, Japan Christophe M. Legendre, Paris, France



121.1 HISTOLOGICAL DIAGNOSIS OF IMMUNOLOGICAL INJURY IN SOLID ORGAN TRANSPLANTATION

Michael Mengel Edmonton, AB, Canada



121.2 NON-HISTOLOGICAL DIAGNOSIS OF ALLOGRAFT INJURY - STATE OF THE ART

**Philip F. Halloran** Edmonton, AB, Canada



121.3 NON-IMMUNE INJURY TO THE ALLOGRAFT

**Brian J. Nankivell**Westmead, Australia

14:00 - 15:30 CONVENTION HALL B-LEVEL 1 BASIC SCIENCE

The Adaptive Immune System: B Cells

Chairs: Yuan Zhai, Los Angeles, CA, United States Andreas Linkermann, Kiel, Germany



122.1 UPDATE ON B CELL ACTIVATION, MEMORY AND ANTIBODY SECRETING CELLS

**Olivier Thaunat** Lyon, France



122.2 NON-ANTIBODY MEDIATED ROLES OF B CELLS IN REJECTION

**Shane T. Grey**Darlinghurst, Australia



122.3 TARGETING B CELLS AND AB-PRODUCING CELLS

**Menna R. Clatworthy**Cambridge, United Kingdom

14:00 - 15:30 THEATRE 2-LEVEL 1

Clinical Trials Design Part 1

Chairs: Dirk Kuypers, Leuven, Belgium Randall E. Morris, Carmel, CA, United States

An Initiative of





### INTRODUCTION

123.2 UNMET MEDICAL NEEDS IN TRANSPLANTATION AND PAST CLINICAL TRIAL (FAILURE)

> John S. Gill Vancouver, BC, Canada



123.3 REPORT ON THE FDA MEETING ON SURROGATE ENDPOINTS

**Dirk Kuypers** Leuven, Belgium



123.4 REPORT ON THE DC MEETING ON CLINICAL TRIAL DESIGN

Randall E. Morris Carmel, CA, United States

15:30 - 16:00 COFFEE BREAK CONVENTION FOYER-LEVEL 1

16:00 - 17:30 THEATRE 1-LEVEL 1 CLINICAL SCIENCE

Ready for Prime Time? Or "Brave New World"

Chairs: Kathryn Tinckam, Toronto, ON, Canada Michael Mengel, Edmonton, AB, Canada



130.1 ARE STEM CELLS KEY TO TRANSPLANT TOLERANCE?

Hung Fat Tse Hong Kong SAR, P.R. of China



130.2 WILL MANIPULATION OF MICROBIOME PLAY A ROLE IN MANAGEMENT OF TRANSPLANT RECIPIENT?

> Marcel R.M. van den Brink New York, NY, United States



130.3 HOW FAR ARE WE FROM PRINTING A SOLID ORGAN FOR TRANSPLANTATION?

**Giuseppe Orlando** Winston Salem, NC, United States

16:00 - 17:30 CONVENTION HALL B-LEVEL 1 BASIC SCIENCE

### Regulation of the Immune Response

Chairs: Shane T. Grey, Darlinghurst, Australia Menna R. Clatworthy, Cambridge, United Kingdom



131.1 UPDATE ON TREGS: FROM MICE TO CLINICAL TRIALS

**Qizhi Tang**San Francisco, CA, United States



131.2 BREGS SHAPE THE ALLORESPONSE IN MICE AND HUMANS

**David Rothstein**Pittsburgh, PA, United States



131.4 CD8+TREGS

**Zhenhua Dai** Guangzhou, People's Republic of China

16:00 - 17:30 THEATRE 2-LEVEL 1

### Clinical Trials Design Part 2

Chairs: Dirk Kuypers, Leuven, Belgium Randall E. Morris, Carmel, CA, United States

An Initiative of



### INTRODUCTION



132.2 RECENT CLINICAL TRIALS: HAVE WE LEARNED FROM THE PAST?

**Steve J. Chadban** Camperdown, Australia



132.3 PLANNING OF THE FUTURE FOR CLINICAL TRIAL DESIGN

**Germaine Wong** Westmead, Australia



132.4 NEXT STEPS


Randall E. Morris Carmel, CA, United States

16:00 - 17:30 CONVENTION HALL A-LEVEL 1 NOT A CME SESSION

China OPO Program - The Brand-New Organ Donation and Procurement Model in China

Chairs: Francis L. Delmonico, Waltham, MA, United States J. Michael Millis, Chicago, IL, United States

In collaboration with



China Organ Transplantation Development Foundation



133.1 THE GREEN PASSAGE SYSTEM FOR ORGAN TRANSPORTATION IN CHINA

### **Yanhong Guo**

Beijing, People's Republic of China

133.2 DEVELOPING AN OPO NETWORK TO INCREASE DONATION RATE AND ORGAN UTILIZATION

### **Oifa Ye**

Changsha, People's Republic of China

133.3 MULTI-CENTRE EXPERIENCE: THE OPO ALLIANCE MODEL

### Xiaoshun He

Guangzhou, People's Republic of China

133.4 SINGLE CENTRE EXPERIENCE: HOSPITAL-BASED OPO MODEL

### **Xuyong Sun**

Nanning, People's Republic of China

133.5 CLOSING REMARKS

José Ramón Núñez Peña

Geneva, Switzerland

NOTES

### MORNING SESSIONS FRIDAY • AUGUST 19

	08:30	10:30	11:00	13:00	
Hall 5E2 - L5					
Hall SE1 - L5					
Hall 5D - L5					
Hall 5BC - L5				Lunch Break	
5-221 - L2		Break			
Conv. Hall C-L1		Coffee Break			
Conv. Hall B - L1	PGC New Techniques and Platform for Organ Tx (Basic Science)		PGC Gan We Apply OMICs to the Clinic Yet? (Basic Science)		
Conv. Hall A - L1 Conv. Hall B - L1 Conv. Hall C - L1	PGC Organ Donation Strategies		PGC Organ Donation Organization	In Collaboration with	International Society For Organ Donation and Procurement
Theater 1-L1 Theater 2-L1	PGC Computational Immunology 1 Course (FOCIS)		PGC Computational Immunology 2 Course (FOCIS)	In Collaboration with In Collaboration with	Federation of Clinical Immunology Societies
Theater 1 - L1	PGC Focused Session on Presentation and Writing Skills		PGC Interactive Sessions: Case Presentation (Clinical Science)	Lunch Break	
	08:30	10:30	11:00	13:00	

### AFTERNOON SESSIONS FRIDAY • AUGUST 19

	14:00	15:30	16:00	17:30	18:30
Hall 5E2 - L5					
Hall 5E1 - L5				all 5BC - L5)	on (Hall SFG - LS)
Hall 5D-L5				TTS 2016 Opening Ceremony (Hall 5BC - L5)	Networking Event: Welcome Reception (Hall 5FG - L5)
Hall 5BC - L5				TTS 2016 Op	Networking Event
S-221 - L2		Break			
Conv. Hall C - L1	Strategies in Personalizing Immunosupp.	Coffee Break	PGC Maximizing Transplant Resources	In Collaboration with	International Transplant Nursea Society
Conv. Hall B - L1	PGC Can We Apply Biomarkers? (Basic Science)			\(	<b>*</b>
Conv. Hall A - L1 Conv. Hall B - L1	PGC Organ Donation Management		PGC Issues in Deceased Organ Donation in Asia	In Collaboration with	International Society For Organ Donation and Procurement
Theater 2 - L1	PGC Focused on Epidemiology and Statistics		PGC Sports in Transplantation (WTGF)		World Transplant Games Federation
Theater 1 - L1	PGC Listing Children for Solid Organ Tx. and Donor Selection		PGC Specific Aspects of Post-Transplant Care	In Collaboration with In Collaboration with	IP I A International Pedatric Fransplant Association
	14:00	15:30	16:00	17:30	18:30



200.1

### MORNING SESSIONS

08:30 - 10:30 THEATRE 1-LEVEL 1

Focused Session:

Presentation and Writing Skills

Chairs: Vivekanand Jha, Chandigarh, India Marcelo Cantarovich, Montreal, QC, Canada

**ELEMENTS OF A SUCCESSFUL GRANT** 

**APPLICATION** 

**Aimin Xu** 

Hong Kong SAR, P.R. of China

200.2 THE ART OF MAKING A GREAT PRESENTATION

John W. Kao Hong Kong SAR, P.R. of China

200.3 HOW TO PUBLISH MY PAPER

Jonathan S. Bromberg
Baltimore, MD, United States

08:30 - 10:30 CONVENTION HALL B-LEVEL 1 BASIC SCIENCE

New Techniques and Platforms for Organ Transplantation

Chairs: David Rothstein, Pittsburgh, PA, United States Nancy Kwan Man, Hong Kong SAR, P.R. of China

201.1 APPLICATION OF GENE-SPECIFIC NUCLEASES
(MEGANUCLEASES, ZFNs, TALEN, CRISPR) IN
TRANSGENIC ANIMALS AND IN VITRO
MODELS OF TRANSPLANT IMMUNOLOGY

**TBA** 

201.2 XENOTRANSPLANTATION

**Kefeng Dou** Xi'an, People's Republic of China

201.3 PLURIPOTENT STEM CELL-DERIVED
MESENCHYMAL STEM CELLS: FROM ANIMAL
MODELS TO CLINICAL PERSPECTIVES

**Qizhou Lian** Hong Kong SAR, P.R. of China





201.4 STEM CELLS: HUMAN IPS CELL-DERIVED PANCREATIC β-CELLS CORRECT HYPERGLYCEMIA IN DIABETIC MICE

**Nicolas Zavazava** Iowa City, IA, United States

08:30 - 10:30 THEATRE 2-LEVEL 1

Computational Data Analysis in Immunology: Transforming Big Data into Smart Data - Part 1

Chair: Megan Sykes, New York, NY, United States

In collaboration with



202.1 INTRODUCTION TO BIOINFORMATICS AND GENOMICS



202.2 BIOINFORMATICS APPROACHES IN IMMUNE AND TRANSLATIONAL RESEARCH

**Emanuele de Rinaldis** London, United Kingdom

08:30 - 10:30 CONVENTION HALL A-LEVEL 1

**Organ Donation Strategies** 

Chairs: Kimberly Young, Edmonton, AB, Canada Faissal Shaheen, Riyadh, Saudi Arabia

In collaboration with



International Society For Organ Donation and Procurement



203.1 STRATEGIES TO IMPROVE DECEASED ORGAN DONATION

Wai Ming Chan Hong Kong SAR, P.R. of China



203.2 LIVING ORGAN DONATION: HOW TO COMMUNICATE RISK TO DONORS?

**Dorry Segev** 

Baltimore, MD, United States



203.3 CROSS-BORDER COLLABORATION TO COMBAT ORGAN TRAFFICKING AND PROTECT THE VULNERABLE

Elmi M. Muller

Cape Town, South Africa



203.4 PRE-TRANSPLANT MALIGNANCIES: WHEN CAN THE PATIENT BE LISTED FOR TRANSPLANTATION?

**Germaine Wong** 

Westmead, Australia

10:30 - 11:00 COFFEE BREAK CONVENTION FOYER-LEVEL 1

11:00 - 13:00 THEATRE 1-LEVEL 1 CLINICAL SCIENCE

Interactive Clinical Cases in Transplant Recipients

Chairs: Helen Pilmore, Auckland, New Zealand Hallvard Holdaas, Oslo, Norway



210.1 INTERACTIVE CLINICAL CASES IN TRANSPLANT RECIPIENTS WITH INFECTIONS (HBV AND HCV)

**Chun-Jen Liu** Taipei City, Taiwan



210.2 INTERACTIVE CLINICAL CASES IN TRANSPLANT RECIPIENTS WITH INFECTIONS (BACTERIAL, FUNGAL AND PARASITIC)

> **Ban Hock Tan** Singapore, Singapore



210.3 INTERACTIVE CLINICAL CASES IN TRANSPLANT RECIPIENTS WITH CARDIOVASCULAR COMPLICATIONS

**Hallvard Holdaas** 

Oslo, Norway



210.4 INTERACTIVE CLINICAL CASES IN TRANSPLANT RECIPIENTS WITH MALIGNANCIES

Chung-Mau Lo Hong Kong SAR, P.R. of China

11:00 - 13:00 CONVENTION HALL B-LEVEL 1 BASIC SCIENCE

Translational Science 1: Can We Apply Omics to the Clinic Yet?

Chairs: Peter William Nickerson, Winnipeg, MB, Canada Alexandre Loupy, Paris, France



211.1 THE GENOMICS OF ALLOGRAFT FIBROSIS AND REJECTION

> Valeria Mas Charlottesville, VA, United States



211.2 ASSESSMENT OF THE ALLOIMMUNE RESPONSE BY MOLECULAR ANALYSIS OF RENAL ALLOGRAFTS

> Michael Mengel Edmonton, AB, Canada



211.3 TOLERANCE: DO DIFFERENT PROFILES EXIST AND HOW CAN THEY BE USED? LIVER

Alberto Sanchez-Fueyo London, United Kingdom



211.4 TOLERANCE: DO DIFFERENT PROFILES EXIST AND HOW CAN THEY BE USED? KIDNEY

> Kenneth A. Newell Atlanta, GA, United States

11:00 - 13:00 THEATRE 2-LEVEL 1

Computational Data Analysis in Immunology: Transforming Big Data into

Smart Data - Part 2

Chair: Megan Sykes, New York, NY, United States

In collaboration with



212.1 BIG DATA DRIVEN RESEARCH

212.2 PRESENTATION OF A SCIENTIFIC SCENARIO

Magnus Fontes Paris, France

11:00 - 13:00 CONVENTION HALL A-LEVEL 1

**Organ Donation Organization** 

Chairs: Howard M. Nathan, Philadelphia, PA, United States Jongwon Ha, Seoul, Korea

In collaboration with



International Society For Organ Donation and Procurement

213.1 LEADERSHIP

Susan Gunderson Minneapolis, MN, United States

213.2 NATIONAL PROGRAM MANAGEMENT

Kimberly Young Edmonton, AB, Canada

S

213.3 OPO ORGANIZATION

**Howard M. Nathan** Philadelphia, PA, United States

(P)(B)

213.4 HOW TO DEVELOP ORGAN DONATION IN ASIA

Jongwon Ha Seoul, Korea



213.5 LIVING DONOR FOLLOW-UP

Mirza Naqi Zafar Karachi, Pakistan



213.6 WHY ORGANIZING BIOVIGILANCE IN ORGAN DONATION

**Aurora Navarro** Barcelona, Spain

13:00 - 14:00 LUNCH BREAK

### AFTERNOON SESSIONS

14:00 - 15:30 THEATRE 1-LEVEL 1

Listing Children for Solid Organ Transplantation and Donor Selection

Chair: Ron Shapiro, New York, NY, United States

In collaboration with



International Pediatric Transplant Association



220.1 WELCOME REMARKS

**Burkhard Tönshoff** Heidelberg, Germany



Christian Benden Zurich, Switzerland



220.2 SPECIFIC ISSUES OF LISTING CHILDREN FOR KIDNEY TRANSPLANTATION

**Paul C. Grimm** Stanford, CA, United States



220.3 SPECIFIC ISSUES OF LISTING CHILDREN FOR THORACIC TRANSPLANTATION

**Anne I. Dipchand** Toronto, ON, Canada



220.4 SPECIFIC ISSUES OF LISTING CHILDREN FOR LIVER TRANSPLANTATION

**George V. Mazariegos**Pittsburgh, PA, United States

14:00 - 15:30 CONVENTION HALL B-LEVEL 1 BASIC SCIENCE

Translational Science 2: Can We Apply Biomarkers to the Clinic Yet?

Chairs: Alberto Sanchez-Fueyo, London, United Kingdom Kenneth A. Newell, Atlanta, GA, USA

221.1 BIOMARKERS FOR RENAL ALLOGRAFT SURVIVAL

**Peter William Nickerson** Winnipeg, MB, Canada

221.2 ROLE OF PROTOCOL BIOPSIES FOR GUIDING THERAPY AND PROGNOSIS IN RENAL ALLOGRAFT PATIENTS

Alexandre Loupy
Paris, France

221.3 BIOMARKERS IN LIVER TRANSPLANTATION

Valeria Mas

Charlottesville, VA, United States

14:00 - 15:30 THEATRE 2-LEVEL 1

Focused Session on Epidemiology and Statistics

Chairs: Gregory Alan Knoll, Ottawa, ON, Canada Philip Masson, Edinburgh, United Kingdom

222.1 HOW TO DESIGN AND IMPLEMENT A CLINICAL TRIAL

**John S. Gill** Vancouver, BC, Canada

222.2 HOW TO PERFORM AND INTERPRET A SYSTEMATIC REVIEW

**Angela Webster** Sydney, Australia

222.3 META-ANALYSIS AND NETWORK META-ANALYSIS: WHAT AND HOW

> Jonathan Craig Sydney, Australia







### 14:00 - 15:30 CONVENTION HALL A-LEVEL 1

### **Organ Donation Management**

Chairs: Susan Gunderson, Minneapolis, MN, United States Eduardo Rocha, Rio de Janeiro, RJ, Brazil

In collaboration with



International Society For Organ Donation and Procurement



223.1 REGIONAL ORGANIZATION FOR ORGAN AND TISSUE DONATION

Paul Robertson Westmead, Australia



223.2 HOW TO DEVELOP ORGAN DONATION IN MIDDLE EAST

**Faissal Shaheen** Riyadh, Saudi Arabia



223.3 COST OF DONATION AND HOW TO GET THE BUDGET

**Eduardo Rocha** Rio de Janeiro, RJ, Brazil

223.4 ICU ROLE IN ORGAN DONATION

**Marti Manyalich** Barcelona, Spain



223.5 WORLD HEALTH ORGANIZATION IN ASIA

José Ramón Núñez Peña Geneva, Switzerland

### 14:00 - 15:30 CONVENTION HALL C-LEVEL 1

Strategies in Personalizing Immunosuppression Management

Chair: Kathy Kable, Westmead, Australia

In collaboration with





224.1 CLINICAL AND BIOMARKER GUIDED APPROACH TO PERSONALIZE IMMUNOSUPPRESSION

**Abraham Shaked** Philadelphia, PA, United States



224.2 PANCREATIC ISLET TRANSPLANTATION AS A BETA CELL REPLACEMENT THERAPY

Piotr Witkowski Chicago, IL, United States



224.3 T FOLLICULAR HELPER CELLS IN TRANSPLANTATION: THE TARGET TO ATTENUATE ANTIBODY MEDIATED RESPONSES

Carla Baan Rotterdam, The Netherlands

15:30 - 16:00 COFFEE BREAK CONVENTION FOYER-LEVEL 1

16:00 - 17:30 THEATRE 1-LEVEL 1

Specific Aspects of Post-Transplant Care in Children

Chairs: Hui Kim Yap, Singapore, Singapore Patrice Pfeiffenberger, Chicago , IL, United States

In collaboration with



International Pediatric Transplant Association



230.1 DONOR-SPECIFIC ANTIBODIES IN PAEDIATRIC SOLID ORGAN TRANSPLANT RECIPIENTS

Lars Pape Hannover, Germany



230.2 PSYCHOSOCIAL ASPECTS OF CHILDREN UNDERGOING SOLID ORGAN TRANSPLANTATION

**Diana Shellmer**Pittsburgh, PA, United States



230.4

230.3 TRANSITION FROM PAEDIATRIC TO ADULT CARE

Christian Benden

Zurich, Switzerland
CLOSING REMARKS



**Burkhard Tönshoff** Heidelberg, Germany

### 16:00 - 17:30 CONVENTION HALL A-LEVEL 1

### Issues in Deceased Organ Donation in Asia

Chairs: Marti Manyalich, Barcelona, Spain
Francis L. Delmonico, Waltham, MA, United States
In collaboration with



International Society For Organ Donation and Procurement



231.1 PHILIPPINES

**Benita Padilla**San Juan City, Philippines



231.2 VIETNAM

Thu Thi Ngoc Du Ho Chi Minh, Viet Nam



231.3 NEPAL

**Dibya Singh Shah** Kathmandu, Nepal



231.4 MYANMAR

**Htar Kyi Swe** Mandalay, Myanmar



BANGLADESH
Mir M. Rahman

Chittagong, Bangladesh



231.6 PAKISTAN

231.5

**Mirza Naqi Zafar** Karachi, Pakistan



231.7 OVERVIEW OF ASIAN DONATION AND TRANSPLANTATION ACTIVITIES (CAST)

**Anwar Naqvi** Karachi, Pakistan

### 16:00 - 17:30 CONVENTION HALL C-LEVEL 1

### Maximizing Transplant Resources for Better Outcomes

Chairs: Joyce A Trompeta, San Francisco, CA, United States Patrice Pfeiffenberger, Chicago , IL, United States

In collaboration with





232.1 RAPID ACCESS CLINIC TRANSFORMING TRANSPLANT CARE

**Kathy Kable** Westmead, Australia



232.2 CHALLENGES OF STARTING A COUNTRY'S FIRST TRANSPLANT PROGRAM

**Roberta J. Al Housani-Blakely** Abu Dhabi, United Arab Emirates



232.3 MAXIMIZING THE USE OF DONOR LUNGS THROUGH INNOVATION, EVOLUTION AND TRANSLATION

**Bronwyn J. Levvey** Melbourne, Australia

16:00 - 17:30 THEATRE 2-LEVEL 1

Sports in Transplantation (World Transplant Games Federation)

Chair: Chris Thomas, Chatswood, Australia

Organized by the World Transplant Games Federation





233.1 THE WORLD TRANSPLANT GAMES
FEDERATION: HELPING RECIPIENTS ADJUST
TO A LIFE-LONG COMMITMENT TO SPORT
AND PHYSICAL ACTIVITY

**Chris Thomas**Chatswood, Australia



233.2 THE ROLE OF SPORT AND PHYSICAL ACTIVITY
IN THE LONG-TERM MANAGEMENT OF
TRANSPLANTATION: STAYING HEALTHY
AROUND A TRANSPLANTED GRAFT

Paul Harden
Oxford, United Kingdom



233.3 INSPIRING NEW RECIPIENTS TO EMBRACE A LIFE OF PHYSICAL ACTIVITY AND WELLNESS

### **Liz Schick** Anzère, Switzerland



233.4 WORLD UPDATES ON TRANSPLANTATION AND SPORT

### **Ka Foon Chau** Hong Kong SAR, P.R. of China



233.5 WORLD UPDATES ON TRANSPLANTATION AND SPORT

### Markus J. Barten Hamburg, Germany

233.6 IS THERE A LIMIT ON THE AMOUNT OF PHYSICAL ACTIVITY AND EXERCISE FOR TRANSPLANTED ORGANS?

### **Panel Discussions**

MUSICAL PRESENTATION BY HONG KONG TRANSPLANT RECIPIENTS

16:00 - 17:00 CONVENTION HALL B-LEVEL 1

TTS 2016 Chairs Briefing

Chair: Jeremy R. Chapman, Westmead, Australia

**NOTE: All Session Chairs are requested to attend** 

17:30 - 18:30 HALL 5BC-LEVEL 5 NOT A CME SESSION

Plenary Session: Opening Ceremony

240.1 WELCOME FROM CONGRESS CHAIR
AND TTS PRESIDENT



Philip J. O'Connell
Australia

240.2 WELCOME ADDRESS FROM THE HONG KONG SAR GOVERNMENT



Wing-Man Ko Hong Kong

240.3 WELCOME FROM THE HONG KONG TOURISM BOARD



Anthony Lau Hong Kong

240.4 WELCOME FROM THE HONG KONG SOCIETY
OF TRANSPLANTATION



**See Ching Chan** Hong Kong

240.5 WELCOME FROM THE THAI SOCIETY OF TRANSPLANTATION



**Vasant Sumethkul** Thailand

18:30 - 20:00 HALL 5FG-LEVEL 5 Welcome Reception

# NOTES


# MORNING SESSIONS SATURDAY • AUGUST 20

Theater 2 - L1 Conv. Hall A - L1 Conv. Hall B - L1 Conv. Hall C - L1	Extablishing Deceased Organ Uniform Definition Deceased Organ Or Beta Cell Oran IX Labs (#5) Orange Caracter Companies Companies Companies Caracter Companies Caracter Companies Caracter Car	Plenary: Basic and Translational Sciences (Hall SBC - LS)  How the Microbiome Shapes the Immune System - Dr. Alexander Rudensky Insights from Large—Scale Human Immune Profiling - Dr. Matthew L. Albert  Mapping Human Immune System - Prof. Donna L Farber	Coffee Break and Poster Viewing (Hall 5FG - L5)	Cos OS	osium Oganized by 12:30 uppression Assected as TRANSPLANT ADMINISTRATION—TOGETHER LS
S-221 - L2 Theater 1 - L1 Theater 2 - I	Starting a Career Personalized Nursing in Tx Medicine in Tx. (Ca)			OS Liver Technical Complications	Industry Symposium Optimizing Immunosuppression (Hall SE3 - LS)
Hall 5E1 - L5	Starti			OS OS OS OS Puture of Organ Antibody Mediated Clinical Outcomes. Preservation / Injury Heart Transplants & VADs (Kdb)	Lunch Break - Exhibition (Hall 5FG - L5)
Hall 5BC-L5 Hall 5D-L5				OS OS Living Donor Outcomes of Transplant / ABO i Tx Pancreas Tx.	
	00:00	08:30	10:00	10:30	12:30

SATURDAY

AFTERNOON SESSIONS SATURDAY • AUGUST 20

	13:30	15:00	15:30	17:00	19:30
Conv. Hall C - L1	SOTA 10th Ann. of DOI Policy & Guidance	Coffee Break and Poster Viewing (Hall 5FG - LS)	OSBarriers in Paediatric Solid Organ Tx.	Symposium: Intibody Monitoring 15E3 - L5) ONE LAMBDA A Thermo Fisher Scientific Brand	
Conv. Hall B - L1	SOTA Advance Nursing Practice		bxploring Cellular Histocompatibility treractions in Tissue hijury BS (H5)	dustry ecific / (Hal	
Theater 2-L1 [Conv. Hall A - L1 ] Conv. Hall B - L1 ] Conv. Hall C - L1	SOTA Tx. & Tx. Tourism in the Tropics		<u>=</u>	0	
Theater 2 - L1	SOTA Transplantomics in Motion BS		OS Regulatory Mechanisms 1	Women in Transplantation Workshop and Networking Event	Offsite at The Pawn
Theater 1 - L1	SOTA Liver Allocation		OS Ischaemia Reperfusion / Preservation	ams (School (V))	TTS Young Investigators Networking Event / 19:30–21:30 Offsite at The Pawn
S-221 - L2	SOTA Are Tx. Registries Relevant or Irrelevant? Reg		OS Making Lung Transplant Work	) Jeveloping Tx. Progra	
Hall 5E2 - L5	SOTA Cellular Therapies in Kidney Tx.		OS Acute Injury	Campfire & Poster Sessions (Hall 5FG - LS) vity 1 / Kidney 1 / Deceased Donation / Liver / De Supported by	
Hall SE1 - L5	SOTA Increased Deceased Donation in Asia		OS Increasing the Organs Pool DCD & Beyond D&P	mpfire & Poster Session: 1 / Kidney 1 / Deceased Dor Supported by	
Hall 5D - L5	SOTA Beta Cell Replacement		OS OS Novel Agents Experimental Islet TX.: Engraffment	Campfire & Poster Sessions (Hall SFG-LS) Unraveling Alloreactivity 1 / Kidney 1 / Deceased Donation / Liver / Developing Tx. Programs Supported by	
Hall 5BC - L5	SOTA Renal Allograft Dysfunction		OS Novel Agents	Unr	
	13:30	15:00	15:30	17:00	19:30



Join members of the Women in Transplantation initiative of TTS and other leaders in the field for a discussion about issues affecting women in the field of medicine as well as topics related to leadership development. This two hour session will provide you with insight and tips from some of transplantation's top female leaders and researchers. A full program of lectures for this event will be updated in the coming weeks. The lecture will be followed by an opportunity to network with your peers over cocktails and canapés.

**THEATRE 2 - LEVEL 1** 



19:30– 21:30

Students, Fellows and Trainees are welcome to an evening of networking, delicious food, drinks, music and good vibes. Proudly supported by Bridge to Life, this event will be held at The Pawn, a communal social venue for arts, design and innovative dining, located only a short walk away from the HKCEC. Don't miss your chance to mingle and learn from younger faculty who have begun successful careers, as well as a special presentation by Dr. Peter Stock.

THE PAWN, 62 Johnston Rd., Wan Chai



07:00 - 08:15 S-221-LEVEL 2

Early Morning Symposia: Starting a Career in Transplantation: Hurdles, Obstacles and Successes

Chairs: Elmi M. Muller, Cape Town, South Africa Jayme E. Locke, Birmingham, AL, United States Sanju Sobnach, Cape Town , South Africa



300.1 TURNING FAILURE INTO SUCCESS

**Dorry Segev**Baltimore, MD, United States



300.2 HOW I BUILT MY CAREER AND MADE CHOICES

**Beatriz Dominguez-Gil** Madrid, Spain



300.3 HOW TO HAVE A LIFE OUTSIDE OF THE OR AS A TRANSPLANT SURGEON

Peter Stock
San Francisco, CA, United States



300.4 WOULD I CHOOSE TRANSPLANTATION AGAIN IF I COULD GO BACK IN TIME?

Nancy Ascher San Francisco, CA, United States



300.5 HOW DID I BALANCE MY CAREER WITH MY FAMILY - TIPS AND TRICKS

Michele I. Morris Miami, FL, United States

07:00 - 08:15 THEATRE 1-LEVEL 1

Early Morning Symposia:
Personalized Medicine in
Transplantation: Time to Translate for
Improving Long-term

Chairs: Christophe Michel Legendre, Paris, France Klemens Budde, Berlin, Germany



301.1 CURRENT CHALLENGES IN KIDNEY TRANSPLANTATION

Brian J. Nankivell

Westmead, Australia



301.2 IMMUNOLOGICAL RISKS OF MINIMIZATION STRATEGIES: SUCCESSES AND UNMET NEEDS

Christophe Michel Legendre



301.3 NOVEL DIAGNOSTICS: BIOMARKERS AND CLINICAL TRIALS, A DESPERATE NEED

**Flavio Vincenti** San Francisco, CA, United States

07:00 - 08:15 THEATRE 2-LEVEL 1

Paris, France



Early Morning Symposia: Nursing Workshop: Health Literacy and Transplant Adherence

Chairs: Kathy Kable, Westmead, Australia Patrice Pfeiffenberger, Chicago , IL, United States



302.1 INTERVENTIONS TO IMPROVE HEALTH LITERACY IN TRANSPLANT RECIPIENTS

**Angela Webster** Sydney, Australia



302.2 PROMOTING ADHERENCE AND SELF-MANAGEMENT IN CLINICAL PRACTICE AMONG KIDNEY TRANSPLANT PATIENTS

> Mirjam Tielen Rotterdam, Netherlands



302.3 HEALTH LITERACY AND ITS IMPLICATIONS IN TRANSPLANT RECIPIENT MEDICATION ADHERENCE

Michael Wolf Chicago, IL, United States





Early Morning Symposia: Establishing Immunogenetics & Transplantation Laboratories & Implementing Newer Technologies

Chairs: Medhat Z. Askar, Dallas, TX, United States Rhonda Holdsworth, Melbourne, Australia



303.1 CHALLENGES IN ESTABLISHING TRANSPLANT IMMUNOLOGY SERVICES IN A LOW RESOURCE COUNTRY

Mirza Naqi Zafar Karachi, Pakistan



303.2 CHALLENGES DRIVE INNOVATION AND NOVEL STRATEGIES: THE STORY OF A TRANSPLANT IMMUNOLOGY LABORATORY IN INDIA

**Dolly Daniel** Vellore, India



303.3 ESTABLISHING AN ORGAN PROCUREMENT ORGANIZATION LABORATORY IN KOREA

> **Myoung Hee Park** Seoul, Korea

## 07:00 - 08:15 CONVENTION HALL B-LEVEL 1



Early Morning Symposia: Deceased Organ Donation Research

Chairs: Kimberly Young, Edmonton, AB, Canada Li Chao, Hangzhou, People's Republic of China



304.1 CRITICAL PATHWAY ANALYSIS PRACTICES IN HONG KONG

**Jenny Koo** Hong Kong SAR, P.R. of China



304.2 ORGAN DONATION RESEARCH IN ICU

**Claus Niemann** San Francisco, CA, United States



304.3 LIVING DONOR QUALITY SAFETY AND TRANSPARENCY

> Fritz Diekman Barcelona, Spain

#### 07:00 - 08:15 CONVENTION HALL C-LEVEL 1



Early Morning Symposia: Towards a Uniform Definition of Beta Cell Graft Failure-Levelling the Playing Field

Chairs: Jon Odorico, Madison, WI, United States Paul R. V. Johnson, Oxford, United Kingdom



305.1 WHY WE NEED A BETTER DEFINITION OF PANCREAS ALLOGRAFT FAILURE

Raja Kandaswamy Minneapolis, MN, United States



305.2 THE CASE FOR HYPOGLYCEMIA CORRECTION AS DEFINITION OF GRAFT SUCCESS IN ISLET TRANSPLANTATION

> **Paul R. V. Johnson** Oxford, United Kingdom



305.3 THE CASE FOR INSULIN-INDEPENDENCE AS DEFINITION OF GRAFT SUCCESS IN ISLET TRANSPLANTATION

François Pattou Lille, France

07:00 - 08:15 S-228-LEVEL 2 BY INVITATION ONLY - NOT A CME SESSION

Meeting of the Hong Kong Society of Transplantation: Presentation of Best Abstracts from Hong Kong

08:30 - 10:00 HALL 5BC-LEVEL 5



Plenary:

Basic and Translational Sciences

Chairs: Megan Sykes, New York, NY, United States Stefan G. Tullius, Boston, MA, United States

310.1 HOW THE MICROBIOME SHAPES THE IMMUNE SYSTEM



**Alexander Rudensky** New York, NY, United States

310.2 INSIGHTS FROM LARGE-SCALE HUMAN IMMUNE PROFILING



Matthew Albert South San Francisco, CA, United States

310.3 MAPPING HUMAN IMMUNE SYSTEM



**Donna L. Farber** New York, NY, United States

10:00 - 10:30 COFFEE BREAK HALL 5FG-LEVEL 5

10:30 - 12:30 HALL 5BC-LEVEL 5



Orals and Mini-Orals Session: Living Donor Transplant / ABOi Tx

Chairs: Andrew Posselt, San Francisco, CA, United States Adibul Hasan Rizvi, Karachi, Pakistan

320.1 POTENTIAL KIDNEY DONORS WITH ASYMPTOMATIC MICROSCOPIC HEMATURIA: HISTOPATHOLOGICAL FINDINGS & OUTCOMES

**Ehab A. Hammad** Riyadh, Saudi Arabia

320.2 COMPARISON OF THE RATE OF DECLINE OF GFR AND 1. 5 AND 10 YEAR OUTCOMES OF LIVE KIDNEY DONORS – UK COHORT STUDY

**Nithya Krishnan** Coventry, United Kingdom

320.3 ACUTE OPERATIVE COMPLICATIONS AND 1, 5, & 10 YEAR OUTCOMES IN LIVING DONORS BY TYPE OF LIVE DONOR NEPHRECTOMY

#### Nithya Krishnan

Coventry, United Kingdom

320.4 THE PERCENTAGE OF CD19 POSITIVE CELLS IN LYMPHOCYTES CAN PREDICT ACUTE ANTIBODY-MEDIATED REJECTION AFTER ADMINISTRATION OF RITUXIMAB IN ABOINCOMPATIBLE KIDNEY TRANSPLANTATION

#### Takayuki Hirose

Sapporo, Japan

320.5 ABO INCOMPATIBLE RENAL
TRANSPLANTATION WITHOUT SPLENECTOMY
OR ANTI-CD20 TREATMENT: COMPARISON
WITH ABO COMPATIBLE RENAL TRANSPLANT

#### **Amit Sharma**

Mohali, Punjab, India

320.6 HLA IDENTICAL RENAL TRANSPLANTS.
IMMUNOLOGICALLY PRIVILEGED WHY DO
THEY FAIL?

#### **Adibul Hasan Rizvi**

Karachi, Pakistan

320.7 RETROPERITONEAL VERSUS
INTRAPERITONEAL HAND ASSISTED
LAPAROSCOPIC DONOR NEPHRECTOMY: A
CASE MATCHED STUDY

#### **Zubir Ahmed**

London, United Kingdom

320.8 DIFFERENT SENSITIVITY OF RITUXIMAB-TREATMENT TO B-CELLS BETWEEN ABO-INCOMPATIBLE KIDNEY AND LIVER TRANSPLANTATION

#### **Asuka Tanaka**

Hiroshima, Japan

320.9 IMMUNOSUPPRESSIVE MYELOID CELLS IN PATIENTS GIVEN COMBINED KIDNEY AND HEMATOPOIETIC CELL TRANSPLANTS IN A TOLERANCE PROTOCOL WITH TLI AND ATG CONDITIONING

#### Samuel Strober

Stanford, CA, United States

#### MINI-ORALS

320.10 TREATMENT OF LARGE PLASMA VOLUMES
USING SPECIFIC IMMUNOADSORPTION TO
DESENSITIZE ABO-INCOMPATIBLE KIDNEYTRANSPLANT CANDIDATES

## **Lionel Rostaing**

Toulouse, France

320.11 "PAIRED KIDNEY EXCHANGE" PROGRAM –
SINGLE CZECH INSTITUTION EXPERIENCE
WITH 50 PAIRED TRANSPLANTS SINCE 2011

#### **Tomas Marada**

Prague, Czech Republic

320.12 MANAGEMENT OF PLASMA CELLS RICH ACUTE REJECTIONS- ROLE OF PROTEASOME INHIBITORS

#### **Khawar Abbas**

Karachi, Pakistan

320.13 THE IMPORTANCE OF RENAL BIOPSY IN CANDIDATE LIVING DONORS WITH PROTEINURIA

#### Handan Özdemir

Ankara, Turkey

10:30 - 12:30 HALL 5D-LEVEL 5



## Orals and Mini-Orals Session: Outcomes of Pancreas Tx

Chairs: Angela Webster, Sydney, Australia Peter J. Morris, London, United Kingdom

321.1 RISK OF ACUTE CARDIOVASCULAR COMPLICATIONS FOLLOWING PANCREAS TRANSPLANTATION

#### Jim Kim

New York, NY, United States

321.2 POSTOPERATIVE MONITORING AND DIAGNOSIS OF COMMON SURGICAL COMPLICATIONS FOLLOWING PANCREAS TRANSPLANTATION BY MICRODIALYSIS CATHETERS

#### Gisle Kjøsen

Oslo, Norway

321.3 LONGITUDINAL ASSESSMENT OF ORAL GLUCOSE TOLERANCE TEST PARAMETERS FOR THE PREDICTION OF PANCREAS TRANSPLANT DYSEUNCTION

#### **Emmanuel Morelon**

Lyon, France

321.4 PANCREAS TRANSPLANTATION RESULTS ARE NOT MORE PROGRESSING AND REQUIRE SIGNIFICANT INNOVATIONS

#### **Diego Cantarovich**

Nantes, France

321.5 RECIPIENT AND PANCREAS GRAFT SURVIVAL
AFTER KIDNEY-PANCREAS
TRANSPLANTATION IN AUSTRALIA AND NEW
ZEALAND: A COHORT STUDY 1984-2014
USING ANZIPTR

## **Angela Webster**

Sydney, Australia

321.6 PANCREAS-AFTER-ISLET TRANSPLANTATION: A PATH FOR LONG TERM INSULIN INDEPENDENCE

#### Steven A. Wisel

San Francisco, CA, United States

321.7 CLINICAL PANCREAS TRANSPLANTATION FROM DECEASED DONOR IN JAPAN

#### Takashi Kenmochi

Toyoake, Aichi, Japan

321.8 THE PREDICTION OF THE ENDOCRINE FUNCTION OF THE GRAFT USING CONTRAST-ENHANCED ULTRASONOGRAPHY IN CLINICAL PANCREAS TRANSPLANTATION

#### **Naohiro Aida**

Toyoake, Japan

321.9 SUPERIOR LONG-TERM OUTCOME OF PANCREAS TRANSPLANTATION ALONE WITH PORTAL VENOUS DRAINAGE VS. SYSTEMIC VENOUS DRAINAGE

#### **Stephen T. Bartlett**

Baltimore, MD, United States

#### MINI-ORALS

321.10 EN BLOC DUAL KIDNEY-PANCREAS
TRANSPLANTATION INTO AN ADULT RECIPIENT
UTILIZING VERY SMALL PEDIATRIC DONOR: NO
CONFLICT WITH LIVER TRANSPLANTATION
CONCERNING ANATOMICAL DIVISION IN
RESPECT TO DIVIDING ARTERIES - ALL ORGANS
CAN BE USED

#### Johan A Nordström

Stockholm, Sweden

321.11 LONG TERM RESULTS IN PANCREAS RE TRANSPLANTATION DEPENDING ON THE CAUSE OF PRIMARY GRAFT FAILURE

#### Lilia Martinez de la Maza

Barcelona, Spain

321.12 THE OPTIMAL RANGE OF NATIVE KIDNEY FUNCTION BEFORE PANCREAS TRANSPLANT ALONE MINIMIZING THE RISK OF END-STAGE RENAL DISEASE

## Sung Shin

Seoul, Korea

321.13 HYPERINSULINEMIA AFTER PANCREAS
TRANSPLANTATION: A RISK FOR EXCESSIVE
WEIGHT GAIN, METABOLIC SYNDROME, AND
FATTY LIVER DISEASE

#### Richard J. Knight

Houston, TX, United States

#### 10:30 - 12:30 HALL 5E1-LEVEL 5



## Orals and Mini-Orals Session: Future of Organ Preservation/Perfusion

Chairs: Jongwon Ha, Seoul, Korea Elmi M. Muller, Cape Town, South Africa

322.1

TRIGLYCERIDE EXPORTATION IN THE PRESERVATION OF DISCARDED STEATOTIC HUMAN LIVERS USING 24 HOURS EX-VIVO NORMOTHERMIC MACHINE PERFUSION

#### **Qiang Liu**

Cleveland, OH, United States

322.2 A COMPARISON OF LIVER TRANSPLANT
BILIARY COMPLICATIONS FOR DECEASED
DONOR DRAFTS PRESERVED WITH HISTIDINETRYPTOPHAN-KETOGLUTARATE AND
UNIVERSITY OF WISCONSIN SOLUTIONS

### **Richard S. Mangus**

Indianapolis, IL, United States

322.3 SURGICAL EXPERIENCE OF NORMOTHERMIC MACHINE PERFUSION IN HUMAN LIVER TRANSPLANTATION

#### **David Nasralla**

Oxford, United Kingdom

322.4 EFFECT OF MACHINE PERFUSION AND UROKINASE ON THE KIDNEY TRANSPLANTS WITH GLOMERULAR THROMBOSIS

#### Xiaopeng Yuan

Guangzhou, People's Republic of China

322.5 A NOVEL METHOD OF SPLIT LIVER EX VIVO PERFUSION

#### **Viola Huang**

Cambridge, MA, United States

322.6 EX VIVO PERFUSION OF HUMAN LIVERS INDUCES LEUKOCYTE MOBILISATION

#### William R. Critchley

Manchester, United Kingdom

322.7 HARMONIC SCALPEL IN THE RAPID PROCUREMENT OF THE PANCREAS FOR TRANSPLANTATION: RECIPIENT OUTCOMES

#### **Ahmer Hameed**

Eastwood, Australia

322.8 HYPOTHERMIC MACHINE PERFUSION OF EN BLOC KIDNEYS FROM INFANT AND NEONATAL DONORS

#### **Imeshi Wijetunga**

Leeds, United Kingdom

322.9 PERFUSION CHARACTERISTICS DURING
CONTROLLED OXYGENATED REWARMING
AND SUBNORMOTHERMIC MACHINE
PERFUSION OF STEATOTIC HUMAN LIVERS

#### **Dieter Hover**

Essen, Germany

#### MINI-ORALS

322.10 PERI-OPERATIVE ORGAN PERFUSION WITH ATG-FRESENIUS RESULTS IN IMPROVED GRAFT FUNCTION IN CLINICAL LIVER AND KIDNEY TRANSPLANTATION

#### **Paul Viktor Ritschl**

Berlin, Germany

322.11 WHAT SHOULD BE MOVED, GRAFT OR MACHINE? TRAVEL STRATEGY IN AN EXPANDED CRITERIA DONOR PROGRAM.
ORGAN PROCUREMENT AND TRANSPLANT ORGANIZATIONS (OPO) PERSPECTIVE

Francisco Javier Burgos Revilla Madrid, Spain

322.12 HYPERBRANCHED POLYGLYCEROL-BASED
ORGAN PRESERVATION SOLUTION:
ADVANTAGES FOR COLD KIDNEY PERFUSION

#### Caigan Du

Vancouver, BC, Canada

322.13 EX VIVO NORMOTHERMIC PERFUSION
REDUCES KIDNEY IMMUNOGENICITY PRIOR
TO TRANSPLANTATION VIA REMOVAL OF
PASSENGER LEUKOCYTES

#### John P. Stone

Manchester, United Kingdom

10:30 - 12:30 HALL 5E2-LEVEL 5



## Orals and Mini-Orals Session: Antibody Mediated Injury

Chairs: Pui Yin Jocelyn Sim, Hong Kong SAR, P.R. of China TBA

323.1 CORRELATION BETWEEN C3D-FIXING DONOR SPECIFIC HLA ANTIBODY AND LUMINEX MFI

#### **Lionel Rostaing**

Toulouse, France

323.2 PRETRANSPLANT ATTRABS ARE ASSOCIATED WITH ACUTE REJECTION IN 2-HAPLOTYPES KIDNEY TRANSPLANT RECIPIENTS

#### Jose Manuel Arreola

Aguascalientes, Mexico

323.3 THE LEVELS OF DE NOVO HLA ANTIBODIES
ARE DETERMINED BY SOLUBLE B CELLACTIVATING FACTOR BELONGING TO THE TNF
FAMILY (BAFF) POST TRANSPLANTATION

#### Junchao Cai

Los Angeles, CA, United States

323.4 PREFORMED C1Q-BINDING DSA ARE MORE
CLEARLY ASSOCIATED WITH ADVERSE
OUTCOMES AFTER HLA-INCOMPATIBLE KIDNEY
TRANSPLANTATION THAN DSA STRENGTH

#### **Jorge Malheiro**

Porto, Portugal

323.5 ABO INCOMPATIBILITY MIGHT PROTECT
AGAINST CHRONIC ANTIBODY MEDIATED
REJECTION CAUSED BY DE NOVO DSA AFTER
RENAL TRANSPLANTATION

#### Manabu Okada

Nagoya, Japan

323.6 DE NOVO DONOR SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANTATION - A SYSTEMATIC REVIEW AND META-ANALYSIS

#### **Ankit Sharma**

Westmead, Australia

323.7 DO WE KNOW HOW TO TREAT RESISTANT
ANTIBODY-MEDIATED REJECTION
EFFECTIVELY? A SINGLE CENTRE EXPERIENCE

#### Janka Slatinska

Prague, Czech Republic

323.8 EARLY ACUTE HUMORAL REJECTION IN THE
ABSENCE OF ANTI-HLA ANTIBODIES:
CLINICO-PATHOLOGICAL DESCRIPTION FROM
A FRENCH NATION-WIDE STUDY

#### **Marianne Delville**

Paris, France

323.9 POST-TRANSPLANT MONITORING OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES AND THEIR CHARACTERISTICS IMPROVES RISK STRATIFICATION OF KIDNEY ALLOGRAFT LOSS

#### **Alexandre Loupy**

Paris, France

#### MINI-ORALS

323.10 COMPLEMENT-BINDING DONOR-SPECIFIC
ANTI-HLA ANTIBODIES ARE ASSOCIATED
WITH SEVERE KIDNEY ALLOGRAFT
ARTERIOSCLEROSIS

## **Alexandre Loupy**

Paris, France

323.11 THE NATURAL HISTORY OF DONOR SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS AND ASSOCIATED CLINICAL OUTCOMES

#### Susan S. Wan

Ultimo, Australia

323.12 NON-VALIDATION OF PRE-TRANSPLANT
SENSITIZATION AGAINST ANGIOTENSIN II
TYPE1 RECEPTOR AS RISK FACTOR OF GRAFT
AND PATIENTS OUTCOMES IN KIDNEY
TRANSPLANTATION

#### Magali Giral

Nantes, France

323.13 URINE IP-10 AS THE BIOMARKER FOR ABMR IN KIDNEY TRANSPLANT RECIPIENT WITH DGF

## **Natavudh Townamchai**

Bangkok, Thailand

10:30 - 12:30 S-221-LEVEL 2



## Orals and Mini-Orals Session: Clinical Outcomes: Heart transplants and VADs

Chairs: Howard Eisen, Philadelphia, PA, United States Katherine Fan, Hong Kong SAR, P.R. of China

324.1 COMBINED EN-BLOC HEART-LIVER
TRANSPLANTATION FOR PATIENTS WITH
CONGENITAL HEART DISEASE COMPLICATED
BY CIRRHOSIS

#### Jacqueline I. Lee

Palo Alto, CA, United States

324.2 EFFECTS OF ACUTE AND CHRONIC
AMIODARONE USE IN PATIENTS BEFORE
HEART TRANSPLANTATION ON POSTTRANSPLANT OUTCOMES

#### **Rasmus Rivinius**

Heidelberg, Germany

324.3 TERLIPRESSIN INCREASES BLOOD PRESSURE
AND FACILITATES WEANING FROM
CARDIOPULMONARY BYPASS IN HEART
TRANSPLANT RECIPIENTS WITH REFRACTORY
HYPOTENSION

#### Pinar Zeyneloglu

Ankara, Turkey

324.4 PRE-ORTHOTOPIC HEART TRANSPLANT (OHT)
ESTIMATED GLOMERULAR FILTRATION RATE
(eGFR) PREDICTS POST-OHT MORTALITY AND
RENAL OUTCOMES

#### Hani Wadei

Jackosonville, FL, United States

324.5 RELATIONSHIP BETWEEN BRACHIAL ARTERY FLOW-MEDIATED DILATION AND CLINICAL CHARACTERISTICS IN HEART TRANSPLANT RECIPIENTS

#### Takuya Watanabe

Osaka, Japan

324.6 EFFECTS OF EXERCISE TRAINING ON CARDIAC
RESERVE AND AUTONOMIC ACTIVITY IN POST
HEART TRANSPLANT PATIENTS AND PATIENTS
RECEIVING LEFT VENTRICULAR ASSIST
DEVICES SUPPORT BY ASSESSMENT OF
HEART RATE PROFILE

#### **Katherine Fan**

Hong Kong SAR, P.R. of China

324.7 PHYSICAL FUNCTION AND SELF-REPORTED
HEALTH STATUS IN PRE-TRANSPLANT
PATIENTS WITH LEFT VENTRICULAR ASSISTED
DEVICE - LOCAL EXPERIENCE OF OUTPATIENT CARDIAC REHABILITATION
PROGRAM IN HONG KONG

#### Jenny Y.Y. Ng

Hong Kong SAR, P.R. of China

324.8 IS PERFECT LONG-TERM RESULT OF CONTINUOUS-FLOW LVAD FOR BRIDGE TO TRANSPLANTATION POSSIBLE?

#### Minoru Ono

Tokyo, Japan

324.9 MEDICAL UTILIZATION AND COSTS OF HERPES
ZOSTER HOSPITALIZATIONS FOLLOWING
HEART TRANSPLANTATION IN TAIWAN

#### **Yi-Chang Lin**

Taipei, Taiwan

#### MINI-ORALS

324.10 METABOLIC PROFILE OF DONATION AFTER CIRCULATORY DEATH HEARTS DURING RECONDITIONING

#### **Hong Chee Chew**

Kingsgrove, Australia

324.11 LOW MOLECULAR WEIGHT HEPARINE AS
ALTERNATIVE ANTICOAGULATION THERAPY
IN PATIENTS WITH LEFT VENTRICULAR ASSIST
DEVICES

#### **Bahadir Gültekin**

Ankara, Turkey

324.12 HOSPITAL READMISSIONS AFTER LEFT
VENTRICULAR ASSIST DEVICE IMPLANTATION

#### **Christian Heim**

Erlangen, Germany

324.13 PRIOR CLOTTING EVENTS AS PREDICTOR OF POST LVAD MORBIDITY AND MORTALITY

#### Justin H. Johannesen

Philadelphia, PA, United States

#### 10:30 - 12:30 THEATRE 1-LEVEL 1



## Orals and Mini-Orals Session: Liver Technical Complications

Chairs: Kyung-Suk Suh, Seoul, Korea Peter Friend, Oxford, United Kingdom

325.1 OUTFLOW RECONSTRUCTION USING THE HOMOLOGOUS VENOUS GRAFTS IN LIVING DONOR LIVER TRANSPLANTATION: EXPERIENCE AT THE UNIVERSITY OF TOKYO HOSPITAL

#### Nobuhisa Akamatsu

Tokyo, Japan

325.2 OUTCOME OF LIVING DONOR LIVER
TRANSPLANTATION USING RIGHT LIVER
ALLOGRAFTS WITH MULTIPLE ARTERIAL
SUPPLY

#### **Kyo Won Lee**

Seoul, Korea

325.3 THE EFFECT OF ANHEPATIC PHASE EXTENDED
BY TEMPORARY PORTOCAVAL SHUNT ON
ANESTHETIC SENSITIVITY TO DESFLURANE
ADMINISTERED AT A CONSTANT AGE-ADJUSTED
MINIMUM ALVEOLAR CONCENTRATION AND
POSTOPERATIVE COGNITIVE FUNCTION IN
PATIENTS UNDERGOING LIVING DONOR LIVER
TRANSPLANTATION

#### **Jong Hae Kim**

Daegu, Korea

325.4 DOMINO LIVER TRANSPLANTATION: TECHNIQUE AND OUTCOME

#### **Neslihan Celik**

Pittsburgh, PA, United States

325.5 OUTCOME OF PARTIAL RECONSTRUCTION OF MULTIPLE HEPATIC ARTERIES IN PEDIATRIC LIVING DONOR LIVER TRANSPLANTATION USING LEFT LATERAL SECTION GRAFTS

#### Seounghyun Kim

Seoul, Korea

325.6 THE NOVEL USE BIODEGRADABLE SX-ELLA
BILIARY STENT PLACED BY PERCUTANEOUS
TRANSHEPATIC APROACH FOR THE
TREATMENT OF BILIARY STENOSIS AFTER
LIVER TRANSPLANTATION

#### **Cristina Dopazo**

Barcelona, Spain

325.7 V5/V8 HEPATIC VEIN THROMBUS AFTER LEFT LOBE DONATION SURGERY

## Kaori Kuramitsu

Kobe, Japan

325.8 AUXILIARY PARTIAL ORTHOTOPIC LIVER
TRANSPLANTATION (APOLT): A SAFE &
EFFECTIVE ALTERNATIVE TO ORTHOTOPIC
LIVER TRANSPLANTATION FOR PATIENTS
WITH ACUTE LIVER FAILURE AND NONCIRRHOTIC METABOLIC LIVER DISEASE

#### **Mettu Srinivas Reddy**

Chennai, India

325.9 REDUCING NON-ANASTOMOTIC BILIARY STRICTURES AFTER DONATION AFTER CIRCULATORY DEATH LIVER TRANSPLANTATION, A MATTER OF TIME?

#### **Nicholas Gilbo**

Leuven, Belgium

#### MINI-ORALS

325.10 LIVER STIFFNESS MEASUREMENT USING
ACOUSTIC RADIATION FORCE IMPULSE (ARFI) IN
LIVING AND DECEASED DONOR ORTHOTOPIC
LIVER TRANSPLANTATION PATIENTS

#### **Murat Haberal**

Ankara, Turkey

325.11 EFFICACY OF ACOUSTIC RADIATION FORCE IMPULSE (ARFI) ELASTOGRAPHY FOR PREDICTING POST-TRANSPLANT CLINICAL OUTCOMES IN LIVING DONOR LIVER TRANSPLANTATION

#### Koji Natsuda

Nagasaki, Japan

325.12 EARLY ENTERAL FEEDING AFTER LIVING
DONOR LIVER TRANSPLANTATION PREVENTS
INFECTIOUS COMPLICATIONS: A
PROSPECTIVE PILOT STUDY

#### Jong Man Kim

Seoul, Korea

325.13 AUXILIARY PARTIAL ORTHOTOPIC LIVER
TRANSPLANTATION VERSUS HETEROTOPIC
AUXILIARY PARTIAL LIVER TRANSPLANTATION
- SINGLE CENTER EXPERIENCE

#### Kohei Miura

Niigata City, Japan

10:30 - 12:30 THEATRE 2-LEVEL 1



## Orals and Mini-Orals Session: Ethics on Donation in Transplantation

Chairs: Vivekanand Jha, Chandigarh, India Alexander M. Capron, Los Angeles, CA, United States

326.1 WHAT KEEPS TTS MEMBERS UP AT NIGHT?
PRELIMINARY RESULTS OF AN
INTERNATIONAL ETHICS SURVEY

**Dominique E. Martin** 

Geelong, Australia

326.2 GPS-ENABLED SMARTPHONE INTEGRATION
INTO DIGITALDONOR ELECTRONIC DONOR
RECORD PRODUCES DOUBLE-DIGIT INCREASE
IN DONATION BY ENSURING RAPID RESPONSE
TO ASSIST DONOR FAMILIES AND PHYSICIANS

#### **Thomas D. Mone**

Los Angeles, CA, United States

326.3 LIVING LIVER DONORS MAY UNDER-REPORT MENTAL HEALTH COMORBIDITIES

#### Hillary J. Braun

San Francisco, CA, United States

326.4 KIDNEY TRANSPLANT PATIENT PREFERENCES
AND TRADE-OFFS FOR OUTCOMES AFTER
TRANSPLANTATION

#### **Martin Howell**

Westmead, Australia

326.5a INTERVIEWS WITH PATIENTS WHO TRAVELLED FROM MACEDONIA, KOSOVO, THE NETHERLANDS AND SWEDEN FOR PAID KIDNEY TRANSPLANTATIONS

(abst. P.1727 in the *Transplantation Journal*)

#### **Willem Weimar**

Rotterdam, The Netherlands

326.6 MOBILE APPS TO IMPROVE ORGAN DONATION RATE

## Sujatha Suriyamoorthi

Chennai, India

326.7 THE "DOHA MODEL OF ORGAN DONATION"
FROM ADOPTION OF THE PRINCIPLES AND
RECOMMENDATIONS OF THE "DECLARATION
OF ISTANBUL" IN 2010 TO INCLUSION OF THE
IMPLEMENTED STRATEGIES IN THE NEW
NATIONAL TRANSPLANT LEGISLATION - 2015

#### Riadh A.S. Fadhil

Doha, Qatar

326.8 A QUALITATIVE STUDY INTO THE MODUS
OPERANDI, INVESTIGATION AND PROSECUTION
OF ORGAN TRAFFICKING NETWORKS IN SOUTH
AFRICA. ISRAEL AND KOSOVO

#### Frederike Ambagtsheer

Rotterdam, The Netherlands

326.9 REPORTING ORGAN TRAFFICKING
NETWORKS: A SURVEY-BASED PLEA TO
BREACH THE SECRECY OATH

Frederike Ambagtsheer
Rotterdam. The Netherlands

#### **MINI-ORALS**

326.10 A SYSTEMATIC REVIEW ON THE PREVALENCE OF PATIENTS WHO PURCHASE ORGAN TRANSPLANTS ABROAD

#### Frederike Ambagtsheer Rotterdam, The Netherlands

326.11 A KIDNEY PAIRED DONATION STANDARD ACQUISITION CHARGE PILOT PROGRAM

#### Michael A. Rees Cleveland, OH, United States

326.12 RESEARCH PRIORITY SETTING IN SOLID ORGAN TRANSPLANTATION: A SYSTEMATIC REVIEW

Claudia L. Harper Sydney, Australia

326.13 HEALTH-RELATED QUALITY OF LIFE IMPROVES FURTHER AFTER LIVER TRANSPLANTATION AND IS INFLUENCED BY LENGTH OF STAY

**Louis G. Onghena** Ghent, Belgium

## 10:30 - 12:30 CONVENTION HALL A-LEVEL 1



Orals and Mini-Orals Session: Experimental Islet Tx: Immunologic Aspects

Chairs: Kenneth A. Newell, Atlanta, GA, United States Thomas Kay, Victoria, Australia

327.1 CD4+CD25+FOXP3+TREG CELLS ARE
CRITICAL TO TOLERANCE INDUCTION BY SAFASL-ENGINEERED PORCINE ISLETS
TRANSPLANTED INTO MICE

#### **Kyle Woodward**

Louisville, KY, United States

327.2 DUAL PHASES AND MECHANISTIC BASIS OF TOLERANCE INDUCED BY ALLOGENEIC PANCREATIC ISLETS ENGINEERED WITH SAFASL PROTEIN

#### **Kyle Woodward**

Louisville, KY, United States

327.3 THE INFLUENCE OF DISSOCIATION ENZYMES
ON ISOLATED ISLETS DURING PANCREATIC
ISLET ISOLATION PROCEDURES

#### Yuki Miyazaki

Sendai, Japan

327.4 PRETREATMENT OF DONOR ISLETS WITH PAPAIN IMPROVES ALLOGRAFT SURVIVAL WITHOUT SYSTEMIC IMMUNOSUPPRESSION IN MICE

## Kenjiro Kumano

Fukuoka, Japan

327.5 SUSTAINED EUGLYCEMIA AFTER ISLET
XENOTRANSPLANTATION IN DIABETIC NOD
MICE USING NOVEL PURIFICATION AND
ENCAPSULATION TECHNOLOGIES

#### **Jonathan Lakey**

Orange, CA, United States

327.6 COTRANSPLANTATION OF PREACTIVATED
MESENCHYMAL STEM CELLS INHIBITS LIVER
NATURAL KILLER CELL-INDUCED ISLET GRAFT
INJURY DURING INSTANT BLOOD-MEDIATED
INFLAMMATORY REACTION AFTER SYNGENEIC
INTRAPORTAL ISLET TRANSPLANTATION

#### Ishida Nobuki

Hiroshima, Japan

327.7 SA-FASL-ENGINEERED PORCINE ISLETS INDUCE TOLERANCE IN MICE FOLLOWING INTRAPORTAL TRANSPLANTATION

#### **Haval Shirwan**

Louisville, KY, United States

327.8 ANTI-INFLAMMATORY CD169+ TIM-4+ ISLET RESIDENT MACROPHAGES INDUCE TREGS AND PROLONG ALLOGRAFT SURVIVAL

#### Periklis P. Kyriazis

Chestnut Hill, MA, United States

327.9 ENDOSCOPIC BIOPSY OF ISLET TRANSPLANTS
IN THE GASTRIC SUBMUCOSAL SPACE
PROVIDES EVIDENCE OF ISLET GRAFT
REJECTION IN DIABETIC PIGS

#### Hidetaka Hara

Pittsburgh, PA, United States

#### **MINI-ORALS**

327.10 SPHINGOLIPIDS REGULATE THE PODOCYTE INSULIN SIGNALING IN DIABETIC KIDNEY DISEASE

#### George W. Burke

Miami, FL, United States

327.11 SPHINGOSINE-1-PHOSPHATE PROMOTES THE MIGRATION OF INTRAISLET VASCULAR CELLS: IMPLICATIONS FOR POST-TRANSPLANT ISLET FUNCTION

#### **Darling Rojas-Canales**

Adelaide, Australia

327.12 HYPOTHERMIC MACHINE PERFUSION
PRESERVATION OF NON-HEART-BEATING
DONOR PANCREAS FOR ISLET
TRANSPLANTATION

#### **Naotake Akutsu**

Chiba, Japan

327.13 ANALYSIS OF POST-TRANSPLANT ISLET BY ORGAN TRANSPARENCY AND MACRO THREE-DIMENSIONAL IMAGE

#### **Kova Shinohara**

Tokyo, Japan

## 10:30 - 12:30 CONVENTION HALL B-LEVEL 1

BS

## Orals and Mini-Orals Session: A Fresh Look at Tolerance and Rejection

Chairs: Marcel R.M. van den Brink, New York, NY, United States Karen Dwyer, Victoria, Australia

328.1 MAINTENANCE OF LONG-TERM TOLERANCE
BY T REGULATORY CELLS IN A MOUSE MODEL
OF HEART TRANSPLANTATION

#### **Junjie Xia**

Xiamen, People's Republic of China

328.2 NEONATAL TOLERANCE IN A MOUSE MODEL OF ABO-INCOMPATIBLE HEART TRANSPLANTATION

#### Lori J. West

Edmonton, AB, Canada

328.3 INTERLEUKIN-5 THERAPY PREVENTS
CHRONIC ALLOGRAFT REJECTION BY
INDUCTION OF ANTIGEN SPECIFIC
CD4+CD25+ T REGULATORY CELLS

#### Suzanne J. Hodkinson

Sydney, Australia

328.4 CONTRASTING EFFECTS OF TACROLIMUS
AND EVEROLIMUS ON REGULATORY T CELL
ACTIVATION AND MIXED HEMATOPOIETIC
CHIMERISM INDUCED BY NATURAL KILLER T
CELL STIMULATION

#### Toshihito Hirai

Tokyo, Japan

328.5 IFN-GAMMA/B7-H1 SIGNALING PATHWAYS IN GRAFT MESNECHYMAL CELLS MEDIATE LIVER TRANSPLANT TOLERANCE

#### John J. Fung

Cleveland, OH, United States

328.6 LIVER REGENERATION WAS ATTENUATED BY DELETION OF CXCL10 OR ITS RECEPTOR CXCR3 VIA YAP1 SIGNALING

#### Yuen Yuen Ma

Hong Kong SAR, P.R. of China

328.7 HEPARIN-GELATIN MIXTURE IMPROVES
VASCULAR RECONSTRUCTION EFFICIENCY AND
HEPATIC FUNCTION IN BIOENGINEERED LIVER

#### **Kamal Hany Hussein**

Chuncheon-si, Korea

328.8 SUPERCHARGING MESENCHYMAL STEM
CELLS WITH INTERLEUKIN-17A: AN
ALTERNATIVE TO INTERFERON-GAMMA
ENHANCEMENT OF MESENCHYMAL STEM
CELL IMMUNOMODULATION

#### Kisha Nandini Siyanathan

Adelaide, Australia

328.9 AN INCREASE IN CD8+ EFFECTOR MEMORY T
CELLS PRECEDES REJECTION IN A PRIMATE
CARDIAC TRANSPLANT MODEL

#### Natalie A. O'Neill

Baltimore, MD, United States

#### MINI-ORALS

328.10 DONOR-SPECIFIC CELL-FREE DNA AS A NON-INVASIVE MARKER OF ORGAN REJECTION AFTER LIVER TRANSPLANTATION: A PILOT STUDY

#### Su Kah Goh

Heidelberg, Australia

328.11 INFLAMMASOME EXACERBATED FATTY GRAFT
INJURY WITH ACCUMULATION OF MYELOIDDERIVED SUPPRESSOR CELLS AFTER LIVING
DONOR LIVER TRANSPLANTATION

#### **Hui Liu**

Hong Kong SAR, P.R. of China

328.12 OPTIMIZING IMMUNOMODULATORY
PROPERTIES AND IMMUNOGENICITY OF MSC
FOR IMMUNOTHERAPY FOLLOWING ORGAN
TRANSPLANTATION

#### Samantha F.H. de Witte

Rotterdam, The Netherlands

328.13 EFFECT OF ADIPOSE-DERIVED

MESENCHYMAL STEM CELLS IN A RAT MODEL

OF CHRONIC RENAL ALLOGRAFT REJECTION

#### Irene Noronha Sr.

Sao Paulo, Brazil

#### 10:30 - 12:30 CONVENTION HALL C-LEVEL 1



## Orals and Mini-Orals Session: Allocation/Donor Variables

Chairs: Claus Niemann, San Francisco, CA, United States Kenneth Siu Ho Chok, Hong Kong SAR, P.R. of China

329.1 TRANSPLANTATION OF GRAFT FROM OLDER DONORS: DOES AGE STILL MATTER?

#### **Nicholas Gilbo**

Leuven, Belgium

329.2 DYNAMIC LIVER COMPLIANCE- A NEW
RADIOLOGICAL METRIC TO PREDICT PERIOPERATIVE COURSE OF DONOR HEPATECTOMY

#### **Mettu Srinivas Reddy**

Chennai, India

329.3 POST-OPERATIVE THROMBOCYTOPENIA DETERMINES THE FATE OF ADULT-TO-ADULT LIVING DONOR PARTIAL LIVER TRANSPLANTATION: PROPOSAL OF "THROMBOTIC MICROANGIOPATHY (LTX-TMA) SCORE"

#### **Koichiro Hata**

Kyoto, Japan

329.4 IMPACT OF THE SHARE 35 LIVER ALLOCATION POLICY ON CANDIDATES WITH MELD **EXCEPTION SCORES** 

#### **Elaine Y. Cheng**

Los Angeles, CA, United States

LIVE DONOR CHAMPION PROGRAM FOR LIVER TRANSPLANTATION: TIME TO REDEFINE THE STRATEGY

#### **Daniel G. Maluf**

Charlottesville, VA, United States

**FACTORS ASSOCIATED WITH WORSE** 329.6 **OUTCOME IN KOREAN SPLIT-LIVER** TRANSPLANTATION: ANALYSIS OF THE 10-YEAR KOREAN NETWORK FOR ORGAN SHARING DATA BASE

#### Nam-Joon Yi

Seoul, Korea

PRINCIPLES FROM HIGH VOLUME LIVING DONOR LIVER TRANSPLANTATION CENTRE DOUBLES THE DONOR POOL IN DECEASED DONOR LIVER TRANSPLANTATION

#### **Shishir Pareek**

Gurgaon, India

329.8 CHANGES IN LIVER ALLOGRAFT STEATOSIS AND ITS IMPACT ON EARLY GRAFT FUNCTION AND LONG TERM SURVIVAL



#### **Jason Davis**

Indianapolis, IN, United States

EVALUATION OF THE POTENTIAL IMPACT OF 329.9 INTER-REGIONAL SHARING FOR HIGH MELD PATIENTS WAITING FOR LIVER TRANSPLANTATION

#### Michael Fink

Heidelberg, Australia

#### MINI-ORALS

329.10 HISTOLOGIC CHANGE AFTER BODY WEIGHT REDUCTION OF POTENTIAL LIVING LIVER DONORS WITH FATTY LIVER

## YoungRok Choi

Seoul, Korea

329.11 PREDICTION OF NONALCOHOLIC FATTY LIVER
IN APPARENTLY HEALTHY LIVING LIVER
DONORS: A LARGE HISTOLOGY BASED
COMPARISON TO NORMAL CONTROLS

#### Saigal Sanjiv

Gurgaon, India

329.12 SIGNIFICANCE OF LIVING DOMINO DONOR LIVER TRANSPLANTATION IN THE CONTEXT OF LIMITED NUMBER OF DECEASED ORGAN DONORS IN JAPAN -A SINGLE CENTER EXPERIENCE-

#### **Shintaro Hayashida**

Kumamoto, Japan

329.13 NONALCOHOLIC STEATOHEPATITIS AS
INDICATION FOR LIVER TRANSPLANTATION
IN EUROPE. CLINICAL ANALYSIS OF OVER
37.000 PATIENTS

#### Barbara Kern

Innsbruck, Austria

12:00 - 14:00 S-228-LEVEL 2 BY INVITATION ONLY - NOT A CME SESSION SONG-Tx Consensus Workshop

12:30 - 13:30 LUNCH BREAK

12:30 - 13:30 HALL 5E3-LEVEL 5 NOT A CME SESSION

Industry Symposium:

Optimizing Immunosuppression: A Key for Improving Long-term Outcomes

Organized by



ADVANCING TRANSPLANTATION—TOGETHER

Please refer to page 342 for details.

13:30 - 15:00 HALL 5BC-LEVEL 5



State-of-the-Art Session:

Renal Allograft Dysfunction: Balancing Between Patient Care and Graft Survival

Chairs: Peter Stock, San Francisco, CA, United States Daniel T.M. Chan, Hong Kong SAR, P.R. of China

340.1 CLINICAL-PATHOLOGICAL FINDINGS IN LATE INDICATION BIOPSIES: WHAT, HOW AND WHEN TO TREAT?

Brian J. Nankivell
Westmead, Australia

340.2 TREATING CHRONIC KIDNEY DISEASE OF THE RENAL ALLOGRAFT (CKDT): SHOULDN'T WE DO THINGS BETTER OR SHOULD WE DO DIFFERENT FROM CKD?

**Bertram L. Kasiske**Minneapolis, MN, United States

340.3 RE-TRANSPLANTATION OR RESTARTING DIALYSIS: THE CHOICE, THE TIMING, THE WORK-UP AND THE RISKS?

**Daniel T.M. Chan** Hong Kong SAR, P.R. of China







State-of-the-Art Session: Beta Cell Replacement: Recent Clinical Trials

Chairs: Thierry P.S. Berney, Geneva, Switzerland Jon Odorico, Madison, WI, United States



341.1 OUTCOMES OF THE COLLABORATIVE ISLET TRANSPLANT NIH TRIAL

**Dixon B. Kaufman** Madison, WI, United States



341.2 TRIMECO STUDY RESULTS: ITA VS. IAK VS. MEDICAL THERAPY

**Pierre Y. Benhamou** Grenoble, France



341.3 PRELIMINARY RESULTS OF THE NIH CTOT-15 SPK TRANSPLANTATION TRIAL

**Kenneth A. Newell** Atlanta, GA, United States

13:30 - 15:00 HALL 5E1-LEVEL 5



State-of-the-Art Session: Increased Deceased Donation – Focus on Asia

Chairs: Kimberly Young, Edmonton, AB, Canada Wai-Leung Chak, Hong Kong SAR, P.R. of China



342.1 THE ICU SPECIALIST ROLE IN ORGAN DONATION

**Wai Ming Chan** Hong Kong SAR, P.R. of China



342.2 ASIAN PRACTICES FOR DECEASED DONATION

Vasant Sumethkul Bangkok, Thailand



342.3 INTERNATIONAL PRACTICES IN DONATION AFTER CIRCULATORY DEATH

Marti Manyalich Barcelona, Spain

13:30 - 15:00 HALL 5E2-LEVEL 5



State-of-the-Art Session: Cellular Therapies in Kidney Transplantation

Chairs: Christophe Michel Legendre, Paris, France Wayne W. Hancock, Philadelphia, PA, United States



343.1 MANY HORSES IN THE RACE: WHAT ARE THE FAVORITES?

**Kathryn J. Wood** Oxford, United Kingdom



343.2 UPDATE FROM THE ONE STUDY: ARE CELLULAR THERAPIES SAFE?

**Edward K. Geissler** Regensburg, Germany



343.3 INNOVATIVE TRIAL DESIGNS IN TOLERANCE STUDIES: HOW WILL EFFICACY BE DEMONSTRATED?

Sindhu Chandran San Francisco, CA, United States

13:30 - 15:00 S-221-LEVEL 2



State-of-the-Art Session: Are Transplantation Registries Relevant or Irrelevant?

Chairs: Stephen McDonald, Adelaide, Australia Bo Ying Cindy Choy, Hong Kong SAR, P.R. of China



344.1 WHAT IS THE FUTURE OF INTERNATIONAL REGISTRIES? CARDIAC EXEMPLARS?

Anne I. Dipchand Toronto, ON, Canada



344.2 TOWARDS A GLOBAL TRANSPLANT REGISTRY

**Beatriz B. Mahillo** Madrid, Spain



344.3 HOW LINKING TRANSPLANT REGISTRIES TO OTHER DATABASES CAN ENHANCE THE VALUE OF REGISTRIES

Germaine Wong
Westmead, Australia





## State-of-the-Art Session: Liver Allocation

Chairs: Abraham Shaked, Philadelphia, PA, United States Jan Lerut, Louvain-la-Neuve, Belgium



345.1 OUT OF TIME: SHOULD LIVING DONOR TRANSPLANTATION BE THE PREFERRED OPTION FOR FULMINANT AND ACUTE ON CHRONIC LIVER FAILURE? THE PERSPECTIVE FROM TURKEY

Yaman Tokat Istanbul, Turkey



345.2 WHAT ARE THE BARRIERS TO DECEASED DONOR LIVER TRANSPLANTATION IN INDIA, AND HOW THIS IMPACTED RECIPIENT SELECTION?

**Mohamed Rela** Chennai, India



345.3 LIVER TRANSPLANTATION IN SOUTH KOREA:
THE BEST OF BOTH WORLDS? THE IMPACT OF
GROWTH OF DECEASED DONOR ORGAN
TRANSPLANTATION IN A REGION WITH A
VERY HIGH VOLUME LDLT PRACTICE

**Kyung-Suk Suh** Seoul, Korea

13:30 - 15:00 THEATRE 2-LEVEL 1



## State-of-the-Art Session: Transplantomics in Motion

Chairs: Elaine F. Reed, Los Angeles, CA, United States Jonathan S. Bromberg, Baltimore, MD, United States



346.1 REDUCING COMPLEXITY IN TRANSPLANTOMICS

Marina Sirota San Francisco, CA, United States



346.2 GENOME/PROTEOME VARIATIONS IN TRANSPLANT INJURY

Minnie M. Sarwal San Francisco, CA, United States



346.3 APPLICATIONS OF HTS TO UNDERSTANDING INNATE AND ALLOIMMUNITY

Joel T. Dudley
New York, NY, United States

#### 13:30 - 15:00 CONVENTION HALL A-LEVEL 1



State-of-the-Art Session:

Caveat Emptor: Transplantation & Transplant Tourism in the Tropics

Chairs: Michele I. Morris, Miami, FL, United States Ka Foon Chau, Hong Kong SAR, P.R. of China



347.1 PERILS OF VIRAL INFECTION TRANSMISSIONS FROM ORGAN DONORS

**Ban Hock Tan**Singapore, Singapore



347.2 PERILS OF FUNGAL AND BACTERIAL INFECTIONS RISKS OF TRANSPLANT TOURISM

Sharon Chen Westmead, Australia



347.3 TRANSPLANTATION IN LATIN AMERICA

Clarisse Machado Sao Paulo, Brazil

#### 13:30 - 15:00 CONVENTION HALL B-LEVEL 1



State-of-the-Art Session: Advance Nursing Practice and its Contribution to Excellence in Transplant Management

Chairs: Kathy Kable, Westmead, Australia Patrice Pfeiffenberger, Chicago , IL, United States



348.1 LUNG TRANSPLANT ADVANCE PRACTICE NURSE

**Bronwyn J. Levvey** Melbourne, Australia



348.2 ADVANCED PRACTICE NURSES AND THEIR ROLE IN TRANSPLANTATION

**Roberta J. Al Housani-Blakely** Abu Dhabi, United Arab Emirates



348.3 LIVER TRANSPLANT ADVANCE PRACTICE

**Julie Pavlovic** Heidelberg, Australia





State-of-the-Art Session: Towards the 10<sup>th</sup> Anniversary of the Declaration of Istanbul – Policy and Guidance

Chairs: Beatriz Dominguez-Gil, Madrid, Spain TBA



349.1 THE COUNCIL OF EUROPE CONVENTION AGAINST TRAFFICKING IN HUMAN ORGANS: PRESENT AND FUTURE

**Marta López Fraga** Strasbourg, France



349.2 DEFINING PROPER TRAVEL FOR TRANSPLANTATION VERSUS TRANSPLANT TOURISM

> **Elmi M. Muller** Cape Town, South Africa



349.3 DECLARATION OF ISTANBUL: SUCCESSES AND FAILURES

Francis L. Delmonico
Waltham, MA, United States

15:00 - 15:30 COFFEE BREAK HALL 5FG-LEVEL 5

15:30 - 17:00 HALL 5BC-LEVEL 5



## Orals Session: Novel Agents

Chairs: Lionel Rostaing, Toulouse, France Flavio Vincenti, San Francisco, CA, United States

350.1 UTILIZATION AND CLINICAL OUTCOMES OF BELATACEPT-BASED IMMUNOSUPPRESSION IN U.S. RENAL TRANSPLANT RECIPIENTS

Karl L. Womer

Gainesville, FL, United States

**OUTCOMES OF DE NOVO BELATACEPT** 350.2 VERSUS TACROLIMUS IN KIDNEY RECIPIENTS OF HIGH RISK DONORS

#### Giselle Guerra

Miami, FL, United States

350.3 BELATACEPT RESCUE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS WITH SEVERELY IMPAIRED RENAL FUNCTION

#### Klemens Budde

Berlin, Germany

PATTERNS OF IMPROVEMENT IN KIDNEY 350.4 FUNCTION AMONG PATIENTS CONVERTED TO BELATACEPT FROM CALCINEURIN INHIBITORS FOR KIDNEY ALLOGRAFT DYSFUNCTION

#### **Dhiren Kumar**

Richmond, VA, United States

350.5 EARLY CONVERSION TO BELATACEPT IN PATIENTS WITH POOR OR DELAYED GRAFT **FUNCTION** 

#### **Ron Shapiro**

New York, NY, United States

350.6 TOFACITINIB IN RENAL ALLOGRAFT RECIPIENTS: LONG-TERM FEFICACY AND SAFETY IN AN ACTIVE-COMPARATOR-CONTROLLED EXTENSION TRIAL

#### Philip J. O'Connell

Westmead, Australia

350.7 EFFICACY OF A CHIMERIC ANTI-HUMAN ICAM-1
MONOCLONAL ANTIBODY, MD-3, FOR KIDNEY
TRANSPLANTATION IN RHESUS MONKEYS

#### Minji Cho

Seoul, Korea

350.8 A NOVEL NON-INVASIVE BLOOD
TRANSCRIPTIONAL ASSAY, KSORT, MONITORS
ALLOIMMUNE RESPONSE IN THE SAILOR
RANDOMIZED MULTICENTER EU TRIAL

#### Minnie M. Sarwal

San Francisco, CA, United States

350.9 IMMUNOLOGIC BASIS FOR A NOVEL ORGAN-SPECIFIC THERAPY: IMMUNOCLOAKING

#### **Lauren Brasile**

Watervliet, NY, United States

15:30 - 17:00 HALL 5D-LEVEL 5



#### Orals Session:

# Experimental Islet Tx: Engraftment

Chairs: Maria Koulmanda, Boston, MA, United States Paul R. V. Johnson, Oxford, United Kingdom

351.1 COMPOSITE PANCREATIC ISLET GRAFTS WITH ADIPOSE TISSUE-DERIVED STEM CELLS ENHANCE THE SURVIVAL AND INSULIN FUNCTION OF ISLET GRAFTS IN DIABETIC MICE

#### **Masahiro Tanemura**

Osaka, Japan

351.2 WHAT ARE FACTORS AFFECTING INSULIN INDEPENDENCE IN PATIENTS AFTER TOTAL PANCREATECTOMY AND ISLET AUTOTRANSPLANTATION (TPIAT)?

#### **Julia Solomina**

Chicago, IL, United States

351.3 CYANIDIN-3-O-GLUCOSIDE (C3G) IMPROVES
THE CELL VIABILITY OF HUMAN ISLETS
TREATED WITH HUMAN AMYLIN OR ABETA142 IN VITRO

#### **Josue Rodrigues Silva**

Edmonton, AB, Canada

351.4 THE PROTECTIVE EFFECT OF DIMETHYL FUMARATE ON HUMAN PANCREATIC ISLETS

#### Hirohito Ichii

Orange, CA, United States

351.5 OPTIMIZATION OF PRE-VASCULARIZATION PROCEDURES FOR IMPROVING ISLET ENGRAFTMENT UNDER THE SKIN

#### Satomi Suzuki Uematsu

Sendai, Japan

351.6 Y1 RECEPTOR ANTAGONISM ENHANCES
INSULIN SECRETION AND IMPROVES ISLET
TRANSPLANTATION EFFICIENCY

#### Stacey N. Walters

Darlinghurst, Australia

351.7 HUMAN MESENCHYMAL STROMAL CELLS
IMPROVE SURVIVAL AND FUNCTION OF
PANCREATIC ISLETS BY CELL-TO-CELL
CONTACT THROUGH N-CADHERIN

#### **Raphael Meier**

Geneva, Switzerland

351.8 PROTECTION OF STEM-CELL-DERIVED INSULIN-PRODUCING CELLS FROM ISCHEMIC INJURY

#### **Gaetano Faleo**

San Francisco, CA, United States

351.9 SPROUTING OF INTRA-ISLET ENDOTHELIAL CELLS TO FORM PERI-ISLET VESSELS IN HUMAN ISLETS

# Balamurugan N. Appakalai

Louisville, KY, United States

15:30 - 17:00 HALL 5E1-LEVEL 5



### Orals Session:

# Increasing the Organs Pool DCD and Beyond

Chairs: Marti Manyalich, Barcelona, Spain Haibo Wang, Hong Kong SAR, P.R. of China

352.1 KIDNEY TRANSPLANTATION FROM UNCONTROLLED DONORS AFTER CIRCULATORY DEATH:
THE SPANISH EXPERIENCE

#### **Beatriz Dominguez-Gil**

Madrid, Spain

352.2 LARGEST US OPO DCD EXPERIENCE: 1014 DCD DONORS OVER TWO DECADES

**Howard M. Nathan** 

Philadelphia, PA, United States

352.3 EXPERIENCE WITH DONATION AFTER
CIRCULATORY DEATH (DCD) IN DONORS AGED
56-65: A PRELIMINARY REPORT ON KIDNEY
UTILIZATION AND INITIAL OUTCOMES

Jeffrey P. Orlowski

Oklahoma City, OK, United States

352.4 WORLD FIRST REPORT OF LIVER
TRANSPLANTATION FROM AN HIV-POSITIVE
DONOR TO AN HIV-POSITIVE RECIPIENT

**Christian van Delden** 

Geneva, Switzerland

352.5 INITIAL EXPERIENCE OF EN-BLOC KIDNEY
TRANSPLANTATION FROM DONORS LESS
THAN TWO MONTHS OF AGE IN THE UNITED
KINGDOM: A POTENTIAL NEW DONOR POOL

Imeshi U. Wijetunga

Leeds, United Kingdom

352.6 ORGAN DONATION AFTER EUTHANASIA LEADS TO GOOD TRANSPLANT RESULTS

#### Jan Bollen

Maastricht, The Netherlands

352.7 SAVING LIVES ONE ORGAN AT A TIME: ONE OPO'S EXPERIENCE IN A SERVICE AREA WITH A HIGH INCIDENCE OF CEREBROVASCULAR ACCIDENTS

#### **Vernon L Langley**

Norcross, GA, United States

352.8 IDENTIFYING NEONATAL POTENTIAL FOR SOLID ORGAN AND TISSUE DONATION IN THE NEWCASTLE UPON TYNE HOSPITALS (UK)

Aranzazu Quiralte Baglietto

Newcastle, United Kingdom

352.9 EVALUATE QUALITY OF KIDNEYS FROM DCD/ECD DONORS BY PARAMETERS OF MACHINE PERFUSION

#### **Guodona Chen**

Guangzhou, People's Republic of China

15:30 - 17:00 HALL 5E2-LEVEL 5



#### Orals Session: Acute Injury

Chairs: Teun Van Gelder, Rotterdam, Netherlands Fritz Diekman, Barcelona, Spain

353.1 STEM CELL-MEDIATED REGENERATION OF ISCHEMICALLY DAMAGED HUMAN RENAL ALLOGRAFTS DURING EX VIVO WARM PERFUSION

#### **Lauren Brasile**

Watervliet, NY, United States

353.2 PROPERDIN DEFICIENCY AGGREVATES THE RENAL INJURY OF ISCHEMIA REPERFUSION

#### **Bin Yang**

Leicester, United Kingdom

353.3 FRACTIONAL EXCRETION OF NGAL INSTEAD
OF 99MTCMAG3 RENOGRAPHY TO MONITOR
RESOLUTION OF DELAYED GRAFT FUNCTION

#### J. R. Bank

Leiden, The Netherlands

353.4 HYPOTHERMIC PULSATILE PRESERVATION OF KIDNEYS FROM UNCONTROLLED DECEASED DONORS AFTER CARDIAL ARREST

#### Palmina Petruzzo

Lyon, France

353.5 ECULIZUMAB FOR PREVENTION AND TREATMENT OF THE KIDNEY GRAFT REPERFUSION IN JURY

#### Michael M. Kaabak

Moscow, Russian Federation

353.6 IMPACT OF PRE-EXISTING DIABETES
MELLITUS ON THE IMMUNOLOGIC OUTCOME
AFTER KIDNEY TRANSPLANTATION

#### **Dmytro Khadzhynov**

Berlin, Germany

353.7 IS PROLONGED COLD ISCHEMIA A
CONTRAINDICATION TO USING KIDNEYS
FROM ACUTE KIDNEY INJURY DONORS?

#### **Giuseppe Orlando**

Winston Salem, NC, United States

RETROSPECTIVE STUDY OF POST RENAL 353.8 TRANSPLANT DELAYED GRAFT FUNCTION -ANALYSIS OF MULTIPLE DEFINITIONS AND RESPECTIVE PROGNOSTIC CAPACITY

Samantha M. Bateman

Fitzroy North, Australia

353.9 INTERIM ANALYSIS TO DETERMINE WHETHER PREOPERATIVE INTRAVENOUS FLUIDS RESULT IN A DECREASE IN DONOR SUBCLINICAL **ACUTE KIDNEY INJURY** 

**Ryan Ghita** 

Glasgow, United Kingdom

15:30 - 17:00 S-221-LEVEL 2



#### Orals Session:

Making Lung Transplant Work Chairs: Bronwyn J Levvev, Melbourne, Australia

Allan R. Glanville, Sydney, Australia **EXTRACORPOREAL MEMBRANE** 354.1

**OXYGENATION PRACTICES CHANGES AS** BRIDGE TO LUNG TRANSPLANTATION: AN INSTITUTIONAL EXPERIENCE AND LITERATURE REVIEW

#### **Daniel Oscar Absi**

Buenos Aires, Argentina

354.2 DONOR CCR2+ CARDIAC MACROPHAGES MEDIATE NEUTROPHIL EXTRAVASATION AFTER HEART TRANSPLANTATION THROUGH MYD88-DEPENDENT PRODUCTION OF

**CHEMOATTRACTANTS** 

#### Wenjun Li

St Louis, MO, United States

TERTIARY LYMPHOID ORGANS WITHIN PULMONARY ALLOGRAFTS PROMOTE **TOLERANCE** 

#### Weniun Li

St Louis, MO, United States

EFFECTS OF BRAIN DEATH (BD) OR CARDIAC DEATH (DCD) ON ALLOGENEIC LUNG GRAFT SURVIVAL IN PRECLINICAL MHC-INBRED **CLAWN MINIATURE SWINE** 

#### Yuichi Ariyoshi

Kagoshima, Japan

INTRAOPERATIVE VASOPRESSIN USE AS A 354.5 **FAVORABLE PROGNOSTIC FACTOR FOR EARLY** SURVIVAL AFTER LUNG TRANSPLANTATION

#### **Kyoung Shik Narm**

Seoul, Korea

THE IMMUNOSUPPRESSIVE FEFECT VIA HGE-354.6 CMET PATHWAY OF AUTOLOGOUS ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN A RAT LUNG TRANSPLANTATION MODEL

#### Hironosuke Watanabe

Nagasaki, Japan

**OUTCOMES OF ACUTE KIDNEY INJURY** 354.7 OCCURRING IMMEDIATELY POST LUNG TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTRE AUDIT

#### **Solomon Menahem**

Melbourne, Australia

RENAL OUTCOMES IN LUNG TRANSPLANT 354.8 RECIPIENTS TREATED WITH THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) INHIBITOR **EVEROLIMUS** 

#### Timothy E. Coughlan

Mount Waverly, Australia

#### 15:30 - 17:00 **THEATRE 1-LEVEL 1**



#### Orals Session: Ischaemia Reperfusion/Preservation

Chairs: William Sharr, Hong Kong SAR, P.R. of China Mehmet Haberal, Ankara, Turkey

A MULTICENTRE RANDOMISED CONTROLLED 355.1 TRIAL TO COMPARE THE EFFICACY OF NORMOTHERMIC MACHINE PERFUSION WITH STATIC COLD STORAGE IN HUMAN LIVER TRANSPLANTATION: EARLY OUTCOMES

#### **David Nasralla**

Oxford, United Kingdom

355.2 DAMP-ASSOCIATED PRESERVATION INJURY AND COMPLICATIONS AFTER LIVER TRANSPLANTATION: PROOF OF CONCEPT



**Denis Efimov** 

Minsk, Belarus

355.3 BILIARY EPITHELIAL DAMAGE, REGENERATIVE
CAPACITY AND LOCAL IMMUNE RESPONSE
AFTER COLD STORAGE OF DBD LIVERS
DETERMINE BILIARY COMPLICATIONS AFTER
LIVER TRANSPLANTATION

#### Hans J. Schlitt

Regensburg, Germany

355.4 IMPORTANCE OF DNA METHYLATION PATTERNS
AND ASSOCIATION WITH GRAFT INJURY
SEVERITY AFTER LIVER TRANSPLANTATION

#### Daniel G. Maluf

Charlottesville, VA, United States

355.5 EXOGENOUS MELATONIN PROMOTES GRAFT REGENERATION IN SMALL-FOR-SIZE LIVER TRANSPLANTATION

#### **Zhuolun Song**

Zurich, Switzerland

355.6 REPERFUSION FIBRINOLYSIS SHUTDOWN
AFTER LIVER TRANSPLANTATION: RATIONALE
FOR PERMISSIVE HYPOCOAGULABILITY IN
THE POST-OPERATIVE SETTING

#### **Hunter B. Moore**

Aurora, CO, United States

355.7 THE EFFECT OF NAFAMOSTAT MESILATE TO MINIMIZE ISCHEMIC-REPERFUSION INJURY OF THE LIVER FOLLOWING LIVER TRANSPLANTATION: A SINGLE ARM PILOT STUDY

#### Young-Dong Yu

Seoul, Korea

355.8 IMPACT OF A NEWLY DEVELOPED SOLUTION
CONTAINING ARTIFICIAL OXYGEN CARRIER
HEMOGLOBIN VESICLES UNDER
SUBNORMOTHERMIC CONDITIONS WITH
MACHINE PERFUSION PRESERVATION FOR
DCD LIVER GRAFTS IN PIGS

#### **Naoto Matsuno**

Asahikawa, Japan

355.9 THE COMPARISON WITH DONATION AFTER CARDIAC DEATH LIVER GRAFTS BY OXYGENATED SUBNORMOTHERMIC WITH REWARMING MACHINE PERFUSION IN PIGS

#### **Naoto Matsuno**

Asahikawa, Japan

#### 15:30 - 17:00 THEATRE 2-LEVEL 1



#### Orals Session: Regulatory Mechanisms 1

Chairs: Andreas Linkermann, Kiel, Germany Kazuhiko Yamada, New York, NY, United States

356.1 DONOR DCs IN CHIMERIC VASCULARIZED THYMIC GRAFTS, BUT NOT ANTIGEN-PRESENTING HOST DCs, PLAY AN ESSENTIAL ROLE IN THE INDUCTION OF TOLERANCE OF SOLID ORGANS IN A PRECLINICAL LARGE ANIMAL MODEL

#### Kazuhiko Yamada

New York, NY, United States

356.2 THE COMBINED EFFECT OF STEM CELL
FACTOR AND GRANULOCYTE MACROPHAGE
COLONY-STIMULATING FACTOR
ADMINISTRATION AFTER 90% PARTIAL
HEPATECTOMY IN RATS

#### **Hyerim Byeon**

Goyang-si, Korea

356.3 INTERLEUKIN-34 IS A TREG-SPECIFIC CYTOKINE AND MEDIATES TRANSPLANT TOLERANCE

#### Séverine Bézie

Nantes, France

356.4 IL-10 EXPRESSION OF IN VITRO ACTIVATED B CELLS AS A BIOMARKER FOR B CELL TOLERANCE

#### **Kiyohiko Hotta**

Boston, MA, United States

356.5 IMMUNE TOLERANCE MONITORING IN RENAL ALLOGRAFT TOLERANCE INDUCED BY TRANSIENT MIXED CHIMERISM IN NONHUMAN PRIMATES AND HUMANS

#### Kiyohiko Hotta

Boston, MA, United States

356.6 RECENTLY ALLOACTIVATED CD4+CD8-CD25+TREG EXPRESS CD8 AND ARE THE ANTIGEN-SPECIFIC TREG

#### Bruce M. Hall

Sydney, Australia

356.7 THE UK ONE STUDY TRIAL: SAFETY AND FEASIBILITY OF REGULATORY T (TREG) CELL THERAPY IN RENAL TRANSPLANTATION

#### **Paul Harden**

Oxford, United Kingdom

356.8 COMBINATION OF VETO CELL TRANSFER AND INKT CELL THERAPY ESTABLISHES COMPLETE HEMATOPOIETIC CHIMERISM IN NON-MYELOABLATIVE BMT RECIPIENTS

#### **Toshihito Hirai**

Tokyo, Japan

356.9 NATURAL KILLER CELLS DEMONSTRATE FUNCTIONAL AND RECEPTOR DIVERSITY IN RESPONSE TO ALLOANTIGEN

#### **Sheri Krams**

Stanford, CA, United States

#### 15:30 - 17:00 CONVENTION HALL A-LEVEL 1



#### Orals Session: Exploring Cellular Interactions in Tissue Injury

Chairs: Olivia M. Martinez, Stanford, CA, United States Midas Seyda, Boston, MA, United States

357.1 CELL-FREE MITOCHONDRIAL DNA
ACTIVATES DCs IN AN AGE-DEPENDENT
FASHION AND COMPROMISES THE SURVIVAL
OF OLDER GRAFTS

#### **Midas Seyda**

Boston, MA, United States

357.2 DONOR BRAIN DEATH INFLUENCES EARLY NK
CELL MIGRATION IN MURINE HEART AND
KIDNEY TRANSPLANTATION

#### **Paul Viktor Ritschl**

Berlin, Germany

357.3 EVOLUTION OF INNATE AND ADAPTIVE
CYTOKINE RESPONSES IN ISCHEMIA
REPERFUSION INJURY IN ORTHOTOPIC LIVER
TRANSPLANTATION

#### **Ali Zarrinpar**

Los Angeles, CA, United States

357.4 BRUTON'S TYROSINE KINASE INHIBITION
ATTENUATES MOUSE LIVER DAMAGE DUE TO
ISCHEMIA AND REPERFUSION

#### **Ali Zarrinpar**

Los Angeles, CA, United States

357.5 PRE-TREATMENT OF HEART ALLOGRAFTS
WITH THE CYTOTOPIC ANTI-THROMBIN
INHIBITOR THROMBALEXIN PROLONGS
TRANSPLANT SURVIVAL AND AUGMENTS THE
THERAPEUTIC EFFICACY OF ADOPTIVELY
TRANSFERRED REGULATORY T CELLS

#### Qi Peng

London, United Kingdom

357.6 REPRESSOR AND ACTIVATOR PROTEIN
ACCELERATES HEPATIC ISCHEMIA
REPERFUSION INJURY BY PROMOTING
NEUTROPHIL INFLAMMATORY RESPONSE

#### **Chang Xian Li**

Hong Kong SAR, P.R. of China

357.7 EXPRESSION OF HUMAN CD55 AND CD59
REDUCES COMPLEMENT DEPOSITION AND
PRESERVES RENAL FUNCTION IN A MOUSE
MODEL OF RENAL ISCHEMIA REPERFUSION
INJURY

#### **David Bo Lu**

Hoppers Crossing, Australia

357.8 AMP-ACTIVATED PROTEIN KINASE
ATTENUATED MARGINAL LIVER GRAFT
INJURY VIA PROMOTING MITOCHONDRIAL
BIOGENESIS AND RESPIRATORY FUNCTION

#### **Jiang Liu**

Hong Kong SAR, P.R. of China

357.9 CHANGES IN ACTIVIN LEVELS AND THE IMPACT OF FOLLISTATIN TREATMENT IN RENAL ISCHEMIA-REPERFUSION INJURY IN MICE

#### **Peter Cowan**

Melbourne, Australia

#### 15:30 - 17:00 CONVENTION HALL B-LEVEL 1



#### Orals Session: Histocompatibility

Chairs; Caner Süsal, Heidelberg, Germany Frans H.J. Claas, Leiden, The Netherlands

358.1 TIME-SERIES VARIATIONS IN CALCULATED PANEL REACTIVE ANTIBODY AMONG KIDNEY TRANSPLANT CANDIDATES

#### Clarence E. Foster III

Irvine, CA, United States

358.2 EARLY DE NOVO DSA WITH T CELL
MEDIATED REJECTION (TCMR) IS ASSOCIATED
WITH ALLOGRAFT DYSFUNCTION WITH
CHRONIC INJURY

#### **Aravind Cherukuri**

Pittsburgh, PA, United States

358.3 THE NEW OPTN KIDNEY ALLOCATION
SYSTEM: A LOOK AT THE ONE YEAR
TRANSPLANT TREND IN THE HIGHLY
SENSITIZED PATIENT COHORT

#### **Taba Kheradmand**

Ann Arbor, MI, United States

358.4 ASSOCIATION OF KIR3DL1/3DS1 ALLELES WITH RENAL ALLOGRAFT REJECTION

#### Swayam Prakash

Lucknow, India

358.5 C1Q-FIXING ANTIBODIES AGAINST DENATURED
HLA AND MICA ANTIGENS ARE ASSOCIATED
WITH ANTIBODY MEDIATED REJECTION

#### Junchao Cai

Los Angeles, CA, United States

358.6 AGREEMENT BETWEEN NUMBER OF DONOR /
RECIPIENT EPLET MISMATCHES CALCULATED
USING TWO-DIGIT SEROLOGICAL VERSUS
FOUR-DIGIT MOLECULAR HUMAN
LEUCOCYTE ANTIGEN (HLA)-TYPING

#### Samantha J. Fidler

Perth, Australia

358.7 CAREFUL DESELECTION OF LOW RISK
UNACCEPTABLE ANTIGENS CAN FACILITATE
RENAL TRANSPLANTATION IN HIGHLY
SENSITISED PATIENTS WITH EXCESSIVE TIME
ON THE WAITING LIST

#### Stuart J. Falconer

Glasgow, United Kingdom

358.8 C1Q/C3D SINGLE ANTIGEN BEAD ASSAY ONLY
DETECTS HIGH TITER/AVIDITY CLASS-I ANTIHLA ANTIBODIES DETECTED BY SINGLE
ANTIGEN BEADS

#### Manish Gandhi

Rochester, MN, United States

358.9 REGULATION OF MICRORNA HSA-MIR-663A BY HLA CLASS I ANTIBODIES IN ENDOTHELIAL CELLS

#### **Omar Moussa**

Charleston, SC, United States

#### 15:30 - 17:00 CONVENTION HALL C-LEVEL 1



#### Orals Session:

Overcoming Medical, Surgical and Immunologic Barriers in Paediatric Solid Organ Transplantation

- Chairs: George V. Mazariegos, Pittsburgh, PA, United States Minnie M. Sarwal, San Francisco, CA, United States
- 359.1 MASS CYTOMETRY REVEALS NK CELL AND T
  CELL SUBSETS IN PEDIATRIC LIVER TRANSPLANT
  PATIENTS WITH ACUTE REJECTION

#### **Sheri Krams**

Stanford, CA, United States

359.2 PEDIATRIC LIVER TRANSPLANTATION USING SEGMENTAL GRAFTS IN JAPAN: A SINGLE-CENTER EXPERIENCE WITH 270 PATIENTS

#### Koichi Mizuta

Tochigi, Japan

359.3 SINGLE KIDNEY TRANSPLANTATION FROM PEDIATRIC DONORS YOUNGER THAN 3 YEARS TO ADULT RECIPIENTS

#### Lan Zhu

Wuhan, People's Republic of China

359.4 OVERCOMING BARRIERS IN COMPLEX PAEDIATRIC RENAL TRANSPLANTATION

#### **Pankaj Chandak**

London, United Kingdom

359.5 BARRIERS TO PREEMPTIVE RENAL TRANSPLANTATION IN NEW ZEALAND CHILDREN

#### **Tonya Kara**

Auckland, New Zealand

359.6 ASSOCIATION OF C1Q FIXING DONOR-SPECIFIC HLA ANTIBODIES WITH LATE GRAFT FAILURE IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS

#### **Burkhard Tönshoff**

Heidelberg, Germany

359.7 ACCEPTABLE POST-HEART
TRANSPLANTATION OUTCOMES OF
CHILDREN LISTED IN TOTAL RENAL FAILURE

#### Nassiba Alami Laroussi

Edmonton, AB, Canada

359.8 CONTRIBUTING FACTORS TO TRANSPLANT
MEDICATION ERRORS IN PEDIATRIC PATIENTS

#### Yew Weng Perry Lau

Singapore, Singapore

359.9 CYTOKINE PROFILES IN CHILDREN AFTER
PEDIATRIC KIDNEY TRANSPLANTATION WITH
ACUTE CELLULAR COMPARED TO CHRONIC
HUMORAL REJECTION AND STABILE
PATIENTS

#### **Nadja Borsum**

Hannover, Germany

17:00 - 17:20 HALL 5FG-LEVEL 5 (Behind TTS booth in aisle 500) NOT A CME SESSION

#### ISN-TTS Sister Transplantation Center Program

360. PRESENTATION OF ISN-TTS SISTER TRANSPLANTATION CENTER PROGRAM

#### Randall Lou Meda

Guatemala, Guatemala

#### Abdullah El-Kishawi

Gaza City, Palestine

17:00 - 18:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



#### Campfire Presentations: Kidney I - Campfire Table 1

Chairs: José Ramón Núñez Peña, Geneva, Switzerland Robert A. Montgomery, New York, NY, United States

370.1 CLINICAL IMPACT OF GRAFT VOLUME
CHANGE AFTER BODY WEIGHT MISMATCHED
KIDNEY TRANSPLANTATION: BASED ON DATA
OF POSTOPERATIVE MAGNETIC RESONANCE
VOLUMETRY

#### Kyungjai Ko

Seoul, Korea

370.2 LONG TERM, SINGLE CENTRE EXPERIENCE
WITH SIMULTANEOUS AORTOILIAC
ALLOGENIC RECONSTRUCTION AND KIDNEY
TRANSPLANTATION

#### **Tomas Marada**

Prague, Czech Republic

370.3 LAPAROSCOPIC DONOR NEPHRECTOMY: A COMPARISON OF RETROPERITONEOSCOPIC VERSUS TRANSPERITONEOSCOPIC APPROACH

#### Zi Qin Ng

Perth, Australia

370.4 THE UPPER URINARY TRACT UROTHELIAL CARCINOMA BEHAVIORS AFTER KIDNEY TRANSPLANTATION IN TAIWAN

#### **Chia-Shen Chien**

Kaohsiung, Taiwan

370.5 COMPARISON OF BASELINE CO-MORBIDITY
AND MORTALITY IN LIVING DONORS – 10
YEAR UK COHORT STUDY

#### Nithya Krishnan

Coventry, United Kingdom

370.6 EFFECTIVENESS OF THREE-DIMENSIONAL
IMAGE ANALYSIS FOR SURGICAL SIMULATION
OF LIVING DONOR KIDNEY
TRANSPLANTATION WITH MULTIPLE RENAL
ARTERY GRAFTING

#### **Koichi Tomita**

Tokyo, Japan

17:00 - 18:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



#### Campfire Presentations: Liver - Campfire Table 2

Chairs: Kieron Lim, Singapore, Singapore Gursharam Singh, Coimbatore, India

371.1 WHICH IS THE PREDICTABLE VALUES OF POST-TRANSPLANT HCC RECURRENCE IN PATIENTS RECEIVED DOWN STAGING THERAPY OR BRIDGING THERAPY?

#### Jae Geun Lee

Seoul, Korea

371.2 ISCHEMIC CHOLANGIOPATHY IS THE ONLY
BILIARY COMPLICATION THAT IMPACTS
OUTCOME FOLLOWING DONATION AFTER
CARDIAC DEATH LIVER TRANSPLANTATION

#### **Shiva Kumar**

Abu Dhabi, United Arab Emirates

371.3 IMPACT OF DONATION AFTER CARDIAC DEATH ALLOGRAFTS ON OUTCOME FOLLOWING SIMULTANEOUS LIVER KIDNEY TRANSPLANTATION

#### **Shiva Kumar**

Abu Dhabi, United Arab Emirates

371.4 EX VIVO SUBNORMOTHERMIC OXYGENATED LIVER PERFUSION JUST BEFORE LIVER TRANSPLANTATION FROM NON-HEART-BEATING DONORS MIGHT IMPROVE GRAFT VIABILITY, IN PIG MODEL

#### Yuta Kakizaki

Sendai, Japan

371.5 ABO INCOMPATIBLE DUAL GRAFT LIVING DONOR LIVER TRANSPLANTATION

#### Jae Hyun Kwon

Seoul, Korea

371.6 INFLAMMATION-BASED PROGNOSTIC SCORE IN LIVING DONOR LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA

#### **Norifumi Harimoto**

Fukuoka, Japan

17:00 - 18:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



# Campfire Presentations: Deceased Donation - Campfire Table 3

Chairs: Howard M. Nathan, Philadelphia, PA, United States Mei Lan May Pong, Hong Kong SAR, P.R. of China

372.1 SIGNIFICANT CHANGES IN THE ORGAN DONOR POOL OVER THE LAST 10 YEARS: DONORS FROM ANOXIC CAUSE OF DEATH (COD) MORE THAN DOUBLE WHICH INCLUDES A 300% INCREASE IN DONORS WITH A DRUG OVERDOSE

#### **Howard M. Nathan**

Philadelphia, PA, United States

372.2 CAN KNOWLEDGE AND ATTITUDES OF CRITICAL CARE PROFESSIONALS INFLUENCE ORGAN DONATION? - A MALAYSIAN PERSPECTIVE

#### James W. Foong

Serdang, Malaysia

372.3 EYE DONATION IN HONG KONG: ATTITUDES OF FAMILY MEMBERS OF DECEASED PATIENTS

#### **Chor Kwan Amanda Luk**

Hong Kong SAR, P.R. of China

372.4 KNOWLEDGE AND ATTITUDES REGARDING
BRAIN DEATH AND ORGAN DONATION
AMONG YOUNG MALES IN THE
NORTHEASTERN THAILAND

Jongruk Pongskul Bangkok, Thailand

372.5 THE DEVELOPMENT AND MANAGEMENT OF CHINA ORGAN PROCUREMENT ORGANIZATION ALLIANCE

#### Xiaoli Fan

Wuhan, People's Republic of China

372.6 OUTCOMES OF KIDNEY TRANSPLANTATION
USING KIDNEYS FROM EXPANDED CRITERIA
DONORS AND DONORS WITH ACUTE KIDNEY
INJURY IN THAILAND

**North Techawathanawanna** Bangkok, Thailand

17:00 - 18:00 HALL 5FG-LEVEL 5 NOT A CME SESSION BS

Campfire Presentations: Unraveling Alloreactivity: Innovative Approaches (I) - Campfire Table 4

Chairs: Nancy Kwan Man, Hong Kong SAR, P.R. of China Rebeca Arroyo Hornero, Oxford, United Kingdom

373.1 EXPRESSION OF THREE ALLOGENEIC MHC
CLASS I IN RECIPIENT LIVER SIGNIFICANTLY
PROLONGS SURVIVAL OF FULLY-ALLOGENEIC
VASCULARISED CARDIAC ALLOGRAFTS

Mamdoh Moawadh Sydney, Australia

373.2 HEIGHTENED EXPRESSION OF HLA-DQB2
AND HLA-DPB1 GENES IN PREIMPLANTATION KIDNEY BIOPSIES IS
ASSOCIATED WITH POOR GRAFT FUNCTION

Maria Gerbase-DeLima Sao Paulo, Brazil

373.4 LONG-TERM SURVIVAL OF HUMAN STEM
CELL-DERIVED INSULIN PRODUCING CELLS
(SCIPCs) TRANSPLANTED TO THE
SUBCUTANEOUS SPACE IN A DIABETIC
MURINE MODEL

#### Steven A. Wisel

San Francisco, CA, United States

373.5 SECRETORY LEUKOCYTE PROTEINASE
INHIBITOR: A BIOMARKER FOR ACUTE KIDNEY
INJURY HAS A PROTECTIVE ROLE IN KIDNEY
TRANSPLANTION

#### **Eduardo Chuluyan**

Buenos Aires, Argentina

373.6 EXPRESSION OF CXCR3 BY ISLET-INFILTRATING MEMORY T CELLS IN THE PANCREAS TRANSPLANT WITH RECURRENT TYPE 1

**George W. Burke**Miami, FL, United States

17:00 - 18:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



# Campfire Presentations: Developing Transplant Programmes Across the World - Campfire Table 5

Chairs: Jongwon Ha, Seoul, Korea Curie Ahn, Seoul, Korea

374.1 KNOWLEDGE AND ATTITUDE OF PEOPLE
TOWARDS END-STAGE KIDNEY DISEASE, KIDNEY
TRANSPLANTATION AND KIDNEY DONATION:
OPINION FROM A DEVELOPING COUNTRY

#### **Palash Mitra**

Dhaka, Bangladesh

374.2 DEVELOPMENT OF A DECEASED DONOR
PROGRAM IN NEW CALEDONIA THROUGH AN
INTERNATIONAL HYBRID MODEL

#### **Nicolas Quirin**

Noumea, New Caledonia

374.3 SUCCESS TRANSFORMATION OF ORGAN DONATION SYSTEM BRINGS POSITIVE FEEDBACK TO DONATION MANNER OF MEDICAL FRONTIERS IN CHINA

#### Nga-Lei Tam

Shenzhen, People's Republic of China

374.4 ORGAN DONATION AND TRANSPLANTATION IN MONTENEGRIN POPULATION

#### **Marina Ratkovic**

Podgorica, Montenegro

374.5a POST TRANSPLANT INFECTIONS:
A SINGLE CENTRE EXPERIENCE
(abst. P.1267 in the *Transplantation Journal*)

#### **Tahir Aziz**

Karachi, Pakistan

374.6 THE TRINIDAD AND TOBAGO EXPERIENCE:
A SUCCESSFUL MODEL TO DEVELOP A
DONATION SYSTEM USING SEUSA PROGRAM
(abst. P.1633 in the *Transplantation Journal*)

#### Gloria Páez

Barcelona, Spain

17:00 - 18:30 HALL 5FG-LEVEL 5 NOT A CME SESSION

#### **Poster Sessions**

Detailed list of all the posters availableon page 273

17:00 - 19:00 THEATRE 2-LEVEL 1 NOT A CME SESSION

Women in Transplantation Workshop and Networking Event

17:30 - 19:00 HALL 5E3-LEVEL 5 NOT A CME SESSION

Industry Symposium: Donor Specific Antibody Monitoring

Organized by



A Thermo Fisher Scientific Brand

Please refer to page 343 for details.

18:00 - 21:00 S-226-LEVEL 2 BY INVITATION ONLY - NOT A CME SESSION

Living Donor Organ Transplantation in Asia (5<sup>th</sup> Vitallink International Workshop)

19:30 - 21:30
OFFSITE - THE PAWN
62 JOHNSTON RD., WAN CHAI
TICKETED EVENT \$ - NOT A CME SESSION

TTS Young Investigators Networking Event


With the Kind Support from Bridge to Life



382. LESSONS LEARNED IN MY CAREER

**Peter Stock** San Francisco, CA, United States

# MORNING SESSIONS SUNDAY • AUGUST 21



# SUNDAY

# AFTERNOON SESSIONS SUNDAY • AUGUST 21

	13:30	15:00	15:30	17:00	18:30
Conv. Hall C - L1	SOTA Vaccination Strategies / Viral Infections	15	hallenges following Paediatric Solid Organ Tx.	71 (M) (M) (M) (M) (M) (M) (M) (M) (M) (M)	18
Conv. Hall B - L1	SOTA Pulmonary AMR: The Way Ahead	Coffee Break and Poster Viewing (Hall 5FG - L5)	_	Campfire & Poster Sessions (Hall 5FG - L5) Unraveling Alloreactivity 2 / Kidney 2 / Optimizing Donation / Paediatrics / Immuno & Beyond	
Conv. Hall A - L1	SOTA Emerging Tech. in Bioeng., Regen. & Repair BS		OC Unraveling DC Function & Migration 6S		2016
Theater 2 - L1 Conv. Hall A - L1 Conv. Hall B - L1 Conv. Hall C - L1	SOTA Cell Tx.		OC Cell Tx.		TSC Mentee-Mentor Awards Networking Event Conv. Hall A - L1
Theater 1 - L1	SOTA Tolerance in Liver Transplantation		OC Viruses & Cancer		
5-221 - 1.2	Sora Gender Effect on Tx. Access & Outcomes	e Break and Poster	OC OC Immunobiology & Viruses & Cancer Rejection	<b>mpfire &amp; Poster Ses</b> / Kidney 2 / Optimizir	<b>TSC Mentee-Ment</b>
Hall 5E2 - L5	SOTA Repurposing Drugs for Transplant Indications	Coffe	OC Kidney Access & Allocation	<b>Ca</b> eling Alloreactivity 2	
Hall 5E1 - L5	SOTA Importance of Non- HLA Antibodies		Malignancy & Cardio-Vascular Comps	Unrav	
Hall 5D - L5	SOTA What's New & Hot in Intestinal Tx.?		Liver & Intestine Tx.		
Hall 5BC - L5	SOTA SOTA SOTA SOTA SOTA SOTA SOTA SOTA		OC Tolerance & Regimens		
	13:30	15:00	15:30	17:00	18:30



# MENTEE-MENTOR NETWORKING EVENT

18:30– 19:30

#### BY INVITATION ONLY

The Transplantation Society celebrates the contributions of basic science to the field of transplantation with the International Transplantation Science Mentee-Mentor Travel Awards. These awards recognize the efforts of basic scientists who have advanced our understanding of transplant science/immunobiology and/or treatment of transplant recipients, and the young investigators who will be the future leaders in transplantation.

#### **CONVENTION HALL A - LEVEL 1**

See the names of this year's awardees on page 39

#### 07:00 - 08:15 THEATRE 1-LEVEL 1



## Early Morning Symposia: KDIGO Kidney Transplant Guidelines

Chairs: Steven J. Chadban, Camperdown, Australia Bertram L. Kasiske, Minneapolis, MN, United States



400.1 PREDICTING INDIVIDUALIZED LIFETIME RISK
OF END-STAGE RENAL DISEASE IN KIDNEY
DONOR CANDIDATES

**Bertram L. Kasiske**Minneapolis, MN, United States



400.2 STRATEGIES FOR OPTIMIZING EFFICIENCY IN LIVING KIDNEY DONOR EVALUATION AND FOLLOW-UP

**Dorry Segev**Baltimore, MD, United States



400.3 EVALUATION AND SELECTION OF CANDIDATES FOR KIDNEY TRANSPLANTATION

> **Gregory Alan Knoll** Ottawa, ON, Canada

07:00 - 08:15 THEATRE 2-LEVEL 1



# Early Morning Symposia: Women in Transplantation

Chairs: Nancy Ascher, San Francisco, CA, United States Lori J. West, Edmonton, AB, Canada



401.1 ARE WOMEN IN TRANSPLANT LEADERSHIP ROLES JUDGED MORE HARSHLY THAN THEIR MALE COLLEAGUES?

Nithya Krishnan Coventry, United Kingdom



401.2 WHY SEX AND GENDER MATTER IN TRANSPLANTATION RESEARCH

**Cara Tannenbaum** Montreal, QC, Canada





Early Morning Symposia: HLA Antibody Assessment for Clinicians

Chairs: Myoung Hee Park, Seoul, Korea Rhonda Holdsworth, Melbourne, Australia



402.1 OVERVIEW OF ADVANCES IN HLA DIAGNOSTICS

Anat R. Tambur Chicago, IL, United States



402.2 INTERPRETING HLA DIAGNOSTICS FOR THE CLINICIAN

**Kathryn Tinckam** Toronto, ON, Canada



402.3 CLINICAL RELEVANCE OF HLA ANTIBODY

**Stefan Schaub**Basel, Switzerland

#### 07:00 - 08:15 CONVENTION HALL B-LEVEL 1



Early Morning Symposia: The Ethics of Choice in Donation and Transplantation

Chairs: Beatriz Dominguez-Gil, Madrid, Spain Dominique E. Martin, Geelong, Australia



403.1 HOW MUCH INFORMATION IS ENOUGH FOR CONSENT TO TRANSPLANTATION OF DECEASED DONOR ORGANS?

Antonia Cronin London, United Kingdom



403.2 DECISION MAKING IN TRANSPLANTATION: WHO DECIDES? PATIENTS, CLINICIANS, POLICY MAKERS

> **Kirsten Howard** Sydney, Australia



403.3 WHAT THE PUBLIC NEEDS OR WANTS TO KNOW WHEN DECIDING WHETHER TO BECOME AN ORGAN DONOR

Alexander M. Capron
Los Angeles, CA, United States

07:00 - 08:15 CONVENTION HALL C-LEVEL 1

Early Morning Symposia: Publishing in Transplantation

Chairs: Jonathan S. Bromberg, Baltimore, MD, United States Edward K. Geissler, Regensburg, Germany



404.1 PANEL DISCUSSIONS

Jeremy R. Chapman

Westmead, Australia



404.2 **Carla Baan**Rotterdam, The Netherlands



404.3 **Stefan G. Tullius**Boston, MA, United States



404.4 **Thierry P.S. Berney** Geneva, Switzerland

07:00 - 08:30 S-228-LEVEL 2 BY INVITATION ONLY - NOT A CME SESSION

Joint Meeting of the Thai, Japanese, and Korean Transplantation Societies: WHO Registry for Organ Coding & Traceability

08:30 - 10:00 HALL 5BC-LEVEL 5

Plenary: Antibody Mediated Injury

Chairs: Dirk Kuypers, Leuven, Belgium Vasant Sumethkul, Bangkok, Thailand

> CURRENT STATUS OF ALLOANTIBODY MEASUREMENT AND MANAGEMENT IN TRANSPLANTATION

Peter William Nickerson Winnipeg, MB, Canada

410.2 POLYREACTIVE ALLOANTIBODIES

Emmanuel Zorn New York, NY, United States

410.3 IMPACT OF COMPLEMENT BINDING AND NON-BINDING ANTIBODIES ON REJECTION

Christophe Michel Legendre Paris, France

10:00 - 10:30 COFFEE BREAK HALL 5FG-LEVEL 5

10:30 - 12:30 HALL 5BC-LEVEL 5 Klm

Orals and Mini-Orals Session: Immunosuppression Adherence

Chairs: Steve J. Chadban, Camperdown, Australia Matthew Kwok Lung Tong, Hong Kong SAR, P.R. of China

420.1 THE IMPACT OF RITONAVIR-BOOSTED PROTEASE INHIBITORS AND NON-DEPLETING ANTIBODY INDUCTION ON OUTCOMES IN HIV-INFECTED KIDNEY TRANSPLANT RECIPIENTS

Ron Shapiro New York, NY, United States

420.2 TRENDS IN IMMUNOSUPPRESSIVE MEDICATION
USE AMONG HEMODIALYSIS PATIENTS WITH
FAILED KIDNEY TRANSPLANTS IN EUROPE,
AUSTRALIA, NEW ZEALAND AND NORTH
AMERICA: RESULTS FROM THE DIALYSIS
OUTCOMES AND PRACTICE PATTERNS STUDY

#### Alan B. Leichtman

Ann Arbor, MI, United States

420.3a CONVERSION FROM TWICE-DAILY PROGRAF TO ONCE-DAILY ADVAGRAF IN MULTI-ETHNIC ASIAN ADULT RENAL TRANSPLANT RECIPIENTS WITH OR WITHOUT CONCOMITANT USE OF DILTIAZEM – IMPACT OF CYP3A5 GENETIC POLYMORPHISM ON TACROLIMUS PHARMACOKINETICS

(abst. P.1512 in the *Transplantation Journal*)

#### **Wai-Ping Yau**

Singapore, Singapore

420.4 USE OF MOBILE INTERNET APPLICATION TO IMPROVE ADHERENCE TO IMMUNOSUPPRESSIVE MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS: PRELIMINARY RESULTS OF THE PRIMA (IMPROVING ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY BY MOBILE INTERNET APPLICATION) STUDY

#### Minji Cho

Seoul, Korea

420.5 CHARACTERIZATION OF GENETIC VARIATION INFLUENCING PHARMACOKINETICS OF ONCE-DAILY TACROLIMUS FORMULATION BY NEXT GENERATION SEQUENCING TECHNOLOGIES IN KOREAN

#### Minji Cho

Seoul, Korea

420.6 ADVERSE EVENTS OF MAINTENANCE IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION REPORTED IN RANDOMIZED CONTROLLED TRIALS: A SYSTEMATIC REVIEW

#### **Martin Howell**

Westmead, Australia

420.7 A HIGH INTRA-PATIENT VARIABILITY IN TACROLIMUS EXPOSURE IS ASSOCIATED WITH POOR LONG-TERM OUTCOME OF KIDNEY TRANSPLANTATION

#### **Teun Van Gelder**

Rotterdam, The Netherlands

420.8 DOES POST-TRANSPLANT ADHERENCE COME AT A COST?

#### **Kunal Yadav**

Minneapolis, MN, United States

420.9 LOW PREVALENCE OF POST POST-TRANSPLANT ANTI-HLA CLASS 2 ANTIBODIES IN LIVING DONOR RENAL TRANSPLANT RECIPIENTS TREATED WITH ATG INDUCTION THERAPY – A SINGLE CENTRE EXPERIENCE

#### Ninoslav Ivanovski

Skopje, The Former Yugoslav Republic of Macedonia

#### MINI-ORALS

420.10 SIMULTANEOUS LIMITED BLOOD SAMPLING
MODELS FOR TACROLIMUS AND
MYCOPHENOLIC ACID PROVIDE AN ACCURATE
AREA UNDER THE CURVE PREDICTION FOR
KIDNEY TRANSPLANT RECIPIENTS

#### Kouhei Nishikawa

Tsu, Mie, Japan

420.11 A COMPARATIVE STUDY BETWEEN LOW DOSE
ANTI-THYMOCYTE GLOBULIN VERSUS
BASILIXIMAB AS INDUCTION THERAPY FOR
STANDARD IMMUNOLOGIC RISK KIDNEY
TRANSPLANT PATIENTS

#### Paolo Miguel A. David

Quezon City, Philippines

420.12 DEPRESSION OF COMPLEMENT REGULATORY FACTORS IN RAT AND HUMAN RENAL GRAFTS IS ASSOCIATED WITH THE PROGRESS OF ACUTE T-CELL MEDIATED REJECTION

#### Kazuaki Yamanaka

Suita, Japan

420.13 EFFECT OF ABCB1 DIPLOTYPE ON TACROLIMUS DISPOSITION IN RENAL RECIPIENTS DEPENDS ON CYP3A5 AND CYP3A4 GENOTYPE

#### **Thomas Vanhove**

Leuven, Belgium

10:30 - 12:30 HALL 5D-LEVEL 5



#### Orals and Mini-Orals Session: Complications

Chairs: Sindhu Chandran, San Francisco, CA, United States William Lee, Hong Kong SAR, P.R. of China

421.1 OUTCOMES OF RECURRENT FOCAL
SEGMENTAL GLOMERULOSCLEROSIS POST
KIDNEY TRANSPLANTATION

#### **Anna Francis**

Nundah, Australia

421.2 AGE-INDEPENDENT INFLUENCE OF PRE-TRANSPLANT CORONARY ARTERY DISEASE AND DIABETES MELLITUS ON PATIENT SURVIVAL AFTER KIDNEY TRANSPLANTATION

#### **Fabian Halleck**

Berlin, Germany

421.3 FRAILTY IN KIDNEY TRANSPLANT RECIPIENTS

#### Mara A. McAdams-DeMarco

Baltimore, MD, United States

421.4 BK VIRUS INFECTION IS A HIGH RISK FACTOR FOR UROTHELIAL CARCINOMA IN RENAL TRANSPLANT RECIPIENTS

#### Masashi Takenaka

Aichi, Japan

421.5 INTRAVOXEL INCOHERENT MOTION IMAGING
IS AN EFFECTIVE WAY TO MONITOR CHRONIC
ALLOGRAFT DYSFUNCTION IN RAT MODELS

#### **Qiang Zhang**

Beijing, People's Republic of China

421.6 THE EFFICACY OF SONOELASTOGRAPHY
METHOD FOR THE DIAGNOSIS OF FIBROSIS IN
RENAL TRANSPLANT PATIENTS

#### **Funda Ulu Ozturk**

Ankara, Turkey

421.7 PREVALENCE AND CHARACTERISTICS OF DUODENAL VILLOUS ATROPHY IN RENAL TRANSPLANT PATIENTS PRESENTING WITH PERSISTENT DIARRHEA

#### **Farina Hanif**

Karachi, Pakistan

421.8 DIFFERENT PATTERNS OF RISK FACTORS FOR LATE GRAFT LOSS ACCORDING RECIPIENT AGE AFTER RENAL TRANSPLANTATION IN THE REAL MEDICINE. AN OBSERVATIONAL, MULTICENTER AND PROSPECTIVE STUDY AT TEN YEARS

#### José María Morales

Madrid, Spain

421.9 AGE ADAPTED IMMUNOSUPPRESSION FOR ELDERLY KIDNEY ALLOGRAFT RECIPIENTS:
BALANCING RISKS FOR CANCER VERSUS
REJECTION

### Francesca Jackson-Spence

Birmingham, United Kingdom

#### **MINI-ORALS**

421.10 CANCER-RELATED OUTCOMES IN KIDNEY
ALLOGRAFT RECIPIENTS IN ENGLAND VERSUS
NEW YORK STATE: A COMPARATIVE
POPULATION-COHORT ANALYSIS BETWEEN
2003 AND 2013

#### Francesca Jackson-Spence

Birmingham, United Kingdom

421.11 EFFECT OF URETERAL STENTS ON BK VIRUS
ACTIVATION IN KIDNEY TRANSPLANT
RECIPIENTS

#### **Rachid Akiki**

Watertown, MA, United States

421.12 CLINICAL PROFILE AND MESSENGER RNA TRANSCRIPTOME SEQUENCING OF KIDNEY ALLOGRAFT RECIPIENTS WITH PLASMA CELL RICH ACUTE REJECTION (PCAR)

#### Thangamani Muthukumar

New York, NY, United States

421.13 TREATMENTS AGAINST RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM COULD INFLUENCE FGF23 AND KLOTHO LEVELS IN RENAL TRANSPLANT RECIPIENTS

#### **Turan Colak**

Ankara, Turkey

#### 10:30 - 12:30 HALL 5E1-LEVEL 5



# Orals and Mini-Orals Session Living Donation and Donor Outcomes

Chairs: John S. Gill, Vancouver, BC, Canada Visist Dhitavat, Bangkok, Thailand

422.1 DEFINING THE TIPPING POINT IN SURGICAL PERFORMANCE IN LAPAROSCOPIC DONOR NEPHRECTOMY DURING ABDOMINAL TRANSPLANT SURGERY FELLOWSHIP: A LEARNING CURVE ANALYSIS

#### Oscar K. Serrano

Minneapolis, MN, United States

422.2 A PREDICTION MODEL FOR LONG-TERM RISK
OF ESRD IN LIVING KIDNEY DONORS BASED
ON INDIVIDUAL CHARACTERISTICS

#### **Allan Massie**

Baltimore, MD, United States

422.3 WHERE DO LIVING DONORS COME FROM?
A COMPARISON OF POTENTIAL LIVING LIVER
AND KIDNEY DONORS AT A HIGH-VOLUME
U.S. CENTER

#### Hillary J. Braun

San Francisco, CA, United States

422.4 PSYCHOSOCIAL EVALUATION OF LIVING
ORGAN DONORS (PELOD):
AN INTERNATIONAL PROFESSIONAL SURVEY
OF CURRENT PRACTICES

#### **Lucinda Wynter**

Sydney, Australia

422.5 LIVING KIDNEY DONOR PRIORITIES FOR OUTCOMES: A NOMINAL GROUP TECHNIOUE STUDY

#### Camilla S. Hanson

Sydney, Australia

422.6 PERI-OPERATIVE EVENTS AND
COMPLICATIONS IN MINIMALLY-INVASIVE
LIVE DONOR NEPHRECTOMY: WHAT SHOULD
WE TELL POTENTIAL DONORS? A SYSTEMATIC
REVIEW AND META-ANALYSIS

#### Kirsten Kortram

Rotterdam, The Netherlands

422.7 EVOLUTION OF LIVING DONOR

NEPHRECTOMY AT A SINGLE CENTER: LONGTERM OUTCOMES WITH 4 DIFFERENT
TECHNIQUES IN > 4,000 DONORS FOR OVER
HALF-CENTURY

#### Raja Kandaswamy

Minneapolis, MN, United States

422.8 PSYCHOSOCIAL LONG IMPACT OF LIVING
KIDNEY DONATION: EVALUATION OF DONORS
SATISFACTION

#### Ana T. Menjivar

Barcelona, Spain

422.9 A 5-YEAR ANALYSIS AFTER LIVE DONOR
NEPHRECTOMY WITHIN THE ERA OF
EXTENDED CRITERIA DONORS – IDENTIFYING
FACTORS FOR DECLINE OF KIDNEY FUNCTION

#### **Khe Tran**

Rotterdam, The Netherlands

#### **MINI-ORALS**

422.10 IMPACT OF SINGLE CENTER KIDNEY PAIRED DONATION TRANSPLANTATION TO INCREASE DONOR POOL IN INDIA

#### **Vivek Kute**

Ahmedabad, India

422.11 WORLD RECORD: 77 KIDNEY PAIRED
DONATION TRANSPLANTATION IN YEAR 2015
AT ONE TRANSPLANT CENTER IN INDIA: A
MODEL FOR THE DEVELOPING WORLD TO
PREVENT COMMERCIAL TRANSPLANTATION

#### **Vivek Kute**

Ahmedabad, India

422.12 SIMULATION OF INTERNATIONAL KIDNEY
EXCHANGE BETWEEN SAUDI ARABIA AND
THE UNITED STATES USING ACTUAL
INCOMPATIBLE PAIR DATA

#### Abdulnaser M. Alabadi

Dammam, Saudi Arabia

422.13 INCREASING DECEASED DONOR
TRANSPLANT ACTIVITY IN INDIA: THE
RAJASTHAN STORY

#### **Christopher Taylor Barry**

Jaipur, India

10:30 - 12:30 HALL 5E2-LEVEL 5



#### Orals and Mini-Orals Session: Access and Allocation

Chairs: Roberta J. Al Housani-Blakely, Abu Dhabi, United Arab Emirates Bertram L. Kasiske, Minneapolis, MN, United States

423.1 EFFICIENT PRA MONITORING STRATEGY FOR COST REDUCTION AND IMPROVED WAITLIST MANAGEMENT

#### Hirohito Ichii

Orange, CA, United States

423.2 FINANCIAL IMPLICATIONS OF PERITONEAL DIALYSIS CATHETER REMOVAL AT THE TIME OF KIDNEY TRANSPLANTATION

#### **Meredith Barrett**

Ann Arbor, MI, United States

423.3 LOW ACCESS OF HIGHLY-SENSITIZED
PATIENTS TO KIDNEY TRANSPLANTATION
ASSOCIATED WITH VIRTUAL CROSSMATCH
USING STANDARD MFI THRESHOLD: DATA
FROM NORTHERN PORTUGAL

#### Jorge Malheiro

Porto, Portugal

423.4 THE NEW KIDNEY ALLOCATION SYSTEM:
EARLY IMPACT AT ONE OF THE MOST ACTIVE
TRANSPLANT CENTERS IN THE US

#### Franco H. Cabeza

Miami, FL, United States

423.5 A SIMPLIFIED METHOD OF CALCULATING CPRA FOR KIDNEY ALLOCATION APPLICATION IN HONG KONG

#### **Janette Kwok**

Hong Kong SAR, P.R. of China

423.6 COMPARISON OF HONG KONG CPRA RESULTS
WITH RESULTS OBTAINED FROM OPTN AND
EUROTRANSPLANT PRA ONLINE CALCULATORS

#### **Janette Kwok**

Hong Kong SAR, P.R. of China

423.7 ACCESS TO KIDNEY TRANSPLANTATION AMONG HIV-INFECTED WAITLIST CANDIDATES

Jayme E. Locke

Birmingham, AL, United States

423.8 PRIORITISING RENAL TRANSPLANTATION
BASED ON CLINICAL NEED: THE ROLE OF AN
"URGENT" KIDNEY WAITING LIST

Emma L. Aitken

Glasgow, United Kingdom

423.9 EFFICIENCY SAVINGS THROUGH REDUCTION
OF RED BLOOD CELL CROSS-MATCH AND
TRANSFUSION IN RENAL TRANSPLANTATION

Sarah-Jayne Edmondson London, United Kingdom

#### **MINI-ORALS**

423.10 KIDNEY TRANSPLANTATION IN THE ELDERLY:
EVALUATION OF EFFECTS OF DONOR AGE ON
SHORT- AND LONG-TERM CLINICAL OUTCOME

**Martin Ronaghi** 

Solna, Sweden

423.11 AVOIDING UNNECESSARY HEALTHCARE
UTILIZATION: THE ADVANTAGES OF
PREEMPTIVE KIDNEY TRANSPLANTATION

Patrick G. Dean

Rochester, MN, United States

423.12 THE END OF THE EXPANDED CRITERIA DONOR ERA: LESSONS LEARNED

**Giuseppe Orlando** 

Winston Salem, NC, United States

423.13 FINANCIAL COST OF COLD ISCHEMIA TIME IN KIDNEY TRANSPLANTATION

**Erik Finger** 

Minneapolis, MN, United States

10:30 - 12:30 S-221-LEVEL 2



#### Orals and Mini-Orals Session: Infections

Chairs: Sharon Chen, Westmead, Australia James Fung, Hong Kong SAR, P.R. of China

424.1 KINETICS OF CMV-SPECIFIC T-CELLS FROM PRE-TO-POSTTRANSPLANTATION PREDICT OUTCOMES IN CMV-SERONEGATIVE KIDNEY TRANSPLANT RECIPIENTS

# Thomas Schachtner Berlin, Germany

424.2 TREATMENT OF CARBAPENEM RESISTANT
ENTEROBACTERIACEAE WITH REDUCED
SUSCEPTIBILITY TO POLYMYXIN AMONG
KIDNEY TRANSPLANT RECIPIENTS
EXPERIENCE DURING AN OUTBREAK PERIOD

#### Maristela Pinheiro Freire São Paulo, Brazil

424.3 VZV-SPECIFIC T-CELL MEMORY RESPONSES
AFTER REACTIVATION IN TRANSPLANT
RECIPIENTS AND AFTER VACCINATION IN
TRANSPLANT CANDIDATES

#### Marcia M.L. Kho

Rotterdam, The Netherlands

424.4 STILL AN EQUAL B-CELL RESPONSE TO A VZV-BOOSTER IN BOTH RENAL TRANSPLANT RECIPIENTS AND HEALTHY INDIVIDUALS AT ONE YEAR POST VACCINATION

#### Marcia M.L. Kho

Rotterdam, The Netherlands

424.5 DIAGNOSTIC POTENTIAL OF INTERFERON
GAMMA RELEASE ASSAY TO DETECT LATENT
TUBERCULOSIS INFECTION IN KIDNEY
TRANSPLANT RECIPIENTS IN ENDEMIC AREA

#### Hassan A. Aleid

Riyadh, Saudi Arabia

424.6 EARLY BLOODSTREAM INFECTIONS AMONG SOLID ORGAN TRANSPLANT RECIPIENTS

#### **Hande Arslan**

Ankara, Turkey

424.7 EFFICACY OF INH PROPHYLAXIS IN RENAL TRANSPLANT RECIPIENTS:
A FOLLOW UP OF 5 YEARS

### **Anwar Nagvi**

Karachi, Pakistan

424.8 EPIDEMIOLOGY OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN INTESTINAL TRANSPLANT (IT) RECIPIENTS

### **Luis F. Guzman Vinasco**

Omaha, NE, United States

424.9 INCIDENCE AND OUTCOME OF PARASITIC INFECTION AFTER KIDNEY
TRANSPLANTATION IN THAILAND

# **Sirion Watcharananan**

Bangkok, Thailand

#### **MINI-ORALS**

424.10 PATHOGENESIS OF POLYOMAVIRUS-ASSOCIATED NEPHROPATHY: INSIGHTS FROM A MOUSE MODEL

## **Gang Huang**

Guangzhou, People's Republic of China

424.11 PNEUMOCYSTIS PNEUMONIA CLUSTER
OUTBREAK AT A SCOTTISH RENAL
TRANSPLANT CENTRE

#### **Andrew WJ McClarev**

Edinburgh, United Kingdom

424.12 NEUTROPHIL FUNCTION ASSAY IN RENAL TRANSPLANT RECIPIENTS WITH BACTERIAL AND FUNGAL INFECTIONS

#### Sabiha Anis

Karachi, Pakistan

424.13 FACTORS ASSOCIATED WITH CLOSTRIDIUM DIFFICILE INFECTION AFTER HEART AND HEART-LUNG TRANSPLANTATION

# **Jackrapong Bruminhent**

Bangkok, Thailand

## 10:30 - 12:30 THEATRE 1-LEVEL 1



# Orals and Mini-Orals Session: Recipient Variables

Chairs: Nancy Ascher, San Francisco, CA, United States Julie Pavlovic, Heidelberg, Australia

425.9 PRE TRANSPLANT RECIPIENT FRAILTY
COMBINED WITH DISEASE SEVERITY
PREDICTS POST LIVER TRANSPLANT (OLT)
MORTALITY

## John J. Fung

Cleveland, OH, United States

425.1 LIVER TRANSPLANTATION IN THE ELDERLY: AN INCREASING AND APPROPRIATE INDICATION

### Gabriel E. Gondolesi

Buenos Aires, Argentina

425.2 LONG TERM OUTCOME RESULTS USING PREDICTIVE SCORES IN LIVER RETRANSPLANTATION

### Gabriel E. Gondolesi

Buenos Aires, Argentina

425.3 PATIENTS ON THE LIVER TRANSPLANT
WAITING LIST AT RISK FOR DEVELOPING NEW
ONSET PORTAL VEIN THROMBOSIS

### **Martin Montenovo**

Seattle, WA, United States

425.4 DETERMINATION OF ALCOHOL ABSTINENCE IN TRANSPLANT CANDIDATES BY ETHYL GLUCURONIDE HAIR ANALYSIS

### Brigitta K.M. Globke

Berlin, Germany

425.5 INFLUENCING FACTORS OF FATIGUE IN LIVER TRANSPLANT RECIPIENTS

### Hongxia Liu

Beijing, People's Republic of China

425.6 PREDICTORS OF MORTALITY IN LIVING DONOR LIVER TRANSPLANTATION



## **Shaimaa Elkholy**

Cairo, Egypt

425.7 LIVER TRANSPLANTATION IN ELDERLY RECIPIENTS: WHEN IS OLD TOO OLD?

**Nicholas Gilbo** 

Leuven, Belgium

425.8 EXTRACORPOREAL MEMBRANE
OXYGENATION SUPPORT FOR CRITICALLY ILL
LIVER TRANSPLANTATION RECIPIENT

**KyeongSik Kim** 

Seoul, Korea

### **MINI-ORALS**

425.10 A NATIONWIDE ANALYSIS OF REOPERATION AFTER LIVER TRANSPLANT

#### Giselle Guerra

Miami, FL, United States

425.11 EFFECT OF GRAFT WEIGHT TO RECIPIENT BODY WEIGHT RATIO ON HEMODYNAMIC AND METABOLIC PARAMETERS IN PEDIATRIC LIVER TRANSPLANTATION: A RETROSPECTIVE ANALYSIS

# **Zeynep Ersoy**

Ankara, Turkey

425.12 THE ROLE OF CURATIVE INTENT SURGICAL
RESECTION FOR THE RECURRENT
HEPATOCELLULAR CARCINOMA AFTER LIVER
TRANSPLANTATION

### **Sukyung Kwon**

Seoul, Korea

425.13 INTRAOPERATIVE BLOOD LOSS IS AN INDEPENDENT PROMOTER OF TUMOR RECURRENCE IN LIVER TRANSPLANT PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

### **Arno Kornberg**

Munich, Germany

## 10:30 - 12:30 THEATRE 2-LEVEL 1



# Orals and Mini-Orals Session: Pregnancy/Metabolic and Surgical Complications

Chairs: Paolo Ferrari, Sydney, Australia Ming Kwong Yiu, Hong Kong SAR, P.R. of China

426.1 BIOINTACT FGF-23 NORMALIZES FASTER AND CORRELATES BETTER WITH INORGANIC PHOSPHORUS AS COMPARED TO INTACT PTH IN LIVING DONOR RENAL ALLOGRAFT RECIPIENTS

# **Narayan Prasad**

Lucknow, India

426.2 ARE THERE RISKS TO FATHERING PREGNANCIES AFTER SOLID ORGAN TRANSPLANTATION?

### Serban Constantinescu

Philadelphia, PA, United States

426.3 IMPACT OF INDUCTION THERAPY ON INCIDENT CARDIOVASCULAR EVENTS IN KIDNEY TRANSPLANT RECIPIENTS

# **Shaifali Sandal**

Montreal, QC, Canada

426.4 PARICALCITOL VERSUS PLACEBO FOR REDUCTION OF PROTEINURIA IN KIDNEY TRANSPLANT RECIPIENTS: A DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL

### Miha Arnol

Ljubljana, Slovenia

426.5 EFFECT OF THE RANKL INHIBITOR
DENOSUMAB ON EARLY LOSS OF BONE
MINERAL DENSITY AND SKELETAL
MICROSTRUCTURE IN FIRST-YEAR KIDNEY
TRANSPLANT RECIPIENTS

### **Rudolf P. Wuthrich**

Zurich, Switzerland

426.6 ARTERIOVENOUS FISTULA (AVF) MATURATION AMONG PREVALENT HEMODIALYSIS PATIENTS WITH FAILED KIDNEY TRANSPLANTS: RESULTS FROM THE UNITED STATES RENAL DATA SYSTEM (USRDS)

### Kenneth J. Woodside

Ann Arbor, MI, United States

426.7 A NATIONWIDE ANALYSIS OF REOPERATION AFTER KIDNEY TRANSPLANT

### Linda J. Chen

Miami, FL, United States

426.8 EFFICACY OF USING FLOSEAL TO PREVENT POST RENAL TRANSPLANTATION LYMPHOCELE FORMATION

### **Yiu Chung Lam**

Hong Kong SAR, P.R. of China

426.9 EXTERNAL URETERAL STENTING IN KIDNEY TRANSPLANTATION; DOES THE TYPE OF STENT MATTER?

### **Robert Minnee**

Rotterdam, The Netherlands

#### **MINI-ORALS**

426.10 STANDARDIZED INTRAOPERATIVE

APPLICATION OF HAEMOCER™ MAY REDUCE

THE INCIDENCE OF LYMPHOCELE AFTER

KIDNEY TRANSPLANTATION

# Christopher K. Burghuber

Vienna, Austria

426.11 PREGNANCY AFTER RENAL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE

### **Toyofumi Abe**

Suita, Japan

426.12 A MULTIDISCIPLINARY APPROACH TO REVIEWING PATIENT CARE IN ABDOMINAL TRANSPLANTATION

### **Ron Shapiro**

New York, NY, United States

426.13 THE IMPACT OF RENAL FUNCTION ON POST-OPERATIVE RESPIRATORY COMPLICATIONS IN BARIATRIC SURGERY

#### Hirohito Ichii

Orange, CA, United States

# 10:30 - 12:30 CONVENTION HALL A-LEVEL 1



# Orals and Mini-Orals Session T-Regs and B-Regs

Chairs: Johannes Wedel, Boston, MA, United States Petra Reinke, Berlin, Germany

427.1 IMBALANCE OF T HELPER 17 CELLS AND T REGULATORY CELLS IS ASSOCIATED WITH CHRONIC ACTIVE ANTIBODY MEDIATED REJECTION IN RENAL ALLOGRAFT RECIPIENTS

# Brijesh Yadav Lucknow, India

427.2 DEPTOR MODULATES ALLOIMMUNITY BY INCREASING REGULATORY T CELL FUNCTION AND STABILIZING FOXP3 EXPRESSION

# **Johannes Wedel**Boston, MA, United States

427.3 ROLE OF BONE MARROW MATURITY,
INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR
(IGF1R) AND FORKHEAD BOX PROTEIN N1
(FOXN1) IN THYMIC INVOLUTION AND
REJUVENATION IN A PRECLINICAL LARGE
ANIMAL MODEL

## Masayuki Tasaki Niigata, Japan

427.4 RAPAMYCIN PROMOTES ALLOGRAFT
SURVIVAL IN ELDERLY TRANSPLANT
RECIPIENTS LINKED TO AN ACCUMULATION
OF IL-10+ CD4+ T CELLS AND
CD4+CD25+FOXP3+ T-REGS

# Stefan G. Tullius

Boston, MA, United States

427.5 NAD+ ALTERS CD4+ T CELL DIFFERENTIATION
AND PROMOTES ALLOGRAFT SURVIVAL
INDEPENDENTLY OF CD4+CD25+FOXP3+
REGULATORY T CELLS

### Stefan G. Tullius

Boston, MA, United States

427.6 BELATACEPT FAILS TO INHIBIT DONOR-REACTIVE TFH-B CELL INTERACTION, BUT FAVORS A REGULATORY TRANSITIONAL B CELL PROFILE OVER TACROLIMUS

## Gretchen N. de Graav

Rotterdam, The Netherlands

427.7 METABOLITES ASSOCIATED WITH BARIATRIC SURGERY REVERSE ACCELERATED REJECTION AND AUGMENTED ALLOIMMUNITY IN OBESE ALLOGRAFT RECIPIENTS

# **Markus Quante**

Boston, MA, United States

427.8 IS TH17 ASSOCIATED WITH CHRONIC CALCINEURIN INHIBITOR TOXICITY IN RENAL ALLOGRAFT RECIPIENTS ?

# **Narayan Prasad**

Lucknow, India

427.9 LYMPHOTOXIN ON HUMAN AND MOUSE TREG PROMOTES MIGRATION ACROSS LYMPHATIC ENDOTHELIUM

# Jonathan S. Bromberg

Baltimore, MD, United States

### **MINI-ORALS**

427.10 T-BET REGULATES nTREG HOMING INTO DRAINING LYMPH NODES TO SUPPRESS ALLOIMMUNE RESPONSES

# Jonathan S. Bromberg

Baltimore, MD, United States

427.11 MONOCYTE-DERIVED DENDRITIC CELLS
PROMOTE TH POLARIZATION, WHEREAS
CONVENTIONAL DENDRITIC CELLS PROMOTE
TH PROLIFERATION

#### **Kevin Chow**

Parkville, Australia

427.12 URINARY LEVELS OF CHEMOKINES AND GROWTH FACTORS IN RENAL TRANSPLANT PATIENTS

### **Ayisha Abid**

Karachi, Pakistan

427.13 POSITIVE ASSOCIATION OF T CELL
HYPORESPONSIVENESS AND AGE OF KIDNEY
TRANSPLANT IN PATIENTS ATTENDING
INKOSI ALBERT LUTHULI CENTRAL HOSPITAL
(DURBAN, SOUTH AFRICA)

### Alain G. Assounga

Durban, South Africa

# 10:30 - 12:30 CONVENTION HALL B-LEVEL 1



# Orals and Mini-Orals Session: Immunology of IRI

Chairs: Xian C. Li, Houston, TX, United States Ali Zarrinpar, Los Angeles, CA, United States

428.1 DEVELOPMENT OF NOVEL FERROPTOSIS INHIBITORS FOR THE TREATMENT OF ISCHEMIA/REPERFUSION INJURIES

### **Bettina Proneth**

Neuherberg, Germany

428.2 PROTEOME ANALYSIS OF RENOPROTECTION
MEDIATED BY A NOVEL CYCLIC HELIX B PEPTIDE
IN KIDNEY ISCHEMIA REPERFUSION INJURY

### **Cheng Yang**

Shanghai, People's Republic of China

428.3 CYCLIC HELIX B PEPTIDE INHIBITS ISCHEMIA
REPERFUSION-INDUCED RENAL FIBROSIS VIA
THE PI3K/AKT/FOXO3A PATHWAY



### **Cheng Yang**

Shanghai, People's Republic of China

428.4 OUTCOMES AFTER DCD HEART
NORMOTHERMIC MACHINE PERFUSION
USING BANKED BLOOD IN A PORCINE MODEL

# **Hong Chee Chew**

Kingsgrove, Australia

428.5 TREATMENT WITH TETRAHYDROBIOPTERIN PROTECTS FROM TRANSPLANT VASCULOPATHY VIA PREVENTION OF eNOS UNCOUPLING

# **Rupert Oberhuber**

Innsbruck, Austria

428.6 ATG5/ATG7-INDEPENDENT
MACROAUTOPHAGY MEDIATES HEPATIC
SINUSOIDAL ENDOTHELIAL CELLS' RESPONSE
TO ISCHEMIA-REPERFUSION INJURY

# **Xiaobing Liu**

Hong Kong SAR, P.R. of China

428.7 DONOR LIVER TRANSPLANT REJUVENATION: FROM BENCH-TO-BEDSIDE

### **Ali Zarrinpar**

Los Angeles, CA, United States

428.8 DENDRITIC CELL PHENOTYPE AND FUNCTION MODIFICATION WITH TARGETED POROUS SILICON NANOPARTICLES

Sebastian O. Stead

Adelaide, Australia

428.9 FOLLISTATIN MODULATES ISCHEMIA-REPERFUSION-INDUCED RENAL FIBROSIS IN MICE

#### **Peter Cowan**

Melbourne, Australia

#### MINI-ORALS

428.10 LIVER SPECIFIC ACTIVATING TRANSCRIPTION FACTOR 5 (ATF5) REGULATES LIVER ISCHEMIA/REPERFUSION INJURY

# John J. Fung

Cleveland, OH, United States

428.11 LOW EXPRESSION IN PREIMPLANTATION
BIOPSIES OF FABP3, A GENE THAT CODES FOR
FATTY ACID BINDING PROTEIN, IS A MARKER
FOR DELAYED KIDNEY GRAFT FUNCTION

### Maria Gerbase-DeLima

Sao Paulo, Brazil

428.12 USING INTRAVOXEL INCOHERENT MOTION MR IMAGING AND BLOOD OXYGEN LEVEL-DEPENDENT MR IMAGING TO EVALUATE RAT ACUTE ALLOGRAFT REJECTION MODEL

#### Song Zeng

Beijing, People's Republic of China

428.13 IMMUNE-MODIFYING NANOPARTICLE THERAPY REDUCES KIDNEY ISCHEMIA REPERFUSION INJURY

### **Huiling Wu**

Sydney, Australia

# 10:30 - 12:30 CONVENTION HALL C-LEVEL 1



# Orals and Mini-Orals Session: Preventing Immune and Inflammatory Injury

Chairs: Takaaki Kobayashi, Nagoya, Japan Leo Buhler, Geneva, Switzerland

429.1 KNOCK-IN OF ANTI-CD2 AND HUMAN THROMBOMODULIN TRANSGENES INTO PIG GGTA1 USING CRISPR/CAS9

### **Peter Cowan**

Melbourne, Australia

429.2 CD39 PLAYS AN IMPORTANT ROLE IN THE SUPPRESSIVE CAPACITY OF XENOANTIGEN STIMULATED AND EXPANDED NON-HUMAN PRIMATE REGULATORY T CELLS

### **Dandan Huang**

Sydney, Australia

429.3 LONG-TERM ISLET XENOGRAFT SURVIVAL
REQUIRES EFFECTIVE EARLY CONTROL OF
XENOGENEIC IL-17 RESPONSE BUT LATE
CONTROL OF XENOGENEIC IFN-y RESPONSE

## **Xunrong Luo**

Chicago, IL, United States

429.4 HUMAN REGULATORY MACROPHAGES ARE MORE POTENT IN SUPPRESSION OF THE XENO-THAN THE ALLO-RESPONSE

### Fei Guo

Changsha, People's Republic of China

429.5 SCR-4 IS REQUIRED FOR CD55-INDUCED SUPPRESSION ON MACROPHAGE-MEDIATED CYTOTOXICITY

### Rieko Sakai

Suita, Japan

429.6 PRETREATMENT OF TRANSGENIC PORCINE ENDOTHELIUM EXPRESSING HUMAN ENDOTHELIAL PROTEIN C RECEPTOR WITH ACTIVATED PROTEIN C ATTENUATES ENDOTHELIAL DAMAGE AND THROMBOSIS DURING HUMAN BLOOD PERFUSION

## **Christopher T. Laird**

Baltimore, MD, United States

429.7 REDUCING THE INFLAMMATORY RESPONSE BY EXPRESSING HUMAN THROMBOMODULIN IN PIGS

#### Hidetaka Hara

Pittsburgh, PA, United States

429.8 GROWTH HORMONE RECEPTOR KNOCKOUT
ON PORCINE ENDOTHELIAL CELLS: EFFECT
ON COMPLEMENT AND COAGULATION

#### Riccardo Sfriso

Bern, Switzerland

429.9 SURFACE MODIFICATION OF PORCINE AORTIC ENDOTHELIAL CELLS WITH CORLINE HEPARIN CONJUGATE (CHC) PROTECTS AGAINST XENOGENEIC THROMBOSIS AND INFLAMMATION

### Anjan K. Bongoni

Fitzroy, Melbourne, Australia

#### MINI-ORALS

429.10 INHIBITION OF XENOGENEIC PLATELET
ACTIVATION AND AGGREGATION BY SURFACE
CONJUGATION OF APYRASE TO PORCINE
AORTIC ENDOTHELIAL CELLS

### Anian K. Bongoni

Fitzroy, Melbourne, Australiaia

429.11 FOXP3+ REGULATORY T CELLS ARE
ESSENTIAL FOR THE INDUCTION AND
MAINTENANCE OF TOLERANCE TO NEONATAL
PORCINE ISLET CELL CLUSTER XENOGRAFTS
INDUCED BY CO-STIMULATORY BLOCKADE

#### Min Hu

Westmead, Australia

429.12 COMPARISON OF POST TRANSPLANT
INFLAMMATORY RESPONSE FROM 6-GENE VS.
3-GENE DONOR PIGS IN HETEROTOPIC
CARDIAC XENOTRANSPLANTATION

### Muhammad M. Mohiuddin

Bethesda, MD, United States

429.13 HUMAN CD200 SUPPRESSES THE MO
MACROPHAGE-MEDIATED CYTOTOXICITY IN
XENOTRANSPLANTATION

### Akira Maeda

Suita, Japan

12:30 - 13:30 LUNCH BREAK

12:30 - 13:30 HALL 5E3-LEVEL 5 NOT A CME SESSION

Industry Symposium: Modern Approaches of Immunosuppressive Therapies for Renal Transplant Patients

Organized by



Please refer to page 343 for details.

13:30 - 15:00 HALL 5BC-LEVEL 5



State-of-the-Art Session: Live Kidney Donation – Donor Selection and Outcomes

Chairs: Dorry Segev, Baltimore, MD, United States Andrew L. Singer, Phoenix, AZ, United States



440.1 RISK OF END-STAGE RENAL DISEASE FOLLOWING LIVE KIDNEY DONATION

**Adibul Hasan Rizvi** Karachi, Pakistan



440.2 ASSESSMENT OF LIVE KIDNEY DONORS: ARE CURRENT PROTOCOLS ADEQUATE TO ENSURE DONOR SAFETY?

**Duck-Jong Han** Seoul, Korea



440.3 DONATION FROM OLD LIVING DONORS: HOW SAFE IS IT?

Hallvard Holdaas Oslo, Norway





State-of-the-Art Session: What's New and Hot in Intestinal Transplantation?

Chairs: Debra L. Sudan, Durham, NC, United States Douglas G. Farmer, Los Angeles, CA, United States



441.1 ANTI-HLA ANTIBODIES AND OUTCOME WITH INTESTINAL TRANSPLANTATION

**George V. Mazariegos**Pittsburgh, PA, United States



441.2 WHEN GASTRIC BYPASS GOES BAD

**Douglas G. Farmer** Los Angeles, CA, United States



441.3 BEST ABSTRACTS FROM THE 2015
INTERNATIONAL SMALL BOWEL TRANSPLANT
SYMPOSIUM

**Gabriel E. Gondolesi** Buenos Aires, Argentina

13:30 - 15:00 HALL 5E1-LEVEL 5



State-of-the-Art Session: Importance of Non-HLA Antibodies in Chronic Rejection

Chairs: Medhat Z. Askar, Dallas, TX, United States Rhonda Holdsworth, Melbourne, Australia



442.1 NON-HLA TARGET ANTIGENS IN KIDNEY TRANSPLANTATION

**Rudolf Oehler** Vienna, Austria



442.2 ANTIBODIES AGAINST G-PROTEIN COUPLED RECEPTORS

**Duska Dragun** Berlin, Germany



442.3 ANTI-VIMENTIN ANTIBODIES AFTER KIDNEY TRANSPLANTATION


> **Caner Süsal** Heidelberg, Germany

13:30 - 15:00 HALL 5E2-LEVEL 5



State-of-the-Art Session: Repurposing Drugs for Transplant Indications

Chairs: Kazunari Tanabe, Tokyo, Japan Josep Grinyo, Barcelona, Spain



**Agnes Azimzadeh**Baltimore, MD, United States

443.2 TOCILIZUMAB

Robert A. Montgomery

New York, NY, United States

443.3 INFLIZUMAB
Petra Reinke

Berlin, Germany

443.4 EFALIZUMAB

Andrew Posselt

San Francisco, CA, United States

13:30 - 15:00

S-221-LEVEL 2

State-of-the-Art Session: Gender Effect on Transplantation Access and Outcomes

Chairs: Germaine Wong, Westmead, Australia Benita Padilla, San Juan City, Philippines

444.1 GENDER RELATED VARIABLES AFFECTING DECEASED DONOR LISTING AND ALLOCATION ALGORITHMS

**Sommer E. Gentry**Baltimore, MD, United States

444.2 GEOGRAPHICAL DISPARITIES IN GENDER
ACCESS TO TRANSPLANTATION ESP LIVING
DONATION - DONORS VS RECIPIENT; LISTING OF
GENDERS ACROSS DIFFERENT GLOBAL REGIONS

**Mona Alrukhaimi** Dubai, United Arab Emirates









444.3 BIOLOGIC IMPACT OF GENDER/SEX ON OUTCOMES OF TRANSPLANTATION AND LIVING DONATION

Kathryn Tinckam Toronto, ON, Canada

13:30 - 15:00 THEATRE 1-LEVEL 1



State-of-the-Art Session: Tolerance in Liver Transplantation

Chairs: Nancy Kwan Man, Hong Kong SAR, P.R. of China John J. Fung, Cleveland, OH, United States



445.1 WITHDRAWAL VERSUS INDUCTION IN ADULT AND PEDIATRIC LIVER TRANSPLANT RECIPIENTS: WHERE DO WE STAND?

**Sandy Feng**San Francisco, CA, United States



445.2 TOLERANCE: CAN WE PREDICT OR INDUCE IT?
ARE ANY APPROACHED READY FOR PRIMETIME?

**Alberto Sanchez-Fueyo** London, United Kingdom



445.3 A CLINICAL TRIAL OF CELL THERAPY-BASED TOLERANCE INDUCTION IN LIVING DONOR LIVER TRANSPLANTATION: LONG-TERM FOLLOW-UP RESULTS

**Kenichiro Yamashita** Sapporo, Japan



445.4 DONOR-SPECIFIC ANTI-HLA ANTIBODY


MEDIATED REJECTION IN LIVER TRANSPLANT
RECIPIENTS

**Tomasz Dziodzio** Berlin, Germany

# 13:30 - 15:00 THEATRE 2-LEVEL 1



# State-of-the-Art Session: Cell Transplantation





446.1 HEPATOCYTE, A CELL SOURCE FOR LIVER REPOPULATION AND ORGANOGENESIS

**Anil Dhawan** London, United Kingdom



446.2 CLINICAL TRIALS FOR STEM-BASED REGENERATIVE MEDICINE

Martin F. Pera Parkville, Australia



446.3 THE ROLE OF INFLAMMATION IN CELL TRANSPLANTATION

Maria Koulmanda Boston, MA, United States

# 13:30 - 15:00 CONVENTION HALL A-LEVEL 1



State-of-the-Art Session: Emerging Technologies in Bioengineering, Regeneration and Repair

Chairs: Lori J. West, Edmonton, AB, Canada Curie Ahn, Seoul, Korea



447.1 REGENERATIVE MEDICINE TECHNOLOGIES APPLIED TO ORGAN TRANSPLANTATION

**Giuseppe Orlando**Winston Salem, NC, United States



447.2 KIDNEY TRANSPLANT REGENERATION THROUGH DELIVERY OF MESENCHYMAL STEM CELLS

> **Martin J. Hoogduijn** Rotterdam, The Netherlands



447.3 CARDIAC REGENERATION USING PLURIPOTENT STEM CELLS

> **Hung Fat Tse** Hong Kong SAR, P.R. of China





State-of-the-Art Session: Pulmonary AMR: The Way Ahead

Chairs: Chi Fong Wong, Hong Kong SAR, P.R. of China Gerhard Opelz, Heidelberg, Germany



448.1 B-CELLS AND PULMONARY AMR: FRIEND OR FOE?

**Tereza Martinu** Toronto, ON, Canada



448.2 PULMONARY AMR CONSENSUS OR NOT?

Allan R. Glanville Sydney, Australia



448.3 CHRONIC PULMONARY AMR AND NON HLA ANTIBODIES: EVIDENCE AND OUTCOMES

**Elaine F. Reed**Los Angeles, CA, United States

# 13:30 - 15:00 CONVENTION HALL C-LEVEL 1



State-of-the-Art Session: Vaccination Strategies/Viral Infections

Chairs: Burkhard Tönshoff, Heidelberg, Germany Ron Shapiro, New York, NY, United States



449.1 USE OF LIVE VIRUS VACCINES POST-TRANSPLANTATION: CLINICAL EXPERIENCE

> **Klara M. Posfay-Barbe** Geneva, Switzerland



449.2 OPTIMAL TIMING AND LONG-TERM IMMUNE MONITORS OF VACCINATION IN CHILDREN

**Sandra Burchett** Boston, MA, United States



449.3 THE ROLE OF VIRUS SPECIFIC T CELLS IN CHILDREN WITH VIRAL INFECTIONS AFTER TRANSPLANTATION

Lars Pape Hannover, Germany

15:00 - 15:30 COFFEE BREAK HALL 5FG-LEVEL 5

# 15:30 - 17:00 HALL 5BC-LEVEL 5



# Orals Session: Tolerance and Regimens to Improve Outcome

Chairs: Jayme E. Locke, Birmingham, AL, United States Edward K. Geissler, Regensburg, Germany

450.1 SEVEN YEAR FOLLOW-UP OF A PHASE 2
CLINICAL TRIAL TO INDUCE TOLERANCE
IN LIVING DONOR RENAL TRANSPLANT
RECIPIENTS

# Suzanne T. Ildstad

Louisville, KY, United States

450.2 RELATIONSHIP BETWEEN MIXED CHIMERISM
AND CLINICAL TOLERANCE AFTER COMBINED
KIDNEY AND HEMATOPOIETIC CELL
TRANSPLANTATION USING TOTAL LYMPHOID
IRRADIATION AND ANTITHYMOCYTE
GLOBULIN CONDITIONING

# John D. Scandling

Stanford, CA, United States

450.3 A RANDOMIZED-CONTROLLED TRIAL
COMPARING THE EFFICACY OF CYP3A5
GENOTYPE-BASED WITH BODYWEIGHTBASED TACROLIMUS DOSING AFTER LIVING
DONOR KIDNEY TRANSPLANTATION

### **Dennis Hesselink**

Rotterdam, The Netherlands

450.4 IMPACT OF INDUCTION AND MAINTENANCE IMMUNOSUPPRESSION ON PRE-TRANSPLANT IGM DSA TO POST-TRANSPLANT IGG DSA CONVERSION

# **Matthew J. Everly**

Los Angeles, CA, United States

450.5 T-REGULATORY CELLS SUPPORT STEM CELLS IN SAFE MINIMIZATION OF IMMUNOSUPPRESSION IN RENALTRANSPLANTATION

# **Aruna Vanikar**

Ahmedabad, India

450.6 TOLERANCE INDUCTION IN RENAL TRANSPLANTATION USING STEM CELL THERAPY: LESSONS LEARNED

#### **Aruna Vanikar**

Ahmedabad, India

450.7 MALIGNANCIES CONTRIBUTE TO
PRESENSITIZATION WITH ALLOREACTIVE TCELLS IN KIDNEY TRANSPLANT RECIPIENTS

### **Thomas Schachtner**

Berlin, Germany

450.8 THE EFFECT OF EVEROLIMUS AND
TACROLIMUS EXPOSURE LEVELS ON RENAL
HISTOLOGY PARAMETERS 6 MONTHS POSTTRANSPLANTATION

#### Flavio Vincenti

San Francisco, CA, United States

450.9 EVEROLIMUS PLUS REDUCED-EXPOSURE
CYCLOSPORIN VERSUS MYCOPHENOLIC ACID
PLUS CYCLOSPORIN: LONG-TERM FOLLOWUP OF AUSTRALIA AND NEW ZEALAND
KIDNEY TRANSPLANT RECIPIENTS IN THE
A2309 RANDOMISED CONTROLLED TRIAL

#### **Wai Lim**

Perth, Australia

15:30 - 17:00 HALL 5D-LEVEL 5



# Orals Session:

# Liver and Intestine Transplantation

Chairs: Gabriel E. Gondolesi, Buenos Aires, Argentina Douglas G. Farmer, Los Angeles, CA, United States

# Supported by



451.1 BROAD ASSESSMENT OF THE CLINICAL IMPACT OF PORTAL VEIN THROMBOSIS IN THE WAITLIST FOR LIVER TRANSPLANTATION

#### Martin Montenovo

Seattle, WA, United States

451.2 CLINICAL AND IMMUNOLOGICAL SIGNIFICANCE OF CONTROLLING PORTAL VEIN PRESSURE IN LIVING DONOR LIVER TRANSPLANTATION

### **Kazuhiro Taguchi**

Hiroshima, Japan

451.3 IMPACT OF HEPATORENAL SYNDROME ON OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE IN 357 PATIENTS

### Yusuke Okamura

Kyoto, Japan

451.4 RISK FACTORS FOR PRIMARY SCLEROSING CHOLANGITIS RECURRENCE AFTER OTHOTOPIC LIVER TRANSPLANTATION

### **Pavel Drastich**

Praha, Czech Republic

451.5 GENERATION OF NAÏVE DONOR-DERIVED LYMPHOCYTES FROM GRAFT-RESIDENT LYMPHOID PROGENITORS AFTER HUMAN INTESTINAL TRANSPLANTATION

### Jianing Fu

Fort Lee, NJ, United States

451.6 DE NOVO DONOR-SPECIFIC HLA ANTIBODIES
AFTER COMBINED INTESTINAL AND
VASCULARIZED COMPOSITE
ALLOTRANSPLANTATION

# **Georgios Vrakas**

Oxford, United Kingdom

451.7 INTESTINAL RETRANSPLANTATION IN CHILDREN: SINGLE CENTER EXPERIENCE

### **Neslihan Celik**

Pittsburgh, PA, United States

451.8 SKIN GVHD IN PAEDIATRIC INTESTINAL TRANSPLANT RECIPIENTS – EXPERIENCE FROM A NATIONAL UK CENTRE

### Suzan S Y Warner

Birmingham, United Kingdom

451.9 DONOR-SPECIFIC ANTIBODIES ARE ASSOCIATED WITH REJECTION AFTER INTESTINAL TRANSPLANT IN PEDIATRIC PATIENTS

#### Jacqueline I. Lee

Palo Alto, CA, United States

15:30 - 17:00 HALL 5E1-LEVEL 5



# Orals Session: Malignancy and Cardio-Vascular Complications

Chairs: Klemens Budde, Berlin, Germany Siu Fai Lui, Hong Kong SAR, P.R. of China

452.1 MICRORNAS IN EBV+ B CELL LYMPHOMAS AND SECRETED EXOSOMES

### **Sheri Krams**

Stanford, CA, United States

452.2 INHIBITION OF THE CONSTITUTIVELY ACTIVE PI3K/AKT/MTOR SIGNALING PATHWAY IN EPSTEIN-BARR VIRUS B CELL LYMPHOMAS DEMONSTRATE BOTH ANTITUMOR AND ANTIRE JECTION PROPERTIES

### Olivia M. Martinez

Stanford, CA, United States

452.3 LYMPHOPROLIFERATIVE DISORDERS AFTER RENAL TRANSPLANTATION ALONG TWO DECADES: A LARGE LONGITUDINAL STUDY OF 21.546 RECIPIENTS

# **Antonio Franco**

Alicante, Spain

452.4 STEM CELL LIKE MEMORY B CELLS
ATTENUATE HEPATITIS B VIRUS RELAPSE IN
HEPATOCELLULAR CARCINOMA PATIENTS
POST LIVER TRANSPLANTATION

### **Yin Fan Lynn Lam**

Hong Kong SAR, P.R. of China

452.5 SEQUENTIAL THERAPY AND RISK-STRATIFICATION IN PTLD: POOLED ANALYSIS OF 222 PATIENTS TREATED IN THE PROSPECTIVE, INTERNATIONAL, MULTICENTRIC PTLD-1 TRIALS

### Ralf Ulrich Trappe

Bremen, Germany

452.6 CANCER-RELATED INCIDENCE AND PROGRESSION TO MORTALITY AMONG KIDNEY ALLOGRAFT RECIPIENTS IN ENGLAND: A POPULATION-COHORT ANALYSIS BETWEEN 2003 AND 2013

### Francesca Jackson-Spence

Birmingham, United Kingdom

IMPACT OF PULSE PRESSURE ON PATIENT 452.7 AND GRAFT SURVIVAL IN RENAL TRANSPLANT RECIPIENTS: RESULTS FROM THE COLLABORATIVE TRANSPLANT STUDY

# Bernd Krüger

Mannheim, Germany

452.8 CARDIAC BIOMARKERS CORRELATE WITH CHANGES IN LEFT VENTRICULAR MASS INDEX AND DIASTOLIC DYSFUNCTION FOLLOWING RENAL TRANSPLANTATION

# Amy A. Crosthwaite

Eaglemont, Australia

INTEGRATIVE, MULTI-COHORT ANALYSIS OF 452.9 EPSTEIN-BARR VIRUS (EBV)-POSITIVE AND NEGATIVE TUMOR SAMPLES TO IDENTIFY GENE-SIGNATURES ASSOCIATED WITH EBV **ONCOGENESIS** 

### **Eden M. Maloney**

Stanford, CA, United States

15:30 - 17:00 **HALL 5E2-LEVEL 5** 



# Orals Session: Kidney Access and Allocation

Chairs: Stefan Schaub, Basel, Switzerland Naoshi Shinozaki, Tokyo, Japan

453.1 THE RELATIVE COSTS AND HEALTH BENEFITS OF AN AGE-MATCHED DECEASED DONOR ALLOCATION ALGORITHM COMPARED TO CURRENT PRACTICE



### Vaishnavi Calisa

Sydney, Australia

DONOR-RECIPIENT AGE MISMATCHES: THE 453.2 RELATIVE BENEFITS AND COSTS OF WAIT-LISTING, TRANSPLANTATION AND DIALYSIS

#### Vaishnavi Calisa

Sydney, Australia

SCOPE AND HETEROGENEITY OF OUTCOMES 453.3 REPORTED IN COCHRANE SYSTEMATIC REVIEWS OF KIDNEY TRANSPLANTATION

### **Benedicte Sautenet**

Westmead, Australia

453.4 TIMELY TRANSPLANTATION: IMPROVING
ACCESS TO EARLY TRANSPLANTATION AND
ACTIVE TRANSPLANTATION LISTING WITHIN
SIX MONTHS OF STARTING RENAL
REPLACEMENT THERAPY

### **John Kanellis**

Melbourne, Australia

453.5 ROUX-EN-Y GASTRIC BYPASS AS A BRIDGE TO KIDNEY TRANSPLANTATION: EFFECTIVE BUT HOW SAFE?

#### Franco H. Cabeza

Miami, FL, United States

453.6 HEPATITIS C RNA-POSITIVE PATIENTS WHO ARE WILLING TO ACCEPT HEPATITIS C SEROPOSITIVE KIDNEYS HAVE BETTER TRANSPLANT ACCESS AND FAVORABLE WAITLIST OUTCOMES

## Junichiro Sageshima

Sacramento, CA, United States

453.7 CHANGE IN DECEASED KIDNEY DONOR
CHARACTERISTICS AND KIDNEY DONOR RISK
INDEX (KDRI) IN AUSTRALIA AND NEW
ZEALAND OVER TWENTY YEARS

### Samuel Shun K. Chan

Woolloongabba, Australia

453.8 99-100% cPRA DECEASED DONOR KIDNEY
TRANSPLANTS PRE AND POST NEW KIDNEY
ALLOCATION SYSTEM (KAS)- A SINGLE
CENTER PERSPECTIVE

#### **Hasan Khamash**

Phoenix, AZ, United States

453.9 A RETROSPECTIVE COHORT STUDY ON THE ASSOCIATION BETWEEN DONOR KIDNEY KDRI SCORE AND RE-HOSPITALIZATION IN TRANSPLANT RECIPIENTS

### **Wilson Lin**

Bronx, NY, United States

15:30 - 17:00 S-221-LEVEL 2



# Orals Session: Immunobiology and Rejection

Chairs: Randall E. Morris, Carmel, CA, United States Tereza Martinu, Toronto, ON, Canada

454.1 ASSESSMENT OF IMMUNE MEDIATORS IN PLASMA FOR DETECTION OF CHRONIC REJECTION AFTER HEART TRANSPLANTATION

# Bianca Przybylek

Hannover, Germany

454.2 AIR POLLUTION CAN SUPPORT A CHRONIC REJECTION AFTER HEART TRANSPLANTATION

# **Christoph Bara**

Hannover, Germany

454.3 PRE-SENSITIZED IMMUNE CONDITION OF HOST EXAGGERATES PROLONGED COLD ISCHEMIA-MEDIATED INJURY OF CARDIAC GRAFT INVOLVING IN REGULATORY T CELLS

# **Liu Baoqing**

Hong Kong SAR, P.R. of China

454.4 ALTERED IMMUNOGENICITY OF PORCINE HEARTS VIA EX VIVO PERFUSION

### William R. Critchley

Manchester, United Kingdom

454.5 C4D POSITIVE STAINING IS A POOR PROGNOSTIC INDICATOR IN CARDIAC TRANSPLANT RECIPIENTS

### Carmela D. Tan

Cleveland, OH, United States

454.6 CALCINEURIN INHIBITOR (CNI) DELAY WITH ATG INDUCTION: TEACHING AN OLD DOG, NEW TRICKS

### Arezu Z. Aliabadi

Vienna, Austria

454.7 CELLULAR REJECTION BEYOND 2 YEARS
AFTER CARDIAC TRANSPLANTATION

### **Christian Heim**

Erlangen, Germany

454.8 CARDIAC ALLOGRAFT VASCULOPATHY
INVOLVING THE ARTERY TO THE
ATRIOVENTRICULAR NODE: AN UNDERRECOGNIZED IMPORTANT PATHOLOGICAL
FINDING IN THE AUTOPSY
(abst. P.1777 in the Transplantation Journal)

# E. R. Rodriguez

Cleveland, OH, United States

454.9 ENDOCAN AND RENALASE:
ARE THEY RELATED IN HEART
TRANSPLANT RECIPIENTS?
(abst. P.1778 in the *Transplantation Journal*)

**Jacek S. Malyszko**Bialystok, Poland

15:30 - 17:00 THEATRE 1-LEVEL 1



# Orals Session:

# Viruses and Cancer

Chairs: Marina Berenguer, Valencia, Spain Simone I. Strasser, Camperdown, Australia

455.1 SURVIVAL BENEFIT OF LIVER
TRANSPLANTATION FOR HIV+ CANDIDATES

### Allan Massie

Baltimore, MD, United States

455.2 TREATMENT OF HCV-RECURRENCE AFTER
LIVER TRANSPLANTATION WITH SOFOSBUVIR/
LEDIPASVIR: THE ROLE OF RIBAVIRIN

### **Dennis Eurich**

Berlin, Germany

455.3 INTERFERON-FREE ANTIVIRAL TREATMENT OF HCV-RECURRENCE WITH SOFOSBUVIR CONTAINING REGIMEN: EVALUATION OF KIDNEY FUNCTION

### **Dennis Eurich**

Berlin, Germany

455.4 A CLOSING CHAPTER – THERAPY OF HCV GENOTYPE III RECURRENCE IN LIVER TRANSPLANTS

#### **Eva Maria EM Teegen**

Berlin, Germany

455.5 THE USE OF HEPATITIS B CORE ANTIBODY POSITIVE DONORS FOR LIVER TRANSPLANTATION DOES NOT LEAD TO INFERIOR SURVIVAL

# **Tiffany CL Wong**

Hong Kong SAR, P.R. of China

455.6 HEPATITIS B VACCINATION IN PATIENTS
RECEIVING ANTIVIRAL MONOTHERAPY AFTER
LIVER TRANSPLANTATION FOR CHRONIC
HEPATITIS B

## **Tiffany CL Wong**

Hong Kong SAR, P.R. of China

455.7 CHILD-PUGH CLASSIFICATION CANNOT PREDICT SURVIVAL OF HEPATOCELLULAR CARCINOMA PATIENTS AFTER LIVER TRANSPLANTATION

# **Walid Elmoghazy**

Doha, Qatar

455.8 HEPATIC EPITHELIOID HAEMANGIOENDOTHELIOMA AND ADULT LIVER
TRANSPLANTATION: EXTRA-HEPATIC DISEASE
IS NOT A CONTRAINDICATION TO LIVER
TRANSPLANTATION. REPORT OF THE
EUROPEAN LIVER TRANSPLANT REGISTRY
INCLUDING 149 PATIENTS

### **Jan Lerut**

Louvain-la-Neuve, Belgium

455.9 LIVER TRANSPLANTATION AND LIVER
RESECTION FOR TREATMENT OF
HEPATOBLASTOMA: 10-YEARS SINGLECENTER EXPERIENCE

# **Oleg Kotenko**

Kiev, Ukraine

# 15:30 - 17:00 THEATRE 2-LEVEL 1



# Orals Session: Cell Transplantation

Chairs: Anil Dhawan, London, United Kingdom TBA

456.1 CHARACTERIZATION OF HEMATOPOIETICALLY-DERIVED CNS MACROPHAGES FOLLOWING BONE MARROW TRANSPLANTATION

### Josef Kurtz

Boston, MA, United States

456.2 CD45RA IDENTIFIES TSDR DEMETHYLATED
REGULATORY T CELLS WITH A STABLE
PHENOTYPE AND SUPPRESSIVE
CYTOKINE PROFILE

# **Rebeca C. Arroyo Hornero** Oxford, United Kingdom

456.3 THE EARLY BEHAVIOR OF MUSCLEPRECURSOR CELL TRANSPLANTATION IN
SKELETAL MUSCLES AND HOW THIS
CONDITIONS THE OUTCOME OF THE GRAFT:
A STUDY IN NON-HUMAN PRIMATES

#### **Daniel Skuk**

Quebec, QC, Canada

456.4 MOBILIZED HUMAN PERIPHERAL BLOOD
MONONUCLEAR CELLS (PBMCs) CONTAIN
HIGHER PROPORTION OF IL-10 PRODUCING B
CELLS IN CD8+TCR- FACILITATING CELL
POPULATION THAN NON-MOBILIZED PBMCs

# Yujie Wen

Louisville, KY, United States

456.5 THERAPEUTIC BENEFIT OF ADIPOSE-DERIVED STEM CELL TRANSPLANTATION IN RATS OF ACUTE-ON-CHRONIC LIVER FAILURE

## **Cheng-Maw Ho**

Taipei, Taiwan

456.6 TRACKING OF IRON NANO-PARTICLE LABELLED MESENCHYMAL STEM CELLS IN OVINE HETEROTOPIC KIDNEY TRANSPLANTATION.

### **Bron D. Lett**

Adelaide, Australia

456.7 **EX-VIVO EXPANSION OF HUMAN** ALLOANTIGEN-REACTIVE REGULATORY T CELLS USING MONOCYTE-DERIVED DENDRITIC CELLS VERSUS CD40L-STIMULATED B CELLS

## **Angus W. Thomson**

Pittsburgh, PA, , United States

456.8 DE- AND RECELLULARIZATION OF PORCINE **PANCREAS** 

## **Erik Elebring**

Gothenburg, Sweden

456.9 STEM CELL THERAPY AS AN EMERGING MODALITY FOR POST-TRAUMATIC PARAPLEGIA AND FOR RENAL PARENCHYMAL DISEASES



**Umang G. Thakkar** Ahmedabad, India

# 15:30 - 17:00 **CONVENTION HALL A-LEVEL 1**

# Orals Session: Unraveling DC Function and Migration

Chairs: Olivier Thaunat, Lyon, France Martin J. Hoogduijn, Rotterdam, The Netherlands

MACROPHAGE-SPECIFIC DELETION OF mTOR 457.1 INHIBITS CHRONIC ALLOGRAFT REJECTION AND INDUCES LONG-TERM HEART ALLOGRAFT SURVIVAL

## Xian C. Li

Houston, TX, United States

SYSTEMIC THERAPY OF REGULATORY 457.2 DENDRITIC CELLS DERIVED FORM INDUCED PLURIPOTENT STEM CELLS ALLOWS ALLOGENEIC CARDIAC GRAFTS ACCEPTANCE

# Songjie Cai

Tokvo, Japan

**HUMAN REGULATORY MACROPHAGES ARE** 457.3 CAPABLE OF SUPPRESSING THE ALLOGENEIC RESPONSE IN VITRO VIA SOLUBLE **MOLECULES** 

### Yuanfei Zhao

Sydney, Australia

457.4 ANTI-A IMMUNE RESPONSE IN MICE TO ABO-BLOOD CARBOHYDRATES ANTIGEN IS T CELL DEPENDENT

### Lori J. West

Edmonton, AB, Canada

457.5 ANTI-ICAM-1 TREATMENT HINDERS
LYMPHATIC TRAFFICKING OF DONOR
PASSENGER LEUKOCYTES AND PROLONGS
MURINE KIDNEY ALLOGRAFT SURVIVAL

## Lucy J. Meader

London, United Kingdom

457.6 SOLUBLE FIBRINOGEN-LIKE PROTEIN 2
REGULATES DIFFERENTIATION AND
ENHANCES IMMUNOSUPPRESSIVE FUNCTION
OF MYELOID-DERIVED SUPPRESSOR CELLS IN
ALLOGRAFT IMMUNITY

### **Cheng Yang**

Shanghai, People's Republic of China

457.7 REDUCTION IN CXCL9—CXCR3 SIGNALS
DIMINISHES TRAIL-EXPRESSING LIVER NK
CELLS IN PARTIALLY HEPATECTOMIZED MICE
UNDER DEPRESSED IMMUNE STATUS

## Takuya Yano

Hiroshima, Japan

457.8 NK CELLS PROMOTE KIDNEY GRAFT REJECTION THROUGH EVASION OF CYCLOSPORINE A THERAPY

# **Muhammad Imtiaz Ashraf**

Berlin, Germany

457.9 KLOTHO DEFICIENCY AGGRAVATES
TACROLIMUS-INDUCED RENAL INJURY VIA
THE PI3K-AKT-FOXO PATHWAY

### **Jian Jin**

Seoul, Korea

## 15:30 - 17:00 **CONVENTION HALL B-LEVEL 1**



# Orals Session:

# Diagnosis and Monitoring of Rejection (I)

Chairs: Maria Hernandez-Fuentes, London, United Kinadom TBA

458.1 VD I IMMUNE REPERTOIRE SEQUENCING PREDICTS PATIENTS AT RISK OF ALLOIMMUNE INJURY

# Minnie M. Sarwal

San Francisco, CA, United States

MINING THE HUMAN PROTEOME FOR 458.2 MONITORING RENAL TRANSPLANT INJURY

### Minnie M. Sarwal

San Francisco, CA, United States

**GUT MICROBIAL COMPOSITION PREDICTIVE OF** 458.3 GRAM-NEGATIVE URINARY TRACT INFECTIONS IN KIDNEY TRANSPLANT RECIPIENTS

#### John Lee

New York, NY, United States

HOST MICROBIOTA OF CARDIAC 458.4 ALLOGRAFT RECIPIENTS IS DURABLY ALTERED BY FECAL MICROBIOTA TRANSPLANT AND THESE CHANGES CORRELATE WITH ALLOGRAFT OUTCOME

# Jonathan S. Bromberg

Baltimore, MD, United States

A MOLECULAR MICROSCOPE DIAGNOSTIC 458.5 SYSTEM (MMDx) FOR HEART TRANSPLANT **BIOPSIES DEVELOPED FROM THE** MOLECULAR PHENOTYPES OF REJECTION IN KIDNEY TRANSPLANTS

## Philip F. Halloran

Edmonton, AB, Canada

BIOMARKERS OF TOLERANCE IN KIDNEY 458.6 TRANSPLANTATION: IMMUNOSUPPRESSION-EFFECTS ON GENE-EXPRESSION. CAN WE REALLY DETECT TOLERANCE?

### **Maria Hernandez-Fuentes**

London, United Kingdom

458.7 IDENTIFICATION OF NOVEL THERAPEUTICS AND TARGETS FOR CHRONIC ALLOGRAFT INJURY USING INTEGRATIVE INFORMATICS APPROACH

#### Li Li

New York, NY, United States

458.8 FIRST CLINICAL RESULTS OF A SALIVA
TESTING FOR MONITORING AFTER RENAL
TRANSPLANTATION

# **Dietmar K. Abendroth**

Ulm, Germany

458.9 MOLECULAR AND FUNCTIONAL IMMUNE
ASSAYS AS NON-INVASIVE DIAGNOSTIC
TOOLS TO ASSESS THE RISK OF ACUTE
SUBCLINICAL REJECTION AFTER KIDNEY
TRANSPLANTATION

### **Josep Grinyo**

Barcelona, Spain

# 15:30 - 17:00 CONVENTION HALL C-LEVEL 1



# Orals Session:

Longterm Challenges following Paediatric Solid Organ Transplantation

Chairs: Jonathan Craig, Sydney, Australia Stanley H.K. Lo, Hong Kong SAR, P.R. of China

459.1 IMPACT OF EVEROLIMUS AND LOW-DOSE CICLOSPORIN ON CYTOMEGALOVIRUS REPLICATION AND DISEASE IN PEDIATRIC RENAL TRANSPLANTATION

### **Burkhard Tönshoff**

Heidelberg, Germany

459.2 VACCINATION STATUS AND TITERS BEFORE
AND AFTER PEDIATRIC RENAL
TRANSPLANTATION: AN ANALYSIS OF THE
CERTAIN REGISTRY

## **Burkhard Tönshoff**

Heidelberg, Germany

459.3 PEDIATRIC KIDNEY TRANSPLANT OUTCOMES: A SINGLE-CENTER EXPERIENCE ACCORDING TO TRANSPLANT ERA

### Marta L. Monteverde

Buenos Aires, Argentina

# AUG21 TTS 2016 Congress

459.4 PERCEPTION, DIAGNOSIS, AND
MANAGEMENT OF BK POLYOMAVIRUS
REPLICATION AND DISEASE IN PAEDIATRIC
KIDNEY TRANSPLANT RECIPIENTS IN EUROPE

### **Lars Pape**

Hannover, Germany

459.5 PUBERTAL DEVELOPMENT IN PEDIATRIC KIDNEY TRANSPLANT PATIENTS RECEIVING MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS OR CONVENTIONAL IMMUNOSUPPRESSION

### **Lars Pape**

Hannover, Germany

459.6 TRANSITIONAL CARE AND ADHERENCE OF ADOLESCENTS AFTER KTX IN GERMANY AND AUSTRIA: A BINATIONAL OBSERVATORY CENSUS WITHIN THE TRANSNEPHRO TRIAL

### **Lars Pape**

Hannover, Germany

459.7 HEALTH AND WEALTH IN CHILDREN AND ADOLESCENTS WITH KIDNEY TRANSPLANTS (K-CAD STUDY)

### **Madeleine Didsbury**

Westmead, Australia

459.8 INCIDENCE OF POST-TRANSPLANT
MALIGNANCY (PTM) AFTER PEDIATRIC
KIDNEY TRANSPLANTATION (PKTx)

### Oscar K. Serrano

Minneapolis, MN, United States

459.9 INCIDENCE OF CARDIOVASCULAR DISEASE AFTER PEDIATRIC KIDNEY TRANSPLANTATION

### Oscar K. Serrano

Minneapolis, MN, United States

17:00 - 17:20 HALL 5FG-LEVEL 5 (Behind TTS booth in aisle 500) NOT A CME SESSION

# ISN-TTS Sister Transplantation Center Program

460 PRESENTATION OF ISN-TTS SISTER
TRANSPLANTATION CENTER PROGRAM

Randall Lou Meda

Guatemala, Guatemala

**Abdullah El-Kishawi** Gaza City, Palestine

17:00 - 18:00 HALL 5FG-LEVEL 5 NOT A CME SESSION

BS

Campfire Presentations: Unraveling Alloreactivity: innovative approaches (II) - Campfire Table 1

Chairs: Duska Dragun, Berlin, Germany TBA

470.1 THE ROLE OF HLA CLASS II ANTIBODIES IN CHRONIC KIDNEY REJECTION

**Gabriel Cantanhede** 

Newcastle-upon-Tyne, United Kingdom

470.2 THE PROPER ISCHEMIC PRECONDITIONING
ATTENUATES AGAINST RENAL ISCHEMIAREPERFUSION INJURY BY INHIBITING
TOLL-LIKE RECEPTOR 4/NF-KB SIGNALING
PATHWAY IN MICE

Kyungjai Ko

Seoul, Korea

470.3 RELATIONSHIP BETWEEN B CELL-RICH
TERTIARY LYMPHOID ORGANS AND
SYSTEMIC AS WELL AS LOCAL HUMORAL
ALLORESPONSES IN A MURINE KIDNEY
ALLOGRAFT MODEL

**Anna Nowocin** 

London, United Kingdom

470.4 KIDNEY TRANSPLANT RECIPIENTS AFTER
SOLID ORGAN TRANSPLANTATION OTHER
THAN KIDNEY SHOW LOW ALLOREACTIVITY
BUT AN INCREASED RISK OF INFECTIOUS
COMPLICATIONS

### **Thomas Schachtner**

Berlin, Germany

470.5 AGING EFFECT ON IMMUNITY IMPLYING TO MINIMIZE IMMUNOSUPPRESSION IN ELDER TRANSPLANT RECIPIENTS IN A MURINE MODEL

# **Kun-Ming Chan**

Taoyuan, Taiwan

470.6 CD3+CD8+GRANZYMEB+ CYTOTOXICT
LYMPHOCYTES PLAY ROLE IN CHRONIC
ANTIBODY MEDIATED TRANSPLANT REJECTION

### **Brijesh Yadav**

Lucknow, India

17:00 - 18:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



# Campfire Presentations: Kidney II - Campfire Table 2

Chairs: Anwar Naqvi, Karachi, Pakistan Carrie A. Schinstock, Rochester, MN, United States

471.1 BODY MASS INDEX (BMI) IS ASSOCIATED WITH MICROALBUMINURIA IN THE LATE RENAL TRANSPLANT PERIOD

### **Boris Zingerman**

Petach-Tikva, Israel

471.2 POSTTRANSPLANT HYPERURICEMIA AS A CARDIOVASCULAR RISK FACTOR:
CORRELATION BETWEEN CARDIOVASCULAR RISK FACTORS

### **Turan Colak**

Ankara, Turkey

471.3 DEFINITE (dBKPVN) AND PRESUMPTIVE (pBKPVN) POLYOMAVIRUS ASSOCIATED NEPHROPATHIES CANNOT BE DISTINGUISHED CLINICALLY BUT VIRAL CLEARANCE IN pBKPVN DEPENDS ON RENAL FUNCTION AT THE TIME OF THE BIOPSY

### Cinthia B. Drachenberg

Baltimore, MD, United States

471.4 THE PREVENTATIVE EFFECT OF mTOR
INHIBITION BY ANTI-A/B ANTIBODY LIGATION
AND mTOR-INHIBITOR ON ANTI-HLA-DR
ANTIBODY MEDIATED COMPLEMENT
DEPENDENT CYTOTOXICITY

# Takaaki Kobayashi

Nagoya, Japan

471.5 OUTCOME OF RENAL TRANSPLANTATION IN OBESE RECIPIENTS

## **Mahir Kirnap**

Ankara, Turkey

471.6 DECREASED NUMBER OF PLASMA CELLS IN PERIPHERAL CIRCULATION IS ASSOCIATED WITH ACUTE REJECTION IN RENAL TRANSPLANTATION

### **Mukut Minz**

Chandigarh, India

17:00 - 18:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



# Campfire Presentations: Optimizing Donation - Campfire Table 3

Chairs: Richard D.M. Allen, Sydney, Australia See Ming Simon Hou, Hong Kong SAR, P.R. of China

472.1 TOWARDS A STANDARDIZED INFORMED CONSENT PROCEDURE FOR LIVE DONOR NEPHRECTOMY: WHAT DO SURGEONS TELL POTENTIAL DONORS?

### **Kirsten Kortram**

Rotterdam, The Netherlands

472.2 ANALYSIS OF DIALYSIS COST AND MEDIAN
WAITING TIME ON RETURN ON INVESTMENT
(ROI) OF THE US NATIONAL LIVING DONOR
ASSISTANCE CENTER (NLDAC) PROGRAM

### **Robert M. Merion**

Ann Arbor, MI, United States

472.3 THE INCREASING NUMBER OF UNSPECIFIED LIVING KIDNEY DONORS

### Willij Zuidema

Rotterdam, The Netherlands

472.4 CHINESE ADULT PERCEPTION TOWARDS ORGAN DONATION IN HONG KONG

## **Wah Chun Li**

Hong Kong SAR, P.R. of China

472.5 KIDNEY TRANSPLANTATION FROM DONORS
WITH RHABDOMYOLYSIS AND ACUTE RENAL
FAILURE: A REPORT OF 16 CASES

### **Xiaopeng Yuan**

Guangzhou, People's Republic of China

472.6 INCREASED CONSENTED-NOT RECOVERED
(CNR) CASES AS A CONSEQUENCE OF
AGGRESSIVE DONOR PURSUIT: IMPACT AND
IMPLICATIONS

## Jeffrey P. Orlowski

Oklahoma City, OK, United States

17:00 - 18:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



# Campfire Presentations: Paediatrics - Campfire Table 4

Chairs: Burkhard Tönshoff, Heidelberg, Germany Diana Shellmer, Pittsburgh, PA, United States

473.1 PEDIATRIC RENAL TRANSPLANTATION IN THE SCANDIATRANSPLANT REGION 1997-2012

## **Lars Wennberg**

Stockholm, Sweden

473.2 RESULTS OF THE FIRST KIDNEY TRANSPLANT IN PEDIATRIC PATIENTS IN ARGENTINA: PERIOD 1998-2014

# Liliana Bisigniano

Buenos Aires, Argentina

473.3 ENBLOC KIDNEY TRANSPLANT IN PEDIATRIC RECIPIENTS - THE MIAMI EXPERIENCE

### Linda J. Chen

Miami, FL, United States

473.4 WHEN THE VENA CAVA INFERIOR IS MISSING:
KIDNEY TRANSPLANTATION IN CHILDREN
WITH VENOUS DRAINAGE TO THE PORTAL VEIN

#### **Udo Vester**

Essen, Germany

473.5 NATIONWIDE CONVERSION TO GENERIC TACROLIMUS IN PAEDIATRIC KIDNEY TRANSPLANT RECIPIENTS

#### **Derisha Naicker**

Auckland, New Zealand

473.6 RECENT ADVANCEMENTS IN THE PEDIATRIC LIVER TRANSPLANTATION: A SINGLE-CENTER STUDY OF 235 PATIENTS OVER 27 YEARS

Nam-Joon Yi Seoul, Korea

17:00 - 18:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



Campfire Presentations: Immuno and Beyond / Patient Outcomes - Campfire Table 5

Chairs: Bronwyn J. Levvey, Melbourne, Australia TBA

474.1 IMMUNOSUPPRESSION AT FIRST HOSPITAL DISCHARGE AFTER TRANSPLANTATION MAY NOT ACCURATELY PREDICT RISK OF CANCER IN SOLID ORGAN TRANSPLANT RECIPIENTS

# Claire M. Vajdic

Sydney, Australia

474.2 LONGITUDINAL IMMUNOSUPPRESSION DATA REDUCES EXPOSURE MISCLASSIFICATION AND IMPROVES OUTCOME PREDICTION AMONG SOLID ORGAN TRANSPLANT RECIPIENTS

## Maarit A. Laaksonen

Sydney, Australia

474.3 NATIONAL TRANSPLANTATION PREGNANCY REGISTRY (NTPR): 25 YEARS OF DATA COLLECTION

#### Michael J. Moritz

Emmaus, PA, United States

474.4 PROSPECTIVE RANDOMIZED CONTROLLED STUDY EVALUATING THE RELATIONSHIP BETWEEN ELECTRONIC ADHERENCE DATA AND TACROLIMUS CONCENTRATION DATA

#### Adam S. Bodzin

Chicago, IL, United States

474.5 AUTOMATIC ISCHEMIA TIME CALCULATION IN THE INTRA-OPERATIVE NURSING RECORD

Carmen J. Sierra

Miami, FL, United States

474.6 IMPACTS OF URETERIC STENT REMOVAL TIMING ON POST RENAL TRANSPLANT MAJOR UROLOGICAL COMPLICATION. A SINGLE CENTRE EXPERIENCE

Hassan A. Aleid

Riyadh, Saudi Arabia

17:00 - 19:00 HALL 5E3-LEVEL 5 NOT A CME SESSION

# Poster Sessions

Detailed list of all the posters available on page 273

18:30 - 19:30 CONVENTION HALL A-LEVEL 1 BY INVITATION ONLY - NOT A CME SESSION


International Transplantation Science Mentee-Mentor Awards Networking Event

# MORNING SESSIONS MONDAY • AUGUST 22

ndii 3DC - L3	Hall 5D - L5	Hall 5E1 - L5	Hall 5E2 - L5	S-221-L2	Theater 1 - L1	Theater 2 - L1	Conv. Hall A - L1	Theater 2 - L1 Conv. Hall A - L1 Conv. Hall B - L1 Conv. Hall C - L1	Conv. Hall C- L1	
				EMS Pancreatic Beta Fr Cell Replacement Therapy	FMS EMS Pancreatic Beta Fostering Innovation Assessing & Cell Replacement To Avoid Extinction Managing Cardio-Therapy PM  Therapy PM  Ther	EMS Assessing & Managing Cardio- Metabolic Risk	EMS Financial Neutrality	正	brosis - All You Ever Cochrane Wanted to Know Systematic Review	07:00
		Plen	ary: Hepatitis CVir. Magnitude of the I Treatment of HCV In Impact of Antiviral	<b>us in Solid Organ Ty</b> Problem (Solved & Ur fection Before and/or Therapy on Hepatic &	ry: Hepatitis C Virus in Solid Organ Tx.: Have the Rules Changed? (Hall SBC Magnitude of the Problem (Solved & Unsolved Issues) Prof. Marina Berenguer Treatment of HCV Infection Before and/or After Organ Tx Prof. Greg T. Everson Impact of Antiviral Therapy on Hepatic & Extra-Hepatic Prof. Simone I. Strasser	Plenary: Hepatitis CVirus in Solid Organ Tx.: Have the Rules Changed? (Hall SBC-LS) Magnitude of the Problem (Solved & Unsolved Issues) Prof. Marina Berenguer Treatment of HCV Infection Before and/or After Organ Tx Prof. Greg T. Everson Impact of Antiviral Therapy on Hepatic & Extra-Hepatic Prof. Simone I. Strasser	-15)			08:30
			Coffe	e Break and Poster	Coffee Break and Poster Viewing (Hall 5FG - L5)	-L5)				10:00
			Pres	ident's Plenary and	President's Plenary and Awards (Hall SBC - L5)	-LS)				10:30
	Lunch Break -	k - Exhibition (Hall 5FG - L5)	I 5FG-L5)		Expanding	Industry Symposium Expanding Treatment Options with ATLG (Hall SE3 - LS)	m ; with ATLG	Organized by	by .	12:30

MONDAY

# AFTERNOON SESSIONS MONDAY • AUGUST 22





# PRESIDENT'S PLENARY AWARDS CEREMONY

10:30– 12:30

In addition to a special lecture by Professor Jiefu Huang on "Transplant Reform in China", please join us in congratulating the recipients of the Young Investigators' Scientific Awards, TTS Recognition Awards, *Transplantation* Best Publication Awards, Women in Transplantation Awards, and the 2016 Medawar Prize.

HALL 5BC - LEVEL 5




# TIS BUSINESS MEETING

17:00– 18:00

- Announcement of the TTS 2020 destination city
- Presentation of the 2016-2018 Council
- TTS 2016 Congress report

Light Refreshments will be served.

**CONVENTION HALL A - LEVEL 1** 



TTS and the members of the Host Country Liaison Committee invite the participants of the 26<sup>th</sup> International Congress of The Transplantation Society to a unique evening under the theme 'Asian Market Place'. This will be taking place at Jumbo Kingdom Floating Restaurant, an internationally renowned tourist attraction, ornated like an ancient Chinese Palace.

JUMBO KINGDOM, Shum Wan Pier Dr., Aberdeen Ticket Required

07:00 - 08:15 S-221-LEVEL 2



Early Morning Symposia: Pancreatic Beta Cell Replacement Therapy: What Will We Be Doing in 2025?

Chair: Peter Stock, San Francisco, CA, United States

Supported by





500.1 SOLID PANCREAS TRANSPLANT

Raphael Meier Geneva, Switzerland



500.2 STEM CELL DERIVED BETA CELLS

Christian Schuetz Boston, MA, United States



500.3 XENO-ISLET TRANSPLANT

**Wayne J. Hawthorne** Westmead, Australia



500.4 AUTO/ALLO ISLET TRANSPLANT

**Hanne Scholz** Oslo, Norway

07:00 - 08:15 THEATRE 1-LEVEL 1

Early Morning Symposia: Fostering Innovation To Avoid Extinction: Current Trends in Health Professions Education

Chairs: Marcelo Cantarovich, Montreal, QC, Canada Medhat Z. Askar, Dallas, TX, United States



501.1 CORE EDUCATOR COMPETENCIES FOR CLINICIANS IN THE NEW MILLENNIUM

**Wayne C. Hodgson** Clayton, Australia



501.2 CURRENT INNOVATIONS IN HEALTH
PROFESSIONS EDUCATION: KEEPING UP WITH
TRAINEES EXPECTATIONS

Margaret Hay Clayton, Australia



501.3 THE ROLE OF PROFESSIONAL SOCIETIES IN ADVANCING PROFESSIONAL HEALTH EDUCATION: THE TTS EDUCATION ACADEMY MODEL

Medhat Z. Askar Dallas, TX, United States

07:00 - 08:15 THEATRE 2-LEVEL 1



Early Morning Symposia: Assessing and Managing Cardio-Metabolic Risk in Transplantation

Chairs: Hallvard Holdaas, Oslo, Norway Helen Pilmore, Auckland, New Zealand



502.1 NEW INSIGHTS INTO THE DIAGNOSIS OF PTDM

**Trond Jenssen** Oslo, Norway



502.2 METABOLIC SYNDROME AFTER LIVER TRANSPLANTATION

> **Simone I. Strasser** Camperdown, Australia



502.3 CVS RISK ASSESSMENT IN 2016

Helen Pilmore Auckland, New Zealand

07:00 - 08:15 CONVENTION HALL A-LEVEL 1



Early Morning Symposia: Financial Neutrality - but Not Financial Incentives - to Further Promote Organ Donation

Chairs: Elmi M. Muller, Cape Town, South Africa Beatriz Dominguez-Gil, Madrid, Spain



503.1 FINANCIAL NEUTRALITY FOR THE LIVING DONOR

**Dominique E. Martin** Geelong, Australia



503.2 FINANCIAL NEUTRALITY FOR DECEASED DONOR FAMILIES

**Alexander M. Capron**Los Angeles, CA, United States



503.3 HEALTH INSURANCE FOR THE LIVING DONOR IN THE FINANCIAL NEUTRALITY FRAMEWORK

John S. Gill Vancouver, BC, Canada

# 07:00 - 08:15 CONVENTION HALL B-LEVEL 1



Early Morning Symposia: Fibrosis - All You Ever Wanted to Know (But Were Afraid to Ask)

Chairs: Brian J. Nankivell, Westmead, Australia Michael Mengel, Edmonton, AB, Canada

504.1 BIOLOGY AND RESOLUTION

**Dany Anglicheau** Paris, France

504.2 BIOPSY ANALYSIS

Alton "Brad" Farris III
Atlanta, GA, United States

504.3 IN VIVO IMAGING OF FIBROSIS

Faikah Gueler Hannover, Germany

07:00 - 08:15 CONVENTION HALL C-LEVEL 1

Early Morning Symposia: Cochrane Systematic Reviews: Useful for Decision Making?

Chairs: Angela Webster, Sydney, Australia Jonathan Craig, Sydney, Australia

505.1 SYSTEMATIC REVIEWS IN THE CONTEXT OF HEALTHCARE, GUIDELINES AND OTHER FORMS OF RESEARCH

**Colin Wilson**Newcastle-upon-Tyne, United Kingdom

505.2 WHAT IS THE DIFFERENCE BETWEEN COCHRANE REVIEWS AND NON COCHRANE REVIEWS

**Philip Masson** Edinburgh, United Kingdom





505.3 WHAT ARE THE PROS AND CONS OF SYSTEMATIC REVIEWS

**David W. Mudge** Brisbane, Australia

08:30 - 10:00 HALL 5BC-LEVEL 5

Plenary:

Hepatitis C Virus in Solid Organ Transplantation: Have the Rules Changed?

Chairs: Chung-Mau Lo, Hong Kong SAR, P.R. in China Nancy Ascher, San Francisco, CA, United States

510.1 MAGNITUDE OF THE PROBLEM (SOLVED & UNSOLVED ISSUES) IN SOLID ORGAN TRANSPLANTATION



Marina Berenguer Valencia, Spain

510.2 TREATMENT OF HCV INFECTION BEFORE AND/OR AFTER ORGAN TRANSPLANTATION



**Gregory T. Everson** Aurora, CO, United States

510.3 IMPACT OF ANTIVIRAL THERAPY ON HEPATIC
AND EXTRA-HEPATIC MANIFESTATIONS OF
CHRONIC HCV INFECTION



**Simone I. Strasser** Camperdown, Australia

10:00 - 10:30 COFFEE BREAK HALL 5FG-LEVEL 5

10:30 - 12:30 HALL 5BC-LEVEL 5 NOT A CME SESSION

Plenary:

President's Plenary and Awards

Chairs: Philip J. O'Connell, Westmead, Australia Nancy Ascher, San Francisco, CA, United States Francis L. Delmonico, Waltham, MA, United States

520 TRANSPLANTATION REFORM IN CHINA

**Jiefu Huang**Beijing, People's Republic of China

520 PRESIDENTIAL ADDRESS

Philip J. O'Connell Westmead, Australia

MEDAWAR PRIZE LECTURE

DISTRIBUTION OF AWARDS

12:30 - 13:30 LUNCH BREAK


12:30 - 13:30 HALL 5E3-LEVEL 5

Industry Symposium:

Expanding Treatment Options with Anti-T Lymphocyte Immunoglobulin (ATLG)

Organized by

Please refer to page 344 for details.





State-of-the-Art Session: Live Kidney Donation – Overcoming Immunological Barriers

Chairs: Chi Yuen Simon Cheung, Hong Kong SAR, P.R. of China Jean-Paul P. Soulillou, Nantes, France



540.1 IS THERE STILL A PLACE FOR LIVING DONOR KIDNEY TRANSPLANTS WITH A POSITIVE CROSSMATCH?

Carrie A. Schinstock
Rochester, MN, United States



540.2 ABO INCOMPATIBLE TRANSPLANTATION, WHEN IS IT NOT SAFE?

**Kazunari Tanabe** Tokyo, Japan



540.3 KIDNEY PAIRED DONATION – PROBLEMS AND SOLUTIONS?

**Paolo Ferrari** Sydney, Australia

13:30 - 15:00 HALL 5D-LEVEL 5



State-of-the-Art Session: When Organ Donation Becomes Routine, Can We Take Ethical Practice for Granted?

Chairs: Jenny Koo, Hong Kong SAR, P.R. of China Marta López Fraga, Strasbourg, France



541.1 PSYCHOSOCIAL EVALUATION OF LIVING KIDNEY DONORS: WHAT DO GUIDELINES SAY, AND WHAT ARE THE CHALLENGES?

> **Allison Tong** Sydney, Australia



541.2 ROUTINE CONSIDERATION OF ORGAN DONATION: AN ETHICAL DUTY FOR THOSE PROVIDING END-OF-LIFE CARE

**Beatriz Dominguez-Gil** Madrid, Spain



541.3 ROUTINE CARE OF FOREIGN DONORS AND RECIPIENTS – IMPLEMENTING ETHICAL GUIDELINES IN THE TRANSNATIONAL SETTING

**Jacqueline J. Chin** Singapore, Singapore





# State-of-the-Art Session: Facing Challenges in the Developing World

Chairs: Shiro Takahara, Osaka, Japan Ifeoma Ulasi, Enugu, Nigeria



542.1 LATIN AMERICA...A HETEROGENEOUS ENVIRONMENT

Rudolf A. Garcia-Gallont Guatemala City, Guatemala



542.2 HIV POSITIVE DONORS AND THE IMPACT OF THE SECOND VIRAL STRAIN ON RECIPIENT KIDNEYS

Elmi M. Muller Cape Town, South Africa



542.3 IMPROVING TRANSPLANTATION PRACTICE IN MONGOLIA

**Byambadorj Batsuuri** Ulaanbaatar, Mongolia

13:30 - 15:00 HALL 5E2-LEVEL 5



State-of-the-Art Session: What's New in VCA

Chairs: Emmanuel Morelon, Lyon, France Linda C. Cendales, Durham, NC, United States



543.1 OUTCOME IN VCA

Palmina Petruzzo Lyon, France



543.2 HISTOPATHOLOGY IN VCA: BANFF SCORE 2015

**Linda C. Cendales**Durham, NC, United States



543.3 IMMUNOLOGY OF VCA: LESSONS FROM THE MOUSE

> **Wayne W. Hancock** Philadelphia, PA, United States

13:30 - 15:00 S-221-LEVEL 2



State-of-the-Art Session: Xenotransplantation Will Provide Solutions, Not Problems

Chairs: Wayne J. Hawthorne, Westmead, Australia Agnes Azimzadeh, Baltimore, MD, United States



544.1 ADVANCES IN GENETIC MODIFICATION OF PIGS

Peter Cowan



544.2 ADVANCES IN SOLID ORGAN XENOTRANSPLANTATION

Melbourne, Australia

**Muhammad M. Mohiuddin** Bethesda, MD, United States



544.3 ADVANCES IN PORCINE ISLET XENOTRANSPLANTATION

Chung-Gyu Park Seoul, Korea

13:30 - 15:00 THEATRE 1-LEVEL 1



State-of-the-Art Session: Two Decades of Living Donor Adult Liver Transplantation: Pushing the Limits

Chairs: Mohamed Rela, Chennai, India See Ching Chan, Hong Kong SAR, P.R. of China



545.1 GETTING MORE HORSEPOWER FROM YOUR GRAFT: SHIFTING FROM RIGHT TO LEFT

**Chao-Long Chen** Kaohsiung, Taiwan




545.2 HOW DOES THE LEFT STACK UP TO THE RIGHT?

Yuji Soejima
Fukuoka, Japan



545.3 EXTENDED CRITERIA LIVING DONORS

**Chung-Mau Lo** Hong Kong SAR, P.R. of China





# State-of-the-Art Session: Post-Transplant Viral Infections

Chairs: Ban Hock Tan, Singapore, Singapore Kelvin Kai-Leung Ho, Hong Kong SAR, P.R. of China



546.1 NEW INSIGHTS INTO THE BIOLOGY OF PTLD

**Olivia M. Martinez** Stanford, CA, United States



546.2 POST TRANSPLANT HEP B

James Fung Hong Kong SAR, P.R. of China



546.3 POST TRANSPLANT TREATMENT OF HIV

**Peter Stock** San Francisco, CA, United States

# 13:30 - 15:00 CONVENTION HALL A-LEVEL 1



State-of-the-Art Session: Epitopes - The Target of HLA Antibodies

Chairs: Janette Kwok, Hong Kong SAR, P.R. of China Peter William Nickerson, Winnipeg, MB, Canada



547.1 OVERVIEW - DEFINITION AND TOOLS FOR IDENTIFYING HLA ANTIBODY EPITOPES

**Frans H.J. Claas** Leiden, The Netherlands



547.2 IMMUNOGENICITY - ARE ALL HLA EPITOPES THE SAME?

> **Anat R. Tambur** Chicago, IL, United States



547.3 CLINICAL RELEVANCE OF HLA EPITOPES - WHERE DO WE STAND?

**Chris J. Wiebe**Winnipeg, MB, Canada





# State-of-the-Art Session: Moving Tolerance Into the Clinic

Chairs: Carla Baan, Rotterdam, The Netherlands Qizhi Tang, San Francisco, CA, United States



548.1 TRACKING THE ALLOREACTIVE T CELL REPERTOIRE: INSIGHTS INTO TOLERANCE AND REJECTION

> Megan Sykes New York, NY, United States



548.2 CLINICAL TRIALS USING TREGS

**Qizhi Tang**San Francisco, CA, United States



548.3 CAR-TREGS

Megan Levings

Vancouver, BC, Canada

# 13:30 - 15:00 CONVENTION HALL C-LEVEL 1



State-of-the-Art Session: Cardiac Perfusion Strategies

Chairs: Peter S. MacDonald, Sydney, Australia Anne I. Dipchand, Toronto, ON, Canada



549.1 IN VIVO RE-ANIMATION

**Simon J. Messer** Cambridge, United Kingdom



549.2 HYPOTHERMIC PERFUSION

**Franklin L. Rosenfeldt** Melbourne, Australia



549.3 NORMOTHERMIC PERFUSION

**Kumud K. Dhital**Darlinghurst, Australia

15:00 - 15:30 COFFEE BREAK HALL 5FG-LEVEL 5

15:30 - 17:00 HALL 5BC-LEVEL 5



# Orals Session: Complications

Chairs: Marcelo Cantarovich, Montreal, QC, Canada Alejandro Niño-Murcia, Bogota, Colombia

550.1 PROSPECTIVE TREATMENT AND NOVEL BIOMARKERS OF BK POLYOMAVIRUS ASSOCIATED NEPHROPATHY

### **Minal Borkar**

Calgary, AB, Canada

550.2 BK VIRUS NEPHROPATHY IN RENAL TRANSPLANTATION- A PATHOLOGIST'S PERSPECTIVE

# **Kamlesh S. Suthar**

Ahmedabad, India

550.3 THE IMPACT OF RECURRENT
GLOMERULONEPHRITIS AFTER KIDNEY
TRANSPLANTATION IN THE ERA OF
CONTEMPORARY MAINTENANCE
IMMUNOSUPPRESSION

# Penelope J. Allen

Hunters Hill, Australia

550.4 TROJAN KIDNEYS: UNEXPECTED DONOR-DERIVED VIRAL TRANSMISSION IN KIDNEY TRANSPLANT RECIPIENTS – A SYSTEMATIC REVIEW

# Rashmi Shingde Sydney, Australia

550.5 SEQUENTIAL BIOPSY FINDINGS OF POLYOMAVIRUS ASSOCIATED NEPHROPATHY

# Handan Özdemir

Ankara, Turkey

550.6 POLYOMAVIRUS (PV) REPLICATION AND SMOKING ARE INDEPENDENT RISK FACTORS FOR BLADDER CANCER AFTER RENAL TRANSPLANTATION

#### John C. Papadimitriou

Baltimore, MD, United States

550.7 BK VIRUS-ASSOCIATED NEPHROPATHY IN SCOTLAND: EVIDENCE OF BETTER TRANSPLANT SURVIVAL BUT VARIATION IN INCIDENCE, MANAGEMENT AND OUTCOME BETWEEN RENAL UNITS

#### Michaela C. Petrie

Edinburgh, United Kingdom

550.8 HIGH NUMBERS OF INTRAGRAFT BLOOD
DENDRITIC CELL ANTIGEN-1 (BDCA-1)-POSITIVE
MYELOID DENDRITIC CELLS DURING BK
POLYOMAVIRUS—ASSOCIATED NEPHROPATHY

#### **Jesper Kers**

Amsterdam, The Netherlands

550.9 OUTCOME AFTER ECULIZUMAB THERAPY TO PREVENT RECURRENCE OF ATYPICAL HEMOLYTIC UREMIC SYNDROME: EXPERIENCE IN TWELVE RENAL TRANSPLANT RECIPIENTS

> Julien Zuber Paris, France

15:30 - 17:00 HALL 5D-LEVEL 5



# Orals Session:

Pancreas/Islet Tx: Donor and Technical Aspects

Chairs: Dixon B. Kaufman, Madison, WI, United States Mitsukazu Gotoh, Osaka, Japan

551.1 INFLUENCE OF PANCREAS IMPORT AND COLD ISCHEMIA ON OUTCOMES FOLLOWING PANCREAS TRANSPLANTATION

# **Robert J. Stratta**

Winston-Salem, NC, United States

551.2 WHY ARE PANCREAS TRANSPLANTS
DECLINING IN THE UNITED STATES IN THE
PAST DECADE?

# Robert J. Stratta

Winston-Salem, NC, United States

551.3 EXTENDED PANCREAS DONOR PROGRAM –
THE EXPAND STUDY, A PROSPECTIVE
MULTICENTRE TRIAL

### **Andrea Proneth**

Regensburg, Germany

551.4 PRESERVATION OF HUMAN PANCREAS WITH HYPOTHERMIC MACHINE PERFUSION

# **Diego Cantarovich**

Nantes, France

551.5 A PROPOSAL FOR NEW DONOR CRITERIA FOR PANCREAS TRANSPLANTATION BASED ON POSTOPERATIVE INSULIN SECRETION

#### Taihei Ito

Aichi, Japan

551.6 TOTAL PANCREATECTOMY WITH ISLET
AUTOTRANSPLANTATION IMPROVES
QUALITY OF LIFE ALLOWING FOR THE
RESOLUTION OF THE INTRACTABLE PAIN
WITH GOOD GLUCOSE CONTROL IN
PROPERLY SELECTED PATIENTS WITH
CHRONIC PANCREATITIS

#### **Julia Solomina**

Chicago, IL, United States

551.7 VALIDATION OF A NEW NORTH AMERICAN
ISLET DONOR SCORE FOR DONOR PANCREAS
SELECTION AND SUCCESSFUL ISLET
ISOLATION

#### **Julia Solomina**

Chicago, IL, United States

551.8 IS SUPERIOR MESENTERIC ARTERY SO INDISPENSABLE FOR PANCREAS TRANSPLANT?

# **Alexey Pinchuk**

Moscow, Russian Federation

551.9 TOTAL PANCREATECTOMY WITH
AUTOLOGOUS ISLET TRANSPLANTATION FOR
CHRONIC PANCREATITIS: CONSIDERATIONS
FOR EARLY OPERATION

# Kenneth L. Brayman

Charlottesville, VA, United States

15:30 - 17:00 HALL 5E1-LEVEL 5



# Orals Session:

Increasing Donation: A Global Perspective

Chairs: Susan Gunderson, Minneapolis, MN, United States Anantharaman Vathsala, Singapore, Singapore

552.1 A NEW ERA FOR ORGAN DONATION AND TRANSPLANTATION IN CHINA

# **Haibo Wang**

Hong Kong SAR, P.R. of China

552.2 PROGRESS IN DECEASED ORGAN DONOR TRANSPLANTATION IN INDIA

# Lalitha Raghuram

Hyderabad, India

552.3 THE AFRICAN AMERICAN JOURNEY IN ORGAN DONATION AND THE METHODOLOGIES THAT RESULTED IN MOVEMENT FROM THE BOTTOM TO THE TOP

#### Clive O. Callender

Washington DC, United States

552.4 CENTER EFFECT ON OUTCOME OF KIDNEY TRANSPLANTATION FROM PEDIATRIC DECEASED DONOR IN CHINA

#### **Huanxi Zhan**

Guangzhou, People's Republic of China

552.5 EXPANDING THE DONOR POOL THROUGH
INTENSIVE CARE TREATMENT TO FACILITATE
ORGAN DONATION: RESULTS OF A SPANISH
MULTICENTER STUDY

# **Beatriz Dominguez-Gil**

Madrid, Spain

552.6 DECEASED ORGAN DONATION
PERFORMANCE IN THE CHINESE
COMMUNITY: AN AUDIT OF HOSPITAL
MEDICAL RECORD IN HONG KONG

# **Chi Yuen Simon Cheung**

Hong Kong SAR, P.R. of China

552.7 ALLOCATION OF EXTENDED CRITERIA
DECEASED DONOR KIDNEYS BASED ON
EXPLANT BIOPSY AND MODIFIED REMUZZI
SCORES OPTIMIZES THEIR UTILIZATION

# **Anantharaman Vathsala**

Singapore, Singapore

552.8 50 YEARS OF TRANSPLANTATION IN POLAND

#### **Roman Danielewicz**

Warsaw, Poland

552.9 RISKY ORGANS: TRENDS IN COMORBIDITIES

AMONG POTENTIAL AND ACTUAL

AUSTRALIAN ORGAN DONORS IN NEW

SOUTH WALES

# Imogen K .Thomson

Sydney, Australia

15:30 - 17:00 HALL 5E2-LEVEL 5



# Orals Session: Living Donor Transplant

Chairs: Paul Harden, Oxford, United Kingdom Mona Alrukhaimi, Dubai, United Arab Emirates

553.1 ADVERSE EARLY OUTCOMES FOR RIGHT-SIDED LIVING DONOR KIDNEY TRANSPLANTS

# **Deepak Chhabra**

Sydney, Australia

553.2 GLOBAL KIDNEY EXCHANGE

# Michael A. Rees

Toledo, OH, United States

553.3 CHRONIC KIDNEY DISEASE AMONG LIVING KIDNEY DONORS: A COHORT STUDY

# **Philip Masson**

Edinburgh, United Kingdom

553.4 TECHNIQUE AND OUTCOME OF ROBOTIC KIDNEY TRANSPLANTATION IN 161 ADULT RECIPIENTS

# **Pranjal Modi**

Ahmedabad, India

553.5 TRANSVAGINAL INSERTION OF KIDNEY AND ROBOTIC KIDNEY TRANSPLANTATION: FIRST 19 CASES

# **Pranjal Modi**

Ahmedabad, India

553.6 PRELIMINARY RESULTS FROM A PILOT STUDY
UTILIZING ERAS PROTOCOL IN LIVING DONOR
NEPHRECTOMY

#### Debra L. Sudan

Durham, NC, United States

553.7 OBESITY IS ASSOCIATED WITH INCREASED RISK OF ESRD AMONG LIVING KIDNEY DONORS

# Jayme E. Locke

Birmingham, AL, United States

553.8 WHAT DISTINGUISHES DONORS FROM NON-DONORS? ANALYSIS OF 2306 POTENTIAL LIVING KIDNEY DONORS

## Hillary J. Braun

San Francisco, CA, United States

553.9 ESTABLISHING A LEARNING CURVE FOR
LAPAROSCOPIC LIVING DONOR NEPHRECTOMY

#### **Zubir Ahmed**

London, United Kingdom

15:30 - 17:00 S-221-LEVEL 2



# Orals Session:

# Enhanced Surgical Techniques in Transplantation (Videos)

Chairs: George W. Burke, Miami, FL, United States Henry H.P. Pleass, Hunters Hill, Australia

554.1 ROBOTIC SIMULTANEOUS PANCREAS KIDNEY TRANSPLANTATION IN OBESE RECIPIENT

#### **Chun Chieh Yeh**

Taichung, Taiwan

554.2 TIPS FOR A SUCCESSFUL NORMOTHERMIC LIVER PERFUSION

#### **David Nasralla**

Oxford, United Kingdom

554.3 CONTRAST-ENHANCED INTRAOPERATIVE ULTRASONIC CHOLANGIOGRAPHY IN LIVING DONOR HEPATECTOMY

#### Takeshi Urad

Kobe, Japan

554.4 TOTAL ARTIFICIAL HEART BRIDGE TO COMBINED HEART-LIVER TRANSPLANTATION FOR TRANSTHYRETIN AMYLOIDOSIS

#### **Amit Sharma**

Richmond, VA, United States

554.5 ROBOTIC ASSISTED KIDNEY TRANSPLANTATION

# Selcuk Sahin

Istanbul, Turkey

554.6 RENO- AND SPLENOPORTAL ANASTOMOSIS FOR A RETRANSPLANT PATIENT WITH SITUS INVERSUS

#### **Hajime Uchida**

Tokyo, Japan

554.7 A CASE OF DECEASED DONOR LIVER
TRANSPLANTATION USING RENOPORTAL
ANASTOMOSIS IN PATIENTS WITH DIFFUSE
PORTOMESENTERIC THROMBOSIS

#### **Tae-Seok Kim**

Daegu, Korea

# 15:30 - 17:00 THEATRE 1-LEVEL 1



# Orals Session: Tolerance - Immunological Aspects

Chairs: Alberto Sanchez-Fueyo, London, United Kingdom Sandy Feng, San Francisco, CA, United States

555.1 PRIMARY OUTCOME OF IWITH: A 12 CENTER
NORTH AMERICAN CLINICAL TRIAL OF
IMMUNOSUPPRESSION WITHDRAWAL IN
STABLE PEDIATRIC LIVER TRANSPLANT
RECIPIENTS

#### Sandy Feng

San Francisco, CA, United States

555.2 AT1R ANTIBODIES AT 1-YEAR NEGATIVELY
IMPACT 5-YEAR NATIVE RENAL FUNCTION IN
LIVER TRANSPLANT RECIPIENTS

# **Duska Dragun**

Berlin, Germany

555.3 THE IMPACT OF PREFORMED DONOR-SPECIFIC ANTIBODIES IN LIVING DONOR LIVER TRANSPLANTATION DEPENDING ON GRAFT VOLUME

# **Ryoichi Goto**

Sapporo, Japan

555.4 THE STRATEGY FOR LIVING DONOR LIVER
TRANSPLANTATION IN THE RECIPIENTS WITH
PREFORMED DONOR SPECIFIC ANTIBODIES

# Atsushi Yoshizawa

Kyoto, Japan

555.5 OUTCOMES OF SIROLIMUS CONVERSION FOR CALCINEURIN INHIBITOR INDUCED
NEUROTOXICITY IN LIVER TRANSPLANTATION

# Greg J. McKenna

Dallas, TX, United States

555.6 COMPARISON OF THE EFFECTS OF BRAND
NAME VERSUS GENERIC
IMMUNOSUPPRESSANTS ON LONG-TERM
GRAFT FAILURE RISK AMONG U.S. LIVER
TRANSPLANT RECIPIENTS: ANALYSIS OF SRTR
AND MEDICARE CLAIMS DATA

## **Jarcy Zee**

Ann Arbor, MI, United States

555.7 NORMAL LIVER ENZYMES DO NOT EXCLUDE SIGNIFICANT PATHOLOGY IN LIVER TRANSPLANT RECIPIENTS

#### **Richard Gilroy**

Fairway, KS, United States

555.8 PREFERENTIAL ACCUMULATION OF T HELPER
CELLS BUT NOT CYTOTOXIC T CELLS
CHARACTERIZES BENIGN SUBCLINICAL
REJECTION OF HUMAN LIVER ALLOGRAFTS

# Richard Taubert

Hannover, Germany

555.9 EXPERIENCE WITH mTOR INHIBITORS IN PEDIATRIC LIVER TRANSPLANTATION

# Figen Ozcay

Ankara, Turkey

# 15:30 - 17:00 THEATRE 2-LEVEL 1



# Orals Session: Chronic Allograft Injury

Chairs: Michael Mengel, Edmonton, AB, Canada Rudolf Oehler, Vienna, Austria

556.1 MODELS OF ALLOGRAFT FAILURE IN PRIMARY RENAL TRANSPLANT RECIPIENTS WITH ANTI-HLA ALLOANTIBODIES (DSA)

# **Matthew J. Everly**

Los Angeles, CA, United States

556.2 TUBULOINTERSTITIAL EXPRESSION OF
CONNECTIVE TISSUE GROWTH FACTOR IN
RENAL ALLOGRAFT PROTOCOL BIOPSIES AT 3
MONTHS PREDICTS INTERSTITIAL FIBROSIS
AT 5 YEARS

#### **Thomas Vanhove**

Leuven, Belgium

556.3 EFFECT OF EPIGENETIC MODIFICATIONS IN GRAFT KIDNEYS PROGRESSING TO CHRONIC ALLOGRAFT DYSFUNCTION

# Sai Vineela Bontha

Charlottesville, VA, United States

556.4 INFLAMMATION IN SCARRING ON 1 YEAR
SURVEILLANCE BIOPSIES DOES NOT CHANGE
THE 5 YEAR PROGNOSTIC OF KIDNEY
TRANSPLANTATION

# **Magali Giral**

Nantes, France

556.5 THE ONE YEAR RENAL BIOPSY INDEX (1-RBI):
A CLINICAL MARKER TO SCREEN PATIENTS
FOR ONE YEAR SURVEILLANCE BIOPSY
INDICATION AFTER THE TRANSPLANTATION

# **Magali Giral**

Nantes, France

556.6 ANGIOTENSIN SYSTEM BLOCKADE REDUCE PROTEINURIA IN KIDNEY TRANSPLANT RECIPIENTS: A META-ANALYSIS

#### **Guodona Chen**

Guangzhou, People's Republic of China

556.7 CHEMOKINE RECEPTOR CXCR4 ANTAGONIST, A NOVEL PATHWAY TO PREVENT CHRONIC ALLOGRAFT NEPHROPATHY

## Yue Xu

Beijing, People's Republic of China

556.8 PERIPHERAL NK-CELL REPERTOIRE
DISTRIBUTION IN CHRONIC ALLOGRAFT
DYSFUNCTION AFTER RENAL
TRANSPLANTATION

# Sailaja Kesiraju Hyderabad, India

556.9 PROGRESSIVE ALLOGRAFT DYSFUNCTION IS
ASSOCIATED WITH AN EARLY (12 MONTHS)
INCREASE IN LEVELS OF VEGF-C, PLGF AND
FOLLISTATIN AFTER RENAL TRANSPLANTATION

#### **Marlies Reinders**

Leiden, The Netherlands

# 15:30 - 17:00 CONVENTION HALL A-LEVEL 1

BS

# Orals Session:

Interplay Between Innate: Adaptive Immune Cells

Chairs: Dany Anglicheau, Paris, France Xunrong Luo, Chicago, IL, United States

557.1 QUANTIFICATION OF LYMPHATIC FLOW
USING SPECT/CT LYMPHOSCINTIGRAPHY
REVEALS INCREASED LYMPH FLOW DURING
CHRONIC REJECTION

# **Wilson Wong**

London, United Kingdom

557.2 RECEPTOR TYROSINE KINASE MER MEDIATES
EXPANSION OF MDSCS CRITICAL FOR
TRANSPLANTATION TOLERANCE

#### **Xunrong Luo**

Chicago, IL, United States

557.4 REGULATORY T CELLS WITH HLA-A\*02-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CAN CONTROL STRONG ALLOGENEIC IMMUNE RESPONSES AND INDUCE OPERATIONAL TOLERANCE

#### **Elmar Jaeckel**

Hannover, Germany

557.5 mIRNA-181 PROMOTES GRAFT
PROLONGATION BY PLASMACYTOID
DENDRITIC CELLS BY DECREASING MARGINAL
ZONE B CELLS AND PLASMABLASTS

#### Olivia M. Martinez

Stanford, CA, United States

557.6 MOLECULAR LANDSCAPE OF ALLOGRAFT
REJECTION: DEFINITIVE MAPPING OF SHARED
AND SELECTIVE MOLECULES FOR T CELLMEDIATED REJECTION AND
ANTIBODY-MEDIATED REJECTION

# Philip F. Halloran

Edmonton, AB, Canada

557.7 EXOSOMES RELEASED INTO THE
CIRCULATION FOLLOWING LUNG AND HEART
TRANSPLANTATION: COMPOSITION AND
ROLE IN ALLOGRAFT REJECTION

#### Thalachallour Mohanakumar

Phoenix, AZ, United States

557.8 NK CELLS ARE REQUIRED IN B-CELL
DEPENDENT ANTIBODY MEDIATED ISLET
TRANSPLANT TOLERANCE

### **Christian Schuetz**

Boston, MA, United States

557.9a THE ROLE OF DNA METHYLATION OF INTERFERON GAMMA AND PROGRAMMED DEATH 1 IN ALLOGRAFT REJECTION AFTER KIDNEY TRANSPLANTATION

(abst. P. 1005 in Transplantation Journal)

## **Carla Baan**

Rotterdam, The Netherlands

# 15:30 - 17:00 CONVENTION HALL B-LEVEL 1



# Orals Session:

Making it Work: Challenges in Immunosuppression

Chairs: Henri G.D. Leuvenink, Groningen, The Netherlands Tianshu Zhanq, Baltimore, MD, United States

558.1 HUMAN ENDOTHELIAL-LIKE CELLS
TRANSDIFFERENTIATED FROM MONOCYTES
SUPPRESS ALLO-REACTIVE T CELLS

#### Yuka Tanaka

Hiroshima, Japan

558.2 INTERACTION BETWEEN MICROCHIMERISM-DERIVED EXOSOMES AND HOST DENDRITIC CELLS GENERATES SPLIT TOLERANCE

# William J. Burlingham

Madison, WI, United States

558.3 HIGH-LEVEL CO-EXPRESSION OF CD86 IN RECIPIENT HEPATOCYTES TRANSDUCED WITH AAV-KD BREAKS TOLERANCE TO KD-BEARING SKIN GRAFTS

# Mario L. Leong

Sydney, Australia

558.4 A COMPARISON OF ANTI-CD28 (FR104) AND
ANTI-B7 (BELATACEPT) IMMUNOTHERAPY IN
MONKEY CARDIAC ALLOGRAFT
TRANSPLANTATION

# Tianshu Zhang

Baltimore, MD, United States

558.5 SELECTIVE BLOCKADE OF CD28
COSTIMULATION PREVENTED HUMAN ALLOSKIN GRAFT REJECTION IN A HUMANISED
MOUSE MODEL

### Masaaki Zaitsu

Sapporo, Japan

558.6 MODULATION OF INFLUENZA-SPECIFIC HUMORAL RESPONSES BY SELECTIVE CD28 BLOCKADE

# **Agnes Azimzadeh**

Baltimore, MD, United States

558.7 MODULATION OF THE IMMUNE SYSTEM BY SECRETOME-DEFICIENT MESENCHYMAL STEM CELLS

# Franka Luk

Rotterdam, The Netherlands

558.8 UPREGULATION OF HEME OXYGENASE-1 IN IMMATURE DENDRITIC CELLS IMPROVES THEIR TOLEROGENIC CAPACITY IN ALLOTRANSPLANTATION

# **Gang Chen**

Wuhan, People's Republic of China

558.9 INDEFINITE SURVIVAL OF MURINE KIDNEY
ALLOGRAFTS INDUCED BY DEPLETION OF
DONOR PASSENGER LEUKOCYTES

#### Wilson Wong

London, United Kingdom

# 15:30 - 17:00 CONVENTION HALL C-LEVEL 1

BS

# Orals Session:

# Diagnosis and Monitoring of Rejection (II)

Chairs: Menna R. Clatworthy, Cambridge, United Kingdom Emmanuel Zorn, New York, NY, United States

559.1 IMMUNOGLOBULIN M THERAPY PREVENTS
DEVELOPMENT OF TYPE 1 DIABETES BY
MODULATING THE EXPRESSION OF
DYSREGULATED PANCREATIC microRNAS
ASSOCIATED WITH DISEASE PATHOGENESIS

# Kenneth L. Brayman

Charlottesville, VA, United States

559.2 THE ROLE OF CALCINEURIN INHIBITION IN THE DENDRITIC CELL RESPONSE TO ASPERGILLUS FUMIGATUS INFECTION IN LUNG TRANSPLANT RECIPIENTS

#### Amit G. Adlakha

London, United Kingdom

559.3 HUMAN B CELL CYTOKINES PREDICT RENAL ALLOGRAFT REJECTION AND EARLY TRANSPLANT OUTCOMES

# **Aravind Cherukuri**

Pittsburgh, PA, United States

559.4 TRANSITIONAL B CELL T1/T2 RATIO IS A PROGNOSTIC MARKER FOR HUMAN RENAL ALLOGRAFT DETERIORATION

#### **David Rothstein**

Pittsburgh, PA, United States

559.5 THE UNHOLY TRIAD OF INFLAMMATION,
INFECTION AND IMMUNE REJECTION OF THE
KIDNEY ALLOGRAFT- PARTNERS IN CRIME?

# Thangamani Muthukumar

New York, NY, United States

559.6 THE HET/HOM RATIO CALCULATED FROM RNA-SEQ DATA: A UNIVERSAL AND UNBIASED QUANTITATIVE MEASURE OF IMMUNE CELL INVASION INTO HUMAN ALLOGRAFTS

# Thangamani Muthukumar

New York, NY, United States

559.7 IMPORTANCE OF THE NATURE AND BINDING SPECIFICITY OF THE SECONDARY ANTIBODY USED IN LUMINEX SINGLE ANTIGEN BEAD ASSAYS FOR MONITORING CLINICALLY RELEVANT HLA IGG ANTIBODIES IN PRE- AND POST-TRANSPLANT PATIENTS

# Mepur H. Ravindranath

Los Angeles, CA, United States

559.8 DE-NOVO DONOR SPECIFIC ANTIBODIES
(DSA) MONITORING IN LIVING RELATED
TRANSPLANTATION

# Rajkumar Sharma

Lucknow, India

559.9 EVIDENCE FOR STRUCTURAL VARIANTS
WITHIN AN INDIVIDUAL HLA-I MOLECULE
COATED ON LUMINEX SINGLE ANTIGEN BEAD
ASSAYS: IMPACT ON MONITORING HLA
ANTIBODIES FOR ORGAN ALLOCATION AND
DE NOVO DSA IN TRANSPLANT PATIENTS

#### **Vadim Jucaud**

Los Angeles, CA, United States

17:00 - 18:00 CONVENTION HALL A-LEVEL 1 NOT A CME SESSION

Society Meeting: TTS Business Meeting

18:00 - 18:20 HALL 5FG-LEVEL 5 (Behind TTS booth in aisle 500) NOT A CME SESSION

# ISN-TTS Sister Transplantation Center Program

565 PRESENTATION OF ISN-TTS SISTER TRANSPLANTATION CENTER PROGRAM

Randall Lou Meda Guatemala, Guatemala

**Abdullah El-Kishawi** Gaza City, Palestine

18:00 - 19:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



# Campfire Presentations: Immunossuppression - Campfire Table 1

Chairs: Luis E. Morales-Buenrostro, Mexico City, Mexico Maggie Kam Man Ma, Hong Kong SAR, P.R. of China

570.1 EVALUATION OF PK PROFILE AND CLINICAL OUTCOMES WITH HEXAL® VERSUS PROGRAF® IN DE NOVO RENAL TRANSPLANT RECIPIENTS: RESULTS FROM SPARTACUS - A MULTICENTRE, PROSPECTIVE RANDOMIZED STUDY

# Peter Schenker

Bochum, Germany

570.2 REDUCED INCIDENCE OF CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS: A COST-EFFECTIVENESS ANALYSES

**Jose Medina Pestana** 

Sao Paulo, Brazil

570.3 ABBREVIATED THYMOGLOBULIN AND
BASILIXIMAB INDUCTION THERAPY IN
PATIENTS UNDERGOING KIDNEY
TRANSPLANTATION RESULTS IN SUPERIOR
GRAFT AND PATIENT SURVIVAL WITH LESS
INFECTIOUS COMPLICATIONS

# Vaughn E. Whittaker

Manlius, NY, United States

570.4 COMPARISON OF MYCOPHENOLIC ACID
(MPA) EXPOSURE AFTER CONVERSION FROM
ENTERIC-COATED MYCOPHENOLATE SODIUM
(EC-MPS) TWICE-DAILY TO ONCE-DAILY IN
ADULT KIDNEY TRANSPLANT RECIPIENTS

# **Diego Cantarovich**

Nantes, France

570.5 IMPACT OF EARLY RED BLOOD CELL
TRANSFUSION AFTER KIDNEY
TRANSPLANTATION ON DE NOVO HLA
SENSITIZATION IN THE SETTING OF
ANTITHYMOCYTE GLOBULIN INDUCTION

#### **Lionel Rostaing**

Toulouse, France

570.6 EVALUATION OF GENETIC VARIANTS IN
DIABETES SUSCEPTIBILITY GENES AND
DISPOSITION-RELATED GENES AS RISK
FACTORS FOR THE DEVELOPMENT OF NEWONSET DIABETES AFTER TRANSPLANTATION
IN SINGAPORE ASIAN ADULT KIDNEY
TRANSPLANT RECIPIENTS

#### **Wai-Ping Yau**

Singapore, Singapore

18:00 - 19:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



# Campfire Presentations: Complications - Campfire Table 2

Chairs: Man Fai Lam, Hong Kong SAR, P.R. of China Ignatius Kum-Po Cheng, Hong Kong SAR, P.R. of China

571.1 MANAGEMENT OF HUMORAL REJECTION IN RENAL TRANSPLANTATION: RESULTS OF A SINGLE CENTER

# **Mahir Kirnap**

Ankara, Turkey

571.2 NEVER EVENTS AND HOSPITAL ACQUIRED CONDITIONS AFTER KIDNEY TRANSPLANT

#### Linda J. Chen

Miami, FL, United States

571.3 CLINICAL OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION ON PATIENTS WITH CARDIAC ALLOGRAFT VASCULOPATHY

# Raymond Chi-yan Fung

Hong Kong SAR, P.R. of China

571.4 NKG2A+ NATURAL KILLER CELLS DOMINATE
THE RESPONSE TO LATENT EPSTEIN-BARR
VIRUS INFECTION

# Olivia M. Martinez

Stanford, CA, United States

571.5 ERYTHROPOIETIN LEVEL AND POSTTRANSPLANT ANEMIA: A COMPARISON OF
LIVING RELATED KIDNEY TRANSPLANT,
STANDARD DECEASED DONOR KIDNEY
TRANSPLANT, AND EXPANDED CRITERIA
DECEASED DONOR KIDNEY TRANSPLANT

#### **Kanin Thammavaranucupt**

Bangkok, Thailand

571.6 MDR1 C3435T, C1236T AND G2677T/A
POLYMORPHISMS IN RENAL TRANSPLANT
PATIENTS WITH TREMOR

#### Maria Outeda Macias III

A Coruña, Spain

18:00 - 19:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



# Campfire Presentations: Infectious Diseases - Campfire Table 3

Chairs: Mirza Naqi Zafar, Karachi, Pakistan Deborah Marriott, Sydney, Australia

572.1 THE VALUE OF INTERFERON-GAMMA
RELEASING ASSAYS (IGRA) DETERMINING
LATENT TUBERCULOSIS INFECTION IN RENAL
TRANSPLANT CANDIDATES

# Füsun Eyüboglu

Ankara, Turkey

572.3 CATHETER-ASSOCIATED URINARY TRACT
INFECTION (CAUTI) IN KIDNEY TRANSPLANT
RECIPIENTS IS HIGH COST BURDEN AND
PROLONG HOSPITAL STAY, REPORT FROM A
SINGLE CENTER IN THE NORTHEASTERN
THAII AND

# **Ubonrat Toimamueang**

Khon Kaen, Thailand

572.4 MYCOBACTERIUM TUBERCULOSIS IN SOLID ORGAN TRANSPLANTATION, IMPACT OF EXPANDED ISONIAZID PROPHYLAXIS

#### Hassan A. Aleid

Riyadh, Saudi Arabia

572.5 BLOODSTREAM INFECTIONS AFTER
HAEMATOPOIETIC STEM CELL
TRANSPLANTATION: RISK FACTORS,
ETIOLOGIC SPECTRUM AND PREDICTORS OF
FATAL OUTCOME

# **Igor Stoma**

Minsk, Belarus

572.6 THE FREQUENCY OF PRETRANSPLANT HHV-8
AND BKV IN RENAL TRANSPLANT RECIPIENTS
AND DONORS AND THE EFFECT OF RENAL
TRANSPLANTATION ON HHV-8 AND BKV
REPLICATIONS

# **Aydin Turkmen**

Istanbul, Turkey

18:00 - 19:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



# Campfire Presentations Intestine - Campfire Table 4

Chairs: Hiroto Egawa, Tokyo, Japan Gabriel E. Gondolesi, Buenos Aires, Argentina

573.1 SERIAL TRANSVERSE ENTEROPLASTY FOR PATIENTS WITH SHORT BOWEL SYNDROME SECONDARY TO RADIATION THERAPY

# Yousheng Li

Nanjing, People's Republic of China

573.2 THE PROPHYLACTIC EFFECT OF SECRETIN FOR INTESTINAL FAILURE-ASSOCIATED LIVER DISEASE

# Yousheng Li

Nanjing, People's Republic of China

573.3 SURGICAL CHALLENGES IN THE LONGTERM FOLLOW-UP AFTER INTESTINAL AND MULTIVISCERAL TRANSPLANTATION

#### **Undine Gerlach**

Berlin, Germany

573.4 CLINICAL PRESENTATION AND OUTCOME OF NOROVIRUS ENTERITIS IN SMALL BOWEL TRANSPLANT RECIPIENTS COMPARED TO NON-SMALL BOWEL TRANSPLANT RECIPIENTS

#### Diana F. Florescu

Omaha, NE, United States

573.5 CONDITIONAL LONG TERM INTESTINE
PATIENT AND GRAFT SURVIVAL IS IMPROVING
UNDER rATG IMMUNOSUPPRESSION IN
PEDIATRIC INTESTINE TRANSPLANTATION

# **Neslihan Celik**

Pittsburgh, PA, United States

573.6 THE EFFECT OF PROBIYOTICS ON THE HEALING OF COLON ANASTOMOSIS AFTER ISCHEMIA AND REPERFUSION INJURY IN THE RAT

#### **Necdet Ozcav**

Ankara, Turkey

18:00 - 19:00 HALL 5FG-LEVEL 5 NOT A CME SESSION



## Campfire Presentations: Ethical Dilemmas in Donation and Transplantation - Campfire Table 5

Chairs: Dominique E. Martin, Geelong, Australia Allison Tong, Sydney, Australia

574.1 PUBLIC PROMOTION OF UNSPECIFIED LIVE KIDNEY DONATION: AN ELPAT VIEW

Frank J.M.F. Dor London, United Kingdom

574.2 DOES PRIVACY EXIST IN DIRECTED ORGAN DONATION

#### **Alvin Wee**

Indianapolis, ID, United States

574.3 TRANSPLANT VOLUME IN CHINA

#### **David Matas**

Winnipeg, MB, Canada

574.4 INTERNATIONAL INITIATIVE TO ENHANCE THE ORGAN DONATION AND TRANSPLANTATION SYSTEMS IN THE BLACK SEA AREA: THE BSA PROJECT

#### **Marti Manyalich**

Barcelona, Spain

574.5 THE EFFECT OF THE SYRIAN CRISIS ON ORGAN TRANSPI ANTATION IN SYRIA

#### Bassam Saeed.

Damascus, Syrian Arab Republic

574.6 ESTABLISHING CREDIBLE EVIDENCE OF HUMAN ORGAN TRAFFICKING. THE NEED TO EFFECTIVELY MANAGE PURPORTED ORGAN TRAFFICKING CLAIMS ORIGINATING FROM SPECIAL INTEREST GROUPS

#### **Campbell Fraser**

Brisbane, Australia

18:00 - 19:00 HALL 5FG-LEVEL 5 NOT A CME SESSION

## **Poster Sessions**

Detailed list of all the posters available on page 273

19:00 - 22:00
OFFSITE: JUMBO KINGDOM
SHUM WAN PIER DR., ABERDEEN
TICKETED EVENT \$


Congress Networking Evening

Please see details on page 72

# MORNING SESSIONS TUESDAY • AUGUST 23

	07:00	08:30	0:00	10:30	12:00	13:00
Conv. Hall C - L1	EMS International Registries - What, Why & How (Reg			Pig-to-Primate Models		
Theater 2 - L1 Conv. Hall A - L1 Conv. Hall B - L1 Conv. Hall C - L1	EMS Understanding Immune ResponsesPA			OC Discoveries from Pre-Clinical Work BS		
Conv. Hall A - L1	EMSNormothermic Organ Perfusion Systems	tor		OC Regulatory Mechanisms 2	5)	
Theater 2 - L1	EMS New Challenges in VCA	Plenary: Transformational Sciences in Transplantation? (Hall SE3 - L5) Proteomics: Eavesdropping on Communicating Immune Cells - Dr. Felix Meissner mTOR Pathway in Aging & Chronic Disease - Dr. Brian K. Kennedy CRISPR / Cas9 — The Promise of Gene Editing Technologies in Transplantation - Prof. Alfred Joseph Tector		Adherence & Global Data (Reg Approaches RA)	Plenary: What Changes Will We See in Tx. over the Next Five Years? (Hall 5E3 - L5) Basic Sciences - Prof. Carla Baan / Clinical Sciences - Dr. John S. Gill	
Theater 1 - L1	EMS B Cells & Antibodies BS	Plenary: Transformational Sciences in Transplantation? (Hall 5E3 - L5) Proteomics: Eavesdropping on Communicating Immune Cells - Dr. Felix Meissner mTOR Pathway in Aging & Chronic Disease - Dr. Brian K. Kennedy . The Promise of Gene Editing Technologies in Transplantation - Prof. Alfred Joseph Te	Coffee Break (Hall 5E -South Concourse)	OC Hepatocellular Cancer	<b>vhat Changes Will We See in Tx. over the Next Five Years? (Ha</b> ) Basic Sciences – Prof. Carla Baan / Clinical Sciences – Dr. John S. Gill	ıy (Hall 5E3 - L5)
S-221 - L2		rmational Sciences opping on Communic nTOR Pathway in Agin e Editing Technologie	offee Break (Hall 51	Antibody Vascularised Mediated Injury Composite Allografis	es Will We See in Tx s - Prof. Carla Baan /	Closing Ceremony (Hall 5E3 - L5)
Hall SE2 -L5		Plenary: Transfo Proteomics: Eavesdr m The Promise of Gen	0	Antibody Mediated Injury	enary: What Change Basic Science	
Hall SE1 - L5		CRISPR / Cas9-		Post Transplant Diabetes & Company Infectious	Ple	
Hall 5D - L5				Complications & Pancreas & Islet Tx.: Immunosupp. & Immunosupp. &		
Hall 5BC-L5 Hall 5D-L5				OC Complications & Immunosupp.		
	02:00	08:30	10:00	10:30	12:00	13:00







## Early Morning Symposia: B Cells and Antibodies

Chairs: Shane T. Grey, Darlinghurst, Australia Menna R. Clatworthy, Cambridge, United Kingdom

600.1 BAFF AS A REGULATOR TREG AND BREG

**Shane T. Grey**Darlinghurst, Australia

600.2 MODULATING TFH IN HUMANS

**Di Yu** Clayton, Australia

**Anat R. Tambur** 

600.3 WHAT DOES THE ANTIBODY SEE

Chicago, IL, United States
600.4 REGULATORY B/PLASMA CELLS IN

TRANSPLANTATION

Menna R. Clatworthy

Cambridge, United Kingdom

07:00 - 08:15 THEATRE 2-LEVEL 1



## Early Morning Symposia: New Challenges in VCA

Chairs: Fadi Issa, Oxford, United Kingdom Stefan Schneeberger, Innsbruck, Austria

601.1 CHRONIC REJECTION IN VCA

Olivier Thaunat

Lyon, France

601.2 NON-MYELOABLATIVE APPROACH FOR TOLERANCE INDUCTION IN VCA

**Suzanne T. Ildstad** Louisville, KY, United States

601.3 EXIT STRATEGIES IN VCA

Emmanuel Morelon Lyon, France

601.4 ONGOING EFFORTS OF UNOS TO ESTABLISH VCA GUIDELINES

**Sue McDiarmid**Los Angeles, CA, United States



#### 07:00 - 08:15 CONVENTION HALL A-LEVEL 1



Early Morning Symposia: Establishing Normothermic Organ Perfusion Systems

Chairs: Marti Manyalich, Barcelona, Spain Feng Huo, Guangzhou, People's Republic of China

602.1 KIDNEY

**Michael L. Nicholson**Cambridge, United Kingdom



602.2 LIVER

**Constantino Fondevila** Barcelona, Spain



602.3 HEART

**Peter S. MacDonald**Sydney, Australia

07:00 - 08:15: CONVENTION HALL B-LEVEL 1

P&I

Early Morning Symposia: Understanding Immune Responses to Transplanted Beta Cells

Chairs: Dixon B. Kaufman, Madison, WI, United States Carole Guillonneau, Nantes, France



603.1 MONITORING AUTOIMMUNITY PRE- AND POST-TRANSPLANT

**George W. Burke** Miami, FL, United States



603.2 PROLONGING ISLET ALLOGRAFT SURVIVAL: MONITORING AND PREVENTING LATE ISLET LOSS

> **Thierry P.S. Berney** Geneva, Switzerland



603.3 OPTIMIZING SURVIVAL OF STEM CELL DERIVED BETA CELL SURVIVAL EARLY AFTER TRANSPLANT

**Qizhi Tang**San Francisco, CA, United States





Early Morning Symposia: International Registries - What, Why and How

Chairs: Stephen McDonald, Adelaide, Australia Caner Süsal, Heidelberg, Germany

604.1 CONTRIBUTIONS OF THE SCIENTIFIC COLLABORATIVE TRANSPLANT STUDY

**Caner Süsal** Heidelberg, Germany

604.2 IN THE WORLD OF LEVEL 1 EVIDENCE RCT, WHAT CAN REGISTRIES ADD?

**Stephen McDonald** Adelaide, Australia

604.4 TOWARDS A GLOBAL TRANSPLANT REGISTRY

**José Ramón Núñez Peña** Geneva, Switzerland

08:30 - 10:00 HALL 5E3-LEVEL 5

Plenary: Transformational Sciences in Transplantation?

Chairs: Mehmet Haberal, Ankara, Turkey
TRA

610.1

PROTEOMICS: EAVESDROPPING ON COMMUNICATING IMMUNE CELLS

Felix Meissner Martinsried/Munich, Germany

610.2 mTOR PATHWAY IN AGING & CHRONIC DISEASE



**Brian K. Kennedy** Novato, CA, United States

610.3 CRISPR / CAS9 - THE PROMISE OF GENE EDITING
TECHNOLOGIES IN TRANSPLANTATION



Alfred Joseph Tector
Birmingham, AL, United States

10:00 - 10:30 **COFFEE BREAK HALL 5E - SOUTH CONCOURSE** 

10:30 - 12:00 HALL 5E3-LEVEL 5



#### Orals Session:

## Complications and Immunosuppression

Chairs: Adisorn Lumpaopong, Bangkok, Thailand Graeme R. Russ, Adelaide, Australia

620.1 PREGNANCY OUTCOMES IN FEMALE SOLID ORGAN TRANSPLANT RECIPIENTS WITH **EXPOSURE TO MYCOPHENOLIC ACID PRODUCTS** 

#### Michael J. Moritz

Emmaus, PA, United States

620.2 **EVALUATION OF IMMUNOSUPPRESSIVE** REGIMENS ON THE INCIDENCE OF NEW-ONSET DIABETES MELLITUS AFTER KIDNEY TRANSPLANTATION: 24-MONTH ANALYSIS OF THE ELEVATE STUDY

#### Steve J. Chadban

Camperdown, Australia

RAPID DISCONTINUATION OF PREDNISONE 620.3 (RDP) IN KIDNEY TRANSPLANT (KTX) **RECIPIENTS: 15-YEAR OUTCOMES** 

#### **Arthur Matas**

Minneapolis, MN, United States

HIGH INTRAPATIENT VARIABILITY OF 620.4 TACROLIMUS CONCENTRATIONS PREDICTS ACCELERATED PROGRESSION OF CHRONIC HISTOLOGIC LESIONS IN RENAL RECIPIENTS

#### **Thomas Vanhove**

Leuven, Belgium

620.5 EVEROLIMUS (EVR) VERSUS MYCOPHENOLATE
SODIUM (MPS) FOR RECIPIENTS OF KIDNEY
TRANSPLANTS FROM EXPANDED CRITERIA
DONORS (ECD) RECEIVING ANTI-THYMOCYTE
GLOBULIN (r-ATG) AND TACROLIMUS (TAC)

#### Jose Medina Pestana

Sao Paulo, Brazil

620.6 EARLY CONVERSION TO PREDNISOLONE AND EVEROLIMUS FROM A CALCINEURIN-INHIBITOR-CONTAINING TRIPLE DRUG THERAPY AS AN ALTERNATIVE WEANING REGIMEN ASSOCIATED WITH BENEFICIAL RENAL TRANSPLANT HISTOLOGY AND FUNCTION: THE RANDOMIZED-CONTROLLED MECANO TRIAL

#### **Jesper Kers**

Amsterdam, Netherlands

620.7 HIGH TACROLIMUS VARIABILITY IS
ASSOCIATED WITH THE EMERGENCE OF DENOVO DONOR SPECIFIC ANTIBODY

#### Marc J. Clancy

Glasgow, United Kingdom

620.8 COMPARISON OF THE EFFECTS OF BRAND
NAME VERSUS GENERIC
IMMUNOSUPPRESSANTS ON LONG-TERM
GRAFT FAILURE RISK AMONG U.S. KIDNEY
TRANSPLANT RECIPIENTS: ANALYSIS OF SRTR
AND MEDICARE CLAIMS DATA

#### **Jarcy Zee**

Ann Arbor, MI, United States

620.9 EFFICACY AND SAFETY OF A 4-MONTH POST-RENAL TRANSPLANT DOSE REDUCTION OF TACROLIMUS PROLONGED -RELEASE

#### **Philippe Gatault**

Tours, France

10:30 - 12:00 HALL 5D-LEVEL 5



## Orals Session Pancreas & Islet Tx: Immunosuppression and Immunology

Chairs: Raja Kandaswamy, Minneapolis, MN, United States Duck-Jong Han, Seoul, Korea

621.1 CNI VS CNI-FREE IMMUNOSUPPRESSION: IMPACT ON 1-YEAR KIDNEY PROTOCOL BIOPSY FOLLOWING SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION

#### **Diego Cantarovich**

Nantes, France

621.2 RABBIT ANTI-THYMOCYTE IN SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION:
DOES DURATION MATTER?

#### Karen L. Hardinger

Kansas City, KS, United States

621.3 ASSOCIATION OF AUTOREACTIVE MEMORY
CD4 T CELLS EXPRESSING THE CHEMOKINE
RECEPTOR CXCR3 IN THE PERIPHERAL BLOOD
OF PANCREAS-KIDNEY TRANSPLANT
RECIPIENTS WITH TYPE 1 DIABETES
RECURRENCE

#### George W. Burke

Miami, FL, United States

621.4 EMPIRIC DOSE REDUCTION IS A RISK FOR LATE ACUTE REJECTION DESPITE

ALEMTUZUMAB INDUCTION IN STEROIDFREE SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANT RECIPIENTS

#### J. R. Bank

Leiden, The Netherlands

621.5 THE CLINICAL RELEVANCE OF ONE-WAY ZERO
HLA MISMATCHES AMONG POST-PANCREAS
TRANSPLANT ACUTE GRAFT-VERSUS HOST
DISEASE POPULATION

#### **Yoshihide Nanno**

Kobe, Japan

621.6 DE-NOVO DONOR-SPECIFIC ANTI-HLA
ANTIBODIES IN ISLET CELL TRANSPLANT
RECIPIENTS IN AUSTRALIA

#### Siu Man Hue

Hong Kong SAR, P.R. of China

621.7 APPLICATION OF TREATMENT WITH
PLASMAPHERESIS AND IMMUNOGLOBULINS
FOR HIGH LEVEL OF HLA DONOR SPECIFIC
ANTIBODIES IN ISLET ALLOGRAFT RECIPIENTS

#### Julia Solomina

Chicago, IL, United States

621.8 TYPE ONE DIABETES DECEASED ORGAN
DONOR ISOLATED HUMAN ISLETINFILTRATING CD4+ T CELLS RECOGNIZE A
DEAMIDATED PROINSULIN EPITOPE
PRESENTED BY HLA-DQ8

#### Vimukti Pathiraja

Sunbury, Australia

621.9 FIBROBLAST GROWTH FACTOR-21 IN CLINICAL ISLET TRANSPLANTATION

#### **Raphael Meier**

Geneva, Switzerland

10:30 - 12:00 HALL 5E1-LEVEL 5



# Orals Session:

Post Transplant Diabetes and Infectious Complications

Chairs: Rudolf A. Garcia-Gallont, Guatemala City, Guatemala Yingyos Avihingsanon, Bangkok, Thailand

622.1 OUTCOMES WITH PRE TRANSPLANT BARIATRIC SURGERY IN RENAL TRANSPLANT RECIPIENTS

#### **Titte R. Srinivas**

Charleston, SC, United States

622.2 POST-TRANSPLANT DIABETES MELLITUS AFTER KIDNEY TRANSPLANTATION IN JAPANESE PATIENTS: THE JAPAN ACADEMIC CONSORTIUM OF KIDNEY TRANSPLANTATION STUDY

#### **Kazuya Omoto**

Toda, Japan

622.3 SODIUM/GLUCOSE COTRANSPORTER 2
INHIBITOR FOR THE TREATMENT OF DIABETES
IN KIDNEY TRANSPLANT PATIENTS

#### Jin M. Kong

Busan, Korea

622.4 ABNORMAL GLUCOSE METABOLISM IN
DIALYSIS PATIENTS AND ITS CORRELATION
WITH THE DEVELOPMENT OF NEW ONSET
DIABETES AFTER RENAL TRANSPLANTATION

#### **Manish Rathi**

Chandigarh, India

622.5 EPIDEMIOLOGY AND RISK FACTORS FOR INFECTION AFTER LIVING DONOR LIVER TRANSPLANTATION

#### Cybele Lara R. Abad

Rochester, MN, United States

622.6 POSTOPERATIVE FUNGAL INFECTION IN LIVER
TRANSPLANT RECIPIENTS: INDICATOR BUT
NOT THE CAUSE OF OVERALL MORTALITY

#### **Katharina Schmidt**

Regensburg, Germany

622.7 AN INTERNATIONAL SURVEY OF INFECTIONS AFTER TOTAL ARTIFICIAL HEART TRANSPLANTATION

#### **Heather E. Chambers**

Omaha, NE, United States

622.8 RISK FACTORS FOR CLINICAL URINARY
TRACT INFECTIONS IN KIDNEY
TRANSPLANT RECIPIENTS WITH
ASYMPTOMATIC BACTERIURIA

#### Azemi A. Barama

Montreal, QC, Canada

622.9 BETA CELL FUNCTION AND INSULIN
RESISTANCE AFTER THE CONVERSION FROM
TACROLIMUS TWICE DAILY TO EXTENDEDRELEASE TACROLIMUS ONCE DAILY IN STABLE
RENAL TRANSPLANT RECIPIENTS

#### Prajej Ruangkanchanasetr

Bangkok, Thailand

10:30 - 12:00 HALL 5E2-LEVEL 5



## Orals Session: Antibody Mediated Injury

Chair: Thomas A. Nakagawa, St. Petersburg, FL, United States

623.1 RACIAL DIFFERENCES IN INCIDENT DE NOVO ANTI-HLA ALLOANTIBODIES AMONG PRIMARY RENAL TRANSPLANT RECIPIENTS

**Matthew J. Everly** 

Los Angeles, CA, United States

623.2 IgG DILUTIONS, SUBCLASSES, C1q, AND IgM: WHAT ARE THE IMPORTANT CHARACTERISTICS OF DE NOVO DSA?

#### **Matthew J. Everly**

Los Angeles, CA, United States

623.3 MICROARRAY ASSESSMENT OF KIDNEY TRANSPLANT INDICATION BIOPSIES IN REAL TIME: FIRST RESULTS OF THE INTERCOMEX STUDY

#### Philip F. Halloran

Edmonton, AB, Canada

623.4 EARLY ACCELERATED REJECTION – AN EMERGING DISTINCT ENTITY IN ANTIBODY INCOMPATIBLE RENAL TRANSPLANTATION WHICH CAN BE TREATED

#### Anna M Adamusiak

London, United Kingdom

623.5 RAPID REMOVAL OF ANTI-HLA ANTIBODIES
IN IMMUNIZED PATIENTS - TWO DOSE
FINDING STUDIES OF THE IgG DEGRADING
ENZYME IdeS

#### **Tomas Lorant**

Uppsala, Sweden

623.6 ULTRASTRUCTURAL CHANGES ADD
VALUABLE DIAGNOSTIC AND PROGNOSTIC
INFORMATION IN EVALUATION OF
ANTIBODY-MEDIATED REJECTION (AMR) IN
RENAL ALLOGRAFT BIOPSIES

#### John C. Papadimitriou

Baltimore, MD, United States

623.7 EFFECT OF COMPLEMENT INHIBITION
THERAPY (ECULIZUMAB) IN PATIENTS WITH
C1Q-BINDING DONOR-SPECIFIC ANTI-HLA
ANTIBODIES: A MOLECULAR APPRAISAL

#### **Carmen Lefaucheur**

Paris, France

623.8 C1-INHIBITOR IN ACUTE ANTIBODYMEDIATED REJECTION NON-RESPONSIVE TO
CONVENTIONAL THERAPY IN KIDNEY
TRANSPLANT RECIPIENTS: A PILOT STUDY

#### **Carmen Lefaucheur**

Paris, France

623.9 COMPOSITE SCORE TO DEFINE THE RISK OF
ALLOGRAFT LOSS AFTER STANDARD-OFCARE TREATMENT OF ANTIBODY-MEDIATED
REJECTION IN KIDNEY TRANSPLANTATION

#### **Carmen Lefaucheur**

Paris, France

10:30 - 12:00 S-221-LEVEL 2



### Orals Session: Vascularised Composite Allografts

Chairs: Sue McDiarmid, Los Angeles, CA, United States Palmina Petruzzo, Lyon, France

624.1 REFRACTORY VASCULAR REJECTION IN A HAND ALLOGRAFT IN THE PRESENCE OF ANTIBODIES AGAINST ANGIOTENSIN II (TYPE 1) RECEPTOR

#### **Karen Dwyer**

Victoria, Australia

624.2 ULTRA-HIGH RESOLUTION NON-CONTRAST IMAGING FOR CHRONIC REJECTION MONITORING AND PROCEDURAL PLANNING IN RECONSTRUCTIVE TRANSPLANTATION

#### Shailesh B. Raval

Pittsburgh, PA, United States

624.3 CHRONIC REJECTION IN VASCULARIZED COMPOSITE ALLOTRANSPLANTATION

#### **Emmanuel Morelon**

Lyon, France

624.4 DYNAMICS AND CORRELATES OF SKIN
DENDRITIC CELLS WITH DISTINCTIVE
IMMUNE RESPONSE PROFILES IN
VASCULARIZED COMPOSITE ALLOGRAFTS

#### Wensheng Zhang

Pittsburgh, PA, United States

624.5 NOVEL APPROACHES TO ASSESSMENT OF FACIAL NERVE REGENERATION IN A SWINE HEMI-FACIAL COMPOSITE TISSUE FLAP MODEL: A PHYSIOLOGICAL AND HISTOLOGY STUDY

#### **Marissa Suchyta**

Rochester, MN, United States

624.6 THE INTERNATIONAL REGISTRY ON HAND
AND COMPOSITE TISSUE
ALLOTRANSPLANTATION (IRHCTT)

#### Palmina Petruzzo

Lyon, France

624.7 TRANSLATIONAL CONSIDERATIONS IN WHOLE EYEBALL TRANSPLANTATION - PORCINE MODEL

#### Vijay Gorantla

Pittsbugh, PA, United States

624.8 ANALYSIS OF ACUTE SKIN REJECTION IN NON-HUMAN PRIMATE MODELS OF FACE AND HAND ALLOTRANSPLANTATION

#### **Zhi Yang Ng**

Boston, MA, United States

624.9 INTRA-GRAFT INJECTION OF TACROLIMUS
MAY MODULATE LOCAL IMMUNE RESPONSE
PROMOTING LONG-TERM ACCEPTANCE OF
VASCULARIZED COMPOSITE TISSUE
ALLOTRANSPLANTATION

#### **Adriano Taddeo**

Bern, Switzerland

#### 10:30 - 12:00 THEATRE 1-LEVEL 1



## Orals Session: Hepatocellular Cancer

Chairs: Yuji Soejima, Fukuoka, Japan

TBA

625.1 DYSREGULATION OF TRANSFORMING
GROWTH FACTOR BETA RECEPTOR III
INDUCES TUMOR PROMOTING
MACROPHAGES VIA COMPLEMENT C3A IN

HEPATOCELLULAR CARCINOMA RECURRENCE
AFTER I IVER TRANSPI ANTATION

AFTER LIVER TRANSPLANTATION

#### **Wai Ho Oscar Yeung**

Hong Kong SAR, P.R. of China

625.2 UP-REGULATION OF GSTA2 AT EARLY-PHASE
AFTER LIVER TRANSPLANTATION INCREASES
THE RISK OF LATE-PHASE HEPATOCELLULAR
CARCINOMA RECURRENCE

#### **Kevin Tak-Pan Ng**

Hong Kong SAR, P.R. of China

625.3 PATIENTS WITH 18F-FDG NON-AVID HCC ON PET BEYOND UP-TO-SEVEN CRITERIA HAVE AN EXCELLENT OUTCOME FOLLOWING LIVER TRANSPLANTATION

#### **Arno Kornberg**

Munich, Germany

625.4 THE CLINICAL SIGNIFICANCE AND POTENTIAL THERAPEUTIC ROLE OF GPx3 IN TUMOR RECURRENCE AFTER LIVER TRANSPLANTATION

#### Xiang Qi

Hong Kong SAR, P.R. of China

625.5 INFLUENCE OF DONOR AGE AND COLD ISCHEMIA ON RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION

#### **Dilip Moonka**

Detroit, MI, United States

625.6 LIVER TRANSPLANTATION OUTCOMES IN PATIENTS WITH PRIMARY LIVER CANCER

#### **Douglas P. Slakey**

New Orleans, LA, United States

625.7 INTEGRATIVE ANALYSES OF ACUTE PHASE LIVER GRAFT INJURY ON LATE PHASE TUMOR RECURRENCE AFTER LIVER TRANSPLANTATION

#### Nikki Lee

Hong Kong SAR, P.R. of China

625.8 A NOVEL PROGNOSTIC INDEX IN PATIENTS
WITH HEPATOCELLULAR CANCER WAITING
FOR LIVER TRANSPLANTATION: TIME—
RADIOLOGICAL-RESPONSE—ALPHA-FETOPRO
TEIN—INFLAMMATION (TRAIN) SCORE

#### Jan Lerut

Louvain-la-Neuve, Belgium

625.9 DEGREE OF TUMOR NECROSIS FROM PRE-TRANSPLANT LOCO-REGIONAL THERAPY IS ASSOCIATED WITH TUMOR FREE SURVIVAL AFTER LIVER TRANSPLANTATION

#### **Dilip Moonka**

Detroit, MI, United States

10:30 - 12:00 THEATRE 2-LEVEL 1



## Orals Session: Adherence and Global Data Approaches

Chairs: Paul Robertson, Westmead, Australia Chun Sang Li, Hong Kong SAR, P.R. China

626.1 PROSPECTIVE RANDOMIZED CONTROLLED STUDY EVALUATING THE IMPACT OF AN ELECTRONIC FEEDBACK SYSTEM (EFS) ON MEDICATION ADHERENCE IN SOLID ORGAN TRANSPLANTATION

#### **Adam S. Bodzin**

Chicago, IL, United States

626.2 RANDOMIZED CONTROLLED STUDY
EVALUATING ADHERENCE MONITORING WITH
ELECTRONIC FEEDBACK ON REDUCING
RENAL ALLOGRAFT REJECTION

#### Adam S. Bodzin

Chicago, IL, United States



IMPORTANCE OF EARLY MEDICATION ADHERENCE FOR LONG-TERM GRAFT SURVIVAL: A PROSPECTIVE, SINGLE-CENTRE COHORT STUDY

#### **Mirjam Tielen**

Rotterdam, The Netherlands

626.4 INTERDISCIPLINARY ORGAN AND TISSUE DONOR SUITABILITY ASSESSMENT SIMULATION TRAINING:" SHARING THE RESPONSIBILITY FOR SAFE ORGANS AND TISSUES FOR TRANSPLANTATION IN TRAINING AND IN PRACTICE"

#### **Maria Stadtler**

Boulder, CO, United States

626.5 THE HINT STUDY: A CROSS-SECTIONAL
SURVEY OF AUSTRALIAN AND NEW ZEALAND
TRANSPLANT CLINICIANS ON HEPATITIS
TRANSMISSION RISK IN SOLID ORGAN
TRANSPLANTATION

#### **Karen Waller**

Lindfield, Australia

626.6 VASCULAR ACCESS TYPES IN PATIENTS
STARTING HEMODIALYSIS WITH FAILED KIDNEY
TRANSPLANTS: A RETROSPECTIVE ANALYSIS

#### Hassan A. Aleid

Riyadh, Saudi Arabia

626.7 ADDITIONAL OPPORTUNITIES IN AUSTRALIA FOR TRANSPLANTING ORGANS FROM DONORS WITH BRAIN MALIGNANCIES? A RETROSPECTIVE COHORT STUDY OF THE NSW ORGAN AND TISSUE DONATION SERVICE ORGAN DONOR REGISTER

#### **Angela Webster**

Sydney, Australia

626.8 18 YEARS OF WORLDWIDE REPORTING IN ORGAN DONATION AND TRANSPLANTATION IRODAT

#### Maria P. Gomez

Sydney, Australia

626.9 A BIG DATA APPROACH TO PREDICTION OF THREE-YEAR GRAFT LOSS RISK IN KIDNEY TRANSPLANTS: STRUCTURED AND UNSTRUCTURED DYNAMIC PATIENT LEVEL DATA IMPROVE PREDICTIVE EFFICACY

**Titte R. Srinivas** 

Charleston, SC, United States

#### 10:30 - 12:00 CONVENTION HALL A-LEVEL 1

BS

## Orals Session: Regulatory Mechanisms 2

Chairs: Megan Levings, Vancouver, BC, Canada Fadi Issa, Oxford, United Kingdom

627.1 DNA-TYPED, MHC-INBRED CLAWN
MINIATURE SWINE REPRESENT A HIGHLYVALUABLE SPECIES FOR THE DEVELOPMENT
OF PRECLINICAL TRANSLATIONAL RESEARCH
IN TRANSPLANTATION AND REGENERATIVE
MEDICINE

#### **Takahiro Murokawa**

Kagoshima, Japan

627.2 AN INTRONIC SNP OF SHROOM3 PROMOTES
KIDNEY INFLAMMATION AND INJURY AFTER
ISCHEMIA-REPERFUSION INJURY IN
FEMALE MICE

#### Min Hu

Westmead, Australia

627.3 ROLE OF IL-7 AND IL-7/ANTI-IL-7ANTIBODY COMPLEXES IN TREG EXPANSION AND A MURINE SKIN ALLOGRAFT TOLERANCE MODEL

#### Min Hu

Westmead, Australia

627.4 PHOSPO-SPECIFIC FLOWCYTOMETRY
UNVEILS THE INCOMPLETE BLOCKADE OF
MONOCYTE ACTIVATION BY TACROLIMUS IN
KIDNEY TRANSPLANT RECIPIENTS

#### **Nynke Kannegieter**

Rotterdam, The Netherlands

627.5 PLACENTA-DERIVED DECIDUAL STROMAL CELLS FOR TREATMENT OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE

#### Olle Ringden

Stockholm, Sweden

627.6 AGE-RELATED CHANGES IN RAT DONOR
KIDNEYS AND OTHER ORGANS RELEVANT
FOR ORGAN OUALITY AND FUNCTION

#### Miriam C. Banas

Regensburg, Germany

627.7 THE FUNCTION OF CD8+/TCR- FACILITATING
CELLS AND REGULATORY T CELLS IS
IMPAIRED IN FLT3-LIGAND KNOCKOUT MICE

#### Yujie Wen

Louisville, KY, United States

627.8 MURINE AND HUMAN CD4T CELL
MIGRATION ACROSS LYMPHATIC
ENDOTHELIUM IS DIFFERENTIALLY
REGULATED BY SPHINGOSINE 1-PHOSPHATE
(S1P) RECEPTORS

#### Jonathan S. Bromberg

Baltimore, MD, United States

627.9 LYMPH NODE STROMAL LAMININS AFFECT CD4+ T FUNCTIONS AND POLARIZATION

#### Jonathan S. Bromberg

Baltimore, MD, United States

#### 10:30 - 12:00 CONVENTION HALL B-LEVEL 1

BS

## Orals Session:

## Discoveries from Pre-Clinical Work

Chairs: Agnes Azimzadeh, Baltimore, MD, United States Valeria Mas, Charlottesville, VA, United States

628.1 MONITORING LEUKOCYTE TRANS-LYMPHATIC ENDOTHELIAL MIGRATION WITH AN IN VITRO MODEL

#### Jonathan S. Bromberg

Baltimore, MD, United States

628.2 VARIABLE EFFECTS OF DIFFERENT
SEROTONIN RECEPTOR SUBTYPE
ANTAGONISTS ON THE DEVELOPMENT OF
TRANSPLANT VASCULOPATHY IN MURINE
AORTIC ALLOGRAFTS

#### **Christian Heim**

Erlangen, Germany

628.3 VARIOUS PATHOGENIC MICROBES INDUCE CNI-RESISTANCE IN B-CELLS RESPONDING TO BLOOD GROUP ANTIGENS THROUGH TLR-MyD88 PATHWAY

#### Hiroshi Sakai

Hiroshima, Japan

628.4 ALLOREACTIVITY DRIVES THE REPOPULATION
AND THE MAINTENANCE OF HUMAN
INTESTINAL GRAFT TISSUE-RESIDENT
MEMORY CELLS

#### **Julien Zuber**

Paris, France

628.5 VASCULAR SEQUESTRATION OF DONOR-SPECIFIC ANTIBODIES PROTECTS ALLOGENEIC ISLETS FROM HUMORAL REJECTION

#### **Chien-Chia Chen**

Lyon, France

628.6 DISRUPTION OF CD8-CORECEPTOR BINDING ABROGATES TOLERANCE INDUCTION VIA LIVER-DIRECTED EXPRESSION OF DONOR MHC CLASS I

#### **Moumita Paul-Heng**

Sydney, Australia

628.7 LONG-LASTING EXPANSION OF MEMORY-LIKE NATURAL KILLER CELLS IN THE LIVER AFTER INTRAPORTAL SYNGENEIC ISLET TRANSPLANTATION IN MICE

#### Yoshihiro Saeki

Hiroshima, Japan

628.8 BLOCKING m-TOR PATHWAY SPECIFICALLY IN MYELOID SYSTEM ABATE CHRONIC ALLOGRAFT REJECTION BY INHIBITING IMMUNE CELL ACTIVATION AND INFILTRATION

#### **Chenglin Wu**

Guangzhou, People's Republic of China

628.9 SOLUBLE BAFF IS ASSOCIATED WITH
INCREASED RISK OF GRAFT LOSS BUT NOT
WITH PRE-TRANSPLANT IGM TO POSTTRANSPLANT IGG DSA CONVERSION

**Matthew J. Everly** 

Los Angeles, CA, United States

#### 10:30 - 12:00 CONVENTION HALL C-LEVEL 1



## Orals Session: Pig-to-Primate Models

Chairs: Peter Cowan, Melbourne, Australia Chung-Gyu Park, Seoul, Korea

629.1 GENETICALLY MODIFIED PORCINE NEONATAL ISLET XENOGRAFTS PROVIDE LONG-TERM SURVIVAL IN BABOONS

## Wayne J. Hawthorne

Westmead, Australia

629.2 MULTI-TRANSGENIC DONOR PIGS COMBINED
WITH TARGETED DRUG TREATMENTS EXTEND
LIFE-SUPPORTING ORGAN FUNCTION IN A
XENOGENEIC LUNG TRANSPLANTATION MODEL

#### **Lars Burdorf**

Baltimore, MD, United States

629.3 KNOCK-OUT OF N-GLYCOLYLNEURAMINIC
ACID (Neu5Gc) IN GaITKO.hCD46 PIG LUNGS
IMPROVES PULMONARY FUNCTION IN A
XENOGENEIC PIG-TO-HUMAN LUNG
PERFUSION MODEL

#### **Lars Burdorf**

Baltimore, MD, United States

629.4 CARBON MONOXIDE REDUCES ACUTE
PULMONARY DYSFUNCTION IN GaIT-KO PIGTO-CYNOMOLGUS MONKEY ORTHOTOPIC
LUNG TRANSPLANTATION

#### Hisashi Sahara

Kagoshima, Japan

629.5 EMPIRICAL STUDY OF GTKO PIG - TIBETAN
MACAQUE SPLENIC FOSSA HETEROTOPIC
AUXILIARY LIVER XENOTRANSPLANTATION

#### **Zhaoxu Yang**

Xi'an, People's Republic of China

629.6 MARKED IMPROVEMENT IN PIG-TO-BABOON LIVER XENOGRAFT SURVIVAL: A MAJOR STEP TOWARDS CLINICAL APPLICATION

Jigesh A. Shah

Charlestown, MA, United States

629.7 USE OF MULTI-TRANSGENE EXPRESSION FOR PREVENTION OF CARDIAC XENOTRANSPLANTATION ASSOCIATED CONSUMPTIVE COAGULOPATHY

Joshua L. Chan

Bethesda, MD, United States

629.8 HUMAN ANTI THROMBOTIC GENES DO NOT OBVIATE THE NEED FOR ANTICOAGULATION IN AIDING LONG TERM XENOGRAFT SURVIVAL

Muhammad M. Mohiuddin

Bethesda, MD, United States

629.9 THE EFFECT OF IL-6 BLOCKADE ON
REVASCULARIZATION OF ISLET AFTER
TRANSPLANTATION IN PIG TO NONHUMAN
PRIMATE (NHP) ISLET XENOTRANSPLANTATION

**Byoung-Hoon Min** 

Seoul, Korea

12:00 - 13:00 HALL 5E3-LEVEL 5

Plenary:

What Changes Will We See in Transplantation over the next Five Years?

Chairs: Nancy Ascher, San Francisco, CA, United States José María Morales, Madrid, Spain

630.1 BASIC SCIENCES



**Carla Baan** Rotterdam, The Netherlands

630.2 CLINICAL SCIENCES



John S. Gill Vancouver, BC, Canada

13:00 - 13:30 HALL 5E3-LEVEL 5 NOT A CME SESSION

Plenary: Closing Ceremony

640.1 CLOSING ADDRESS



Philip J. O'Connell Westmead, Australia

640.2 CLOSING ADDRESS

Nancy Ascher San Francisco, CA, United States

640.3 PRESENTATION OF TTS 2018 CONGRESS IN MADRID, SPAIN



**José María Morales** Madrid, Spain

#### **EDUCATIONAL GRANT:**

TTS gratefully acknowledges the support of Gilead Sciences, Inc. through the provision of an educational grant.

#### ■ Poster List

#### POSTER SESSIONS ARE NOT CME ACCREDITED

Posters will be available for attendees to view during the day from August 20 at 12:30 until August 22 at 19:00 in the Exhibit Area, Hall 5FG-Level 5.

The poster presenters are required to be available for questions only during the three Poster Sessions noted below.

Date	Time
Saturday, Aug 20	17:00-18:30
Sunday, Aug 21	17:00-18:30
Monday Aug 22	18.00-19.00

Please note that some posters, although accepted under one track, will be presented at a different location on the floor in order to be grouped with other posters from the same presenter. These posters are listed below both in their original track (at the end of the track list) and in their display order (they have been numbered as such).

A floorplan showing where posters are located is available inside the Hall 5FG – Level 5.

Please also note that any cancellations and additions to the poster list that occurred after the printing of this program is available as an addendum sheet at the Registration Desk.

## Basic and Translational Sciences Posters



- P.1000 Solving the Structural Basis for Alloantibody Recognition of Asian HLA in Solid Organ Transplantation

  Gu Yue, Singapore, Singapore
- P.1001 Phenotypic patterns of B cells subsets in the peripheral blood of patients with long-term kidney allograft function

  Marian Klinger, Wrocław, Poland
- P.1002 Human ABH antibody repertoire elucidated by coupled high throughput sequencing and proteomics

  Liu Logen, Henngyang, People's Republic of China
- P.1003 mHLA-G Expression on CD4+CD25(high) T Cell and CD16+ Natural Killer Cell Associated With Clinical Status in Renal Transplantation Patients

  Bilkay Bastürk, Adana, Turkey
- P.1004 Ectopic lymphoid follicles are present in type IT-cell mediated kidney transplant rejection
  - Carla Baan, Rotterdam, The Netherlands

## **POSTER LIST**



P.1006	Mechanism of FK506 Induced TNF Related Apoptosis
	In Jurkat T Cells

Sang Young Chung, Gwangju, Korea

- P.1007 Isatis tinctoria L. combined with co-stimulatory molecules blockade inhibits accelerated rejection mediated by allo-primed CD4+ memory T cells in mice

  Feifei Du, Xiamen, People's Republic of China
- P.1008 A delay of bone marrow transplantation after low dose irradiation impairs engraftment

Suzanne T. Ildstad, Louisville, KY, United States

- P.1009 Investigation of a novel multi-lineage human-mouse chimeric model for in vivo transplantation research

  Fadi Issa, Oxford, United Kingdom
- P.1010 Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus- induced diabetic rats

Jian Jin, Seoul, Korea

- P.1011 Clinical Features Indicating Irreversible Rejection after
  Uterus Allotransplantation in Cynomolgus Monkey
  Iori Kisu, Tokyo, Japan
- P.1012 Hepatic miR-301a: its mode of action on T-helper 17 cell-mediated rejection via targeting interleukin-6/STAT3 axis in rats

Chia-Yun Lai, Kaohsiung, Taiwan

- P.1013 Combining Monoclonal Antibodies with 1,25(OH)2D3
  Treatment to Prolong the Survival Time of Cardiac
  Allograft in Accelerated Rejection Models of Mice

  Yaguang Li, Xiamen, People's Republic of China
- P.1015 Activation of Human CD4+CD25+CD127loFOXP3+Treg by IL-4 and alloantigen induces activated Treg that do not express CD45RA and express the IL-5 receptor alpha (CD125)

Nirupama D. Verma, Liverpool, Australia

P.1016 Regulatory T-cell mediated suppression of T-cell responses induced by primary human hepatocytes in vitro is cell-contact dependent

Florian WR Vondran, Hannover, Germany

P.1017 A Traditional chinese herbal medicine "Huaier" induced prolongation of fully MHC-mismatched murine cardiac allograft

Enzhi Yin, Tokyo, Japan



P.1018	Transplant tolerance induced by a single infusion of
	extracorporeal photopheresis treated donor
	splenocytes prior to transplantation

**Zheng Zhang**, Chicago, IL, United States

P.1019 The effect of donor's chemokines (CXCL9, CXCL10 and CCL5) and growth factor (TGF $\beta$ 1) on the renal allograft dysfunction

Ayisha Abid, Karachi, Pakistan

P.1020 Negative influence of liver irradiation on liver resident NK cells

Ryosuke Nakano, Hiroshima, Japan

- P.1021 Ex vivo generation of alloantigen-specific
  Immunomodulatory cells with co-stimulation
  blockade: do we need Treg purification for cell therapy?

  Torbjorn Lundgren, Stockholm, Sweden
- P.1022 A non-hematopoietic erythropoietin analogue, ARA 290, prolonged allogeneic islet graft survival in a mouse model

  Torbjorn Lundgren, Stockholm, Sweden
- P.1023 Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus

  Long Jin, Seoul, Korea
- P.1024 Immune Modulatory Effect of Thalidomide and Dexamethasone Co-Treatment on T cell Subsets

  Eun Jee Kim, Seoul, Korea
- P.1025 Effect of isolated intraperitoneal sirolimus treatment on the kidneys of C57BL/6 mice

Joon Ye Kim, Seoul, Korea

- P.1026 Synergistic Anticancer Effect of Metformin in Combination with Immunosuppressant on Hepatocellular Carcinoma Cell Lines
  - Sukwon Suh, Seoul, Korea
- P.1027 The liver-wrapping nanofiber releasing nitirc oxide downregulated the cleaved Caspase-3 expression on rat hepatic ischemia-reperfusion injury

Hyung Joon Ahn, Seoul, Korea

P.1028 Remote perconditioning on rat hepatic ischemiareperfusion injury downregulated the Bax and cleaved Caspase-3 expression

Hyung Joon Ahn, Seoul, Korea

P.1029 Supplemented Celsior and Peri-mortem Heparin Enhances Recovery of Rodent DCD Hearts

Hong Chee Chew, Kingsgrove, Australia

# **POSTER LIST**



P.1030	Pretreatment of cilostazol attenuates hepatic ischemia/reperfusion injury in rats  Taku Fujii, Hiratsuka, Japan
P.1031	Donor pretreatment with carbon monoxide prevents ischemia/reperfusion injury following heart transplantation in rats  Noritomo Fujisaki, Nishinomiya, Japan
P.1032	Effects of Ulinastatin on liver cold ischemia/reperfusion injury and graft survival in mice Lianyue Guan, Chang Chun, People's Republic of China
P.1033	Effects of Ulinastatin on liver warm ischemia reperfusion injury in mice  Lianyue Guan, Chang Chun, People's Republic of China
P.1034	Perfusion of Porcine Kidneys with Macromolecular Heparin Ameliorates Early Ischemia Reperfusion Injury Amir Sedigh, Uppsala, Sweden
P.1035	Hydrogen sulfide prevents renal ischemia-reperfusion injury in CLAWN miniature swine  Mitsuhiro Sekijima, Kagoshima, Japan
P.1036	The effects of resveratrol on liver transplantation from non-heart-beating donors in pigs  Kenji Shimizu, Sendai, Japan
P.1037	The renoprotective effects of epigallocatechin gallate and dipeptidyl peptidase IV inhibitor gemigliptin on tacrolimus-induced nephrotoxicity in mice
P.1038	Byung Chul Shin, Gwangju, Korea  CHBP and Caspase-3 SiRNA Ameliorate Mouse Renal Ischemia Reperfusion Injury  Bin Yang, Leicester, United Kingdom
P.1039	A study of oxidative stress biomarkers in renal allograft transplant recipients  Sunil Kumar, Chandigarh, India
P.1040	Polymicrobial oroesophageal infection presenting with dysphagia in a renal allograft transplant recipient  Sunil Kumar, Chandigarh, India
P.1041	Intra-peritoneal administration of sodium acetate improves renal function and prolongs survival in a murine model of renal allograft transplantation
P.1042	Steve J. Chadban, Camperdown, Australia  IL-17 production and inflammatory cascade is decreased by ATG  Dietmar K. Abendroth, Ulm, Germany



- P.1043 Hypothermic Machine Perfusion Oxigenation. A Real Step Forward? Tissue and Perfusate mRNA Expression Victoria Gomez Dos Santos, Madrid, Spain
- P.1044 MicroRNAs Panel Validation in Kidney Graft Hipothermic Machine Perfusion Fluid as Novel Biomarkers for Graft Disfunction
  - Victoria Gomez Dos Santos, Madrid, Spain
- P.1045 Reduced plasmalogens and increased ceramides in the sera from acute hepatic allograft rejection

  Nayoung Kim, Seoul, Korea
- P.1046 A simple and precise LC/MS method to quantitate 6 beta-hydroxycortisol and cortisol in human urine: Use of the 6 beta-hydroxycortisol to cortisol ratio as an indicate of the remnant-liver function in a donor for liver transplantation
  - Satoshi Kishino, Kiyose/Tokyo, Japan
- P.1047 Budget Impact Analysis of Quantiferon-CMV Assay for High-risk Kidney Transplant Recipients

  Frank K. Kuhr, Germantown , PA, United States
- P.1048 Impact of circulating exosomes on the development and recurrence of hepatocellular carcinoma in rats

  Toshiaki Nakano, Kaohsiung, Taiwan
- P.1049 Association of Delayed Graft Function (DGF) with
  Serum Level of Soluble Fibrinogen-like Protein 2
  (sFGL2) in Patients with Kidney Transplantation

  Hassan Nikoueinejad, Tehran, Iran (Islamic Republic of)
- P.1050 CD28-positive cytomegalovirus specific cytotoxic T lymphocytes as a novel biomarker associated with cytomegalovirus viremia in kidney allorecipients

  Maciej Zielinski, Gdansk, Poland
- P.1051 Human Blood Cell-Free Circulating DNA (cfDNA) and miRNA as Biomarkers of Liver and Kidney Antibody Mediated Rejection (AMR) or Cellular Allograft Rejection (ACR). Pilot study
  - Tomasz Kozlowski, Chapel Hill, NC, United States
- P.1052 Natural History of Spontaneous Porto-Systemic Shunt (PSs) and Transplant Outcomes in Liver Allograft Recipients

  Tomasz Kozlowski, Chapel Hill, NC, United States
- P.1053 Development of de-novo donor specific antibody
  (DSA) and vitamin D status after renal transplantation

  Sonia Mehrotra, Lucknow, India



P.1054	De-novo donor specific antibody (DSA) against HLA- DQ antigens by lysate based cross match on Luminex platform resulting in acute antibody mediated rejection in a renal transplant patient
	Sonia Mehrotra, Lucknow, India
P.1055	Association Between Donor Toll-Like Receptors-4 Polymorphism and Acute Rejection After Liver Transplantation in Belarus
	<b>Denis Efimov</b> , Minsk, Belarus
P.1056	Minocycline targets multiple key driver genes in a model of acute allograft rejection
	Karen L. Keung, North Epping, Australia
P.1057	Gene Polymorphisms and Acute Rejection following Kidney Transplantation
	Hong joo Lee, Seoul, Korea
P.1058	Association between Interleukin 7 receptor α gene polymorphism and chronic rejection after renal transplantation in Korean Patients
	Hong joo Lee, Seoul, Korea
P.1059	Biomarker Discovery of Delayed Graft Function from Perfusate Proteome
	Somchai Chutipongtanate, Bangkok, Thailand
P.1064	Extracellular matrix extract as a therapeutic approach for ischemic liver in mice
	Kamal Hany Hussein, Chuncheon-si, Korea
P.1065	Optimization of a therapeutic protocol of human mesenchymal stem cells in mice heart transplant model
	Longshan Liu, Guangzhou, People's Republic of China
P.1066	Biliary tree as a window for repopulation of the decellularized liver scaffold
	Satoshi Ogiso, Kyoto, Japan
P.1067	Efficacious combination of substrate and medium for feeder-free culture of naïve porcine iPS
	Shiori Waki, Kagoshima, Japan
P1068	Immunodenletion and hypoxia preconditioning of

P.1068 Immunodepletion and hypoxia preconditioning of mouse compact bone cells as a novel protocol to isolate highly immunosuppressive Mesenchymal Stem Cells

Kisha Nandini Sivanathan, Adelaide, Australia

P.1069 Graft Maturation After Repopulation of Decellularized Rat Livers

Benjamin Struecker, Berlin, Germany



P.1070	Serum levels of stem cell factor and granulocyte
	colony-stimulating factor during hepatic regeneration
	after partial hepatectomy in humans
	Laura Tariciotti Rome Italy

- P.1071 IL-6 blockade attenuates posthepatectomy liver injury, accelerates liver regeneration and improves survival

  Yinzhe Xu, Beijing, People's Republic of China
- P.1072 The Property of Modulatory T cells Generated by Mixed Lymphocyte Culture with CD154 Blockade

  Kiyohiko Hotta, Boston, MA, United States
- P.1073 Targeting histone deacetylase in renal tubular epithelial cells inhibits amplification of Th1 cell-mediated inflammation
  - Sun-woo Kang, Busan, Korea
- P.1074 Expression of Endoplasmic Reticulum-Mediated Stress
  Proteins in FK506-Treated T Lymphocytes
  Ho kyun Lee, Gwangju, Korea
- P.1076 Anti-CD272 antibody (6B2) induced prolongation of fully MHC-mismatched murine cardiac allograft and generation of Foxp3+ regulatory T cells

  Masateru Uchiyama, Tokyo, Japan
- P.1077 Screening of medical supplements to prevent and ameliorate non-alcoholic steatohepatitis (NASH)

  Li-Wen Hsu, Kaohsiung City, Taiwan
- P.1078 Pre-clinical insight into the use of dendritic cells as cellular therapies in inducing tolerance to liver allografts

  Muhammad Atif, Birmingham, United Kingdom
- P.1079 High Peripheral Transitional B Cells and High
  Expression of B Cell Associated Genes in Peripheral
  Blood at 3 Months After Kidney Transplantation:
  Identification of Low Risk Phenotype
  Petra Hruba, Prague, Czech Republic
- P.1080 Heart En Bloc Thymus Transplantation Permits Long-Term, Acute Rejection-Free Cardiac Allograft Survival in Nonhuman Primates (NHPs)
- P.1081 NKT cells in the liver are important for peripheral tolerance induction in mice

  Zhanpeng Wang, Changchun, People's Republic of China
- P.1082 In vitro immune cell monitoring as a guide for long-term immunosuppression in adult liver transplant recipients

  Eunkyoung Jwa, Seoul, Korea



P.1083 Survival outcomes of combined hepatocellular carcinoma-cholangiocarcinoma following liver resection and liver transplantation

Eunkyoung Jwa, Seoul, Korea

P.1086 Mitochondrial Damage-Associated Molecular Patterns (MTDs) Released from Hepatic Ischemia Reperfusion Induce Inflammatory Response

lan P. Alwayn, Halifax, NS, Canada

The posters below belong to the Basic and Translational Sciences track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1106 Protective Effect of Crepidiastrum denticulatum Extract Pretreatment Against Hepatic Ischemia-Reperfusion Injury in Mice

Cheon-Soo Park, Gangneung-Si, Korea

P.1110 Bile as a diagnostic tool after liver transplantation: miRNA pattern and protein based biomarkers may predict acute cellular rejection

Rosa B. Schmuck, Berlin, Germany

## **Liver Posters**



- P.1100 Donor's age and Body mass index are independent factors for estimation of liver weight in deceased donor liver transplantation
  - Gyu-seong Choi, Seoul, Korea
- P.1101 Inferior Hepatic Veins are Inherited to Offsprings
  Dominantly- Lessions Learned from Donor Volumetry

  Gyu-seong Choi, Seoul, Korea
- P.1102 Aborted liver transplantation Single center experience
  - Gyu-seong Choi, Seoul, Korea
- P.1103 Younger donor age poses a risk for overestimation of graft weight in adult living donor liver transplantation

  Toshihiro Kitajima, Kyoto, Japan
- P.1104 Indocyanin green retention rate at 15 minutes of 20% or higher can be a predictive factor of living liver donor with right hepatectomy?
  - Cheon-Soo Park, Gangneung-Si, Korea
- P.1105 Early Experiences of Adult Living Donor Liver Transplantation in Single Hospital

Cheon-Soo Park, Gangneung-Si, Korea



P.1106	Protective Effect of Crepidiastrum denticulatum
	Extract Pretreatment Against Hepatic Ischemia-
	Reperfusion Injury in Mice

Cheon-Soo Park, Gangneung-Si, Korea

P.1107 Difference in donor complications by types of skin incision in LDLT

Jonghwan Lee, Seoul, Korea

P.1108 Living donor liver transplantation using a graft procured from an advanced age-donor

Atsuyoshi Mita, Matsumoto, Japan

P.1109 Single Pass Albumin Dialysis (SPAD) – Optimizing bridging therapy for liver transplantation in acute liver failure

Rosa B. Schmuck, Berlin, Germany

P.1110 Bile as a diagnostic tool after liver transplantation: miRNA pattern and protein based biomarkers may predict acute cellular rejection

Rosa B. Schmuck, Berlin, Germany

P.1111 Successful Transplantation after Normothermic
Machine Perfusion of a Liver Procured from a Donor
with Cold Agglutinin Formation Secondary to
Mycoplasma Pneumoniae Infection – A Case Report
Maren Schulze, Essen, Germany

P.1112 Outcomes of living and deceased donor liver transplant recipients according to the MELD score

Jae Geun Lee, Seoul, Korea

P.1113 Outcome of Second Kidney Transplantation Compared to Primary Transplantation

Jae Geun Lee, Seoul, Korea

P.1114 CoCl2 Induced ER Stress Protein Mediated Cytotoxicity
In FK506 Treated Hepatoma HepG2 Cells

Soo Jin Na Choi, Gwangju, Korea

P.1115 Changes in T cells in Peripheral Blood after Adult Liver Transplantation

Jong Man Kim, Seoul, Korea

P.1116 Differences in Peripheral Blood Lymphocytes Between Brand-Name and Generic Tacrolimus Treated in Stable Liver Transplant Recipients

Jong Man Kim, Seoul, Korea

P.1117 Selection of Immunosuppression in Hepatitis C Virus Liver Transplant Recipients Prevents Biopsy-proven Acute Rejection

Jong Man Kim, Seoul, Korea

## **POSTER LIST**



P.1118 Hepatitis C Patients in a Multicenter Study Who Received Living Donor Liver Transplants Are Likely to Have Increased Survival

Jong Man Kim, Seoul, Korea

P.1119 A modified heterotopic auxiliary liver transplantation for wilson's disease with the graft implanted in the splenic fossa

Kefeng Dou, xi'an, People's Republic of China

P.1120 Clinical Outcomes with Modified Release Tacrolimus in Liver Transplant Recipients: a single centre observational study

Elankumaran Krishnan, Chennai, India

P.1121 Long term observation of children after liver transplantation across ABO blood groups. A single center experience

Malgorzata Markiewicz-Kijewska, Warsaw, Poland

P.1122 Early conversion from twice-daily tacrolimus to prolonged-release tacrolimus in liver transplantation: a single-center experience

Yasuhiro Ogura, Nagoya, Japan

P.1123 Liver Transplantation in Germany – with specific focus on adult transplantation of extremely ill patients receiving "bottom-up" immunosuppression early after transplantation

Hans J. Schlitt, Regensburg, Germany

P.1124 ABO-incompatible liver transplantation – a single center experience

Mariana Mihaila, Bucharest, Romania

P.1126 Single use of Anti-platelet agent for prevention of early hepatic artery thrombosis after liver transplantation

Young Yeon Choi, Daegu, Korea

P.1127 Aggressive preoperative haemodialysis improves left ventricular ejection fraction in primary hyperoxaluria for combined kidney and liver transplantation

Ilankumaran Kaliamoorthy, Medavakkam, India

P.1128 A case of successful deceased donor liver transplantation of grand old age recipient

Pyoung-Jae Park, Seoul, Korea



P.1129 Postoperative Blood Glucose Level Lesser than 150 mg/dL is Associated with Decreased Cytomegalovirus Infection in Seropositive Liver Transplant Recipients

Jun Chul Shin, Seoul, Korea

P.1130 Transfusion of Old Red Blood Cells Stored During Greater Than 2 Weeks is Not Associated with Liver Transplant Death

Jun Chul Shin, Seoul, Korea

P.1131 The immunoexpression of HSP70, Glipican3, Glutamin synthetase and Beta-Catenin in HCC post-liver transplantation. The association between Glipican 3 and Beta-Catenin with the presence of larger nodules

Elaine C. Ataide, Campinas, Brazil

P.1132 The possibility of radiotherapy for downstaging before living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus

Jin Yong Choi, Seoul, Korea

P.1133 Impact of autologous and homologous blood transfusion in liver transplant on outcome of patients with hepatocellular carcinoma

Walid Elmoghazy, Doha, Qatar

P.1134 Predictors of intra-operative red blood cell transfusion during liver transplant: A single center experience over 20 years

Walid Elmoghazy, Doha, Qatar

P.1135 Long term results of liver transplantation for malignances

Gabriel E. Gondolesi, Buenos Aires, Argentina

P.1136 Hepatocellular carcinoma is an independent predictor of recurrent hepatitis C infection following donation after cardiac death liver transplantation

Shiva Kumar, Abu Dhabi, United Arab Emirates

P.1137 Immunohistochemical Markers for Prognosis of Hepatocellular Carcinoma after Liver Resection and Liver Transplantation

Soo Ho Lee, Uijeongbu-si, Korea

P.1138 Should Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Be Contraindicated for Living Donor Liver Transplantation?

Deok-Bog Moon, Seoul, Korea

## **POSTER LIST**



P.1139 Impact of endoscopic ultrasound guided fine needle aspiration on prospective liver transplant patients with cirrhosis and hepatocellular carcinoma or pyrexia of unknown origin

Saigal Sanjiv, Gurgaon, New Delhi, India

P.1141 Technical Refinement to Prevent Hepatic Outflow
Disturbance in Right Lobe Living Donor Liver
Transplantation: New Simplified One-Orifice Venoplasty

Donglak Choi, Daegu, Korea

P.1142 Is Systemic Heparinization Necessary During Living Donor Hepatectomy?

Donglak Choi, Daegu, Korea

P.1143 The Best Level of Recipient's Biliary Duct for Anastomosis to Prevent Postoperative Anastomosis Stricture

Keisuke Arai, Kobe-city, Hyogo, Japan

P.1144 Causes of mortality in patients transplanted for NASH or Cryptogenic cirrhosis: A single center experience over 23 years!

Chandra Bhati, Richmond, VA, United States

P.1145 The Correlation Between Platelet Counts and Spleen
Size after Successful Liver Transplantation

Ahmet Sedat Boyacioglu, Ankara, Turkey

P.1146 Long-Term Outcomes in Pediatric Live-Donor Liver Transplantation

Neslihan Celik, Pittsburgh, PA, United States

P.1147 Durability of Initial Successful Treatment for Biliary Anastomotic Strictures in Right Lobe Living Donor Liver Transplantation

Kenneth Siu Ho Chok, Hong Kong SAR, P.R. of China

P.1148 Intrahepatic artery pseudoaneurysm-induced hemobilia caused by a plastic biliary stent after ABO-incompatible living donor liver transplantation: A Case Report

Jae Min Chun, Daegu, Korea

P.1149 Late hepatic venous outflow obstruction following inferior vena cava stenting in the patient with deceased donor liver transplantation using modified piggyback technique: A case report

Jae Min Chun, Daegu, Korea



P.1150	Does Matching Donor–Recipient Age Impact Long-
	Term Survival in Liver Transplantation?

Cristina Dopazo, Barcelona, Spain

P.1151 Low Dose of Anti-human T-lymphocyte Globulin (ATG) warrant a good Glomerular Filtration Rate after Liver Transplant on recipients with pre-transplant renal dysfunction

Cristina Dopazo, Barcelona, Spain

- P.1152 Evaluation of protocol biopsies after liver transplantation

  Henrik A. Gjertsen, Stockholm, Sweden
- P.1153 Liver transplantation in the presence of diffuse Portal Vein Thrombosis: A 16-year experience with Cavoportal Hemitransposition

Sofia Gyllenswärd, Gothenburg, Sweden

P.1154 Technical solution to upper caval stricture after liver transplantation

Sofia Gyllenswärd, Gothenburg, Sweden

P.1155 Novel technique for arterial conduits in liver and multivisceral transplantation

Sofia Gyllenswärd, Gothenburg, Sweden

- P.1156 Use stapling devices with caution in order to avoid cavastrictures in liver transplantation

  Sofia Gyllenswärd, Gothenburg, Sweden
- P.1157 Incidence and outcomes of de novo malignancies after living donor liver transplantation in comparison with the Japanese general population

Taizo Hibi, Tokyo, Japan

- P.1158 Management of CNI Induced Posterior Reversible encephalopathy Syndrome with Everolimus Change after Living Donor Liver Transplantation (case)

  Geun Hong, Seoul, Korea
- P.1159 Treatment of Biliary Stone and Cast After Liver
  Transplantation Using the Percutaneous Transhepatic
  Cholangioscopy (PTCS); A Case Report

  Julk Moon, Daejeon, Korea
- P.1160 The Impact of Recipient's BMI at the Deceased Donor Kidney Transplantation

Julk Moon, Daejeon, Korea

P.1161 Outcome of Deceased Donor Liver Transplantation for Alcoholic Liver Disease

Suk Kyun Hong, Seoul, Korea



	Suk Kyun Hong, Seoul, Korea
	Transplantation (LT) focused on Deceased Donor LT (DDLT)
P.1162	Graft versus Host Disease (GVHD) After Liver

P.1163 Posttransplant mellitus (PTDM) after liver Transplantation: Risk factors and outcome

Byeongju Kang, Ulsan, Korea

P.1164 The influence of perioperative acute kidney injury for the prediction of decreased renal function after liver transplantation

Gun Woo Kang Jr., Daegu, Korea

P.1165 Steal Syndrome After Liver Transplantation: A Single Center Experience

**Gokhan Moray**, Ankara, Turkey

P.1166 Percutaneous ultrasound guided biliary interventions after pediatric liver transplantation using fine needle and 0.014 inch guide-wire

Gokhan Moray, Ankara, Turkey

P.1167 Simultaneous percutaneous large profile multiple plastic stents for biliary anastomotic strictures after liver transplantation

Gokhan Moray, Ankara, Turkey

P.1168 Successful percutaneous management of recurrent sclerosing cholangitis after liver transplantation with multiple intrahepatic plastic biliary stent placement with only one access

Gokhan Moray, Ankara, Turkey

P.1169 Extensive Indications for HCC in Living Donor Liver Transplantation

Gokhan Moray, Ankara, Turkey

P.1170 Renal cell carcinoma in transplanted kidney

Gokhan Moray, Ankara, Turkey

P.1171 Dual stent placement for suprahepatic inferior vena cava stenosis after deceased donor liver transplantation with piggy-back technique

Tae-Seok Kim, Daegu, Korea

P.1172 A case of early organizing portal vein thrombosis followed by arterio-portal shunt without hepatic dysfunction after liver transplantation

Tae-Seok Kim, Daegu, Korea



P.1173 Immune modulation with CMV-hyperimmunoglobulin improves outcome in high-risk (MELD  $\geq$  30) liver transplant patients

Arno Kornberg, Munich, Germany

P.1174 Liver transplantation for alcoholic liver disease without pre-transplant abstinence

Hae Won Lee, Seoul, Korea

P.1175 Surgical Results of Outflow Reconstruction in Living Donor Liver Transplantation

Yang Won Nah, Ulsan, Korea

P.1176 Risk factors in primary liver transplantation - a retrospective single centre analysis

Manuel Maglione, Innsbruck, Austria

P.1177 Successful Retransplantation of an Allograft after Early Recurrence of Focal Segmental Glomerulosclerosis in the First Recipient

Manuel Maglione, Innsbruck, Austria

P.1178 Acquired haemostatic disorders by orthototic liver transplantation

Eviatar Nesher, Ein Vered, Israel

P.1179 Percutaneous transhepatic bililary drainage after living donor liver transplantation resulting inacute hepatic failure: a case of hepatic compartment syndrome

Je Ho Ryu, Yangsan-si, Korea

P.1180 Surgical techniques and outcome of autologous portal vein interposition for anomalous right portal veins in living donor liver transplantation

Je Ho Ryu, Yangsan-si, Korea

P.1181 Surgical Technique for Hepatic Arterial Reconstruction in Pediatric Patients Undergoing Monosegmental Living Donor Liver Transplantation

Yukihiro Sanada, Shimotsuke, Japan

P.1182 Postoperative outcomes of Controlled Donation after Cardiac Death compared with Donation after Brain Death: a meta-analysis

Jianxin Tang, Guangzhou, People's Republic of China

P.1183 Analysis of initial 100 cases of a new liver transplantation program: the Korea University Anam hospital experience

Young-Dong Yu, Seoul, Korea



P.1184	Testosterone deficiency a diagnosis to consider: In
	adult male post liver transplant (LTx) recipients with
	failure to thrive, muscle wasting or sarcopenia is
	observed

Ashokkumar Jain, Hershey, PA, United States

- P.1185 Measurement of Creatinine clearance in immediate post Kidney transplant (KTx) period with functioning allograft Ashokkumar Jain, Hershey, PA, United States
- P.1186 Incidence and Management of Bile Stone After Liver
  Transplantation: Report of a Single Center

  Mahir Kirnap, Ankara, Turkey
- P.1187 Management of Early Hepatic Arterial Thrombosis
  After Liver Transplantation
  Mahir Kirnap, Ankara, Turkey
- P.1188 Unusual Indications for a Liver Transplant: a Single-Center Experience

Mahir Kirnap, Ankara, Turkey

- P.1189 Effects of the Natural Immune System on Acute
  Rejection of Living donor Renal Transplantation

  Mahir Kirnap, Ankara, Turkey
- P.1190 Outcomes for pediatric liver re-transplantation at a single center

Akinari Fukuda, Tokyo, Japan

- P.1191 Retransplantation of the liver: single center results

  Sergey V. Gautier, Moscow, Russian Federation
- P.1192 Poor Patient Outcome in Combined Liver-Kidney

  Transplant: a fifteen years experience from a single centre

  Niaz Ahmad, Leeds, United Kingdom
- P.1193 Pediatric living donor liver transplantation at KFSH&RC
   implementation of the laparoscopic retrieval in a
  high volume center

Markus U. Boehnert, Riyadh, Saudi Arabia

P.1194 Right-sided diaphragmatic hernia after living donor Right hepatectomy: A rare complication after living donor

Gyu-seong Choi, Seoul, Korea

P.1195 Living donor liver transplantation in a Jehovah's Witness- the first adult living donor liver transplantation in Korea

Gyu-seong Choi, Seoul, Korea



P.1196 Anastomosis of type 2 portal vein variation and lowlying right posterior duct anomaly in living donor liver transplantation

Kwangsik Chun, Daejeon, Korea

- P.1197 More Than 16 Years Follow Up of Living Donor Liver
  Transplantation for Two Cases of Homozygous Familial
  Hypercholesterolemia from the Heterozygous Donor
  Naoki Kawagishi, Sendai, Japan
- P.1198 Renal function status in liver transplant patients in the first month post-transplant is associated with progressive chronic kidney disease

Naoki Kawagishi, Sendai, Japan

- P.1199 Early Experience of Living Donor Liver Transplantation at Dong-A University Hospital : Initial 24 cases

  Kwan Woo Kim, Busan, Korea
- P.1200 Right lobe living donor liver transplantation with middle hepatic vein for treatment end stage liver diseases

  Oleg Kotenko, Kiev, Ukraine
- P.1201 Early Term Results of Biliary Reconstruction Using Microsurgical Outer Knotted Suture Technique in Living Donor Liver Transplantation

  Shigehito Miyagi, Sendai, Japan
- P.1202 Prior kidney donation does not impact the outcome of subsequent living right liver lobe donation

  Amit Sharma, Richmond, VA, United States
- P.1203 The study of the measurement of liver volume by methods of multi-slice spiral CT and displacement method

  Chao Sun, Tianjin, People's Republic of China
- P.1204 Successful living donor liver transplantation for primary biliary cirrhosis with ABO blood type incompatibility and strongly positive donor-specific HLA antibodies

Yuki Takano, Tokyo, Japan

P.1205 Rapid preparation for ABO-incompatible living donor liver transplantation in acute liver failure with high isoagglutinin titers

Tsunghan Wu, Taoyuan, Taiwan

P.1206 ABO incompatible living donor liver transplantation in patient with fulminant hepatic failure

Sam-Youl Yoon, Seoul, Korea



P.1207	The Czech single centre experience with split liver
	transplantation: 3 years of the program, 37 splits and
	72 transplants

Jiri Fronek, Prague, Czech Republic

P.1208 Deceased donor uterus retrieval as part of uterus transplant trial – the first Czech experience

Jiri Fronek, Prague, Czech Republic

P.1209 ABO-Incompatible liver Transplantatin, Full Size, Partial,
Auxiliary - Single Centre Experience

Jiri Fronek, Prague, Czech Republic

P.1210 ABO Incompatible Living Donor Liver Transplantation in Patient with History of Platelet Transfusion Related Anaphylaxis

Jai Young Cho, Seongnam, Korea

P.1211 Liver transplantation in a small volume center; initial outcome

Ho Joong Choi, Bucheon, Korea

P.1212 Urgent living-donor liver transplantation in a patient with concurrent active tuberculosis: a case report

Bo-Hyun Jung, Busan, Korea

P.1213 Living donor liver transplantation in over 70 years old patients

Jae Hyun Kwon, Seoul, Korea

P.1214 Embolization of an intrahepatic portal systemic shunt for the treatment of hepatic encephalopathy to defer urgent liver transplantation

I Ha Lao, Tainan, Taiwan

P.1215 Impact of serial change of donor specific antibodies on the graft outcomes after liver transplantation

Jung Jun Lee, Seongnam-si, Korea

P.1216 Living Donor Liver Transplantation in Patients Older Than 60 Years: Single center experiences

Byunggon Na, Dae-gu, Korea

P.1217 Survival analysis for patients with MELD score < 15
Wong Hoi She, Hong Kong SAR, P.R. of China

P.1218 Role of Liver Transplantation in Patients of Acute Liver Failure with Hepatic Coma requiring Mechanical Ventilation: Is it justified? Single center successful experience

Ashok Thorat, Taichung, Taiwan



- P.1219 Successful Living Donor Liver Transplantation in a Case of Pulmonary Hypertension
  - Youngkyoung You, Seoul, Korea
- P.1220 Outcome Results of Cardiac Surgery and Cardiac Intervention After Liver Transplantation

  Mitsuru Nakatsuka, Richmond, VA, United States
- P.1221 Safety and Complications of Living Donor Hepatectomy

  Mitsuru Nakatsuka, Richmond, VA, United States
- P.1222 Current Status of Cadaveric and Living Donor Kidney Transplantation of The Last 6 Years, Compared With Previous 6 Years Experience
  - Mitsuru Nakatsuka, Richmond, VA, United States
- P.1223 Neoplasms or cancers in HCVab-positive OLT recipients with hepatocellular carcinoma: the analysis of the outcomes
  - Olga M. Tsiroulnikova, Moscow, Russian Federation
- P.1224 HCV treatment after liver transplantation 2006-2016: result assessment
  - Olga M. Tsiroulnikova, Moscow, Russian Federation
- P.1225 Transforming growth factor beta 1 blood level relates with liver disease etiology and fibrosis severity in pediatric liver recipients
  - Olga M. Tsiroulnikova, Moscow, Russian Federation
- P.1226 Pediatric living donor liver transplantation: correlation plasma level of transforming growth factor beta -1 with tacrolimus dosage but not with its concentration

  Olga M. Tsiroulnikova, Moscow, Russian Federation
- P.1229 Single center experience treating post-transplant
  Hepatitis C patients with direct acting antivirals (DAAs)

  Ashish Sharma, Chandigarh, India
- P.1230 Daclatasvir plus asunaprevir as interferon-free regimen for recurrent hepatitis C virus infection after liver transplantation: A preliminary study

  Motofumi Tanaka, Kobe, Japan

The posters below belong to the Liver track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1052 Natural History of Spontaneous Porto-Systemic Shunt (PSs) and Transplant Outcomes in Liver Allograft Recipients

Tomasz Kozlowski, Chapel Hill, NC, United States



P.1083	Survival outcomes of combined hepatocellular
	carcinoma-cholangiocarcinoma following liver
	resection and liver transplantation
	Eunkyoung Jwa, Seoul, Korea

P.1269 ABO Incompatible Liver Transplantation using Plasma Exchange and Anti-CD20 Monoclonal Antibody

Nam Kyu Choi, Gwangju, Korea

P.1432 The relation between the inflamatory cytokine expression with acute rejection episodes and hepatitis recurrence in liver allograft recipients

Handan Özdemir, Ankara, Turkey

Handan Ozdemir, Ankara, Turkey

P.1574 Extracorporeal Membrane Oxygenation after Liver
Transplantation in a Patient with Hepatopulmonary
Syndrome and Refractory Hypoxemia
Pinar Zeyneloglu, Ankara, Turkey

P.1589 Epidemiology and risk factors of cholangitis after liver transplantation – single center experience

Jolanta Gozdowska, Warsaw, Poland

P.1590 Post-transplantation lymphoproliferative disease in a patient after two liver transplant because of cirrhosis of the liver's own post-inflammatory etiology HCV and HBV

Jolanta Gozdowska, Warsaw, Poland

#### **Kidney Posters**



- P.1250 Plasmapharesis on Demand in ABO Incompatible (ABOi) Post Kidney Transplant Management

  Abdulnaser M. Alabadi, Dammam, Saudi Arabia
- P.1251 Anti-HLA antibody-induced rejection in ABOincompatible kidney transplant patients

  Joon Heon Jeong, Busan, Korea
- P.1252 Role of plasmapheresis in management of ABO incompatible renal transplantation: A single centre experience

Kamal V. Kanodia, Ahmedabad, India

- P.1253 De novo focal and segmental glomerulosclerosis in renal allograft: a single center five year experience

  Kamal V. Kanodia, Ahmedabad, India
- P.1254 Successful transplantation in ABO- and HLAincompatible living kidney-transplant patients: a report on 12 cases

**Lionel Rostaing**, Toulouse, France



	transplant impaired fasting glucose
	blood level in relatively more elderly patients with pre-
P.1255	NODAT development is associated with Tacrolimus

Selcuk Sahin, Istanbul, Turkey

- P.1256 Peak Panel Reactive Antibody Related States of
  Patients Awaiting for Deceased Kidney Transplantation
  Selcuk Sahin, Istanbul, Turkey
- P.1257 Rituximab induction significantly reduced acute rejection in ABO-incompatible kidney transplantation:

  A cohort study of 405 patients over 25 years

  Akihito Sannomiya, Tokyo, Japan
- P.1258 Gastrointestinal perforation after renal transplantation

  Sung Shin, Seoul, Korea
- P.1259 Clinical outcomes of DSA positive alone in kidney transplantation

Sung Shin, Seoul, Korea

- P.1260 Living donor renal transplantation in patients with antiphospholipid syndrome

  Sung Shin, Seoul, Korea
- P.1261 Clinical significance of ABO incompatible kidney transplantation from spousal donors

  Chul Woo Yang, Seoul, Korea
- P.1262 Outcomes of ABO Incompatible Kidney
  Transplantation Without Antibody Remove:
  Multicenter Experiences from China
  - Wang Yi, Hengyang, People's Republic of China
- P.1263 Pilot Conversion Study from Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients

Junjji Uchida, Osaka, Japan

- P.1264 Acute Cellular Rejection in ABO-Incompatible Kidney
  Transplant Recipients Receiving Rituximab is
  Associated with Late-Onset Neutropenia
  Junjji Uchida, Osaka, Japan
- P.1265 Impact of low BMI on renal graft outcome

Tahir Aziz, Karachi, Pakistan

P.1266 Dialysis vintage: A dominating factor affecting growth and final height after pediatric renal Transplantation: A single center experience

Tahir Aziz, Karachi, Pakistan



P.1268	The safety using intraoperative ureteric double J stent for prevention of urological complications in kidney transplant recipients
	Nam Kyu Choi, Gwangju, Korea
P.1269	ABO Incompatible Liver Transplantation using Plasma Exchange and Anti-CD20 Monoclonal Antibody
	Nam Kyu Choi, Gwangju, Korea
P.1270	Age-dependent impact of acute rejection on graft survival in young and old kidney transplant recipients
	Tomasz Dziodzio, Berlin, Germany
P.1271	Outcomes of kidney transplantation for elderly aged more than 70 years
	Akira Kurosawa, Tochigi, Japan
P.1272	Outcomes in kidney transplantation from older donors: A single center experience
	<b>Kyung Hee Lee</b> , Daegu, Korea
P.1273	The new Kidney Allocation System Hits the 305
	Franco H. Cabeza, Miami, FL, United States
P.1275	It is Safe to Transplant Kidneys with Renal Masses  Giselle Guerra, Miami, FL, United States
P.1276	Transplantation of Kidneys from Donors with Renal Artery Aneurysm
	Giselle Guerra, Miami, FL, United States
P.1277	Long-term outcomes after kidney transplantation in patients with the history of hemodialysis vascular access thromboses
	Janis Jushinskis, Riga, Latvia
P.1278	Quantitative measurement of elasticity of the donor kidney using shear wave elastography to evaluate donor kidney status – pilot study
	Sung Hoon Kim, Wonju, Korea
P.1279	Kidney donor profile index trend analyses <b>Debra L. Sudan</b> , Durham, NC, United States
P.1280	Is Weight Gain a Barrier to Transplant Listing for Peritoneal Dialysis Patients?
	Denise A. Fracchia, Melbourne, Australia
P.1281	Validation In Veracruz Mexico Of The Estimated Posttransplant Survival Score For Allocation Of Deceased Donor Kidney In The United States
	Frnesto Soto-Miranda Veracruz Mexico



P.1282 Validation in Veracruz Mexico of Kidney Donor Profile Index for Allocation of Deceased Donor Kidney in the **United States** 

Ernesto Soto-Miranda, Veracruz, Mexico

P.1283 Successful short-term kidney transplantation outcomes after desensitization with plasmapheresis, intravenous immunoglobulin and rituximab in highly sensitized living donor kidney transplant patients: Mexican single-center experience

Ernesto Soto-Miranda, Veracruz, Mexicoo

P.1284 Thymoglobulin induction in living donor renal transplant recipients: Southern Mexican center experience Ernesto Soto-Miranda, Veracruz, Mexico

P.1285 Impact of Brain Death Duration on Kidney Transplant Outcomes in Veracruz, Mexico

Ernesto Soto-Miranda, Veracruz, Mexico

P.1286 Relationship Between Dialysis Duration and Prevalence of Cardiovascular Diseases in Kidney Transplantation Recipients

Keisuke Hata, Tokyo, Japan

P.1287 Development of protocol for deceased kidney transplantation recipients while waiting for kidney transplantation

Hyun Jung Kim, Seoul, Korea

P.1288 Anti-Diuretic Hormone Response Related to Kidney Transplantation in Dialysis Patients

Jin Soo Kim, Busan, Korea

P.1289 Comparison of Barriers to Wait Listing for Kidney Transplantation between hemodialysis center Keun-Myoung Park, Incheon, Korea

P.1290 Mean fluorescence intensity by Luminex single antigen bead and one year graft outcome in DSA positive kidney transplantation

Leslie A. Yap, San Juan, Philippines

P.1291 Evolution of Renal Transplantation - Experience From a Single Center

Viktor Denisov, Donetsk, Ukraine

P.1292 Surgical and technical aspects of re-operative (>/=3) Kidney transplantation

Tarunjeet S. Klair, New York, NY, United States



P.1293	Renal Transplant for Patients on Long-Term Dialysis
	(more than 20 years) at our Center

Koichi Kozaki, Ibaraki, Japan

P.1294 Need for more than just renal replacement - Analysis of a special cohort

Mettu Srinivas Reddy, Chennai, India

P.1295 Decremental Change in Perioperative Hemoglobin
Concentration is Associated with Poor Early Graft Function
in Kidney Transplant Patients: a Retrospective Study

Arpa Chutipongtanate, Bangkok, Thailand

P.1296 Rate of Dysregulation of Serum Immunoglobulins is Higher in Acute Allograft Rejection in Renal Transplant Recipients

Ravi Dhital, Chandigarh, India

P.1297 Paricalcitol pretreatment attenuates apoptosis and inflammation in renal ischemia-reperfusion injury via EP4 pathway

Suk Young Kim, Daejeon, Korea

P.1298 Pretreatment with cilastatin attenuates renal ischemiareperfusion injury

Suk Young Kim, Daejeon, Korea

P.1299 Intra-abdominal cooling system prevents ischemiareperfusion injury during robotic-assisted renal transplantation

Raphael Meier, Geneva, Switzerland

P.1300 Increased Gene expression of BAFF-R, TACI and BCMA is associated with acute rejection in kidney transplantation

Mukut Minz, Chandigarh, India

P.1301 Plasma neutophil gelatinase-associated lipocalin (NGAL) - biomarker in kidney injury. Is it a useful tool to predict the renal function after transplantation?

Marta Sekowska, Poznan, Poland

P.1302 When Does Delayed Graft Function not Make a Difference in Deceased Donor Kidney Transplant Outcomes?

Robert J. Stratta, Winston-Salem, NC, United States

P.1303 The role of alloimmunity in death-censored kidney allograft failure

Mohamad M. Alkadi, New York, NY, United States



P.1304 Urine metabolomics: quinolinate, a product of tryptophan metabolism, is associated with BK virus nephropathy and intragraft inflammation in kidney transplant recipients

Mohamad M. Alkadi, New York, NY, United States

P.1305 Breast implants surgery in patient who had kidney transplantation

Marina Ratkovic, Podgorica, Montenegro

P.1306 Case of rapamycine induced pancreatitis and deep venous thrombosis

Marina Ratkovic, Podgorica, Montenegro

P.1307 Plasmapheresis and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis

Marina Ratkovic, Podgorica, Montenegro

P.1308 Complications of kidney transplantation performed through black organ markets affiliations

Marina Ratkovic, Podgorica, Montenegro

P.1309 Does C1q SAB assay have any value in prediction of kidney transplantation outcome in highly sensitized patients?

Arpita Ghosh-Mitra, Kolkata, India

P.1310 Bortezomib and Antibody Mediated Rejection in Renal Allograft Recipients

Lorna K. Henderson, Edinburgh, United Kingdom

P.1311 A flare up of de novo donor-specific antibodies following the ruptured ectopic pregnancy after kidney transplant from spousal donor

Cheol Woong Jung, Seoul, Korea

P.1312 Relationship between de novo donor-specific anti-HLA-DQ antibody and chronic antibody-mediated rejection in kidney transplant recipients

Furusawa Miyuki, Tokyo, Japan

P.1313 Analysis of Significance of Vascular Rejection in Kidney Transplant Biopsy Samples

Marek Novotny, Prague, Czech Republic

P.1314 Clinical relevance of de novo donor-specific HLA antibodies (DSA) in renal transplantation

Florian Sommer, Augsburg, Germany



POS	STER LIST (Kdn) _
P.1315	Clinical and Pathological Evaluations of Combination Therapy for Active Antibody Mediated Rejection in Renal Transplantation; a Single-Center Experience
P.1316	Masayuki Tasaki, Niigata, Japan Eculizumab rescue from acute antibody-mediated rejection and long-term stable graft function
P.1317	Rolf Weimer, Giessen, Germany  Do anti-HLA antibodies as detected by the Luminex assay have an impact on kidney allograft survival beyond 10 years post transplant?
P.1318	Angeline Goh, Singapore, Singapore  Long term follow up glycemic status of live kidney donors
P.1319	Angeline Goh, Singapore, Singapore  Anti-HLA Antibody Reduced Graft Survival in Living- Related Transplants: Over 20 Years Experience
P.1320	Kazuo Mizutani, Tokyo, Japan  Assessment of EGFR and One-Hour Biopsy Using In- Situ-Cooling Double-Balloon Catheters in Deceased Kidney Transplants
P.1321	<b>Kazuo Mizutani</b> , Tokyo, Japan Phytohemagglutinin-Induced II2 Mrna as a Useful Marker of Kidney Transplants
P.1322	Kazuo Mizutani, Tokyo, Japan C4D Binding Correlated with Strong HLA Antibodies in Kidney Transplantation

Kazuo Mizutani, Tokyo, Japan

P.1323 Effective monitoring of CMV infection by quantitative analysis of CMV mRNA. Case report in renal transplant Kazuo Mizutani, Tokyo, Japan

P.1324 Donor specific HLA-antibodies are a risk factor for graft dysfunction in both presumptive BKVN and biopsy positive BKVN

Essa A. Abuhelaiga, New York, NY, United States

P.1325 Polyomavirus Associated Nephropathy with Concurrent Recurrence of IgA Nephropathy in a post Kidney Transplant patient: A Case Report

Ramona Espera-Lobaton, Taguig City, Philippines

P.1326 Sirolimus leads to Negative Conversion of BK Virus in **Renal Transplantation Patients** 

Sang Youb Han, Goyang, Korea



	Kyubok Jin, Daegu, Korea
	in Kidney Transplant Recipients
P.1327	Clinical Outcomes of BK Virus Associated Nephropathy

- P.1328 BK Polyomavirus Prophylaxis with Ciprofloxacin in Kidney Transplant Recipients: a Prospective Study

  Xiaopeng Yuan, Guangzhou, People's Republic of China
- P.1329 Implantation biopsy of cardiac death donors and its implication in predicting renal graft outcomes

  Xiaopeng Yuan, Guangzhou, People's Republic of China
- P.1330 Retrospective review on the prevalence of hyperuricaemia before and after renal transplantation and the risk factors predicting hyperuricaemia after renal transplantation in a single centre

  Siu Kim Chan, Hong Kong SAR, P.R. of China
- P.1331 Is There a Link Between Proteinuria and Increased FGF-23 Levels in Renal Transplant Patients?

  Turan Colak, Ankara, Turkey
- P.1332 Alkaline Phosphatase a New Marker for Graft Outcome and High Pulse Wave Velocity in Renal Transplant Recipients

  Turan Colak, Ankara, Turkey
- P.1333 Ambulatory blood pressure measurement as a prognostic tool in renal transplant recipients

  Turan Colak, Ankara, Turkey
- P.1334 Arteriolar Hyaline Formation caused by Hypertension and High TG Levels as well as CNI Toxicity Appeared to be a Long-Term Risk Factor of Allograft Function

  Yoshihiro Itabashi, Tokyo, Japan
- P.1335 Correlation between Resistance Index and urinary albumin excretion at early stage after renal transplantation Kabei Kazuya, Osaka, Japan
- P.1336 Serum cystatin C as a good predictor of chronic allograft dysfunction in renal transplant recipients

  Sirilak Leawseng, Bangkok, Thailand
- P.1339 New Risk factor of Newly Onset Diabetes Mellitus after Kidney Transplantation
  - Michal P. Nowicki, Lodz, Poland
- P.1340 Impaired Fastig Glucose according to different diagnostic criteria in kidney transplanted patients

  Liliana Miriam Obregon, La Plata, Argentina



P.1341 Serum 25-hydroxyvitamin D levels with metabolic profiles in renal transplant recipients with chronic allograft nephropathy

Bancha Satirapoj, Bangkok, Thailand

P.1342 Using analgesics including nonsteroidal antiinflammatory drugs in patients with chronic kidney disease (CKD 1-4) and after kidney transplantation – one center experiences

Alicja Debska-Slizien, Gdańsk, Poland

P.1343 The Treatment of Hypertension in Patients after renal Transplantation - One Center Observational Study Alicja Debska-Slizien, Gdańsk, Poland

P.1344 Achromobacter denitrificans pneumonia in a renal transplant patient—dose-dependent decrease of phagocytic activity as a potential mechanism for the everolimus pulmonary toxicity

Alicja Debska-Slizien, Gdańsk, Poland

P.1345 Preimplantation and intragraft molecular transcripts in serial biopsies of standard and extended criteria donor kidneys: effect of donor type and immunosuppressive protocols

Mario Abbud-Filho, Sao Jose do Rio Preto, Brazil

P.1346 Outcomes of Kidney Transplantation from DBD, DCD or DBCD Donors: A Single Center Experience from China

Guodong Chen, Guangzhou, People's Republic of China

P.1347 Kidney transplantation from pediatric donors of deceased organ donation

**Chen Chuanbao**, Guangzhou, People's Republic of China

P.1348 The analysis of discarded kidneys from donors of deceased organ donation

Chen Chuanbao, Guangzhou, People's Republic of China

P.1349 Long Term Graft and Recipient Outcome of Deceased Donor Renal Transplantation at the National Kidney and Transplant Institute

Romina A. Danguilan, Quezon, Philippines

P.1350 Clinical research of kidney transplantation from cardiac death pediatric donors

Han Feng, Xi'an, People's Republic of China

P.1351 Clinical Investigation of kidney transplantation from cardiopulmonary resuscitation of DCD

Han Feng, Xi'an, People's Republic of China



- P.1352 Pyeloureteric junction obstruction in renal allografts

  Andrej Grajn, Brisbane, Australia
- P.1353 Patient and Graft survival and graft function three years after Living-related donation and Brain-dead donation: results from a single center

Hai An Ha Phan, Hanoi, Viet Nam

P.1354 BK virus infection among kidney transplant recipients: data from Department of Kidney Diseases and Dialysis, Viet Duc hospital

Hai An Ha Phan, Hanoi, Viet Nam

P.1355 Establishing of uncontrolled donation after circulatory determination of death (UDCDD) protocol in Poland – first two cases

Marek Karczewski, Poznan, Poland

- P.1356 Identifying Risk Severity Using Proposed Wuhan Chart In Deceased Donor Kidney Transplantation
  - Kiran J. Kunwar, Kathmandu, Nepal
- P.1357 The impact of delayed graft function after kidney transplantation on long-term graft function and survival **Sukyung Kwon**, Seoul, Korea
- P.1358 Incidence and outcome of vascular complications in kidney transplantation after expanding acceptance criteria: Single centre experience
  - Mohamed Morsy, London, United Kingdom
- P.1359 Incidence and outcome of Post-transplant urological complications in kidney transplantation after expanding acceptance criteria: Single centre experience
  - Mohamed Morsy, London, United Kingdom
- P.1360 Pathological analysis of 544 cases of indicated renal allograft biopsies
  - Changxi Wang, Guangzhou, People's Republic of China
- P.1361 En Bloc Kidney Transplantation from Infant Donors
  Less Than 10 kg surgical skill, clinical management
  and outcome in a transplant center in China
  - Changxi Wang, Guangzhou, People's Republic of China
- P.1362 Comparison of kidney transplantation from living and deceased donation: a consecutive data analysis since implement of donation after citizen's death in China

  Changxi Wang, Guangzhou, People's Republic of China



P.1363	Conversion from mycophenolate mofetil to mizoribine and its therapeutic exposure in Chinese renal transplant recipients with leucopenia
	<b>Longshan Liu</b> , Guangzhou, People's Republic of China
P.1364	Hemodynamics in Transplant Renal Artery Investigated by Computational Fluid Dynamics
	<b>Changxi Wang</b> , Guangzhou, People's Republic of China
P.1365	Universal vascular index to predict organ quality during rewarming machine perfusion for Kidney transplantation from Donation after Cardiac Death  Hiromichi Obara, Hachiouji, Tokyo, Japan
P.1366	Outcome of Kidney Transplantation from Expanded Criteria Decease Donors
	Mohammad Raslan, Kuwait, Kuwait
P.1368	Kidney Donor Profile Index as a Prognostic Factor in Transplants in Colombia
	Alejandro Niño-Murcia, Bogota, Colombia
P.1369	induction in "low risk" Kidney transplantation in Colombia
	Alejandro Niño-Murcia, Bogota, Colombia
P.1370	Intensive Care Unit Feedback About Organ Donation  Alejandro Niño-Murcia, Bogota, Colombia
P.1371	En Bloc Dual Kidney Transplantation: a Novel Technique <b>Dai Nghiem</b> , Westminster, CA, United States
P.1372	A New Approach to the Hostile Bladder in Transplantation
	Dai Nghiem, Westminster, CA, United States
P.1374	Pre-transplant deceased donor kidney biopsy is decision- making for single versus dual kidney transplantation Kamlesh S. Suthar, Ahmedabad, India
D4275	
P.13/5	Excellent Long-term Outcomes of Renal Transplantation from Donation after Cardiac Death Donors: A Single Center Experience
	Masashi Takenaka, Aichi, Japan
P.1376	Comparison of hypothermic and normothermic pulsatile machine perfusion in an ex-vivo porcine kidney model
	Natalie Vallant, London, United Kingdom
P.1377	Extraction of green fluorescent protein labelled Mesenchymal Stem Cells to investigate their
	mechanisms of action on Ischemia- Reperfusion Injury
	in a rat kidney transplant model
	Natalie Vallant, London, United Kingdom



	Punlop Wiwattanathum, Bangkok, Thailand
	Standard Donors and Expanded Criteria Donors
	Stages of Acute Kidney Injuries: a Comparison with
P.1378	Kidney Transplant from Deceased Donors with Several

- P.1379 Effects of Plasmapheresis and Antigen- Specific Immunoadsorption on Complement Levels in Antibody-Incompatible Live Renal Transplant

  Archana Jain, Coventry, United Kingdom
- P.1380 Dengue Fever in Patients with Renal Transplantation
  Analysis Cases Report
  Ling-Hsien Lee, Tainan City, Taiwan
- P.1381 Management of highly sensitized patients in kidney transplantation: prospective single center strategy

  Michel Mourad, Brussels, Belgium
- P.1382 Living kidney transplantation from older donor aged
  60 and older

  Kiyokazu Akioka, Omihachiman, Japan
- P.1383 Post-nephrectomy inflammatory syndrome: A common complication post minimal access live donor nephrectomy?
  - Marc J. Clancy, Glasgow, United Kingdom
- P.1384 Living longer and better after kidney transplant in southern Spain
  - Javier de Teresa Alguacil Sr., Granada, Spain
- P.1385 Identifying the main causes of kidney allograft loss: a large cohort study in Spain

  Javier de Teresa Alguacil Sr., Granada, Spain
- P.1386 Donors with stone-bearing kidneys are eligible for living kidney donation: a systematic review and cohort analysis

  Frank JMF Dor, London, United Kingdom
- P.1387 Recurrent focal segmental glomerular sclerosis after renal transplantation; prevention and treatment with Rituximab Kenta Futamura, Nagoya, Japan
- P.1388 50-year donor and recipient survival after non-twin living donor kidney transplantation

  Oscar K. Serrano, Minneapolis, MN, United States
- P.1389 The impact of viral replication in recipient urine, oral wash and blood before transplant on post-transplant infection

  Oscar K. Serrano, Minneapolis, MN, United States
- P.1390 The impact of graft thin upper pole artery ligation on living donor kidney transplantation

  Takahisa Hiramitsu, Nagoya, Japan



P.1391	Efficacy and feasibility of radiotherapy for localized prostate cancer in renal transplant recipients: a single-center experience
	Junpei lizuka, Tokyo, Japan
P.1392	A Safer 2-Layer Method of Inguinal Hernia Repair for the Renal Transplant Recipient
	Nobuhiro Ishido, Kobe, Japan
P.1393	Results of paired kidney exchange transplantation: initial experience of a single institution
	Feza Karakayali, Ankara, Turkey
P.1394	Results of BK Virus Screening in Renal Transplant Recipients
	Feza Karakayali, Ankara, Turkey
P.1395	Investigation of Body Mass Index and Cases of Living Renal Transplantation Performed in this Department
	Yu Kihara, Tokyo, Japan
P.1396	Long-term renal allograft survival after sequential liver-kidney transplantation from a single living donor
	Kumiko Kitajima, Tokyo, Japan
P.1397	Impact of serum creatinine levels at 1 year on 5-year graft survival
	Mirza Naqi Zafar, Karachi, Pakistan
P.1398	A living donor risk model for predicting kidney allograft and patient survival in an emerging economy
	Mirza Naqi Zafar, Karachi, Pakistan
P.1399	High prevalence of post transplant donor specific HLA-DQ antibody in live related renal transplantation. Is it time to extend typing to HLA-DQ in renal transplantation?
	Mirza Naqi Zafar, Karachi, Pakistan
P.1403	Intra-operative fluid management for robotic kidney transplantation: an initial experience
	Manisha P. Modi, Ahmedabad, India
P.1404	Preemptive kidney transplantation in Japanese patients: A propensity score-matched study
	Masayoshi Okumi, Tokyo, Japan
P.1405	Who is at Risk in Living Kidney Donation?
	Rajesh Sivaprakasam, London, United Kingdom
P.1406	Effect of Tacrolimus trough-level variability on New-Onset Diabetes After Transplantation in
	D IT I

Rajesh Sivaprakasam, London, United Kingdom



P.1407	What Component of the Cold Ischemia Time is
	Important?

Rajesh Sivaprakasam, London, United Kingdom

- P.1410 Renal transplantation after laparoscopic radical nephrectomy due to neoplastic disease case report

  Marek Ostrowski, Szczecin, Poland
- P.1411 Obstacles facing Living Related Donor Kidney
  Transplant Program at an urban non-transplanting
  Center, U.K

Husham Rasheed, Birmingham, United Kingdom

- P.1412 Successful direct-acting antiviral therapy for renal transplant recipients with hepatitis C virus infection

  Tamotsu Tojimbara, Atami-City, Japan
- P.1413 Right-sided laparoscopic live-donor nephrectomy: results and technical aspects

Pablo Troncoso, Santiago, Chile

P.1414 Laparoscopic right donor nephrectomy: Analysis of different technique

Anant Kumar, Saket, India

- P.1415 Renal Transplant in patients with abnormal bladder: Is the outcome same in developing country?

  Anant Kumar, Saket, India
- P.1416 TRANSFORM: Everolimus with reduced calcineurin inhibitors vs mycophenolate with standard calcineurin inhibitors in de novo kidney transplant recipients baseline data according to donor type

  Yoshihiko Watarai, Nagoya, Japan
- P.1417 Comparison of Live Donor Pretransplant Renal Volume and Posttransplant Recipient Renal Volume

  Masaaki Yanishi, Hirakata, Japan
- P.1418 Clinical Outcomes in Recipients of Living Donor Kidney
  Transplants from Elderly Donors

  Takayoshi Yokoyama, Tokyo, Japan
- P.1421 When to Abort a Liver Donor Laparoscopic Nephrectomy?

  Linda J. Chen, Miami, FL, United States
- P.1422 New application of powered vascular stapler for laparoscopic live kidney donor nephrectomy

  Linda J. Chen, Miami, FL, United States
- P.1423 Successful use of a collateral vein in renal transplantation First case report in an ADULT recipient Linda J. Chen, Miami, FL, United States



P.1424	Using kidneys with a congenital anomalies for
	Transplantatio : A judgement call
	I I I I I I I I I I I I I I I I I I I

Linda J. Chen, Miami, FL, United States

- P.1425 Clinical utility of surveillance kidney transplant biopsies at one year post-transplantation: a long-term survival comparison among renal transplant recipients

  Magali Giral, Nantes, France
- P.1426 Borderline changes on dysfunctional renal allograft biopsies: Clinical relevance in a live related renal transplant setting

M. Mubrarak Nuhari, Karachi, Pakistan

- P.1427 Renal allograft biopsy findings in 475 pediatric live related renal transplant patients from a single center

  M. Mubrarak Nuhari, Karachi, Pakistan
- P.1428 Renal Allograft with Calcium Oxalate Deposition: its
  Association with Urinary Tract Infection and
  Development of Interstitial Fibrosis

Handan Özdemir, Ankara, Turkey

- P.1429 Ultrastructural findings and capillary HLA-DR expression in renal allografts with humoral, vascular and tubulointerstitial rejection: Correlation with development of transplant glomerulopathy

  Handan Özdemir, Ankara, Turkey
- P.1430 What is the Role of Cytomegalovirus on Interstitial Fibrosis and Graft Survival?

Handan Özdemir, Ankara, Turkey

P.1431 Comparison of light and electron microscope renal biopsy findings with proteinuria levels of candidate living kidney donors

Handan Özdemir, Ankara, Turkey

P.1432 The relation between the inflamatory cytokine expression with acute rejection episodes and hepatitis recurrence in liver allograft recipients

Handan Özdemir, Ankara, Turkey

P.1433 Prevention of Vascular Stricture by Using an Expanded Polytetrafluoroethylene (ePTFE) Graft in a Porcine Model: Preliminary Study

Handan Özdemir, Ankara, Turkey

P.1434 Bridging technique of bile duct anastomosis using an expanded polytetrafluoroethylene (ePTFE) graft in a porcine model

Handan Özdemir, Ankara, Turkey



	Tomokazu Shimizu, Tokyo, Japan
	${\it Tubular\ Atrophy\ (IF/TA)\ Cases\ After\ Kidney\ Transplantation}$
P.1435	Clinical and Pathological Analyses of Interstitial Fibrosis and

- P.1436 The Oxford Classification as a predictor of outcome in patients with IgA nephropathy in the renal allograft

  Sansanee Thotsiri, Bangkok, Thailand
- P.1437 Treatment and outcomes of recurrent focal segmental glomerulosclerosis post kidney transplantation in children

  Anna Francis, Nundah, Australia
- P.1438 Tonsillectomy and steroid pulse therapy for recurrence of IgA nephropathy after kidney transplantation

  Kengo Horia, Gifu City, Japan
- P.1439 Successful Approach to Kidney Transplantation in Patients with Secondary Hyperoxaluria

  Joke I. Roodnat, Rotterdam, Netherlands
- P.1440 Biopsy correlation of recurrent FSGS

  Shafi Malik, Leicester, United Kingdom
- P.1441 Urinary Tract Infections in Kidney Transplant Recipients

  Shafi Malik, Leicester, United Kingdom
- P.1442 Good patient and graft survival in recipients of kidney transplantation due to diabetic nephropathy

  Amgad El-Agroudy, Manama, Bahrain
- P.1443 Mycophenolate Mofetil dose reduction are associated with the risk of acute rejection and graft failure after renal transplantation
- P.1444 Kidney Transplantation Tourism: High risk and bad outcome for the recipients
  - Amgad El-Agroudy, Manama, Bahrain

Amgad El-Agroudy, Manama, Bahrain

- P.1446 Single center experience of pediatric renal transplantation at PKI, SIH

  Saeed Akhter, Islamabad, Pakistan
- P.1447 Single center experience of open versus hand assisted live donor nephrectomies
  - Saeed Akhter, Islamabad, Pakistan
- P.1448 Hand Assisted Laparoscopic Donor Nephrectomy initial experience of junior surgeons at PKI, SIH

Saeed Akhter, Islamabad, Pakistan



The posters below belong to the Kidney track, but have been placed under another track in order to be grouped with other posters from the same presenter.

- P.1113 Outcomes of Second Kidney Transplantation
  Compared to Primary Transplantation
  - Jae Geun Lee, Seoul, Korea
- P.1160 The Impact of Recipient's BMI at the Deceased Donor Kidney Transplantation
  - Julk Moon, Daejeon, Korea
- P.1177 Successful Retransplantation of an Allograft after Early Recurrence of Focal Segmental Glomerulosclerosis in the First Recipient
  - Manuel Maglione, Innsbruck, Austria
- P.1185 Measurement of Creatinine clearance in immediate post
  Kidney transplant (KTx) period with functioning allograft

  Ashokkumar Jain, Hershey, PA, United States
- P.1222 Current Status of Cadaveric and Living Donor Kidney
  Transplantation of The Last 6 Years, Compared With
  Previous 6 Years Experience

  Mitsuru Nakatsuka, Richmond, VA. United States
- P.1653 Decreased resistive index (RI) in renal transplant recipients—a treatable imaging finding
  - Rehan Mohsin, Karachi, Pakistan
- P.1657 Psychosocial long-term impact of donation on donation on kidney living donors- a comperative study of two major europea transplant centres

  Ana T. Menjivar, Barcelona, Spain
- P.1668 The effects of Normal saline solution versus
  Hartmann's solution on the acid–base and electrolytes
  status and renal function after kidney transplantation
  Won-Hyun Cho, Daegu, Korea
- P.1708 NODAT in Africans: Is it higher than in other ethnic groups?

  Ihab A. M. Ahmed, Khartoum, Sudan
- P.1752 Pre transplant at1r antibodies and the risk of recurrent focal segmental glomerulosclerosis (FSGS)

  Hatem Amer, Rochester, MN, United States



P.1811 Comparison of Baseline Proteinuria and Outcomes and
Baseline Comorbidities and New Onset Proteinuria in
Live Kidney Donors - UK Cohort Study

Nithya Krishnan, Coventry, United Kingdom

P.1892 The effects of MyD88 inhibitor local infusion in ischemia-reperfusion kidney injury

Hong R. Cho, Ulsan, Korea

#### **Kidney Immunosuppression Posters**



- P.1475 Effect of conversion from cyclosporine to tacrolimus on cardiovascular risk profile in renal transplant recipients

  Minjung Kim, Daegu, Korea
- P.1476 Variation of Induced Tolerance Practices and Outcomes across Countries: A Scoping Review

  Jathurong Kittrakulrat, Bangkok, Thailand
- P.1477 Study of Serum BKV Load in Patients prior to Renal
  Transplantation
  William Chi-Shing Tai, Hong Kong SAR, P.R. of China
- P.1478 Longitudinal Study of Serum BKV load in Patients before and after Renal Transplantation

  William Chi-Shing Tai, Hong Kong SAR, P.R. of China
- P.1479 A Comparison of Early Postoperative Results of
  Living-Donor Kidney Transplantations Using
  Calcineurin Inhibitors (Tacrolimus Extended-Release
  Formulation vs. Cyclosporine)

  Osamu Konno, Tokyo, Japan
- P.1480 Cost of kidney transplant in Colombia

  Eyner Lozano, Bogota, Colombia
- P.1483 Outcomes of patients on non-standard immunosuppression after renal transplantation

  Asha M. Zimmerman, Cranston, RI, United States
- P.1484 Impact of conversion from original MMF to generic MMF in kidney transplant recipients: a single-center experience

  Hajime Hirano, Takatsuki, Japan
- P.1485 What has changed in Renal transplantation in some small islands in Japan? Strategy of our center

  Hajime Hirano, Takatsuki, Japan



P.1486 Excellent antirejection prophylaxis and low incidence of infections after kidney transplant with low dose rabbit antithymocyte globulin induction therapy in high immunologic risk patients

Pedro W. Baron, Redlands, CA, United States

P.1487 Outcome of Deceased Donor Renal Transplantation
Patients who Underwent Induction Therapy with
Basiliximab and Rabbit Anti-Thymocyte Globulin at
National Kidney and Transplant Institute from January
2007 to December 2011

Joel B. Benavidez, Quezon City, Philippines

P.1488 Non Induction Therapy In Low Risk Living Related
Kidney Transplantation In India

Kshitija G. Gadekar, Aurangabad, India

P.1489 After Alemtuzumab Induction, Tac+MMF is Superior to CsA+MMF in Pediatric Kidney Transplantation

Michael M. Kaabak, Moscow, Russian Federation

P.1490 Antibody Induction Therapy for Kidney Transplant before the Introduction of Thai Transplant Care

Krit Pongpirul, Bangkok, Thailand

P.1491 Antithymocyte globulin induction prescription heterogeneity. Results of an observational study on the French DIVAT kidney transplant network

Chapal Marion, La Roche sur Yon, France

P.1492 Efficacy of administration of rabbit anti thymocyte globulin as induction therapy in living-donor kidney transplant sensitized patients

Toru Murakami, Tokyo, Japan

P.1493 Experience of 120 cases using Antithymocyte globulin as an induction immunosuppressant in Kidney transplantation in Korea

Kyungjai Ko, Seoul, Korea

P.1494 Lymphocyte Subset Test as a Determinant of
Cytomegalovirus Prophylaxis in Renal Transplant
Recipients with Antithytocyte Globulin Induction
Therapy: A Pilot Study

Yungjai Ko, Seoul, Korea

P.1495 Efficacy and Safety of Rabbit Antithymocyte Globulin or Interleukin-2 Receptor Antagonist for Induction Therapy in Chinese Living Donor Renal Transplantation Recipients: a Retrospective Study

Jiang Qiu, Guangzhou, People's Republic of China



P.1496	Mica Positive Status and Immunosuppression
	Vijava Rajakumari, New Delhi, India

- P.1497 Optimal Dose of Thymoglobulin for Induction Therapy in High Risk Kidney Transplant Recipients

  Seungyeup Han, Daegu, Korea
- P.1498 A Case of Coexistence of Intracranial and Intramedullary Tuberculomas in Kidney
  Transplantation Recipient
  - Seungyeup Han, Daegu, Korea
- P.1499 Cost-effectiveness of Single Daily-dose of Sirolimus and Tacrolimus-XR for Kidney Transplantation

  Yingyos Avihingsanon, Bangkok, Thailand
- P.1500 Therapeutically Equivalent Results to Caucasians in
  Black Kidney Transplant Recipients Using Astagraf XL
  Despite a Higher Degree of HLA Mismatch: A Post-Hoc
  Analysis of Phase III Data from over 2000 Patients

  Jason J. Schwartz, Northbrook , IL, United States
- P.1501 Comparative performance of apparent oral midazolam clearance and plasma 4β-hydroxycholesterol to predict tacrolimus disposition in renal recipients

Thomas Vanhove, Leuven, Belgium

- P.1502 The P-glycoprotein probe fexofenadine does not predict tacrolimus disposition in renal recipients

  Thomas Vanhove, Leuven, Belgium
- P.1503 Evaluation and inter-laboratory comparison of a realtime PCR-based DNA demethylation assay to assess the frequency of naturally occurring regulatory T cells (nTregs) in peripheral blood

Eberhard Wieland, Stuttgart, Germany

P.1504 Influence of CYP3A4\*22 and CYP3A5\*3 genetic polymorphisms on tacrolimus pharmacokinetics in adult renal transplant patients

Pilar Salvador, A Coruña, Spain

P.1505 Effect of MDR1 C3435T, C1236T and G2677T/A polymorphisms on 5-year tacrolimus pharmacokinetics and renal function in renal transplant recipients

Pilar Salvador, A Coruña, Spain

P.1506 Influence of CYP3A5 polymorphisms on 5-year tacrolimus pharmacokinetics and renal function in renal transplant recipients

Pilar Salvador, A Coruña, Spain



	Maria Outeda Macias III. A Coruña Spain
	tacrolimus interaction in adult renal transplant patients
	G2677T/A genetic polymorphisms on itraconazole-
P.1507	Influence of CYP3A4*1 and MDR1 C3435T, C1236T and

- P.1508 Levetiracetam treatment of epileptic seizures in transplant patients
  - Maria Outeda Macias III, A Coruña Spain
- P.1509 The association between trough blood level and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation

  Sayamon Sukkha, Bangkok, Thailand
- P.1510 Pharmacokinetics Study of Once Daily
  Immunosuppression in Kidney Transplantation
  Natavudh Townamchai, Bangkok, Thailand
- P.1511 Comparison of the Pharmacokinetics and Pathology for Low-Dose Once-Daily and Twice-Daily Tacrolimus following Living Kidney Transplantation: Five-Year Results from a Prospective Trial

  Kohei Unagami, Tokyo, Japan
- P.1513 Increased starting dose of Everolimus did not affect early renal function after renal transplantation

  Mary Eng, Louisville, KY, United States
- P.1515 Adherence to immunosuppression after conversion of twice-daily Tacrolimus to once-daily Tacrolimus in stable kidney transplant patients in Thailand: A prospective study
  - Sopon Jirasiritham, Pathumtanee, Thailand
- P.1516 A Change in Insulin Sensitivity and Lipid Profile in Renal Transplant Recipients Converted from Cyclosporine or Standard Release Tacrolimus to Once-Daily Prolonged Release Tacrolimus
  - Soo Kyoung Kang, Pusan, Korea
- P.1517 The prevalence of renal transplant recipients with low exposure to mycophenolic acid taking mofetil mycophenolate or enteric-coat sodium mycophenolate and possible influence factors

  Elizete Keitel, Porto Alegre, Brazil
- P.1518 Effect of Everolimus Conversion in Hepatitis C Viremia in Adult Kidney Recipients

Elizete Keitel, Porto Alegre, Brazil



- P.1519 Association of Tacrolimus Trough Levels with Incidence of New Onset of Diabetes after Transplantation and the Graft Function Assessed by Concentration and Dose Ratio

  Sailaja Kesiraju, Hyderabad, India
- P.1520 Conversion to once-daily tacrolimus extended-release formulation (TAC XL) in renal transplantation: A multicenter experience in Argentina

  Rafael A. Maldonado, Cordoba, Argentina
- P.1521 Efficacy and Safety of Enteric-Coated Mycophenolate
  Sodium in Chinese Living-Donor Kidney Transplant
  Recipients: A Multicenter Prospective Cohort Study
  Chunbai Mo Sr., Tianjin, People's Republic of China
- P.1523 Impact of preoperative donor-specific anti-HLA antibody in adult living donor kidney transplantation

  Young M. Song, Seoul, Korea
- P.1524 Optimal Initial Everolimus Dose in Renal Transplant
  Recipients Administered Tacrolimus

  Hironori Takeuchi, Hachioji, Tokyo, Japan
- P.1525 Survival of HLA Class Two Positive Recipients
  Compared to Standard Risk Recipients After Renal
  Transplantation at the National Kidney and Transplant
  Institute from January 1, 2009 to December 31, 2013

  Jonathan John F. Tamin, Quezon City, Philippines
- P.1526 Successful early additional mTORi therapy with a low-dose calcineurin inhibitor in renal transplant patients:
  a single-center pilot study

  Yuki Nakamura, Hachioji, Tokyo, Japan
- P.1527 The examination of the breaking point of expanded criteria deceased donor in Japan

Yuki Nakamura, Hachioji, Tokyo, Japan

- P.1528 5 Year Follow-Up Results of the HERAKLES Study:
  Superior Renal Function after Early Conversion to an
  Everolimus-Based Calcineurin Inhibitor Free Regimen
  Wolfgang Arns, Cologne, Germany
- P.1529 Efficacy and Safety of Three Different Treatment
  Regimen in De Novo Renal Transplant Patients: 5 Year
  Follow-Up Results of The HERAKLES Trial
  Klemens Budde, Berlin, Germany
- P.1530 Baseline characteristics of Asian and non-Asian renal transplant recipients: Findings from the TRANSFORM trial

  Po-Chang Lee, Tainan, Taiwan



The posters below belong to the Kidney Immunosuppression track, but have been placed under another track in order to be grouped with other posters from the same presenter.

- P.1189 Effects of Natural Immune System on Acute Rejection of Living Donor Renal Transplantation
  - Mahir Kirnap, Ankara, Turkey
- P.1284 Thymoglobulin induction in living donor renal transplant recipients: Southern Mexican center experience

  Ernesto Soto-Miranda, Veracruz, Mexico
- P.1321 Phytohemagglutinin-Induced II2 Mrna As A Useful Marker Of Kidney Transplants

Kazuo Mlzutani, Tokyo, Japan

- P.1344 Achromobacter denitrificans pneumonia in a renal transplant patient– dose-dependent decrease of phagocytic activity as a potential mechanism for the everolimus pulmonary toxicity
  - Alicja Debska-Slizien, Gdańsk, Poland
- P.1363 Conversion from mycophenolate mofetil to mizoribine and its therapeutic exposure in Chinese renal transplant recipients with leucopenia
  - Longshan Liu, Guangzhou, People's Republic of China
- P.1369 Basiliximab Vs. rabbit antithymocyte globulin (rATG) induction in "low risk" Kidney transplantation in Colombia

  Alejandro Niño-Murcia, Bogota, Colombia
- P.1406 Effect of Tacrolimus trough-level variability on New-Onset Diabetes After Transplantation in Renal Transplantation
  - Rajesh Sivaprakasam, London, United Kingdom
- P.1443 Mycophenolate Mofetil dose reduction are associated with the risk of acute rejection and graft failure after renal transplantation
  - Amgad El-Agroudy, Manama, Bahrain
- P.1731 Factors affecting medication non-adherence among kidney transplant recipients
  - **Ninoslav Ivanovski**, Skopje, The Former Yugoslav Republic of Macedonia
- P.1861 Variable Hernia Rates Following Transplantation: The Role that Transplant Type, Incision and Immunosuppression Play
  - Wayne J. Hawthorne, Westmead, Australia

#### **Complications Posters**



- P.1550 Intracranial Hemorrhage After Liver Transplantation; A Case

  Seong-Hwan Chang, Seoul, Korea
- P.1551 Serum Osteoprotegerin is an Independent Marker of Peripheral Arterial Disease in Kidney Transplantation Patients
  - Bang-Gee Hsu, Hualien, Taiwan
- P.1552 Positive Correlation of Serum Adipocyte Fatty Acid
  Binding Protein Levels with Metabolic Syndrome in
  Kidney Transplantation Patients

  Bang-Gee Hsu, Hualien, Taiwan
- P.1553 Patient and graft outcomes among kidney transplant recipients who underwent pre-transplant coronary angiography
  - Jason Paul T. Medina, Quezon City, Philippines
- P.1554 Mineral metabolism and vascular calcification before and at one year of the kidney transplantation

  Eduardo Chuluyan, Buenos Aires, Argentina
- P.1556 Prevalence of Transfusion-transmitted Virus infection and its association with renal post-transplant complications

  Eghlim Nemati, Tehran, Iran (Islamic Republic of)
- P.1557 Recalcitrant warts in solid organ transplantation **Hugo S. Petrone**, Buenos Aires, Argentina
- P.1558 Endovascular treatment of arteriovenous fistulas secondary to renal graft biopsy. Presentation of 3 cases Hugo S. Petrone, Buenos Aires, Argentina
- P.1559 Post-transplantation lymphoproliferative disorder (PTLD) intestinal after renal transplantation: a case report and review of the literature
  - Hugo S. Petrone, Buenos Aires, Argentina
- P.1560 Surgical complications of ureteric anastomosis following renal transplantation a study in techniques

  Abheesh Prasad, Coventry, United Kingdom
- P.1561 Cancer incidence after kidney transplantation in Saudi Arabia
  - Hassan A. Aleid, Riyadh, Saudi Arabia
- P.1562 Predictive model for new onset diabetes in renal transplant recipients
  - Hassan A. Aleid, Riyadh, Saudi Arabia
- P.1563 Urological Cancers after Renal Transplantation

  Wael A. Alshomali Sr., Kuwait City, Kuwait



P.1564	Chemoprevention of Cutaneous Squamous Cell
	Carcinoma in Renal Transplant Recipients: A Case-
	Controlled Analysis

Antonia Cronin, London, United Kingdom

P.1565 Complete molecular response of de novo chronic myelogenic leukemia with dasatinib therapy in renal transplant recipient

Heungman Jun, Seoul, Korea

P.1566 High incidence of urothelial carcinoma in Thai renal transplant recipients, 24 years experience

Wisit Liwlompaisan, Bangkok, Thailand

P.1568 Immortal Time Bias Correction: Comparing the Cancer Risk Between Patients who had Undergone Kidney Transplantation and those Waiting for the Procedure Shih-Feng Weng, Kaohsiung, Taiwan

P.1569 First case of spindle cell lipoma in an end-stage renal allograft

**Zitong Zhao**, Singapore, Singapore

P.1570 Posterior Reversible Encephalopathy Syndrome after Solid Organ Transplantation

Pinar Zeyneloglu, Ankara, Turkey

P.1571 Acute respiratory distress syndrome in solid organ transplant recipients

Pinar Zeyneloglu, Ankara, Turkey

P.1572 Venoarterial Extracorporeal Membrane Oxygenation Support as a Bridge to Heart Transplantation: Report of three cases

Pinar Zeyneloglu, Ankara, Turkey

P.1573 Left Ventricular Assist Device as the Bridge to Heart Transplantation: Five-Case Series

Pinar Zeyneloglu, Ankara, Turkey

P.1574 Extracorporeal Membrane Oxygenation after Liver Transplantation in a Patient with Hepatopulmonary Syndrome and Refractory Hypoxemia

Pinar Zeyneloglu, Ankara, Turkey

P.1575 Calcineurin-inhibitor induced pain syndrome (CIPS):
A review of 4 cases in Renal Retransplantation

Fabio Ruben Acosta, Rosario, Argentina

P.1576 Adherence to Bone-Mineral Metabolism Guidelines among Kidney Transplant Candidates

Fabio Ruben Acosta, Rosario, Argentina



P.1577	Histopathological Compilcations in the New Onset
	Diabetes Mellitus after Kidney Transplantation
	Bernadett Borda, Szeged, Hungary

P.1578 Computed tomography measures of nutrition deficits in patients with liver and intestine failure

Jason Davis, Indianapolis, IN, United States

P.1579 Use of Cinacalcet in the treatment of post-renal transplantation hyperparathyroidism. Experience from an Argentinean site

Carlos H. Diaz, Buenos Aires, Argentina

P.1580 A prospective study of renal transplant recipients: the inter-relationship between insulin secretion and sensitivity underpins dysglycemia post following renal transplantation

Karen Dwyer, Victoria, Australia

P.1581 Balloon Kyphoplasty is a Safe and Effective Option for the Treatment of Vertebral Compression Fractures in Solid Organ Transplant Recipients

Mehmet Haberal, Ankara, Turkey

P.1582 Diabetic Nephropathy in Patients with new Onset Diabetes after Kidney Transplantation

Hyeon Joo Jeong, Seoul, Korea

P.1585 Obesity and overweight as a potential risk factors of graft function loss and death in renal transplant recipients

Przemyslaw Miarka, Krakow, Poland

P.1586 Change of bone densitometry after kidney transplantation Yeon Ho Park, Incheon, Korea

P.1588 Comparison of metabolic syndrome rates in livingdonor and deceased-donor kidney recipients – a three-year follow-up

Jolanta Gozdowska, Warsaw, Poland

P.1589 Epidemiology and risk factors of cholangitis after liver transplantation – single center experience

Jolanta Gozdowska, Warsaw, Poland

P.1590 Post-transplantation lymphoproliferative disease in a patient after two liver transplant because of cirrhosis of the liver's own post-inflammatory etiology HCV and HBV

Jolanta Gozdowska, Warsaw, Poland

P.1591 Adherence to Treatment Among Renal Post-Transplant Patients

Jolanta Gozdowska, Warsaw, Poland



P.1592 Characteristics of alert pathogens isolated from inpatients of a Department of Transplantation and Nephrology at one of Warsaw hospitals in 2014

Jolanta Gozdowska, Warsaw, Poland

The posters below belong to the Complications track, but have been placed under another track in order to be grouped with other posters from the same presenter.

- P.1170 Renal cell carcinoma in transplanted kidney

  Gokhan Moray, Ankara, Turkey
- P.1364 Hemodynamics in Transplant Renal Artery Investigated by Computational Fluid Dynamics

  Changxi Wang, Guangzhou, People's Republic of China
- P.1442 Good patient and graft survival in recipients of kidney transplantation due to diabetic nephropathy

  Amgad El-Agroudy, Manama, Bahrain
- P.1494 Lymphocyte Subset Test as a Determinant of
  Cytomegalovirus Prophylaxis in Renal Transplant
  Recipients with Antithytocyte Globulin Induction
  Therapy: A Pilot Study

  Kyungjai Ko, Seoul, Korea
- P.1508 Levetiracetam treatment of epileptic seizures in transplant patients

Maria Outeda Macias III, A Coruña Spain

P.1780 Underrecognition and underestimation of disturbances In calcium-phosphate balance in kidney transplant recipients

Jacek S. Malyszko, Bialystok, Poland

#### **Infectious Diseases Posters**



- P.1601 Urinary tract infections in renal transplant recipients

  Hande Arslan, Ankara, Turkey
- P.1602 Late-Onset BK Viruria in Renal Transplant Recipients

  Mediha Boran, Ankara, Turkey
- P.1603 Disseminated Cryptococcosis Initially Presenting as
  Lower Limb Cellulitis in a Renal Transplant Recipient

  Katrina Chakradeo, Mackay, Australia
- P.1604 Parvovirus B19 Associated Pure Red Cell Aplasia After Renal Transplantation

Takashi Fujita, Nagoya, Japan



P.1605	Spectrum of Pneumonia in Renal Transplant Recipients
	in a Tertiary Care Centre

Krishan L. Gupta, Chandigarh, India

- P.1606 Efficacy of Valganciclovir for Prevention of
  Cytomegalovirus in High–Risk Renal Transplantation
  Taiji Hayashi, Osaka, Japan
- P.1607 Usefulness of valacyclovir prophylaxis for preventing cytomegalovirus infection after anti-thymocyte globulin treatment as antirejection therapy

  Eun Jeong Ko, Seoul, Korea
- P.1608 Non-tuberculous mycobacterial infections in transplant patients in Singapore an emerging cause for concern

Lionel H. Lum, Singapore, Singapore

P.1610 A predictive pharmacokinetic model of ribavirin plasma concentration in lung transplant recipients with active respiratory syncytial virus or human metapneumovirus infection

Eliza JT Milliken, Sydney, Australia

P.1611 Antibiotic prophylaxis for ureteral stent removal after kidney transplantation: to use, or not to use, that's the question

Thangamani Muthukumar, New York, NY, United States

- P.1612 Furunculosis and its complications: a cause of morbidity in renal transplant recipients?

  Asma Nasim, Karachi, Pakistan
- P.1613 Cryptococcal Meningitis after Kidney Transplantation:
  Two Cases Report

Hien Trong Nguyen, Ho Chi Minh, Viet Nam

P.1614 The Effect of Direct Acting Antiviral Medications in Kidney Transplant Recipients with Hepatitis C Virus: A Case Report

Sho Nishida, Kumamoto, Japan

P.1615 Chikungunya infection in a kidney transplant recipiente: a case report.

Ligia C. Pierrotti, São Paulo, Brazil

- P.1616 Pre-emptive Screening and Management of BK
  Polyoma virus in Renal Transplant Recipients

  Joyce Popoola, London, United Kingdom
- P.1617 Profile of infections in renal transplant recipients in a tertiary care hospital from India

Sriram Sriperumbuduri, Visakhapatnam, India



P.1618	Urinary tract infection in kidney transplant recipients
	in King Chulalongkorn Memorial Hospital
	Sarita Thawananhong Rangkok Thailand

P.1619 Tuberculosis before and after the Modern Era of Kidney Transplantation

Sirion Watcharananan, Bangkok, Thailand

P.1620 An insight into the predisposing risk factors of pneumonia in renal transplant patients

Nikhil Vijaykumar Mahajan, Chandigarh, India

P.1621 A novel single port retroperitoneal approach of donor nephrectomy using non muscle cutting lombotomy incision

Nikhil Vijaykumar Mahajan, Chandigarh, India

P.1622 The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg) positive donor and/or recipients: A center experience

Berna Yelken, Istanbul, Turkey

P.1623 The Effect of C1q Test Done Before Kidney
Transplantation on Acute Rejections: Center
Experience

Berna Yelken, Istanbul, Turkey

The posters below belong to the Infectious Diseases track, but have been placed under another track in order to be grouped with other posters from the same presenter.

- P.1040 Polymicrobial oroesophageal infection presenting with dysphagia in a renal allograft transplant recipient Sunil Kumar, Chandigarh, India
- P.1323 Effective monitoring of CMV infection by quantitative analysis of CMV mRNA. Case report in renal transplant

  Kazuo Mizutani, Tokyo, Japan
- P.1389 The impact of viral replication in recipient urine, oral wash and blood before transplant on post-transplant infection

  Oscar K. Serrano, Minneapolis, MN, United States
- P.1441 Urinary Tract Infections in Kidney Transplant Recipients

  Shafi Malik, Leicester, United Kingdom
- P.1498 A Case of Coexistence of Intracranial and Intramedullary
  Tuberculomas in Kidney Transplantation Recipient
  Seungyeup Han, Daegu, Korea



- P.1592 Characteristics of alert pathogens isolated from inpatients of a Department of Transplantation and Nephrology at one of Warsaw hospitals in 2014

  Jolanta Gozdowska, Warsaw, Poland
- P.1663 To identify the risk factors for Pneumocystis jiroveci Pneumonia (PcP) in Renal Transplant Recipients

  Navdeep Singh, Chandigarh, India

### **Donation and Procurement Posters**



- P.1625 Implementing a collaborative request model for organ donation in an Australian ICU the art of change management
  - Bettina R. Clark, Eltham, Australia
- P.1626 The organ preservation and enhancement of donation success ratio effect of Extracorporeal Membrane
  Oxygenation in circulatory unstable brain death donor
  Xiaoli Fan, Wuhan, People's Republic of China
- P.1627 Hypothermic machine perfusion attenuate liver warm ischemia injury on a novel venous bypass supported pig liver auto-transplantation model

  Xiaoli Fan, Wuhan, People's Republic of China
- P.1628 Tissue Recovery Activity from 2012 to 2014 in Eastern
  Japan and Tokyo Area: More struggle than Organ
  Donation and Much to Learn from the United States

  Yumi Akashi, Tokyo, Japan
- P.1629 The interaction between health care personnel and parents approached for organ and/or tissue donation and their adjustment to loss
  - Tamar Ashkenazi, Tel Aviv, Israel
- P.1630 The effect of Family Accommodation on the organ donation process in Israel
  - Tamar Ashkenazi, Tel Aviv, Israel
- P.1631 Comparative analysis of the last 5 edition of the Master degree in Donation and Transplantation of organs, tissues and cells of the University of Barcelona

  Gloria Páez, Barcelona, Spain
- P.1632 European Mediterranean Postgraduate Program on Organ Donation and Transplantation (EMPODAT)

  Gloria Páez, Barcelona, Spain
- P.1634 Closing the Flamingo Highway: heroin deaths in Florida

  Jean Davis, Tampa, FL, United States



P.1635	Deciding to discuss organ donation with parents: An in-depth interview study with Chinese young adults
	Timothy K. F. Fung, Hong Kong SAR, P.R. of China
P.1636	Main Factors Affecting Loss of The Potential Deceased Donors for Kidney Transplantation
	Luis García Covarrubias, México City, Mexico
P.1637	Correlation in a year Of Monitoring Kidney Donors Glomerular Filtration Rate Between DTPA Renal Scan
	Vs Renal Creatinine Clearance in 24 Hrs Urine, MDRD-4, CKD-EPI and Cockcroft – Gault
	Luis García Covarrubias, México City, Mexico
P.1638	Impact of the Network of Clinicians and School Teachers on Awareness and Attitudes of Adolescents Toward Organ Donation and Transplantation
	Hee Jung Jeon, Seoul, Korea

- P.1639 The experience of donation coordinator

  Anes Kim. Seoul. Korea
- P.1640 Measures to improve family discussion for deceased organ donation

Taehyun Lee, Seoul, Korea

- P.1641 Deceased Organ Donation in Hong Kong (1995-2014):
  An Age-Period-Cohort Analysis

  Maggie Kam Man Ma, Hong Kong SAR, P.R. of China
- P.1642 Organ and tissue donation in Emergency Clinical Hospital of Oradea Romania

Carmen Pantis, Oradea, Romania

P.1643 Unexpected Donors after Circulatory Death:
Coagulation Profiles after Prolonged Cardiac Arrest in a
Porcine Model

Alvaro Rojas-Pena, Ann Arbor, MI, United States

P.1644 Vascularized Composite Allografts: Prolonged (24hr) Ex situ Perfusion of Human Limbs

Alvaro Rojas-Pena, Ann Arbor, MI, United States

P.1645 The Effectives of an Organ Donation Process in Chiangrai Prachanukroh Hospital

Thanyapat Phongwiwat, Chiang Rai, Thailand

- P.1646 Is the Kidney Donor Risk Index (KDRI) applicable to all populations? The Puerto Rican experience

  Rafael G. Ramos, Pittsburgh, PA, United States
- P.1647 Demographic and patient profiles in an area of low organ donation rate

Ming-Hui Shih, Hualien, Taiwan



P.1648 Doubts and questions – Differences in the attitude	
	healthcare staff and lay people towards organ donation
	Aniko Smudla Rudanest Hungary

P.1649 Deceased organ donation in a public hospital - A model programme

Sujatha Suriyamoorthi, Chennai, India

P.1650 Barriers to Early Post-Operative Discharge in Living
Liver Donors

Hillary J. Braun, San Francisco, CA, United States

P.1651 Endourological management of live donors with urolithiasis at the time of donor nephrectomy: a single centre experience

Sandeep Guleria, New Delhi, India

P.1652 Laparoscopic live donor nephrectomy: a single centre experience

Rehan Mohsin, Karachi, Pakistan

P.1653 Decreased resistive index (RI) in renal transplant recipients—a treatable imaging finding

Rehan Mohsin, Karachi, Pakistan

P.1654 Donor Comprehension of Provided Information During Informed Consent Process in Live Donor Nephrectomy;
Does It Matter What We Tell Donors? A Pilot study

Kirsten Kortram, Rotterdam, The Netherlands

P.1655 Quality of life and socio-psychological issues in donors after kidney donation

Anwar Naqvi, Karachi, Pakistan

P.1656 Living organ donation high quality practices: LIDOBS network recommendations

Ana T. Menjivar, Barcelona, Spain

P.1657 Psychosocial long-term impact of donation on donation on kidney living donors- a comperative study of two major europea transplant centres

Ana T. Menjivar, Barcelona, Spain

P.1658 Long term outcome of post living kidney donation monitored by the international foundation for organ transplant incorporated

Rose Marie Rosete-Liquete, Quezon City, Philippines

P.1659 Robotic-assisted versus laparoscopic hand-assisted live donor nephrectomy

Pamela Sun, Genève, Switzerland



P.1660	Ultrasonography versus CT-scanning as imaging
	modality for long term follow up after kidney donation
	Khe Tran, Rotterdam, The Netherlands

- P.1661 Retroperitoneal Single Port Donor Nephrectomy through Lumbotomy incision A novel approach

  Navdeep Singh, Chandigarh, India
- P.1662 Hybrid Laparo-endoscopic single-site (LESS) donor nephrectomy with homemade port; An initial experience

  Navdeep Singh, Chandigarh, India
- P.1663 To identify the risk factors for Pneumocystis jiroveci Pneumonia (PcP) in Renal Transplant Recipients

  Navdeep Singh, Chandigarh, India
- P.1664 Risky organs: using organs from donors with bloodborne viruses in New South Wales (NSW), Australia, 2010-2015

Karen Waller, Lindfield, Australia

P.1666 Long period follow-up of renal function of living renal donor

Kazunari Yoshida, Sagamihara, Kanagawa, Japan

P.1667 Promotional Effects of Organ Donation on Online Communities

Won-Hyun Cho, Daegu, Korea

- P.1668 The effects of Normal saline solution versus
  Hartmann's solution on the acid–base and electrolytes
  status and renal function after kidney transplantation
  Won-Hyun Cho, Daegu, Korea
- P.1669 A report of deceased donor organ preservation with histidine-tryptophan-ketoglutarate solution (HTK) at a single, large volume U.S. center over 12 years' time

  Richard S. Mangus, Indianapolis, IN, United States
- P.1670 Effects of Purification Perfusate during
  Subnormothermic Machine Perfusion for Porcine Liver
  Donation after Cardiac Death
  - Noriyuki Morito, Hachioji, Japan
- P.1671 Amino acid metabolism as viability assessment of liver grafts in a porcine model during ex vivo normothermic machine perfusion

Noriki Okada, Tochigi-ken shimotsuke-shi, Japan

P.1672 Impact of Machine Perfusion on Long-Term Kidney
Transplant Outcomes

Shaifali Sandal, Montreal, QC, Canada



P.1673 Non-standardized preservation techniques may lead to freezing of the donor kidney during storage and may preclude transplantation

Imeshi U. Wijetunga, Leeds, United Kingdom

P.1677 Demands of overseas organ transplant recipients' family caregivers: comparing gender and Chinese family relationships

Hong-Mei Chen, Taipei, Taiwan

The posters below belong to the Donation and Procurement track, but have been placed under another track in order to be grouped with other posters from the same presenter.

- P.1208 Deceased donor uterus retrieval as part of uterus transplant trial the first Czech experience

  Jiri Fronek, Prague, Czech Republic
- P.1285 Impact of Brain Death Duration on Kidney Transplant
  Outcomes in Veracruz, Mexico

  Ernesto Soto-Miranda, Veracruz, Mexico
- P.1318 Long term follow up glycemic status of live kidney donors

  Angeline Goh, Singapore, Singapore
- P.1370 Intensive Care Unit Feedback About Organ Donation

  Alejandro Niño-Murcia, Bogota, Colombia
- P.1407 What Component of the Cold Ischemia Time is Important?

  Rajesh Sivaprakasam, London, United Kingdom
- P.1527 The examination of the breaking point of expanded criteria deceased donor in Japan

  Yuki Nakagawa, Niigata City, Japan
- P.1829 Waiting time of children in list for renal transplantation: one center experience

  Esra Baskin, Ankara, Turkey

## Transplantation in Developing Countries Posters



P.1700 The use information technology to develop organ fundraising education courses in Taiwan

Ming-Hsin Hsieh, Taipei, Taiwan

P.1701 How to Build a Liver Transplant Unit in India: Rajasthan's Success

Christopher Taylor Barry, Jaipur, India



P.1702 International collaborative program as a way of development of adult-to-adult living-donor liver transplantation program in National Scientific Medical Research Center

Marlen Doskali, Astana, Kazakhstan

P.1704 Recurrent Nephrotic Syndrome After Renal Transplantation in Syrian Children: Does it Compare with the International Experience?

Bassam Saeed, Damascus, Syrian Arab Republic

P.1705 The Impact of Living-Unrelated Transplant on
Establishing Deceased Donor Liver Program in Syria

Bassam Saeed, Damascus, Syrian Arab Republic

P.1706 Novel Hepatitis C Treatment increases access to Kidney Transplantation

Pankaj R. Shah, Ahmedabad, India

P.1707 Long Term Outcome of Living and Deceased Donor Renal Transplantation in ADPKD

Pankaj R. Shah, Ahmedabad, India

P.1708 NODAT in Africans: Is it higher than in other ethnic groups?

Ihab A. M. Ahmed, Khartoum, Sudan

P.1709 A new renal transplant centre: Experience and challenges

Ihab A. M. Ahmed, Khartoum, Sudan

P.1710 Kidney transplantation From the United States to Sub-Saharan Africa: Establishing a kidney transplant center in a resource limited country, Ethiopia

Mekdim Taddese Siyoum, Addis Ababa, Ethiopia

P.1711 Medical Students' Knowledge About Brain Death: A South African Contribution

Sanju Sobnach, Cape Town, South Africa

P.1712 Comparison of cost and quality of life outcomes (qol) in hemodialysis patients and renal transplant recipients

Ayub Ali Chowdhury, Dhaka, Bangladesh (abst. 374.5 in the *Transplantation Journal*)

The posters below belong to the Transplantation in Developing Countries track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1415 Renal Transplant in patients with abnormal bladder: Is the outcome same in developing country?

Anant Kumar, Saket, India



P.1444 Kidney Transplantation Tourism: High risk and bad outcome for the recipients

Amgad El-Agroudy, Manama, Bahrain

P.1485 What has changed in Renal transplantation in some small islands in Japan? Strategy of our center

Hajime Hirano, Takatsuki, Japan

## Ethics, Community and Economics & Declaration of Istanbul Posters



- P.1725 A model for provision of liver transplantation services on a nation-wide basis a novel approach by the Omani health care system
  - Mettu Srinivas Reddy, Chennai, India
- P.1726 A Google Advanced Search for illegal and immoral activities related to organ transplantation in twenty-five developed and developing countries

  Ruhul H. Kuddus, Orem, UT, United States
- P.1728 Organ donation: viewpoint analysis of Lithuanian doctors and future physicians in accordance with opinion influencing factors
  - Valdone Kolaityte, Kaunas, Lithuania
- P.1729 The transplantation of organs from deceased donors due to irreversible cardiac arrest in Poland in 2013 and 2014

  Edyta Agata Skwirczynska, Szczecin, Poland
- P.1730 The sad story of kidney buyers on the Balkans

  Ninoslav Ivanovski, Skopje, The Former Yugoslav
  Republic of Macedonia
- P.1731 Factors affecting medication non-adherence among kidney transplant recipients
  - **Ninoslav Ivanovski**, Skopje, The Former Yugoslav Republic of Macedonia
- P.1732 Risk Factors Associated With Early Readmission After
  Renal Transplantation: Effects on Cost and Graft Survival

  Deanne Leonard, Jacksonville, FL, United States
- P.1733 Kidney Transplantation Outcomes in Patients with a History of Renal Cancer: a National Perspective

  Douglas P. Slakey, New Orleans, LA, United States
- P.1734 Balneotherapy an intriguing option of rehabilitation after kidney transplantation
  - Barbara Grandtnerova, Banska Bystrica, Slovakia



- P.1735 Health-Related Quality of Life and its Influencing
  Factors in Chinese Renal Transplant Recipients
  Hongxia Liu, Beijing, People's Republic of China
- P.1736 The Impact of Transplant Nephrectomy for Patient
  Survival over the Last 15 Years A Single Centre Study
  Masaki Muramatsu, Tokyo, Japan
- P.1737 Health-Related Quality of Life is Improved After Liver
  Transplantation and is Related to Disease Acceptance,
  Helplessness and Perceived Disease Benefits
  Louis G. Onghena, Ghent, Belgium

The posters below belong to the Ethics, Community and Economics / Declaration of Istanbul tracks, but have been placed under another track in order to be grouped with other posters from the same presenter.

- P.1308 Complications of kidney transplantation performed through black organ markets affiliations

  Marina Ratkovic, Podgorica, Montenegro
- P.1591 Adherence to Treatment Among Renal Post-Transplant Patients

Jolanta Gozdowska, Warsaw, Poland

### **Composite Tissues Posters**



- P.1750 Skin as a Harbinger of Rejection of Underlying
  Structures In VCA: Concordance or Discordance?

  Linda C. Cendales, Durham, NC, United States
- P.1751 A Clinical Hand Transplant Program Five Years On:
  Lessons Learned and Future Direction
  Hatem Amer. Rochester, MN, United States
- P.1752 Pre transplant at1r antibodies and the risk of recurrent focal segmental glomerulosclerosis (FSGS)

  Hatem Amer, Rochester, MN, United States
- P.1753 On-demand drug delivery system with self-assembled hydrogel in vascularized composite allotransplantation

  Dzhuliya V. Dzhonova, Bern, Switzerland
- P.1754 Bilateral arm allotransplantation: a case report in Mexico

  Raul M. Favela, Chihuahua, Mexico
- P.1755 Comic for the promotion of donation of vascularized composite allografts in Mexico

  Raul M. Favela, Chihuahua, Mexico



	Huseyin Karagoz, Istanbul, Turkey
	vascularized composite allograft rejection studies
	microscopy: a reference study for experimental
P.1756	Rat skin morphology by reflectance confocal

P.1757 The Effect of Donor/Recipient Chimeric Cells on Donor-Specific Chimerism and Composite Tissue Allograft Survival in Face Transplantation Model

Fatih Zor, Ankara, Turkey

P.1758 Composite Eye and Periorbital Allotransplantation
Flap: From rat model to cadaveric study

Fatih Zor, Ankara, Turkey

P.1759 Composite Tissue Xenopreservation: A New Living Tissue Bank

Fatih Zor, Ankara, Turkey

P.1760 A Novel Murine Orthotopic Forelimb Transplantation
Model that Allows for Reliable Assessment of Functional
Recovery Resulting from Nerve Regeneration

Barbara Kern, Innsbruck, Austria

P.1761 Vascularized composite allotransplantation in orthotopic porcine hind limb model

Chen Hsiang Kuan, Taipei, Taiwan

P.1762 Our experience with immunosuppression protocols for composite tissue transplant

(bilateral hand transplantation) **George Kurian**, Ernakulam, India

P.1763 AMD3100 (Plerixafor) As A Clinically Relevant Stem Cell Mobilizing Agent In Vascularized Composite Tissue Allograft (VCA) Transplantation

David W. Mathes, Aurora, CO, United States

The poster below belongs to the Composite Tissue track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1644 Vascularized Composite Allografts: Prolonged (24hr) Ex situ Perfusion of Human Limbs

Alvaro Rojas-Pena, Ann Arbor, MI, United States

### **Heart and Lung Posters**



- P.1775 The natural course of renal function with Everolimus after heart transplantation
  - Tsao Chuan-I, Taipei, Taiwan
- P.1776 Life's a Beach Spending Holidays after LVAD Implantation
  - Christian Heim, Erlangen, Germany
- P.1779 VItamin D status in heart and kidney transplant recipients

  Jacek S. Malyszko, Bialystok, Poland
- P.1780 Underrecognition and underestimation of disturbances In calcium-phosphate balance in kidney transplant recipients
  - Jacek S. Malyszko, Bialystok, Poland
- P.1782 Influence of CYP3A5 Polymorphism on
  Pharmacokinetic Interaction of Fluconazole and
  Tacrolimus, and Effect of Fluconazole on Everolimus
  Pharmacokinetics in Heart Transplant Recipient
  Yuka Terada, Suita, Japan
- P.1783 Initial experience of lung transplantation with a national organ procurement organization effort to use lungs from brain and cardiac death donors or cardiac death donors in a single Chinese center

  Jingyu Chen, Wuxi, People's Republic of China
- P.1784 The Early Outcome of Extracorporeal Membrane
  Oxygenation for Primary Graft Dysfunction After Lung
  Transplantation: Experience in Korean Single Center
  Jin Gu Lee, Seoul, Korea
- P.1785 Optimum serum level of mycophenolate mofetil in chronic phase after lung transplantation

  Yasushi Matsuda, Sendai, Japan
- P.1786 Pediatric lung transplantation in patients with chemoradiation associated pulmonary fibrosis: limited medium term survival compared to age-matched controls

  Ernestina Melicoff, Houston, TX, United States
- P.1787 Journey of Lung Transplant Program in Saudi Arabia

  Imran Nizami, Riyadh, Saudi Arabia
- P.1788 Mycobacterium Tuberculosis Infection After Lung
  Transplantation, Saudi Arabia Experience
  Imran Nizami, Riyadh, Saudi Arabia



P.1789 The prevalence, possible risk factors and the outcome of swallowing abnormalities in post lung transplant patients Imran Nizami, Riyadh, Saudi Arabia

The posters below belong to the Heart /Lung tracks, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1572 Venoarterial Extracorporeal Membrane Oxygenation Support as a Bridge to Heart Transplantation: Report of three cases

Pinar Zeyneloglu, Ankara, Turkey

P.1573 Left Ventricular Assist Device as the Bridge to Heart Transplantation: Five-Case Series

Pinar Zeyneloglu, Ankara, Turkey

P.1831 Lung Transplantation in Argentina: Results after Changes in the Clinical Emergency Setting

Liliana Bisigniano, Buenos Aires, Argentina

### **Histocompatibility Posters**



- P.1800 Pre- transplant immunological risk assessment: CDC cross-match supplemented by Luminex antibody Screen (Qualitative) -more sensitive approach to prevent early antibody mediated rejection

  Feroz Aziz, Calicut, India
- P.1802 The Frequency and the Reactivity Patterns of HLA Class I Donor-Specific Epitope Antibodies Identified in Korean Patients

Soo-Kyung Kim, Seoul, Korea

- P.1803 Positive Rates of Preliminary T and B Cell Flow
  Cytometry Crossmatches Among Transplant
  Candidates in the Korean Network for Organ Sharing
  Myoung Hee Park, Seoul, Korea
- P.1804 An inventory of the presence of pretransplant Donor-Specific HLA Antibodies as tested with Luminex Single Antigen tests of Lifecodes and One Lambda and their complement variants

Dave Roelen, Leiden, The Netherlands

P.1805 Effect of Recipient Age (<3 years) During Liver
Transplantation on the Prevalence of Post-Transplant
Class II Anti-Human Leukocyte Antigen Antibody

Kazuaki Tokodai, Sendai, Japan



P.1806	Transplantation of highly sensitized patients with
	circulating preformed donor specific antibodies: how
	safe is it?

Angeliki G. Vittoraki, Athens, Greece

- P.1807 Antibodies against Angiotensin II type 1 receptor and HLA donor specific antibodies in renal allograft rejection Angeliki G. Vittoraki, Athens, Greece
- P.1808 Presence of Day-14 Post Transplantation Donor
  Specific IgM Antibody Predicts Poor Graft Survival in
  HLA-incompatible Renal Transplantation
  Nithya Krishnan, Coventry, United Kingdom
- P.1809 Clinical Relevance of Pre-formed IgM HLA- Donor
  Specific Antibodies (DSA) in HLA-Incompatible
  Kidney Transplantation
  Nithya Krishnan, Coventry, United Kingdom
- P.1810 Removal of Unacceptable Antigens to Increase the
  Likelihood of a Patient Receiving Aa Renal Transplant:
  A Cross-Sectional Study

  Nithya Krishnan, Coventry, United Kingdom
- P.1811 Comparison of Baseline Proteinuria and Outcomes and Baseline Comorbidities and New Onset Proteinuria in Live Kidney Donors UK Cohort Study

  Nithya Krishnan, Coventry, United Kingdom
- P.1812 Glass cliff effect in transplantation Myth or Reality?

  Nithya Krishnan, Coventry, United Kingdom
- P.1813 Non-HLA and HLA antibodies in lung transplantation (LTx): Results from a prospective study

  Duncan C. Walton. West Melbourne. Australia
- P.1814 Reducing cold ischemia time of organs by increasing the speed of laboratory testing for deceased donor workups better methodologies, better outcomes

  Prakash Rao, New Providence, NJ, United States

The posters below belong to the Histocompatibility track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1054 De-novo donor specific antibody (DSA) against HLA-DQ antigens by lysate based cross match on Luminex platform resulting in acute antibody mediated rejection in a renal transplant patient

Sonia Mehrotra, Lucknow, India



P.1322 C4d Binding Correlated with Strong Hla Antibodies in Kidney Transplantation

Kazuo Mizutani, Tokyo, Japan

P.1399 High prevalence of post transplant donor specific HLA-DQ antibody in live related renal transplantation. Is it time to extend typing to HLA-DQ in renal transplantation?

Mirza Nagi Zafar, Karachi, Pakistan

### **Paediatrics Posters**



- P.1825 Perspectives of the Development of Renal
  Transplantation in Children in Kazakhstan

  Dinara Galiyeva, Edinburgh, United Kingdom
- P.1826 A Ten-Year Review on the Surgical Outcomes of Paediatric Renal Transplantation: A Hong Kong Experience

  Alan Lo, Hong Kong SAR, P.R. of China
- P.1827 Predictive value of early period doppler ultrasonography on early and long-term allograft function

  Esra Baskin, Ankara, Turkey
- P.1828 Effects of renal transplant age on the graft functions in pediatric transplant patients
  - Esra Baskin, Ankara, Turkey
- P.1829 Waiting time of children in list for renal transplantation: one center experience

  Esra Baskin, Ankara, Turkey
- P.1830 Mortality on First Linting for Kidney Transplant in Pediatric Patients in Argentina: Period 1998-2015

  Liliana Bisigniano, Buenos Aires, Argentina
- P.1831 Lung Transplantation in Argentina: Results after
  Changes in the Clinical Emergency Setting
  Liliana Bisigniano, Buenos Aires, Argentina
- P.1832 Postoperative mortality in infants following liver transplantation; impact of large for size graft and preoperative portal vein size

Chan Woo Cho, Seoul, Korea

- P.1833 Experience with Two Cases of Living Donor Liver
  Transplantation for Neonatal Hemochromatosis
  Developed in Siblings
  - Takumi Katano, Tochigi, Japan
- P.1834 Coordinating Living Donor Liver Transplantation for Neonatal Fulminant Hepatic Failure

Erika Onuma, Simotuke, Japan



P.1835 Liver Transplantation in a Pediatric Patient After Treatment for Yolk Sac Tumor

Taiichi Wakiya, Hirosaki, Japan

P.1836 Acquired Diaphragmatic Hernia following Pediatrics
Living Donor Liver Transplantation

Kai Wang, Tianjin, People's Republic of China

P.1837 Back to School and Normality after Lung
Transplantation in Childhood and the Need for PsychoSocial Interventions

Andrea Caby, Hamburg, Germany

The posters below belong to the Paediatrics track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1225 Transforming growth factor beta 1 blood level relates with liver disease etiology and fibrosis severity in pediatric liver recipients

Olga M. Tsiroulnikova, Moscow, Russian Federation

P.1226 Pediatric living donor liver transplantation: correlation plasma level of transforming growth factor beta -1 with tacrolimus dosage but not with its concentration

Olga M. Tsiroulnikova, Moscow, Russian Federation

P.1266 Dialysis vintage: A dominating factor affecting growth and final height after pediatric renal Transplantation: A single center experience

Tahir Aziz, Karachi, Pakistan

P.1704 Recurrent Nephrotic Syndrome After Renal Transplantation in Syrian Children: Does it Compare with the International Experience?

Bassam Saeed, Damascus, Syrian Arab Republic

### **Pancreas and Islet Posters**



P.1850 Effect off different glutathione-related compounds on survival of hypoxic human islets

Heide Brandhorst, Oxford, United Kingdom

P.1851 Mesenchymal stem cell-preconditioned medium increases survival of hypoxic human islets

Heide Brandhorst, Oxford, United Kingdom

P.1852 Different effects of neutral proteases on human islet viability

Heide Brandhorst, Oxford, United Kingdom



P.1853	3 Tetrahydrocurcumin Enhances Islet Cell Function	
	Attenuates Apoptosis in Mouse Islets	

Hyuk Jai Jang, Gangneung, Korea

P.1854 How About Heparin-Pegylated Islets in Allo-Islet Transplantation in Cynomolgus Monkeys

Kyo Won Lee, Seoul, Korea

P.1855 Australia's first successful remote centre paediatric islet auto-transplant after pancreatectomy in a 7 year old for hereditary pancreatitis

Toni M. Radford, Adelaide, Australia

P.1856 Evaluation of donor characteristics including histological analysis of pancreases allocated for islet isolations

Frantisek Saudek, Praha, Czech Republic

P.1857 Evaluation of a newly developed pancreas preservation solution, F6H8S5, for clinical islet isolation and transplantation

Hanna Schierbeck, Uppsala, Sweden

P.1858 The investigation on target matrix of collagenase G for achieving tailor-made islet isolation

Satoru Yoshida, Sendai, Japan

P.1859 The availability of marmoset diabetes modeling as a transplantation model

Wenji Yuan, Tokyo, Japan

P.1860 Factors Effecting Islet Isolation Outcomes Over the Past
15 Years for the Westmead Islet Transplant Program

Wayne J. Hawthorne, Westmead, Australia

P.1861 Variable Hernia Rates Following Transplantation: The Role that Transplant Type, Incision and Immunosuppression Play

Wayne J. Hawthorne, Westmead, Australia

P.1865 Pancreas rejection with graft necrosis presenting with episodic massive intestinal bleeding

Shih-Chin Chen, Taipei, Taiwan

P.1866 ATG induction markedly reduced acute rejection and improved graft survival in pancreas transplantation

Kazuhiro lwadoh, Tokyo, Japan

P.1867 Exocrine drainage in pancreas transplantation: medium-term results of enteric conversion and significance of bladder drainage

Ichiro Koyama, Tokyo, Japan



- P.1868 Hybrid laparoscopic distal pancreatectomy of living donor using Shuriken shaped umbilicoplasty

  Yoshinobu Sato, Yokohama City, Japan
- P.1869 Pancreas Transplant at Taipei Veterans General Hospital

  Yi-Ming Shyr, Taipei, Taiwan
- P.1870 Hepatic Veno-Occlusive Disease Related to Tacrolimus after Pancreas Transplantation

  Yi-Ming Shyr, Taipei, Taiwan
- P.1871 Severe transplantation-mediated alloimmune thrombocytopenia in two recipients of organs from the same donor

Isabella Sönnerborg, Stockholm, Sweden

P.1872 Successfull Simultaneous Pancreas Kidney Transplantation in a patient with Congenital Partial Lipodystrophy

Pablo D. Uva, Buenos Aires, Argentina

The poster below belongs to the Pancreas and Islet track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1022 A non-hematopoietic erythropoietin analogue, ARA 290, prolonged allogeneic islet graft survival in a mouse model

Torbjorn Lundgren, Stockholm, Sweden

# Cell Transplant & Xenotransplantation Posters



- P.1875 Optimization of procedures for short-time hepatocyte preservation prior to transplantation

  Kengo Fukuoka, Sendai, Miyaqi, Japan
- P.1876 New strategies for cell banking for regulatory T cell (Treg)- based therapy in order to overcome compromise of cell viability and Treg altered phenotype during cryopreservation

  Karolina Golab, Chicago, IL, United States
- P.1877 A parallel comparison of suppressive capacity in immune responses: regulatory T cells versus

regulatory macrophages

Fei Guo, Changsha, People's Republic of China

P.1878 Comparison of three transplantation techniques in a mouse model of hepatocyte transplantation

Bo Goran Ericzon, Stockholm, Sweden



- P.1880 Coming home: Hepatocyte transplantation to the liver via the splenic artery in a juvenile large animal model

  Nathanael Raschzok, Berlin, Germany
- P.1881 Humoral Diagnosis of Acute Rejection in Myogenic Cell Allotransplantation in Skeletal Muscles: a Study in Nonhuman Primates
  - Daniel Skuk, Quebec, QC, Canada
- P.1882 Evaluation of Potential of Umbilical Cord Blood-Derived
  Regulatory Macrophages for Cellular Immunotherapy

  Xiaoqian Ma, Changsha, People's Republic of China
- P.1883 Necroptosis plays a central role in hypoxia-induced islets cell death

  Xiaoqian Ma, Changsha, People's Republic of China
- P.1884 Induced pluripotent stem cells play an immunomodulatory role in skin allograft acceptance

  Charles Yuen Yung Loh, Taoyuan Hsien, Taiwan
- P.1885 Generation of novel Cag-Luc-EGFP transgeneexpressing murine embryonic stem cell derived hepatoblasts as a transplantable cell source Olivia M. Martinez, Stanford, CA, United States
- P.1886 Intravascular transplantation of CD34+ stem cells inhibit intimal hyperplasia after vascular injury

  Piotr Religa, Stockholm, Sweden
- P.1888 Relevance of Immunomodulatory factors : HLA-G,
  Treg Cells and Cytokine Levels in Hematopoietic Stem
  Cell Transplantation
  - **Uma Kanga**, New Delhi, India
- P.1889 HLA-G Molecules: Possible Predictor of GvHD

  Manish Kumar Mourya, Delhi, India
- P.1890 Development of an anti-HLA antibody-producing humanized mouse model

  Senichiro Yanagawa, Hiroshima, Japan
- P.1891 The transforming chronic GVHD toward acute GVHD by deletion of host CD137 signaling
  - Hong R. Cho, Ulsan, Korea
- P.1892 The effects of MyD88 inhibitor local infusion in ischemia-reperfusion kidney injury

  Hong R. Cho, Ulsan, Korea
- P.1896 Preformed IgM antibody target in non-human primate received α-GTKO pig heart and artery

  Yun Shin Chung, Seoul, Korea



P.1897	Histological and ultra-structure characterization of human immune cells against neonatal porcine islet xenograft  Wenlong Huang, Edmonton, AB, Canada
P.1899	Student Opinions in Xenotransplantation <b>Kyeonghee Jang</b> , Abilene, TX, United States
P.1900	No PERV infection in pig islets recipients after 15 years of xenotransplantation  Xiaofeng Jiang, Guangzhou, People's Republic of China
P.1901	Levels of anti-Gal IgG2 negatively correlate with the survival of porcine islet graft in non-human primates under immunosuppression of anti-CD154  Hee Jung Kang, Anyang-si, Korea
P.1902	Janus kinase 3 inhibitor, Tofacitinib prolonged pig-to- mouse xenogeneic islet transplantation  Seong-jun Sung Kang, Seoul, Korea
P.1904	Enhancement of CRISPR-mediated homology-directed repair using small molecule in porcine fibroblasts.  Young June Kim, Pyeong Chang, Korea
P.1905	The analysis of C5 inhibitor efficacy in antibody mediated xenogeneic immune responses modulation using a microfluidic system  Eun Mi Lee, Seoul, Korea
P.1906	The analysis of αGal antigen in tree shrew <b>Yanping Li</b> , Xiamen, People's Republic of China
P.1907	Induction of diabetes in cynomolgus monkey with one injection of streptozotocin  Zhengzhao Liu, Shenzhen, People's Republic of China
P.1908	Gene editing techniques in Cardio-xenotransplantation  Meisam Naeimi Kararoudi, Perugia, Italy
P.1909	Comparison of Islet Isolation Yields from Three Different Wild Type Adult Pig Breeds Jun-Seop Shin, Seoul, Korea
P.1910	Immunosuppressive Effect of Arsenic Trioxide (A2O3) on Xeno-Islet Transplantation  Bin Zhao, Xiamen, People's Republic of China
P.1911	Acute Rejection Patterns of Outbred Rats to Heterotopic Heart Xenotransplantation
P.1912	Necdet Ozcay, Ankara, Turkey  Surgical technique of harvesting two kidneys from a mouse for xenotransplantation studies  Necdet Ozcay, Ankara, Turkey



The poster below belongs to the Xenotransplantation track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1759 Composite Tissue Xenopreservation: A New Living Tissue Bank.

Fatih Zor, Ankara, Turkey

### **Surgical Techniques Posters**



- P.1925 Temperature change in the kidney graft during laparoscopic kidney transplant
  - **Bulang He**, Perth, Australia
- P.1926 Laparoscopic kidney transplant by extra peritoneal approach: Two years follow up **Bulang He**, Perth, Australia
- P.1927 Real-time intraoperative fluorescent lymphography a new technique for lymphatic sparing surgery

  Giuseppe letto, Varese, Italy
- P.1928 Our Experience with Modified Lich-Gregoir Technique in the Prevention of Urological Complications Post Kidney Transplant
  - Zi Qin Ng, Perth, Australia
- P.1929 "Artery first, Vein Second" Approach for Vascular
  Anastomosis in Kidney Transplantation
  Zi Qin Ng, Perth, Australia
- P.1930 3D surgical planning in complex renal artery aneurysms: mid term results

  Gabriele Soldini, Varese, Italy
- P.1931 Minimal Invasive Access in Kidney Transplantation -
  - Marek Ostrowski, Szczecin, Poland

Self Experience

- P.1932 End-to-side versus end-to-end uretero-ureteral anastomosis in kidney transplant recipients with disused atrophic bladder
  - Volkan Turunç, Istanbul, Turkey
- P.1933 Vena Cava Resection without Venous Bypass for Liver Transplant (LT) Does Not Increase Morbidity But Does Decrease Operative Time

Juan Francisco Guerra, Santiago, Chile



The posters below belong to the Surgical Techniques track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1130 Transfusion of Old Red Blood Cells Stored During Greater Than 2 Weeks is Not Associated with Liver Transplant Death

Jun Chul Shin, Seoul, Korea

P.1423 Successful use of a collateral vein in renal transplantation - First case report in an ADULT recipient Linda J. Chen, Miami, FL United States

P.1424 Using kidneys with a congenital anomalies for Transplantation: A judgement call

Linda J. Chen, Miami, FL, United States

P.1433 Prevention of Vascular Stricture by Using an Expanded Polytetrafluoroethylene (ePTFE) Graft in a Porcine Model: Preliminary Study

Handan Özdemir, Ankara, Turkey

P.1434 Bridging technique of bile duct anastomosis using an expanded polytetrafluoroethylene (ePTFE) graft in a porcine model

Handan Özdemir, Ankara, Turkey

P.1621 A novel single port retroperitoneal approach of donor nephrectomy using non muscle cutting lombotomy incision

Nikhil Vijaykumar Mahajan, Chandigarh, India

P.1912 Surgical technique of harvesting two kidneys from a mouse for xenotransplantation studies

Necdet Ozcay, Ankara, Turkey

# Registries & Transplantation Nursing Posters



P.1950 HLA Haplotype Frequencies of Hong Kong

Jenny C.Y. Ho, Pokfulam, People's Republic of China

P.1951 Survey of questionnaire for transplant and dialysis patients on preparation for disaster

Masae Ikeda, Sagamihara, Japan

P.1952 An analysis of waiting period of deceased donor kidney transplant - Korean single center analysis

Sarome Lee, Seoul, Korea



P.1953 The acquiring skill of the adolescents and young adults to get along with the difficulties in their social activities after transplantations

Yasuko Suzuki, Matsumoto, Japan

P.1954 Analyses of Relationship Between Obstetric
Complications and Preterm Delivery in Japanese
Recipients Received Kidney Transplant

Yuki Yoshikawa, Hirakata City, Osaka, Japan

P.1955 "Preventing": A New Application for Smartphones to Assess and Improve Immunosupressant's Adherence in Renal Transplant Recipients

Jorge Morales-Barría, Santiago, Chile

### Gender in Transplantation Posters



The posters below belong to the Gender in Transplantation track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1677 Demands of overseas organ transplant recipients' family caregivers: comparing gender and Chinese family relationships

Hong-Mei Chen, Taipei, Taiwan

P.1812 Glass cliff effect in transplantation – Myth or Reality?

Nithya Krishnan, Coventry, United Kingdom

## SPONSORED SYMPOSIA

### Industry Organized Sessions

Light meals will be served inside the Hall at the beginning of the sessions for attendees attending the session ONLY. Please note that only a LIMITED NUMBER of meals have been ordered by our sponsors, and those will be distributed on a first-come first-serve basis. No attendees will be allowed to leave the room with a meal, all food items to be consumed in the session room.

#### SATURDAY, AUGUST 20, 2016, 12:30-13:30 HALL 5E3 - LEVEL 5

Optimizing Immunosuppression: A Key for Improving Long-term Outcomes

#### Organized by



ADVANCING TRANSPLANTATION—TOGETHER

#### WEI COME NOTE AND OPENING

#### **Wai-Leung Chak**

Hong Kong SAR, P.R. of China

#### Simone I. Strasser

Sydney, Australia

NATURAL HISTORY OF THE ORGAN TRANSPLANT:
OPPORTUNITIES TO OPTIMIZE IMMUNOSUPPRESSION

#### Philip F. Halloran

Edmonton, AB, Canada

THE IMMUNOSUPPRESSIVE MANAGEMENT FOR LONG-TERM OUTCOME

#### Jong Man Kim

Seoul, Korea

PANEL DISCUSSIONS

SATURDAY, AUGUST 20, 2016, 17:30-19:00 HALL 5E3 - LEVEL 5

Donoe Specific Antibody Monitoring

Organized by



A Thermo Fisher Scientific Brand

STRATEGIES TO IMPROVE LONG-TERM GRAFT OUTCOMES: BEGIN AT THE BEGINNING

#### **Peter William Nickerson**

Winnipeg, MB, Canada

LONG TERM GRAFT SURVIVAL: THE NEXT FRONTIER

#### John J. Friedewald

Chicago, IL, United States

SUNDAY, AUGUST 21, 2016, 12:30-13:30 HALL 5E3 - LEVEL 5

Modern Approaches of Immunosuppressive Therapies for Renal Transplant Patients

Organized by



mTORI PROTOCOL TO OVERCOME KEY CHALLENGES IN KIDNEY TRANSPLANT PATIENTS: A LONG TERM CLINICAL EXPERIENCE

#### Josep M. Campistol

Barcelona, Spain

A REVIEW OF CLINICAL EXPERIENCE WITH THE USE OF MPA IN RENAL TRANSPLANTATION

#### **Wai Lim**

Perth, Australia

AN ART OF IMMUNOSUPPRESSANT REGIMEN ADJUSTMENT IN CHINA TO MEET NEW ERA OF TRANSPI ANTATION

#### **Tao Lin**

Chengdu, People's Republic of China

## SPONSORED SYMPOSIA

MONDAY, AUGUST 22, 2016, 12:30-13:30 HALL 5E3 - LEVEL 5

Expanding Treatment Options with Anti-T Lymphocyte Immunoglobulin (ATLG)

Organized by



#### ATLG IN LIVER TRANSPLANTATION

#### **Jan Lerut**

Louvain-la-Neuve, Belgium

COMPARISON OF TWO DOSE REGIMENS OF ATLG IN KIDNEY TRANSPLANTATION

#### **Xiaodong Zhang**

Beijing, People's Republic of China

ATLG IN LIVE DONOR KIDNEY TRANSPLANT

#### **Mumtaz Yilmaz**

Izmir, Turkey










## EXHIBIT INFORMATION



### **■** Exhibit Opening Hours

The Exhibit Area is located in Hall 5FG, on Level 5 of the HKCEC.

Access to the Exhibit Area is open to all registered participants and guests of the TTS 2016 Congress. Please note that you must wear your badge to access the Exhibit Area.

Coffee and tea will be served within the Exhibit Area during the coffee breaks every day from August 20 to 22, 2016.




EXHIBIT AREA (HALL 5FG - LEVEL 5)			
Date	Time		
Friday, Aug 19	18:30-20:00		
Saturday, Aug 20	09:30-18:30		
Sunday, Aug 21	09:30-18:30		
Monday, Aug 22	09:30-19:00		

## EXHIBIT INFORMATION

### ■ The Transplantation Society

Booth #001

Come by our booth located centrally in the Exhibit Area and celebrate The Transplantation Society's 50th anniversary. Our official journal, *Transplantation*, as well as *Transplantation Direct* will have their own interactive station, and a corner designated for our Historical Project. Why not come and get your picture taken at our photo booth to commemorate this moment! Please visit us for information on membership, our sections, and our Alternate Year Program of meetings. And lastly, we will feature the beautiful city of Madrid as our next destination for the Congress in 2018!

Over the last 50 years, The Transplantation Society has grown exponentially and has become the largest international transplant community. Established in 1966, it serves as the principle international forum for the advancement of both basic and clinical transplantation science throughout the world. The Transplantation Society is a Non-Governmental Organization (NGO) and is comprised of over 6,700 professionals including but not limited to, physicians, surgeons, and scientists in over 105 countries. The Transplantation Society's mission is to provide the focus for global leadership in transplantation through the development of the science and clinical practice, scientific communication, continuing education, and the guidance on ethical practices.

TTS is also proud to have a distinguished group of sections: Cell Transplant and Regenerative Medicine Society (CTRMS), International Pancreas & Islet Transplant Association (IPITA), International Society for Organ Donation and Procurement (ISODP), International Xenotransplantation Association (IXA), Transplant Infectious Disease (TID), Intestinal Rehabilitation & Transplant Association (IRTA), International Society of Vascularized Composite Allotransplantation (ISVCA), and the International Pediatric Transplant Association (IPTA).

International Headquarters
505 René-Lévesque Blvd. West, Suite 1401
Montreal, QC H2Z 1Y7 Canada
Phone + 1 514.874.1717
Fax + 1 514.874.1716
www.tts.org
membership@tts.org

### ■ ISN-TTS Sister Transplant Center Program





The ISN-TTS Sister Transplant Center Program is a new joint partnership between the International Society of Nephrology (ISN) and The Transplantation Society (TTS) to create new kidney transplant centers and develop existing kidney transplant programs in emerging countries. This initiative encourages transplant centers to work together to increase opportunities for kidney transplant patients in developing countries. An experienced transplant center in the developed world lends its support to an emerging transplant center to facilitate vital multidisciplinary training and encourage both centers to exchange their knowledge and expertise.

#### **POSTER PRESENTATIONS:**

During the congress, posters will be presented by two centers: a center from Guatemala that teamed up with UCLA in Californa, USA, and a center from Gaza, Palestine that teamed up with the Royal Liverpool University Hospital in the UK.

#### Location: Hall 5FG, behind the TTS Booth in Aisle 500

Date	Time
Saturday, Aug 20	17:00-17:20
Sunday, Aug 21	17:00-17:20
Monday, Aug 22	18:00-18:20

## SPONSORS & CONTRIBUTORS

■ Astellas Pharma Inc.

Booth #501

### PREMIER SPONSOR



ADVANCING TRANSPLANTATION—TOGETHER

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com

#### ■ F. Hoffmann-La Roche Ltd

### **PRINCIPAL SPONSOR**



Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche's transplant treatments are designed to support the long-term survival of transplanted organs.

www.roche.com

#### Neovii Pharmaceutical

**SPONSOR** 



Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders. Neovii was founded in 2013 by the acquisition of Fresenius Biotech inheriting more than three decades of experience in specialty pharmaceuticals. Neovii's global headquarters are located in Rapperswil, Switzerland.

www.neovii.com

■ Novartis Pharmaceutical

Booth #201

**SPONSOR** 



Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas.

www.novartis.com

## SPONSORS & CONTRIBUTORS

One Lambda - A Thermo Fisher Scientific Brand

**Booth #701** 

#### **SPONSOR**



#### A Thermo Fisher Scientific Brand

One Lambda, Inc., a Thermo Fisher Scientific Brand, is a global leader in transplant diagnostics offering a full range of HLA Typing and antibody monitoring products to support clinicians and laboratories in the management of transplant patients. Visit www.onelambda.com to discover how we can help you improve patient outcomes.

■ Dr. Franz Köhler Chemie GmbH Booth #403

#### CONTRIBUTOR



DFKC is an independent, family-owned business with representations on all five continents. DFKC has been an establishment for over 55 years, providing products in the field electrolytes, contrast media, antidotes, anesthetic pharmaceuticals as well as organ protective and cardioplegic solutions. These latter products in particular have made DFKC a committed partner of cardiac and transplant surgery worldwide.

www.koehler-chemie.de

#### JDRF International

#### **CONTRIBUTOR**



www.jdrf.org

### ■ Shire

#### **CONTRIBUTOR**



Newly combined with Baxalta, Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions that are often misunderstood, undiagnosed and life-threatening.

www.shire.com

### **EXHIBITORS**



Booth #106



Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these diseases often have no effective treatment options, and they and their families suffer with little hope. Alexion's goal is to deliver medical breakthroughs where none currently exist.

Alexion was established in 1992 and is headquartered in New Haven, Connecticut with approximately 3,000 employees around the world serving patients in 50 countries.

www.alexion.com

### Baskent University

Booth #804





Baskent University was founded in 1993, as one of the foundation universities of Turkey. The founder and honorary president, Prof. Dr. Mehmet Haberal, performed the first successful transplantation surgery in Turkey (1975) and is renowned worldwide in the medical community. Baskent University has a broad spectrum of faculties in all branches of science including medicine, dentistry, engineering, administration, social and political financial sciences and law.

www.baskent.edu.tr

### ■ Bridge to Life

Booth #703



Bridge to Life supplies organ preservation solutions under the Belzer UW® trademark and high flow tubing and cannulas. We now supply our products to 35 countries in 5 continents. Please stop by to ask us more about exciting future developments.

www.bridgetolife.com

#### ■ CAST 2017

**Booth #802** 



The Congress of the Asian Society of Transplantation (CAST) is the region's largest and longest running gathering of transplant physicians, surgeons and other health professionals involved in transplantation held every two years in participating countries in Asia. The 15th CAST will be hosted by the Transplantation Society of the Philippines and is to be held in Cebu, Philippines on November 27-30, 2017.

## **EXHIBITORS**

### ■ Epoch Group Limited

Booth #307



Epoch Times is an independent voice in print (8 languages) and on the web (in 21 languages). We report news responsibly and truthfully so that readers can improve their own lives and increase their understanding and respect for their neighbors next door and around the globe. In our approach and in our content, we uphold universal human values, rights, and freedoms. We are a business that puts our readers' interests first, in all that we do.

www.epochtimes.com

European Society for Organ Transplantation (ESOT)

Booth #405



ESOT is Europe's main umbrella transplantation body, under which all transplant activities are organized. ESOT's mandate is to represent the goals and needs of transplantation surgery, with members including physicians, surgeons, scientists and transplant professionals. ESOT works with organizations to structure and streamline activities, give advice, promote strong educational programs and scientific networking and pursues scientific knowledge and best clinical practices professionals.

www.esot.org

### ■ Gift of Life Institute

Booth #302



Gift of Life Institute is an international training center for donation professionals offering comprehensive, interdisciplinary resources for skills-based learning, continuing education, collaborative research, and consulting services.

www.giftoflifeinstitute.org

■ Glycorex Transplantation AB

Booth #305



Glycorex Transplantation AB (publ) is a world-leader in ABO-incompatible technologies. As a medical technology company, we are involved in the development, production and sales in the fields of organ transplantation and other closely related disciplines. Our main product has been used clinically for more than 15 years and is currently being used in 24 countries on 4 continents.

www.glycorex.se

### **EXHIBITORS**

### ■ Hong Kong Kidney Foundation

Booth #902



Hong Kong Kidney Foundation (HKKF) is a non-profit voluntary organization incorporated on July 10th, 1979. The HKKF Board of Governors is responsible for the governance of HKKF. The Board members are medical professionals, society leaders and interested members of the general public, who serve as volunteers for HKKF. Our major services include the following:

- 1. Provide assistance, treatment and services to persons suffering from kidney failure.
- 2. Promote kidney health and awareness of kidney disease through general public activities and education programs.
- 3. Promote organ donation.
- 4. Promote research into kidney disease and treatment.
- 5. Support training for medical and nursing staff.

www.hkkf.org.hk

■ The Hong Kong Liver Foundation Booth #903



The Hong Kong Liver Foundation is a charitable organization established in August 1992 by a group of concerned members of the community with the support of doctors specialising in liver diseases.

www.liverfound.org.hk

Hong Kong Liver Transplant Patients' Association

Booth #205



The Hong Kong Liver Transplant Patients' Association is a patient support group chartered 18 years ago in 1998 through the assistance of Professor Fan Sheung Tat and Professor Lo Ching Mau. As a charitable non-profit organization, we have been proactively advocating the vision and mission "to celebrate rebirth through self-offering to help the needy". Our goal is to encourage mutual support care for liver patients and their families and care takers; and promoting the organ transplant scheme; educating secondary schools' student and communities on the importance of prevention of liver diseases.

www.livertpa.org

Hong Kong Society of Transplantation

Booth #204



The Hong Kong Society of Transplantation was incorporated in March 1995:

- To promote for the public benefit the interests in and a better understanding of the advancement of science and knowledge in the transplantation and harvesting of organs and tissues
- To promote organ donation
- To promote research, education, training, and appreciation in the science and technology of transplantation, and to make available to the community up-to-date information on new developments in transplantation and organ/tissue harvesting for public benefit
- To promote academic and social exchange among local and overseas transplant community, and to organize activities/conferences in this respect

www.hkst.org

### **EXHIBITORS**

 Hong Kong Transplant Sports Association Ltd

**Booth #905** 



香港移植運動協會 Hong Kong Transplant Sports Association

The Hong Kong Transplant Sports Association (HKTSA) was incorporated in March 2008, and is formed by organ transplant recipients, organ donors (and their families) and health care workers related to transplantation. Its mission is to develop, promote and organize sports activities for organ transplant recipients, provide a chance for them to demonstrate their potential, and to help them build up confidence, be positive and optimistic towards life. The association also promotes organ donation and helps promulgate the knowledge on organ transplantation to the public.

www.hktsa.org

International Society of Nephrology

Booth #306



The International Society of Nephrology (ISN) is dedicated to advancing the diagnosis, treatment, and prevention of kidney diseases in the world. The Society represents a wide international network and provides an efficient platform for timely scientific exchange, debate and dissemination between healthcare professionals around the world. ISN has over 9,000 professional members from more than 126 countries. In addition, ISN closely collaborates with over 70 national and regional nephrology societies around the world, representing about 20,000 professionals.

www.theisn.org

Kidney Disease: Improving Global Outcomes (KDIGO)

Booth #704



Kidney Disease: Improving Global Outcomes (KDIGO) is an independent foundation incorporated in Belgium accountable to the public and the patients it serves. Its mission is to improve the care and outcomes of kidney disease patients worldwide through the development and implementation of global clinical practice guidelines.

www.kdigo.org

Organ Recovery System (ORS)

Booth #304



Supporting over 218 transplant programs in 32 countries, Organ Recovery Systems is the global market-leading provider of organ preservation products and services. We are committed to advancing organ preservation for transplantation by developing innovative medical technologies and systems to preserve and protect donor organs, helping clinicians transform outcomes post transplantation.

www.organ-recovery.com

### **EXHIBITORS**



Booth #105



OrganOx® Limited is a medical device company with a mission to increase the quality and supply of organs for transplantation. OrganOx's normothermic machine perfusion technology allows the preservation of donor livers for up to 24 hours using physiological flows, pressures and temperature.

www.organox.com

Otsuka Pharmaceutical (H.K.) Ltd

Booth #303



Otsuka Pharmaceutical (H.K.), Ltd. was founded in 1997, and operates as a subsidiary of Otsuka Pharmaceutical Co., Ltd. We are committed to a holistic approach to health and well-being of people and are striving to create innovative, thoroughly-original pharmaceutical and nutraceutical products based on our corporate philosophy "Otsuka-people creating new products for better health worldwide".

www.otsuka.hkg

Pfizer Corporation Hong Kong Ltd.

Booth #406



At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

www.pfizer.com.hk



Booth #901



QIAGEN is the leading global provider of Sample to Insight solutions, enabling our customers to gain valuable molecular insights from their samples. Our technologies isolate DNA, RNA and proteins from blood and tissue samples. Our diagnostic assays make these biomolecules available for analysis. Finally, our bioinformatics and automation solutions combine for cost-effective workflows, providing relevant, actionable insights for transplantation teams.

www.giagen.com

### **EXHIBITORS**

### QRS International

Booth #207



We believe that every patient deserves the best possible care. For this reason we only want to supply products which meet the highest quality standards! Products which perform at the highest possible level like you expect they will do at the most crucial moments. To enable us providing the highest quality of services to our customers, we constantly search the world markets for new and even better solutions for the patients and the car which is provided to them.

www.grsinternational.nl

### ■ Swoop Films

Booth #805



SWOOP FILMS is an American film production company based in New York that creates engaging documentaries and feature films for worldwide theatrical distribution.

www.swoopfilms.com

 Taiwan Association for International Care of Organ Transplants

Booth #206



Since Taiwan Association for International Care of Organ Transplants (TAICOT) was established in 2006, the organization has been dedicated to raising public awareness of organ donation and promoting medical ethics of organ transplantation. Our objective is to ensure patients' fundamental rights to decent medical care. We also endeavor to stop any existing transplant malpractice.

www.organcare.org.tw

### ■ Thai Transplantation Society

Booth #104



The Thai Transplantation Society is a center for the information about the transplantation in Thailand. Thailand has long been providing organ transplantation services to Thai patients with almost all types of organ failure. Organ Transplantation in Thailand is considered to have World-class academic excellence. Thailand's organ transplant profession is well developed, and has contributed to advancement of both solid organs and bone marrow / stem cell transplantation services.

### www.transplantthai.org

■ Thompson Surgical Instruments Inc.

Booth #705



Thompson Surgical celebrates 50 years as a leader in exposure and the original manufacturer of the table-mounted retractor. We understand the value of exposure in surgery and are dedicated to providing innovative, high quality systems that deliver safe, versatile, and low-profile retraction. From pediatric to obesity, simple to complex exposures, we offer unlimited customization and safe, independent, retraction. The Thompson Retractor allows surgeons in multiple specialties to achieve Uncompromised Exposure.

www.thompsonsurgical.com

### **EXHIBITORS**

### ■ TPM-DTI Foundation

Booth #803





TPM-DTI Foundation is an international non-profit organization committed since 1991 to raise organ donation by providing counseling and support to international entities, and to the public and private health sector in the creation, development and strengthening of networks, programs and services related to the donation and transplantation of organs, tissues and human cells.

www.tpm-dti.com

### World Transplant Games Federation

Booth #904



The World Transplant Games Federation promotes the power of the gift of life through the staging of the world's largest event for the success of transplantation – the Summer World Transplant Games. For nearly 40 years the Federation has been staging international multi-class sports competitions for solid organ and bone marrow recipients. The games unite more than 60 countries in the celebration of the gift of life and cast a spotlight on the need for more organ donors. Core to the purpose of the Federation is the necessity to promote the full rehabilitation and wellbeing of transplant athletes through healthy lifestyle achieved through exercise and sport. The Federation has produced a Fit for Life programme to help all recipients' live life to the fullest.

www.wtgf.org

### Local Partners



Agency for Volunteer Service (AVS) founded in 1970, is a nonprofit organization mainly financed by funds from the Government of the Hong Kong Special Administrative Region, The Community Chest of Hong Kong, The Hong Kong Jockey Club Charities Trust and public and private donations. With the vision to build a civil society and caring community, AVS is dedicated to playing a proactive and pivotal role in the promotion and development of sustainable volunteerism, and to develop partnership with all sectors of the community to provide value-added and quality volunteer service.

For more information, visit www.avs.org.hk/en/intro.



The Hong Kong Tourism Board established **Meetings and Exhibitions Hong Kong (MEHK)** to continue strengthening the city's position as the number one destination for meetings, incentive trips, conventions and exhibitions in Asia-Pacific. MEHK offers extensive support services that make world-leading MICE events simple to set up and smooth to execute. Together with the city's network of highly qualified professionals, and a "can do" attitude that's famously Hong Kong, the MEHK team is dedicated to helping before, during and after your event to achieve success at every stage.

For more information, please visit www.mehongkong.com/eng



**USA** 



# IPITA 2017

June 20–23 Oxford United Kingdom



### **2017** Organ Donation Congress

Sept. 6–9 Geneva Switzerland





May 27–30 Barcelona Spain



# **ISVCA** 2017

October 26–27 Salzburg Austria

# 2017 MEETINGS CALENDAR

To view the complete calendar and to learn more about our up-coming meetings, including Milestones and Program Themes, please visit www.tts.org

### **TRAVELER** Information

### ■ Discover Hong Kong

A few weeks, days or just hours are enough to get you hooked on the incredible city that is Hong Kong! Whether you're a first timer, or already have a love-affair with our great city, this series of guides has something new for you: it's a compilation of stories, recommendations and tips on Hong Kong from people in the know. Pick a topic that interests you—from incredible Chinese superstitions in "Traditions and Spirituality", to funky art galleries in "Industrial Revolution"—and you'll discover real, upto-the-minute local advice to guide you through many exciting experiences and adventures. We also put the spotlight on particular districts, providing detailed itineraries, so you can do more and see more—and yet still go home wanting more.

For further information, please visit www.discoverhongkong.com.

You can also visit our Congress Services Desk at Hall 5E South Concourse, Level 5 for personalized assistance.

### Participating Hotel Info

ICC, TTS' Official Housing Bureau will be available on-site throughout the TTS 2016 congress to assist participants with their hotel booking. Their representative will have a counter at the Delegate Services Area, located on Hall 5E South Concourse.

Please see the full city map with hotel locations found on the inside back cover fold out of this program:

### **Grand Hyatt Hong Kong – Headquarter Hotel**

1 Harbour Road, Wanchai, Hong Kong

### Renaissance Harbour View Hotel - Headquarter Hotel

1 Harbour Road, Wanchai, Hong Kong

### **Empire Hotel Hong Kong – Wanchai**

8 Wing Hing Street, Causeway Bay, Hong Kong

### **Gloucester Luk Kwok Hong Kong**

72 Gloucester Road, Wanchai, Hong Kong

### **Novotel Century Hong Kong**

238 Jaffe Road, Wanchai, Hong Kong

### **The Excelsior Hong Kong**

281 Gloucester Road, Causeway Bay, Hong Kong

### The Harbourview

4 Harbour Road, Wanchai, Hong Kong

### The Wharney Guang Dong Hotel Hong Kong

57-73 Lockhart Road, Wanchai, Hong Kong

### ■ Transportation

### **GETTING TO HKCEC**

### **From Hong Kong International Airport**

24 minutes to Hong Kong Island by Airport Express (Hong Kong station then transfer to headquarter hotels with free shuttle bus).

45 minutes by taxi – You must take a red taxi, and payments are cash-only in Hong Kong dollars.

(only red taxis operate on Hong Kong Island; blue and green taxis operate on other islands).

40 minutes by MTR

(Hong Kong station then transfer to Wanchai station)

80 minutes by Bus

(Route A11 or E11 to Wanchai then transfer to route 40M)

Visit www.discoverhongkong.com for more information.

### **From Hung Hom Railway Station**

20 minutes by Bus (Route 104 or 101 to Wanchai)

30 minutes by taxi

The HKCEC is located only a short walking distance from Wanchai Station (MTR) and from Wanchai ferry terminal.

### **GETTING AROUND HONG KONG**

MTR (Mass Transit Railway) – Day passes available for unlimited travel to experience Hong Kong.

Taxis – Can typically be hailed on the street, with the exception of certain restricted areas, or summoned by phone. Taxis are relatively cheap in Hong Kong and are equipped with a meter as well as air conditioning. Red taxis operate throughout most of Hong Kong, green taxis only serve the New Territories and blue taxis operate on Lantau Island.

**Buses** – Bus routes cover almost all of Hong Kong and are a very comfortable way to travel. Popular among tourists are the 'double-decker' buses which offer a great view of the city. Exact change is required if paying by cash, otherwise you can purchase an Octopus Card (see below).

**Ferries** – The legendary Star Ferry has been offering scenic transfers between Hong Kong Island and Kowloon since 1888.

**Outlying Island Services** – Other Ferry services provide transfers to Outlying Islands of Peng Chau, Cheung Chau, Lamma and Lantau. You can either opt for standard ferries, or faster slightly more expensive ferries.

### TRAVELER Information

Trams – Another way to visit the Island is by taking a step back in time with the historic tram system which has been travelling the city since 1904. Exact change is required if paying by cash, otherwise you can purchase an Octopus Card (see below).

**Peak Tram** – Known as the steepest funicular railway in the world, the Peak Tram is by far the easiest way to get the most spectacular view of the city. Exact change is required if paying by cash, otherwise you can purchase an Octopus Card (see below).

Visit www.discoverhongkong.com for more information.

**Octopus Card** – This handy rechargeable chip card can be used across the entire MTR system, buses, ferries, coaches and trams, as well as in various convenience and department stores, supermarkets, bakeries, fast food chains, cafés, cinemas, skating rinks, theme parks, etc.

Visit www.octopus.com.hk for more information.

### Currency Exchange

The official currency is the Hong Kong Dollar (HKD). One (\$) USD will give you approx. 7.76 HKD.

Major banks open from 09:00 to 16:30 on weekdays and 09:00 to 12:30 on Saturdays. You can exchange your currency for Hong Kong dollars at any authorised money exchanger. For extra peace of mind, look for a money exchanger that is accredited by the Quality Tourism Services (QTS) Scheme. ATMs are widespread and operate 24 hours. Exchange rates fluctuate daily depending on currency markets.

### ■ Traveller's Cheques and Credit Cards

Traveller's cheques are accepted by most leading banks and hotels. International credit cards such as American Express, VISA, Diners Club and MasterCard are also welcome at many hotels, retail shops and restaurants. Such premises usually display stickers showing the credit cards they accept at their entrances.

### ■ Taxes

There are no goods and services tax (GST), harmonized sales tax, value added tax (VAT) or any other sales tax in Hong Kong.

### Tipping and Means of Payments

International credit cards are welcome everywhere in Hong Kong, although most local smaller restaurants prefer cash payments, and taxis only take cash.

A 10 to 15% tip is usually left on the table or at the cash register. However, some tea cafes do not impose service charges. Please check with the waiter about the charges before being seated.

### ■ ATM

ATMs can be found almost everywhere. Many take international cards and some HSBC 'Electronic Money' machines provide 24-hour cash withdrawal (HK\$) facilities for Visa and MasterCard holders.

NOTES

NOTES

Abad, Cybele Lara R	622.5
Abbas, Khawar	
Abbud-Filho, Mario	
Abe, Toyofumi	
Abendroth, Dietmar K.	
Abid, Ayisha	
Absi, Daniel Oscar	
Abuhelaiga, Essa A	
Acosta, Fabio Ruben	
Adamusiak, Anna M	
Adlakha, Amit G	
Ahmad, Niaz	
Ahmed, Ihab A. M.	
Ahmed, Zubir	
Ahn, Hyung Joon	
Aida, Naohiro	
Aitken, Emma L	
Akamatsu, Nobuhisa	
Akashi, Yumi	
Akhter, Saeed	
Akiki, Rachid	
Akioka, Kiyokazu	
Akutsu, Naotake	
Al Housani-Blakely, Roberta J.	
Alabadi, Abdulnaser M	
Albert Matthews	
Albert, Matthew	
Aleid, Hassan A.	
Aliabadi, Arezu Z	
Alkadi, Mohamad M	
Allen, Penelope J.	
Alotaibe, Fahad	
Alrukhaimi, Mona	
Alshomali Sr., Wael A	P.1563
Alshomali Sr., Wael AAlwayn, Ian P	P.1563
Alshomali Sr., Wael A	
Alshomali Sr., Wael A	
Alshomali Sr., Wael A	P.1563 P.1086 326.8, 326.9, 326.10 P.1751, P.1752 504.1
Alshomali Sr., Wael A	P.1563 P.1086 326.8, 326.9, 326.10 P.1751, P.1752 504.1 424.12
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 R.1086 R.1751, P.1752 R.1751, P.1752 R.1424.12 R.1561 R.1561 R.1561 R.1561 R.1561 R.1561 R.1561 R.1561 R.1563
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1751, P.1752 P.1751, P.1753
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1751, P.1752 P.1751, P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1753 P.1751
Alshomali Sr., Wael A	P.1563 P.1086 R.1086 R.26.8, 326.9, 326.10 P.1751, P.1752 S.04.1 424.12 R.1519 R.1143 R.1519 R.1143 R.1544 R.264
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 R.1086 R.1087 P.1751, P.1752 S.04.1 A24.12 R.1519 R.1143 R.1528 R.1528 P.1528
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1751, P.1752 P.1751, P.1752 P.1751, P.1752 P.1751, P.1752 P.1751, P.1752 P.1751, P.1752 P.1752,
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1751, P.1752 P.1752, P.1752, P.1528 P.1528 P.1528 P.1528 P.1528 P.1528
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1751, P.1752 P.1752, P
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 R.1086 R.1086 R.1086 R.1751, P.1752 R.1751 R.1752 R.1751 R.1752 R.1751 R.1752 R.1751 R.1752 R.1751 R.1752 R.1751 R.1752 R
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 R.1086 R.
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 R.1086 R.1086 R.1086 R.1751, P.1752 S.04.1 R.1424.12 R.1528 R.1648 R.164
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 R.1086, 326.8, 326.9, 326.10 P.1751, P.1752 P.1751 P.1752 P.1143 P.1143 P.1528
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 P.1751, P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1752 P.1752 P.1753 P
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 P.1751, P.1752 P.1751, P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1751 P.1752 P.1751 P.1752 P.1751
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 P.1751, P.1752 P.1751, P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1752 P.1753 P.1756 P.1756 P.1756 P.1756 P.1756 P.1756 P.1756 P.1756 P.1757 P.1757 P.1757
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 P.1751, P.1752 P.1751 P.1752 P.1751 P.1752 P.1753 P.1753 P.1753 P.1754 P.1754 P.1755 P.1757 P.1775 P.1778
Alshomali Sr., Wael A	P.1563 P.1086 P.
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 R.1086, 326.8, 326.9, 326.10 P.1751, P.1752 P.1751 P.1752 P.1751 P.1752 P.1753
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 P.1751, P.1752 P.1751, P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1752
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 P.1751, P.1752 P.1751, P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1752
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 P.1751, P.1752 P.1751, P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1752 P.1751 P.1752 P.1752 P.1753 P.1758 P.1768 P.1769 P.1760
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 R.1088, 326.9, 326.10 P.1751, P.1752 S.04.1 P.1751, P.1752 P.1751, P.1752 P.1751, P.1752 R.1751, P.1753 R.1751, P.1753 R.1751, P.1753 R.17558.6 R.1800 R.1755, P.1266 R.2243, 404.2, 557.9a, 630.1, P.1004 R.1752, P.1265 R.2243, 404.2, 557.9a, 630.1, P.1004 R.1752, P.1265 R.1751, P.1004 R.1751,
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 R.1086, 326.8, 326.9, 326.10 P.1751, P.1752 S.04.1 P.1751 P.1752 P.1143 P.1143 P.1143 P.1086 P.1528 P.1601
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 R.1086, 326.8, 326.9, 326.10 P.1751, P.1752 P.1751 P.1752 P.1143 P.1143 P.1143 P.1528 P.1528 P.1528 P.1528 P.1528 P.1528 P.1601
Alshomali Sr., Wael A	P.1563 P.1086 P.1086 P.1086 P.1751, P.1752 P.1751, P.1752 P.1751 P.1752 P.1751, P.1752 P.1751, P.1752 P.1751, P.1752 P.1751, P.1752 P.1751, P.1752 P.1751, P.1752 P.1752, P.1630 P.1620, P.1630 P.1620, P.1630 P.1620, P.1630 P.16

Baron, Pedro W.	P.1486
Barrett, Meredith	
Barry, Christopher Taylor	422.13, P.1701
Barten, Markus J	233.5
Bartlett, Stephen T	321.9
Baskin, Esra	P.1827, P.1828, P.1829
Bastürk, Bilkay	
Bateman, Samantha M	
Batsuuri, Byambadorji	
Benavidez, Joel B	
Benden, Christian	
Benhamou, Pierre Y	
Berenguer, Marina	
Berney, Thierry P.S	
Bézie, Séverine	
Bhati, Chandra	
Bisigniano, Liliana Bodzin, Adam S	
Boehnert, Markus U	
Bollen, Jan	
Bongoni, Anjan K.	
Bontha, Sai Vineela	
Boran, Mediha	
Borda, Bernadett	
Borkar, Minal	
Borsum, Nadja	
Boyacioglu, Ahmet Sedat	
Brandhorst, Heide	
Brasile, Lauren	350.9, 353.1
Braun, Hillary J	
Brayman, Kenneth L.	551.9, 559.1
Bromberg, Jonathan S111.2, 200.3, 427.10, 4	27.9, 458.4, 627.8, 627.9, 628.1
Bruminhent, Jackrapong	42 4 12
Drumment, sackrapong	424.13
Budde, Klemens	
Budde, Klemens	350.3, P.1529 449.2
Burdorf, Lars	
Budde, Klemens Burchett, Sandra Burdorf, Lars Burghuber, Christopher K	
Budde, Klemens	
Budde, Klemens	
Budde, Klemens	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burghuber, Christopher K Burgos Revilla, Francisco Javier. Burke, George W. Burlingham, William J. Byeon, Hyerim	
Budde, Klemens Burchett, Sandra Burdorf, Lars Burghuber, Christopher K Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H.	
Budde, Klemens	
Budde, Klemens	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burghuber, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Gai, Junchao Cai, Songjie.	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burgbuber, Christopher K Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi.	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burghuber, Christopher K Burgos Revilla, Francisco Javier. Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O.	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burghuber, Christopher K Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel	
Budde, Klemens Burchett, Sandra Burdorf, Lars Burghuber, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel. Cantarovich, Diego	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burghuber, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel Cantarovich, Diego Capron, Alexander M.	
Budde, Klemens Burchett, Sandra Burdorf, Lars Burghuber, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel. Cantarovich, Diego	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burdspher, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao. Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel. Cantarovich, Diego Capron, Alexander M. Celik, Neslihan	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burgbuber, Christopher K Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Gabeza, Franco H. Caby, Andrea Cai, Junchao Gai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel. Cantarovich, Diego Capron, Alexander M. Celik, Neslihan Cendales, Linda C.	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burgbuber, Christopher K Burgos Revilla, Francisco Javier. Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea. Cai, Junchao. Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel Cantarovich, Diego Capron, Alexander M. Celik, Neslihan Cendales, Linda C. Chadban, Steve J.	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burghuber, Christopher K Burgos Revilla, Francisco Javier. Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea. Cai, Junchao. Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel Cantarovich, Diego Capron, Alexander M. Celik, Neslihan Cendales, Linda C. Chadban, Steve J. Chakradeo, Katrina	
Budde, Klemens Burchett, Sandra Burdorf, Lars Burghuber, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel Cantarovich, Diego Capron, Alexander M. Celik, Neslihan Cendales, Linda C. Chadban, Steve J. Chakradeo, Katrina Chambers, Heather E.	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burgbuber, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel. Cantarovich, Diego Capron, Alexander M. Celik, Neslihan Cendales, Linda C. Chadban, Steve J. Chakradeo, Katrina Champers, Heather E. Chan, Joshua L. Chan, Joshua L. Chan, Joshua L. Chan, Kun-Ming	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burgbuber, Christopher K Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songije. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel. Cantarovich, Diego Capron, Alexander M. Celik, Nesilhan Cendales, Linda C. Chadban, Steve J. Chakradeo, Katrina Chambers, Heather E. Chan, Daniel TM. Chan, Joshua L. Chan, Kun-Ming Chan, Samuel Shun K.	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burgbuber, Christopher K Burgos Revilla, Francisco Javier. Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea. Cai, Junchao. Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel Cantarovich, Diego Capron, Alexander M. Celik, Neslihan Cendales, Linda C. Chadban, Steve J. Chakradeo, Katrina Chambers, Heather E. Chan, Daniel TM Chan, Joshua L. Chan, Kun-Ming Chan, Samuel Shun K. Chan, Samuel Shun K. Chan, Samuel Shun K.	350.3, P.1529
Budde, Klemens Burchett, Sandra Burdorf, Lars Burghuber, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel Cantarovich, Diego Capron, Alexander M. Celik, Neslihan Cendales, Linda C. Chadban, Steve J. Chakradeo, Katrina Chambers, Heather E. Chan, Daniel TM. Chan, Joshua L. Chan, Kun-Ming Chan, Samuel Shun K. Chan, See Ching.	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burdorf, Lars Burghuber, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel Cantarovich, Diego Capron, Alexander M. Celik, Neslihan Cendales, Linda C. Chadban, Steve J. Chakradeo, Katrina Chambers, Heather E. Chan, Daniel TM. Chan, Joshua L. Chan, Samuel Shun K. Chan, Samuel Shun K. Chan, Sae Ching. Chan, Siu Kim. Chan, Wi Kim.	
Budde, Klemens Burchett, Sandra Burdorf, Lars Burdorf, Lars Burgbaer, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim  Cabeza, Franco H. Caby, Andrea  Cai, Junchao  Cai, Junchao  Cai, Songjie.  Calisa, Vaishnavi.  Callender, Clive O.  Cantanhede, Gabriel.  Cantarovich, Diego  Capron, Alexander M.  Celik, Neslihan  Cendales, Linda C.  Chadban, Steve J.  Chakradeo, Katrina  Chambers, Heather E.  Chan, Daniel TM.  Chan, Joshua L.  Chan, Samuel Shun K.  Chan, Sawel Shun K.  Chan, Swi Kim.  Chan, Wai Ming.  Chandwing Ming.  Chandwing Ming.  Chandwing Ming.  Chandak, Pankaj.	
Budde, Klemens Burchett, Sandra. Burdorf, Lars Burgbuber, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim Cabeza, Franco H. Caby, Andrea Cai, Junchao Cai, Songjie. Calisa, Vaishnavi. Callender, Clive O. Cantanhede, Gabriel. Cantarovich, Diego Capron, Alexander M. Celik, Neslihan Cendales, Linda C. Chadban, Steve J. Chakradeo, Katrina Chambers, Heather E. Chan, Daniel TM. Chan, Joshua L. Chan, Kun-Ming Chan, Samuel Shun K. Chan, Samuel Shun K. Chan, See Ching. Chan, Willing. Chandak, Pankaj. Chandak, Pankaj. Chandak, Pankaj. Chandak, Pankaj.	
Budde, Klemens Burchett, Sandra Burdorf, Lars Burdorf, Lars Burgbaer, Christopher K. Burgos Revilla, Francisco Javier Burke, George W. Burlingham, William J. Byeon, Hyerim  Cabeza, Franco H. Caby, Andrea  Cai, Junchao  Cai, Junchao  Cai, Songjie.  Calisa, Vaishnavi.  Callender, Clive O.  Cantanhede, Gabriel.  Cantarovich, Diego  Capron, Alexander M.  Celik, Neslihan  Cendales, Linda C.  Chadban, Steve J.  Chakradeo, Katrina  Chambers, Heather E.  Chan, Daniel TM.  Chan, Joshua L.  Chan, Samuel Shun K.  Chan, Sawel Shun K.  Chan, Swi Kim.  Chan, Wai Ming.  Chandwing Ming.  Chandwing Ming.  Chandwing Ming.  Chandak, Pankaj.	

Chapman, Jeremy R.	404.1
	233.4
	545.1
Chen, Chien-Chia	628.5
Chen, Gang	558.8
Chen, Guodong	352.9, 556.6, P.1346
Chen, Hong-Mei	P.1677
Chen, Jingyu	120.7, P.1783
Chen, Linda J	426.7, 473.3, 571.2, P.1421, P.1422, P.1423, P.1424
Chen, Sharon	347.2
Chen, Shih-Chin	P.1865
Cheng, Elaine Y	329.4
	358.2, 559.3
Cheung, Chi Yuen Simon	552.6
	324.10, 428.4, P.1029
	553.1
	541.3
	P.1832
	P.1891, P.1892
	P.1210
	350.7, 420.4, 420.5
	P.1667, P.1668
	P.1100, P.1101, P.1102, P.1194, P.1195
	P.1211
	P.1208, F.1209
	329.10
	427.11
	P.1712
	P.1775
	P.1347, P.1348
	373.5, P.1554
Chun, Jae Min	P.1148, P.1149
Chun, Kwangsik	P.1196
	P.1006
	P.1896
	P.1295
	P.1059
	547.1
	620.7, P.1383
	P.1625
	421.13, 471.2, P.1331, P.1332, P.1333
	426.2
	354.8
	357.9, 428.9, 429.1, 544.1
	452.8
	P.1349
3 .	
	552.8
	420.11
•	P.1634
	427.6
,	202
de Teresa Alguacil Sr., Javier	P.1384, P.1385

de Witte, Samantha F.H.	378 17
Dean, Patrick G.	
Debska-Slizien, Alicja	
Delmonico, Francis L.	
Delville, Marianne	
Denisov, Viktor	
Dhawan, Anil	446.1
Dhital, Kumud K	549.3
Dhital, Ravi	
Diaz, Carlos H	
Didsbury, Madeleine	
Diekman, Fritz	
Dipchand, Anne I.	
Dominguez-Gil, Beatriz	
Dopazo, Cristina	325.6, P.1150, P.1151
Dor, Frank JMF	574.1, P.1386
Doskali, Marlen	•
Dou, Kefeng	
Drachenberg, Cinthia B.	
Dragun, Duska	
Drastich, Pavel	
Du, Caigan	322.12
Du, Feifei	P.1007
Du, Thu Thi Ngoc	
Dudley, Joel T	
Dwyer, Karen	
Dzhonova, Dzhuliya V	
Dziodzio, Tomasz	
Edmondson, Sarah-Jayne	
Efimov, Denis	355.2, P.1055
El-Agroudy, Amgad	P.1442, P.1443, P.1444
El-Kishawi, Abdullah	
Elebring, Erik	
Elkholy, Shaimaa	
Elmoghazy, Walid	455.7, P.1133, P.1134
Elmoghazy, Walid Eng, Mary	455.7, P.1133, P.1134
Elmoghazy, Walid	455.7, P.1133, P.1134
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran	455.7, P.1133, P.1134 P.1513 P.1878
Elmoghazy, Walid	455.7, P.1133, P.1134 
Elmoghazy, Walid	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Ean, Katherine Fan, Xiaoli Farber, Donna L	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fany, Kiooli Farber, Donna L Farmer, Douglas G.	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fany, Kandin Farmer, Dounda G Farmer, Dounda G Farmer, Douglas G Farris III, Alton "Brad"	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fany, Kiooli Farber, Donna L Farmer, Douglas G.	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fany, Kandin Farmer, Dounda G Farmer, Dounda G Farmer, Douglas G Farris III, Alton "Brad"	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falkoner, Stuart J Faleo, Gaetano Fan, Katherine Fan, Xiaoli Farrer, Donna L Farrer, Douglas G Farris III, Alton "Brad" Favela, Raul M Feng, Han	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Eyüboglu, Füsun Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Xiaoli Farmer, Douglas G Farris III, Alton "Brad" Favela, Raul M	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Xiaoli Farber, Donna L Farmer, Douglas G Farris III, Alton "Brad" Favela, Raul M Feng, Han Feng, Han Feng, Sandy Ferrari, Paolo	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fany, Katherine Farber, Donna L Farmer, Douglas G Farris III, Alton "Brad" Favela, Raul M Feng, Sandy Feng, Sandy Ferrari, Paolo Fidler, Samantha J	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Katherine Farber, Donna L Farmer, Douglas G Farris III, Alton "Brad" Favela, Raul M Feng, Han Feng, Sandy Ferrari, Poolo Fidler, Samantha J Finger, Erik	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Xiaoli Farmer, Douglas G Farris III, Alton "Brad" Favela, Raul M Feng, Sandy Ferrari, Paolo Fidler, Samantha J Finger, Erik Fink, Michael	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Xiaoli Farrer, Dounha Farmer, Douglas G Farris III, Alton "Brad" Favela, Raul M Feng, Han Feng, Sandy Ferrari, Paolo Finder, Samantha J Finner, Erik Fink, Michael Florescu, Diana F	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Xiaoli Farmer, Douglas G Farris III, Alton "Brad" Favela, Raul M Feng, Sandy Ferrari, Paolo Fidler, Samantha J Finger, Erik Fink, Michael	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Xiaoli Farrer, Dounha Farmer, Douglas G Farris III, Alton "Brad" Favela, Raul M Feng, Han Feng, Sandy Ferrari, Paolo Finder, Samantha J Finner, Erik Fink, Michael Florescu, Diana F	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Katherine Fan, Xiaoli Farrer, Donna L Farrer, Donna L Farrer, Douglas G Farris III, Alton "Brad" Favela, Raul M Feng, Han Feng, Sandy Ferrari, Paolo Finder, Samantha J Finner, Erik Finner, Kichael Florescu, Diana F Fondevila, Constantino	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Katherine Fany, Bouglas G Farrier, Douna L Farmer, Douglas G Farris III, Alton "Brad" Favela, Raul M Feng, Han Feng, Sandy Ferrari, Paolo Filder, Samantha J Finger, Erik Fink, Michael Florescu, Diana F Fondevila, Constantino Fondey, James W	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Xiaoli Farmer, Douglas G Farrier, Donna L Farrier, Donna L Farrer, Ponna L Farrer, Pouglas G Farrier, Janual M Feng, Sandy Ferrari, Paolo Finler, Samantha J Finger, Erik Fink, Michael Florescu, Diana F Fondevila, Constantino Fontey, Magnus Fondey, James W Foster III, Clarence E	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Kaioli Farber, Donna L Farmer, Douglas G Farrier III, Alton "Brad" Favela, Raul M Feng, Han Feng, Sandy Ferrari, Paolo Fiidler, Samantha J Finger, Erik Fink, Michael Florescu, Diana F. Fondevila, Constantino Fontey III, Clarence E. Fracchia, Denise A	
Elmoghazy, Walid Eng, Mary Ericzon, Bo Goran Ersoy, Zeynep Espera-Lobaton, Ramona Eurich, Dennis Everly, Matthew J Everson, Gregory T Eyüboglu, Füsun Fadhil, Riadh A.S. Falconer, Stuart J Faleo, Gaetano Fan, Katherine Fan, Xiaoli Farmer, Douglas G Farrier, Donna L Farrier, Donna L Farrer, Ponna L Farrer, Pouglas G Farrier, Janual M Feng, Sandy Ferrari, Paolo Finler, Samantha J Finger, Erik Fink, Michael Florescu, Diana F Fondevila, Constantino Fontey, Magnus Fondey, James W Foster III, Clarence E	

Franco, Antonio	452.3
Fraser, Campbell	
Freire, Maristela Pinheiro	424.2
Fronek, Jiri	P.1207, P.1208, P.1209
Fu, Jianing	451.5
Fujii, Taku	P.1030
Fujisaki, Noritomo	P.1031
Fujita, Takashi	
Fukuda, Akinari	
Fukuoka, Kengo	P.1875
Fung, James	
Fung, John J	
Fung, Raymond Chi-yan	
Fung, Timothy K. F.	
Futamura, Kenta	
Gadekar , Kshitija G	
Galiyeva, Dinara Gandhi, Manish	
García Covarrubias, Luis	
Garcia-Gallont, Rudolf A.	
Gatault, Philippe	
Gautier, Sergey V	
Geissler, Edward K	
Gentry, Sommer E	
Gerbase-DeLima, Maria	
Gerlach, Undine	
Ghita, Ryan	
Ghosh-Mitra, Arpita	
Gilbo, Nicholas	
Gill, John S.	
Gilroy, Richard	555.7
Giral, Magali	323.12, 556.4, 556.5, P.1425
Gjertsen, Henrik A	P.1152
Glanville, Allan R	448.2
Globke, Brigitta K.M.	425.4
Goh, Angeline	
Goh, Su Kah	
Golab, Karolina	
Gomez, Maria P	
Gomez Dos Santos, Victoria	
Gondolesi, Gabriel E.	
Gorantla, Vijay	
Goto, Ryoichi	
Gozdowska, Jolanta	
Grajn, Andrej	
Grandtnerova, Barbara	
Grey, Shane T	
Grimm, Paul CGrinyo, Josep	
Guan, Lianyue	
Gueler, Faikah	
Guerra, Giselle	
Guerra, Juan Francisco	
Guleria, Sandeep	
Gültekin, Bahadir	
Gunderson, Susan	
Guo, Fei	
Guo, Yanhong	
Gupta, Krishan L	
Guzman Vinasco, Luis F	
Gyllenswärd, Sofia	
Ha, Jongwon	
Ha Phan, Hai An	
Haberal, Mehmet	P.1581
Haberal, Murat	325.10

Hall, Bruce M.	356.6
Halleck, Fabian	
Halloran, Philip F	
Hameed, Ahmer	
Hammad, Ehab A	
Han, Duck-Jong	
Han, Sang Youb	
Han, Seungyeup	
Hancock, Wayne W	
Hanson, Camilla S	
Hara, Hidetaka	
Harden, Paul	
Hardinger, Karen L	
Harimoto, Norifumi	
Harper, Claudia L.	
Hata, Keisuke	
Hata, Koichiro	
Hawthorne, Wayne J	
Hay, Margaret	
Hayashi, Taiji	
Hayashida, Shintaro	
He, Bulang	P.1925, P.1926
He, Xiaoshun	133.3
Heim, Christian	324.12, 454.7, 628.2, P.1776
Henderson, Lorna K	
Hernandez-Fuentes, Maria	
Hesselink, Dennis	
Hibi, Taizo	
Hirai, Toshihito	,
Hiramitsu, Takahisa	
Hirano, Hajime	,
Hirose, Takayuki	
Ho, Cheng-Maw	
Ho, Jenny CY	
Hodgson, Wayne C	
Hodkinson, Suzanne J	
Holdaas, Hallvard	
Hong, Suk Kyun	
Hoogduijn, Martin J.	
Horia, Kengo	
Hotta, Kiyohiko	
Howard, Kirsten	
Howell, Martin	
Hoyer, Dieter	
Hruba, Petra	
Hsieh, Ming- Hsin	P.1700
Hsu, Bang-Gee	
Hsu, Li-Wen	P.1077
Hu, Min	429.11, 627.2, 627.3
Huang, Dandan	429.2
Huang, Gang	
Huang, Jiefu	
Huang, Viola	322.5
Huang, Wenlong	
Hue, Siu Man	
Hussein, Kamal Hany	,
Ichii, Hirohito	
letto, Giuseppe	
lizuka, Junpei	
Ikeda, Masae	
Ildstad, Suzanne T.	
Ishido, Nobuhiro	
Issa, Fadi	

Itabashi, Yoshihiro	P1334
Ito, Taihei	
Ivanovski, Ninoslav	
lwadoh, Kazuhiro	
Jackson-Spence, Francesca	421.9, 421.10, 452.6
Jaeckel, Elmar	
Jain, Archana	
Jain, Ashokkumar	
Jang, Hyuk Jai	
Jang, Kyeonghee	P.1899
Jenssen, Trond	502.1
Jeon, Hee Jung	P.1638
Jeong, Hyeon Joo	P.1582
Jeong, Joon Heon	P.1251
Jiang , Xiaofeng	P.1900
Jin, Jian	457.9, P.1010
Jin, Kyubok	P.1327
Jin, Long	P.1023
Jirasiritham, Sopon	
Johannesen, Justin H	
Johnson, Paul R. V.	
Jucaud, Vadim	
Jun, Heungman	
Jung, Bo-Hyun	
Jung, Cheol Woong	
Jushinskis, Janis	
Jwa, Eunkyoung	
Kaabak, Michael M	
Kable, Kathy	
Kakizaki, Yuta	
Kaliamoorthy, Ilankumaran	
Kandaswamy, Raja Kanellis, John	
Kang, Byeongju	
Kang Jr., Gun Woo	
Kang, Hee Jung	
Kang, Seong-jun Sung	
Kang, Soo Kyoung	
Kang, Sun-woo	
Kanga, Uma	
Kannegieter, Nynke	
Kanodia, Kamal V.	
Kao, John W.	
Kara, Tonya	359.5
Karagoz, Huseyin	P.1756
Karakayali, Feza	P.1393, P.1394
Karczewski, Marek	P.1355
Kasiske, Bertram L	340.2, 400.1
Katano, Takumi	P.1833
Kaufman, Dixon B	
Kawagishi, Naoki	,
Kazuya, Kabei	
Keitel, Elizete	
Kenmochi, Takashi	
Kennedy, Brian K.	
Kern, Barbara	
Kers, Jesper	
Kesiraju, Sailaja	,
Keung, Karen L.	
Khadzhynov, Dmytro	
Khamash, Hasan	
Kheradmand, Taba	
Kho, Marcia M.L.	
Kihara, Yu	
Kim, Anes	

Kim, Eun Jee	P.1024
Kim, Hyun Jung	
Kim, Jim	
Kim, Jin Soo	
Kim, Jong Hae	
Kim, Jong Man3	
Kim, Joon Ye	
Kim, Kwan Woo	
Kim, KyeongSik	
Kim, Minjung	
Kim, Nayoung	
Kim, Seounghyun	
Kim, Soo-Kyung	
Kim, Suk Young	
Kim, Sung Hoon	
Kim, Tae-Seok	
Kim, Young June	
Kirnap, Mahir471.5,	
Kiriap, Maiii	
Kisu, lori Kitajima, Kumiko	
Kitajima, Toshihiro	
Kittrakulrat, Jathurong	
Kjøsen, Gisle	
Klair, Tarunjeet S	
Klinger, Marian	
Knight, Richard J	
Knoll, Gregory Alan	
Ko, Eun Jeong	
Ko, Kyungjai	
Ko, Wing-Man	
Kobayashi, Takaaki	
Kolaityte, Valdone	
Kong, Jin M	622.3
Konno, Osamu	P.1479
Koo, Jenny	
Kornberg, Arno	425.13, 625.3, P.1173
Kortram, Kirsten	
Kotenko, Oleg	455.9, P.1200
Koulmanda, Maria	446.3
Koyama, Ichiro	P.1867
Kozaki, Koichi	P.1293
Kozlowski, Tomasz	
Krams, Sheri	356.9, 359.1, 452.1
Kreisel, Daniel	101.1
Krishnan, Elankumaran	P.1120
Krishnan, Nithya320.2, 320.3, 370.5, 401.1, I	P.1808, P.1809, P.1810, P.1811, P.1812
Krüger, Bernd	
Kuan, Chen Hsiang	
Kuddus, Ruhul H	
Kuhr, Frank K	
Kumano, Kenjiro	
Kumar, Anant	
Kumar, Dhiren	
Kumar, Shiva	
KUMAR, SUNIL	
Kunwar, Kiran J	
Kuramitsu, Kaori	
Kurian, George	
Kurosawa, Akira	
Kurtz, Josef	
Kute, Vivek	
•	•
Kuypers, Dirk	
Kwok, Janette	
Kwon, Jae Hyun	

Kwon, Sukyung	425.12, P.1357
Kyriazis, Periklis P.	
Laaksonen, Maarit A	
Lai, Chia-Yun	P.1012
Laird, Christopher T	
Lakey, Jonathan	
Lam, Yin Fan Lynn	
Lam, Yiu Chung	
Langley, Vernon L	
Lao, I Ha	
Lau, Yew Weng Perry	
Leawseng, SirilakLee, Eun Mi	
Lee, Hae Won	
Lee, Ho kyun	
Lee, Hong joo	
Lee, Jacqueline I	
Lee, Jae Geun	
Lee, Jin Gu	
Lee, John	
Lee, Jonghwan	P.1107
Lee, Jung Jun	
Lee, Kyo Won	
Lee, Kyung Hee LKH	
Lee, Ling-Hsien	
Lee, Nikki	
Lee, Po-Chang	
Lee, Sarome	
Lee, Soo Ho	
Lee, Taehyun Lefaucheur, Carmen	
Legendre, Christophe Michel	
Leichtman, Alan B	
Leonard, Deanne	
Leong, Mario L	558.3
Lerut, Jan	
Lett, Bron D	
Levings, Megan	548.3
Levvey, Bronwyn J	
Li, Li	
Li, Wah Chun	
Li, Wenjun	
Li, Xian C	
Li, Yangina	
Li, YanpingLi, Yousheng	
Li , Chang Xian	257.6
Lian, Qizhou	
Lim, Wai	
Lin, Wilson	
Lin, Yi-Chang	
Linkermann, Andreas	
Liu, Chun-Jen	210.1
Liu, Hongxia	425.5, P.1735
Liu, Hui	
Liu, Jiang	
Liu, Longshan	
Liu, Qiang	
Liu, Xiaobing	
Liu/ Zhengzhao	
Liwlompaisan, Wisit	
Lo, Alan	
Locke, Jayme E	
Logen, Liu	
2032.1, 2.2	

Loh, Charles Yuen Yung	P.1884
López Fraga, Marta	
Lorant, Tomas	623.5
Lou Meda, Randall	360, 460, 565
Loupy, Alexandre	
Lozano, Eyner	P.1480
Lu, David Bo	
Luk, Chor Kwan Amanda	372.3
Luk, Franka	
Lum, Lionel H	P.1608
Lundgren, Torbjorn	
Luo, Xunrong	429.3, 557.2
Ma, Maggie Kam Man	
Ma, Xiaoqian	P.1882, P.1883
Ma, Yuen Yuen	328.6
MacDonald, Peter S	602.3
Machado, Clarisse	347.3
Macias III, Maria Outeda	571.6, P.1507, P.1508
Maeda, Akira	429.13
Maglione, Manuel	P.1176, P.1177
Mahajan, NIkhil Vijaykumar	P.1620, P.1621
Mahillo, Beatriz B	344.2
Maldonado, Rafael A	P.1520
Malheiro, Jorge	323.4, 423.3
Malik, Shafi	P.1440, P.1441
Maloney, Eden M	
Maluf, Daniel G	329.5, 355.4
Malyszko, Jacek S	454.9, P.1779, P.1780
Mangus, Richard S	
Manyalich, Marti	223.4, 342.3, 574.4
Marada, Tomas	
Marion, Chapal	P.1491
Markiewicz-Kijewska, Malgorzata	P.1121
Martin, Dominique E	326.1, 503.1
Martinez, Olivia M45	2.2, 546.1, 557.5, 571.4, P.1885
	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885 321.11 448.1
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885 321.11 448.1 211.1, 221.3
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885 321.11 448.1 211.1, 221.3
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885 321.11 448.1 211.1, 221.3 422.2, 455.1
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885 
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885 
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885 
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885 
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885 321.11 
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885 321.11 
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez de la Maza, Lilia.  Martinu, Tereza.  Mas, Valeria Massie, Allan.  Masson, Philip Matas, Arthur Matas, David Mathes, David W. Matsuda, Yasushi.  Matsuno, Naoto Mazariegos, George V. McAdams-DeMarco, Mara A McClarey, Andrew WJ McDiarmid, Sue McDonald, Stephen McKenna, Greg J Meader, Lucy J Medina, Jason Paul T Medina Pestana, Jose Mehrotra, Sonia Meier, Raphael	2.2, 546.1, 557.5, 571.4, P.1885
Martinez de la Maza, Lilia.  Martinez de la Maza, Lilia.  Martinu, Tereza.  Mas, Valeria  Massie, Allan.  Masson, Philip  Matas, Arthur  Matas, David  Mathes, David W.  Matsuda, Yasushi  Matsuda, Yasushi  Matsuno, Naoto.  Mazariegos, George V.  McAdams-DeMarco, Mara A  McClarey, Andrew WJ.  McDiarmid, Sue.  McConald, Stephen  McKenna, Greg J.  Medina, Jason Paul T.  Medina, Jason Paul T.  Medina Pestana, Jose.  Mehrotra, Sonia  Meier, Raphael  Meissner, Felix	2.2, 546.1, 557.5, 571.4, P.1885
Martinez de la Maza, Lilia.  Martinu, Tereza.  Mas, Valeria Masse, Allan.  Masson, Philip Matas, Arthur Matas, David Mathes, David Mathes, David Mathes, David Matsund, Yasushi Matsund, Naoto Mazariegos, George V. McAdams-DeMarco, Mara A McClarey, Andrew WJ McDiarmid, Sue McDonald, Stephen McKenna, Greg J Meader, Lucy J Medina, Jason Paul T Medina Pestana, Jose Mehrotra, Sonia Meier, Raphael Meissner, Felix Melicoff, Ernestina.	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez, Olivia M	2.2, 546.1, 557.5, 571.4, P.1885
Martinez de la Maza, Lilia.  Martinez de la Maza, Lilia.  Martinu, Tereza.  Mas, Valeria  Massie, Allan.  Masson, Philip  Matas, Arthur  Matas, David.  Mathes, David W.  Matsuda, Yasushi.  Matsuno, Naoto  Mazariegos, George V.  McAdams-DeMarco, Mara A  McClarey, Andrew WJ  McDiarmid, Sue  McDonald, Stephen  McKenna, Greg J  Meader, Lucy J  Medina, Jason Paul T  Medina Pestana, Jose  Mehrotra, Sonia  Meier, Raphael  Meissner, Felix  Meliosff, Ernestina.  Menahem, Solomon  Menane, Michael  Mengle, Michael  Menjivar, Ana T	2.2, 546.1, 557.5, 571.4, P.1885
Martinez de la Maza, Lilia.  Martinez de la Maza, Lilia.  Martinu, Tereza.  Mas, Valeria  Massie, Allan.  Masson, Philip  Matas, Arthur  Matas, David.  Mathes, David W.  Matsuda, Yasushi  Matsuno, Naoto.  Mazariegos, George V.  McAdams-DeMarco, Mara A  McClarey, Andrew WJ  McDiarmid, Sue  McDonald, Stephen  McKenna, Greg J  Medina, Jason Paul T  Medina, Jason Paul T  Medina Pestana, Jose  Mehrotra, Sonia  Meier, Raphael  Meissner, Felix  Melicoff, Ernestina  Menapel, Michael  Mengle, Michael  Menglen, Robert M.	2.2, 546.1, 557.5, 571.4, P.1885
Martinez de la Maza, Lilia.  Martinez de la Maza, Lilia.  Martinu, Tereza.  Mas, Valeria  Massie, Allan.  Masson, Philip  Matas, Arthur  Matas, David.  Mathes, David W.  Matsuda, Yasushi  Matsuno, Naoto.  Mazariegos, George V.  McAdams-DeMarco, Mara A  McClarey, Andrew WJ  McDiarmid, Sue  McDonald, Stephen  McKenna, Greg J  Medina, Jason Paul T  Medina, Jason Paul T  Medina Pestana, Jose  Mehrotra, Sonia  Mehrotra, Sonia  Melicoff, Ernestina  Menahem, Solomon  Mengel, Michael  Mengle, Michael  Menjivar, Ana T  Menjivar, Ana T  Merion, Robert M.  Messer, Simon J.	2.2, 546.1, 557.5, 571.4, P.1885
Martinez de la Maza, Lilia.  Martinu, Tereza.  Mas, Valeria Masse, Allan.  Masson, Philip Matas, Arthur Matas, David Mathes, David W.  Matsuda, Yasushi Matsuno, Naoto Mazariegos, George V.  McAdams-DeMarco, Mara A  McClarey, Andrew WJ  McDiarmid, Sue McDonald, Stephen McKenna, Greg J  Meader, Lucy J  Medina, Jason Paul T  Medina Pestana, Jose Mehrotra, Sonia Meier, Raphael Meissner, Felix Melicoff, Ernestina Menahem, Solomon Mengel, Michael Menjivar, Ana T  Merion, Robert M  Messer, Simon J  Miarka, Przemysław  Messer, Simon J  Miarka, Przemysław	2.2, 546.1, 557.5, 571.4, P.1885
Martinez de la Maza, Lilia.  Martinez de la Maza, Lilia.  Martinu, Tereza.  Mas, Valeria  Massie, Allan.  Masson, Philip  Matas, Arthur  Matas, David.  Mathes, David W.  Matsuda, Yasushi  Matsuno, Naoto.  Mazariegos, George V.  McAdams-DeMarco, Mara A  McClarey, Andrew WJ  McDiarmid, Sue  McDonald, Stephen  McKenna, Greg J  Medina, Jason Paul T  Medina, Jason Paul T  Medina Pestana, Jose  Mehrotra, Sonia  Mehrotra, Sonia  Melicoff, Ernestina  Menahem, Solomon  Mengel, Michael  Mengle, Michael  Menjivar, Ana T  Menjivar, Ana T  Merion, Robert M.  Messer, Simon J.	2.2, 546.1, 557.5, 571.4, P.1885

	P.1610
Min, Byoung-Hoon	
Minnee, Robert	
Minz, Mukut	
Mita, Atsuyoshi	
Mitra, Palash	
Miura, Kohei	
Miyagi, Shigehito	
Miyazaki, Yuki	
Miyuki, Furusawa	
Mizuta, Koichi	
Mizutani, Kazuo	P.1319, P.1320, P.1321, P.1322, P.1323
Mo Sr., Chunbai	
Moawadh, Mamdoh	
Modi, Manisha P	
Modi, Pranjal	
Mohanakumar, Thalachallour	
Mohiuddin, Muhammad M	
Mohsin, Rehan	P.1652, P.1653
Mone, Thomas D	326.2
Montenovo, Martin	
Monteverde, Marta L	459.3
Montgomery, Robert A	100.3, 443.2
Moon, Deok-Bog	P.1138
Moon, Ju lk	P.1159, P.1160
Moonka, Dilip	625.5, 625.9
Moore, Hunter B	355.6
Morales, José María	421.8, 640.3
Morales-Barría, Jorge	
Moray, GokhanP.	1165, P.1166, P.1167, P.1168, P.1169, P.1170
Morelli, Adrian E	111.1
Morelon, Emmanuel	321.3, 601.3, 624.3
Morito, Noriyuki	
Moritz, Michael J	
Morris, Michele I	200 F
Morris, Randall E	123.4, 132.4
Morris, Randall E	123.4, 132.4 
Morris, Randall E	

Nesher, Eviatar	P.1178
Newell, Kenneth A.	
Ng, Jenny Y.Y.	
Ng, Kevin Tak-Pan	
Ng, Zhi Yang	624.8
Ng, Zi Qin	370.3, P.1928, P.1929
Nghiem, Dai	
Nguyen, Hien Trong	P.1613
Nicholson, Michael L	602.1
Nickerson, Peter William	221.1, 410.1
Niemann, Claus	304.2
Nikoueinejad, Hassan	P.1049
Niño-Murcia, Alejandro	P.1368, P.1369, P.1370
Nishida, Sho	
Nishikawa, Kouhei	420.10
Nizami, Imran	P.1787, P.1788, P.1789
Nobuki, Ishida	327.6
Nordström, Johan A	321.10
Noronha Sr., Irene	328.13
Novotny, Marek	P.1313
Nowicki, Michal P	P.1339
Nowocin, Anna	470.3
Nuhari, M. Mubrarak	P.1426, P.1427
Núñez Peña, José Ramón	133.5, 223.5, 604.4
O'Connell, Philip J.	120.1, 240.1, 350.6, 520, 640.1
O'Neill, Natalie A	328.9
Obara, Hiromichi	P.1365
Oberbarnscheidt, Martin	101.4, 111.4
Oberhuber, Rupert	
Obregon, Liliana Miriam	P.1340
Oehler, Rudolf	
Ogiso, Satoshi	P.1066
Ogura, Yasuhiro	P.1122
Okada, Manabu	323.5
Okada, Noriki	P.1671
Okamura, Yusuke	451.3
Okumi, Masayoshi	P.1404
Omoto, Kazuya	
Onghena, Louis G	
Ono, Minoru	324.8
Onuma, Erika	P.1834
Orlando, Giuseppe	
Orlowski, Jeffrey P	352.3, 472.6
Ostrowski, Marek	
Ozcay, Figen	
Ozcay, Necdet	
Özdemir, Handan320.13, 550.5, P.1428, P.1429, P.	
Padilla, Benita	
Páez, Gloria	
Pantis, Carmen	
Papadimitriou, John C	
Pape, Lars	
Pareek, Shishir	
Park, Cheon-Soo	
Park, Chung-Gyu	
Park, Keun-Myoung	
Park, Myoung Hee	
Park, Pyoung-Jae	
Park, Yeon Ho	
Pathiraja, Vimukti	
Pattou, François	
Paul-Heng, Moumita	
Pavlovic, Julie	
Peng, Qi	
Pera, Martin F	446.2

Petrie, Michaela C	550.7
Petrone, Hugo S.	
Petruzzo, Palmina	353.4, 543.1, 624.6
Phongwiwat, Thanyapat	P.1645
Pierrotti, Ligia C	P.1615
Pilmore, Helen	
Pinchuk, Alexey	551.8
Pongpirul, Krit	
Pongskul, Jongruk	
Popoola, Joyce	
Posfay-Barbe, Klara M	
Posselt, Andrew	
Prakash, Swayam	
Prasad, Abheesh	
Prasad, Narayan	
Proneth, Andrea	
Proneth, Bettina	
Przybylek, Bianca	
Qi, Xiang	
Qiu, Jiang	
Quante, Markus	
Quirin, Nicolas	
Radford, Toni M	
Raghuram, Lalitha	
Rahman, Mir M	
Rajakumari, Vijaya	
Ramos, Rafael G	
Raschzok, Nathanael	
Rasheed , Husham	
Raslan, Mohammad	
Rathi, Manish	
Ratkovic, Marina	
Raval, Shailesh B	
Ravindranath, Mepur H.	
Reddy, Mettu Srinivas	
Reed, Elaine F.	
Rees, Michael A.	
Reinders, Marlies	
Reinke, Petra	
Rela, Mohamed	
Religa, Piotr	
Ringden, Olle	
Ritschl, Paul Viktor	
Rivinius, Rasmus	
Rizvi, Adibul Hasan	
Robertson, Paul	223.1
Rocha, Eduardo	223.3
Rodrigues Silva, Josue	351.3
Rodriguez, E R	454.8
Roelen, Dave	
Rojas-Canales, Darling	
Rojas-Pena, Alvaro	P.1643, P.1644
Ronaghi, Martin	
Roodnat, Joke I	P.1439
Rosenfeldt, Franklin L.	
Rosete-Liquete, Rose Marie	
Rostaing, Lionel	
Rothstein, David	
Ruangkanchanasetr, Prajej	
Rudensky, Alexander	
Ryu, Je Ho	
Saeed, Bassam	
Saeki, Yoshihiro	
Sageshima, Junichiro	453.6


Sahara, Hisashi	620 /
Sahin, Selcuk	
Sakai, Hiroshi	
Sakai, Rieko	
Salvador, Pilar	
Sanada, Yukihiro	
Sanchez-Fueyo, Alberto	
Sandal, Shaifali	426.3, P.1672
Sanjiv, Saigal	
Sannomiya, Akihito	
Sarwal, Minnie M.	
Satirapoj, Bancha	
Sato, Yoshinobu	
Saudek, Frantisek	P.1856
Sautenet, Benedicte	453.3
Scandling, John D.	
Schachtner, Thomas	
Schaub, Stefan	
Schenker, Peter	
Schick, Liz	
Schierbeck , Hanna	P.1857
Schinstock, Carrie A	540.1
Schlitt, Hans J.	
Schmidt, Katharina	
Schmuck, Rosa B	
Scholz, Hanne	
Schuetz, Christian	
Schulze, Maren	P.1111
Schwartz, Jason J	P.1500
Sedigh, Amir	P.1034
Segev, Dorry	
Sekijima, Mitsuhiro	
Sekowska, Marta	
36KOM3Ka, Malaa	
Serrano, Oscar K	422.1, 459.8, 459.9, P.1388, P.1389
Serrano, Oscar K	422.1, 459.8, 459.9, P.1388, P.1389 357.1
Serrano, Oscar K	422.1, 459.8, 459.9, P.1388, P.1389 357.1
Serrano, Oscar K	422.1, 459.8, 459.9, P.1388, P.1389 
Serrano, Oscar K	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ashish Sharma, Ashish Sharma, Rajkumar She, Wong Hoi	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shim, Ming-Hui Shimizu, Kenji Shimizu, Tomokazu	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Kenji Shim, Byung Chul	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Kenji Shim, Byung Chul	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Kenji Shin, Byung Chul Shin, Byung Chul	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Tomokazu Shin, Byung Chul Shin, Jun Chul Shin, Jun Chul	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Tomokazu Shin, Jun-Seop Shin, Jun-Seop	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Tomokazu Shin, Byung Chul Shin, Jun Chul Shin, Jun Chul Shin, Jun-Seop Shin, Sung. Shingse, Sashmi	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Tomokazu Shin, Byung Chul Shin, Jun Chul Shin, Jun Chul Shin, Jun Chul Shin, Jun Seop Shin, Sung Shingde, Rashmi Shinohara, Koya	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Amit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Kenji Shimizu, Tomokazu Shin, Byung Chul Shin, Jun-Seop Shin, Sung Shin, Sung Shingde, Rashmi Shingde, Rashmi Shingde, Rashmi Shingde, Rashmi	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ankit Sharma, Ashish Sharma, Bajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Kenji Shimizu, Tomokazu Shin, Byung Chul Shin, Jun-Seop Shin, Jun-Seop Shin, Jun-Seop Shin, Sung Shingde, Rashmi Shinohara, Koya Shirwan, Haval	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Amit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Kenji Shimizu, Tomokazu Shin, Byung Chul Shin, Jun-Seop Shin, Sung Shin, Sung Shingde, Rashmi Shingde, Rashmi Shingde, Rashmi Shingde, Rashmi	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ankit Sharma, Ashish Sharma, Bajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Tomokazu Shin, Bung Chul Shin, Jun Chul Shin, Jun-Seop Shin, Jun-Seop Shin, Sung Shingde, Rashmi Shinohara, Koya Shirwan, Haval Shyr, Yi-Ming Sierra, Carmen J	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Ankit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shih, Bingyi Shih, Ming-Hui Shimizu, Kenji Shimizu, Tomokazu Shin, Bung Chul Shin, Jun-Seop Shin, Sung Shiry	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Amit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shin, Ming-Hui Shimizu, Tomokazu Shin, Byung Chul Shin, Jun Chul Shin, Jun Chul Shin, Jun Ceop Shin, Sung Shingde, Rashmi Shinohara, Koya Shirwan, Haval Shyr, Yi-Ming Sierra, Carmen J Singh, Navdeep Singh Nadeep	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Amit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shimizu, Tomokazu Shin, Bung Chul Shin, Jun Chul Shin, Jun Chul Shin, Jun-Seop Shin, Sung Shingde, Rashmi Shinohara, Koya Shirwan, Haval Shyr, Yi-Ming Sierra, Carmen J Singh Navdeep Singh Shavdeep Singh Navdeep Singh Navdeep Singh Navdeep Singh Navdeep	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Amit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shimizu, Kenji Shimizu, Kenji Shimizu, Kenji Shimizu, Tomokazu Shin, Jun-Seop Shin, Jun-Seop Shin, Sung Shin, Shana, Shi, Shingde, Rashmi Shinohara, Koya Shirwan, Haval Shyr, Yi-Ming Sierra, Carmen J Singh Navdeep Singh Shah, Dibya Sirota, Marina Sivanathan, Kisha Nandini	
Serrano, Oscar K Seyda, Midas Sfriso, Riccardo Shah, Jigesh A Shah, Pankaj R Shaheen, Faissal Shaked, Abraham Shapiro, Ron Sharma, Amit Sharma, Amit Sharma, Ashish Sharma, Rajkumar She, Wong Hoi Shellmer, Diana Shi, Bingyi Shimizu, Tomokazu Shin, Bung Chul Shin, Jun Chul Shin, Jun Chul Shin, Jun-Seop Shin, Sung Shingde, Rashmi Shinohara, Koya Shirwan, Haval Shyr, Yi-Ming Sierra, Carmen J Singh Navdeep Singh Shavdeep Singh Navdeep Singh Navdeep Singh Navdeep Singh Navdeep	

Siyoum, Mekdim Taddese	P1710
Skuk, Daniel	
Skwirczynska , Edyta Agata	P1729
Slakey, Douglas P.	
Slatinska, Janka	
Smudla, Aniko	
Sobnach, Sanju	
Soejima, Yuji	
Soldini, Gabriele	
Solomina, Julia	
Sommer, Florian	
Song, Young M.	
Song, Zhuolun	
Sönnerborg, Isabella	
Soto-Miranda, ErnestoP.128	
Srinivas, Titte R	
Sriperumbuduri, Sriram	
Stadtler, Maria	
Stead, Sebastian O	428.8
Stock, Peter	300.3, 382, 546.3
Stoma, Igor	572.5
Stone, John P	
Strasser, Simone I	502.2, 510.3
Stratta, Robert J	551.1, 551.2, P.1302
Strober, Samuel	320.9
Struecker, Benjamin	P.1069
Suchyta, Marissa	624.5
Sudan, Debra L.	
Suh, Kyung-Suk	345.3
Suh, Sukwon	P.1026
Sukkha, Sayamon	P.1509
Sumethkul, Vasant	240.5, 342.2
Sun, Chao	
Sun, Pamela	
Sun, Xuyong	
Suriyamoorthi, Sujatha	
Süsal, Caner	
Suthar, Kamlesh S	
Suzuki, Yasuko	
Swe, Htar Kyi	
Sykes, Megan	
Taddeo, Adriano	
Taguchi, Kazuhiro	
Tai, William Chi-Shing	P.1477, P.1478
Takano, Yuki	
Takenaka, Masashi	
Takeuchi, Hironori Tam, Nga-Lei	
Tambur, Anat R	
Tamin, Jonathan John F	
Tan, Ban Hock Tan, Carmela D	
Tanabe, Kazunari	
Tanaka, Asuka	
Tanaka, Motofumi	
Tanaka, Yuka	
Tanemura, Masahiro	
Tang, Jianxin	
Tang, Qizhi	
Tannenbaum, Cara	
Tariciotti, Laura	
Tasaki, Masayuki	
Taubert, Richard	
Techawathanawanna, North	
Tector, Alfred Joseph	

T	
Teegen, Eva Maria EM	
Terada, YukaThakkar, Umang G.	
Thammavaranucupt, Kanin	
Thaunat, Olivier	
Thawanaphong, Sarita	
Thomas, Chris	
Thomson, Angus W.	
Thomson, Imogen K	
Thorat, Ashok	
Thotsiri, Sansanee	P.1436
Tielen, Mirjam	
Tinckam, Kathryn	
Toimamueang, Ubonrat	
Tojimbara, Tamotsu	
Tokat, Yaman	
Tokodai, Kazuaki	
Tomita, Koichi	
Tong, Allison	
Tonsho, Makoto Tönshoff, Burkhard	
Townamchai, Natavudh	
Tran, Khe	
Trappe, Ralf Ulrich	
Troncoso, Pablo	
Tse, Hung Fat	
Tsiroulnikova, Olga M.	
Tullius, Stefan G	
Turkmen, Aydin	572.6
Turunç, Volkan	
Uchida, Hajime	554.6
Uchida, Junjji	P.1263, P.1264
Uchiyama , Masateru	P.1076
Uematsu, Satomi Suzuki	
Ulu Ozturk, Funda	
Unagami, Kohei	
Urade, Takeshi	
Uva, Pablo D	
Vallant Natalia	
Vallant, NatalieVan Delden, Christian	
van den Brink, Marcel R.M.	
Van Gelder, Teun	
Vanhove, Thomas	
Vanikar, Aruna	
Vathsala, Anantharaman	
Verma, Nirupama D.	
Vester, Udo	
Vincenti, Flavio	
Vittoraki, Angeliki G	
Vondran, Florian WR	P.1016
Vrakas, Georgios	451.6
Wadei, Hani	
Waki, Shiori	
Wakiya, Taiichi	
Waller, Karen	
Walters, Stacey N	
Walton, Duncan C	
Wan, Susan S	
Wang, Changxi	
Wang, Haibo	
Wang, Kai Wang, Zhanpeng	
Warner, Suzan S Y	
Watanabe, Hironosuke	
	JJ-1.0

Watanabe, Takuya	324.5
Watarai, Yoshihiko	
Watcharananan, Sirion	424.9, P.1619
Webster, Angela	222.2, 302.1, 321.5, 626.7
Wedel, Johannes	427.2
Wee, Alvin	574.2
Weimar, Willem	
Weimer, Rolf	
Wen, Yujie	
Weng, Shih-Feng	
Wennberg, Lars	
West, Lori J	
Whittaker, Vaughn E	
Wiebe, Chris J	
Wieland, Eberhard	
Wijetunga, Imeshi U	
Wisel, Steven A	
Witkowski, Piotr	
Wiwattanathum, Punlop	
Wolf, Michael	
Womer, Karl L	
Wong, Germaine	
Wong, Tiffany CL	
Wong, Wilson	
Wood, Kathryn J.	
Woodside, Kenneth J	
Woodward, Kyle	
Wu, Chenglin	
Wu, Huiling	
Wu, Tsunghan	P.1205
Wuthrich, Rudolf P	426.5
Wynter, Lucinda	422.4
Xia, Junjie	328.1
Xu, Aimin	
Xu, Yinzhe	
Xu, Yue	
Yadav, Kunal	
Yadav , Brijesh	
Yamada, Kazuhiko	
Yamanaka, Kazuaki	
Yamashita, Kenichiro	445.3
Yanagawa, Senichiro	
Yang, BinYang, Cheng	
Yang, Chul Woo	
Yang, Zhaoxu	
Yanishi, Masaaki	
Yano, Takuya	
Yap M.D., Leslie A	
Yau, Wai-Ping	
Ye, Qifa	
Yeh, Chun Chieh	
Yelken, Berna	
Yeung , Wai Ho Oscar	
Yi, Nam-Joon	
Yi, Wang	
Yin, Enzhi	P.1017
Yokoyama, Takayoshi	
Yoon, Sam-Youl	P.1206
Yoshida, Kazunari	P.1666
Yoshida, Satoru	
Yoshikawa, Yuki	
Yoshizawa, Atsushi	
You, Youngkyoung	P.1219

Young, Kimberly	213.2
Yu, Di	600.2
Yu, Young-Dong	355.7, P.1183
Yuan, Wenji	P.1859
Yuan, Xiaopeng	322.4, 472.5, P.1328, P.1329
Yue, Gu	P.1000
Zafar, Mirza Naqi	213.5, 231.6, 303.1, P.1397, P.1398, P.1399
Zaitsu, Masaaki	558.5
Zarrinpar, Ali	357.3, 357.4, 428.7
Zavazava, Nicolas	201.4
Zee, Jarcy	555.6, 620.8
Zeng, Song	428.12
Zeyneloglu, Pinar	324.3, P.1570, P.1571, P.1572, P.1573, P.1574
Zhai, Yuan	101.2
Zhang, Huanxi	552.4
Zhang, Qiang	421.5
Zhang, Tianshu	558.4
Zhang, Wensheng	624.4
Zhang, Zheng	P.1018
Zhao, Bin	P.1910
Zhao, Yuanfei	457.3
Zhao, Zitong	P.1569
Zheng, Shusen	120.4
Zheng, Zhe	120.6
Zhu, Lan	359.3
Zielinski, Maciej	P.1050
Zimmerman, Asha M	P.1483
Zingerman, Boris	471.1
Zor, Fatih	P.1757, P.1758, P.1759
Zorn, Emmanuel	410.2
Zuber, Julien	550.9, 628.4
Zuidema, Willij	472.3





NGO in official relations with the World Health Organization (WHO)

# **Join TTS TODAY!**

...and become part of a growing organization focused on the entire global transplant community.

### **BENEFITS INCLUDE:**

- Free Online Access to Transplantation Journal
- Reduced Registration Fees for TTS 2018 Madrid
- Substantial discounts for TTS Section Members and those from Emerging Economies
- Entitlement for travel grants for Young Investigator Awards
- Access to Webinars & Multimedia Library with over 5000 Presentations and Growing

... and much more

Come and visit our booth in the Exhibit Area, Level 5 for your free give away!

By joining TTS BETTER way to there is no BETTER invest in YOUR CAREER

and in one of the most dynamic professions in medical science





Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrologyand Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

### ASTELLAS LUNCH SYMPOSIUM

# **Optimizing immunosuppression:**A key for improving long-term outcomes

12:15-13:30 • Saturday, 20 August 2016
Hall 5E3, Level 5, Hong Kong Convention and Exhibition Centre

Time	Topic	Speaker
12:15-12:30	Lunch	
12:30-12:35	Welcome note and opening	Wai-Leung Chak, Hong Kong Simone Strasser, Australia
12:35-12:55	Natural history of the organ transplant: opportunities to optimize immunosuppression	Philip Halloran, Canada
12:55-13:15	The immunosuppressive management for long-term outcome	Kim Jong Man, Korea
13:15-13:30	Panel discussion	All

Seats and lunchboxes will be available on a first-come, first-served basis.



HDV/10/KUZOKAP1 JULIE ZUTO

<u> MADRID • SPAIN -</u>

27<sup>th</sup> International Congress of **The Transplantation Society** 

**SAVE the DATE!** 





